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Abstract  
Periodontal ligament inflammation or periodontitis is a common disease 
characterised by gradual destruction of connective tissue fibres that attach a tooth to 
the alveolar bone within which it sits. Diabetes and inflammation enhances 
periodontal bone loss through enhanced resorption and diminished bone formation. 
Periodontal ligament fibroblast attachment to collagen-I and function was impaired 
by methylglyoxal (MG) modification in vitro. The glyoxalase system is an anti-
glycation defence in all cells that metabolises MG and thereby suppresses MG-
mediated protein damage. Overexpression of Glo1 decreased the intracellular levels 
of MG The aim of this investigation was to improve the understanding of protein 
damage in PDL in diabetes, focusing on protein damage by MG in human 
periodontal ligament fibroblasts (hPDLFs) in hyperglycaemia and to evaluate the 
effects of high and low glucose concentrations on MG metabolism in hPDLFs with 
or without Glo1 inducers. 
The effect of high glucose concentration on the formation and metabolism of 
MG was studied in hPDLFs in vitro. The ability of two small molecule Glo1 
inducers, individually and in synergistic combination, to counter dicarbonyl stress in 
hPDLFs in vitro was studied. Interactions between hPDLFs to the extracellular 
matrix protein, collagen-I, were investigated and impairments in hPDLFs adhesion to 
MG-modified collagen-I coated plates were assessed. Protein susceptible to MG 
modification and inactivation in the cytosol of hPDLFs were identified by high 
resolution mass spectrometry proteomics. The effect of clinical periodontitis on 
plasma protein glycation, oxidation and nitration was also investigated in a pilot 
clinical investigation. 
When hPDLFs were incubated with high glucose concentration in vitro there 
was a 45% decrease in Glo1 activity and 42% increase in D-lactate flux – surrogate 
indication of MG flux of formation, which contributed to increased cellular 
concentration of MG and increase in MG-H1 residue content of cell protein, 
compared to low glucose control. This indicated dicarbonyl stress was induced in 
hPDLFs by high glucose concentration in vitro, a model for hyperglycaemia in vivo. 
Decrease of Glo1 activity and increase in cellular MG concentration and MG-H1 
residue content of cell protein was corrected with the addition of Glo1 inducers. The 
binding of hPDLFs to collagen-I was decreased by 30% in high glucose 
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concentration and was corrected by addition of Glo1 inducers. Proteomics analysis of 
cytosolic extracts of hPDLFs indicated that high glucose incubations produced 
changes in MG-modified proteins and also up-regulated and down-regulated 
unmodified proteins in hPDLFs. The pilot investigation of clinical periodontitis 
suggested a systemic effect of this local inflammation which was associated with 
changes in plasma protein glycation, oxidation and nitration. 
This study reveals that dicarbonyl stress is a potential contributory pathogenic 
mechanism in hPDLFs in periodontitis and countering it may provide new treatment 
options to prevent and treat decline in periodontal health, particularly in diabetes. 
Small molecule inducers of Glo1 expression may in future contribute to improving 
periodontal health, particularly in diabetes.  
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1. Introduction 
The periodontal ligament (PDL) is a specialized connective tissue, which 
occupies the space between the root of the tooth and the alveolar bone. In addition to 
its essential role in attaching the tooth to the alveolus, the PDL helps the tooth to 
withstand the substantial forces resulting from mastication and keeps it embedded in 
its socket. It also contributes to tooth sensation and nutrient supply to the 
surrounding structures (Palumbo, 2011). PDL inflammation, or periodontitis, is the 
commonest chronic inflammatory disease in the mouth, which characterised by 
breakdown of the supporting structures of the teeth including the periodontal 
ligament and alveolar bone. PDL inflammation can be caused by different factors; 
these causative factors can be external such as excessive plaque accumulation around 
the tooth (Selwitz et al., 2007), or systemic such as chronic systemic diseases like 
diabetes (Chang and Lim, 2012). Severe PDL inflammation affects 10–15% of adults 
and has several adverse effects on quality of life (Preshaw et al., 2013). 
Diabetes is a common chronic metabolic condition that can cause PDL 
diseases. Such is the strong association with diabetes and development of a 
characteristic pathology that PDL disease has been called the “sixth complication of 
diabetes” along with retinopathy, nephropathy, neuropathy, macroangiopathy and 
delayed wound healing (Furukawa et al., 2007). 
 
1.1 Periodontium and periodontal diseases 
The periodontium is the tissue that surrounds and supports the teeth in their 
physical attachment and function. The formation of periodontal tissue occurs at the 
same time as formation and development of the tooth. The macroscopic components 
of periodontium are the gingiva, periodontal ligament (PDL), cementum and alveolar 
bone. These components maintain teeth in the maxillary and mandibular bones of the 
upper and lower jaw (Palumbo, 2011). Although the periodontium contains four 
different structures, each component interacts to co-operate dynamically and support 
each other (Bartold, 2006). 
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1.1.1 Components of periodontium  
1.1.1.1 Gingiva 
The gingiva is the soft tissue that overlies the mandible and maxilla inside the 
oral cavity and forms a seal around the base of tooth at its border with alveolar bone 
(Nanci and Bosshardt, 2006, Palumbo, 2011). 
 
Macroscopic Anatomy of Gingiva  
Gingiva is a coral pink tissue forms a scalloped outline around teeth cervices. 
It bonds to the underlying bone firmly and ascends apically to become alveolar 
mucosa. The alveolar mucosa is bounded to bone palatally but not labially (Weinberg 
et al., 2014). The gingival tissue is composed of two main parts: free gingiva and 
attached gingiva. The free gingiva extends by 2 mm from the gingival margin at 
tooth cervix to the free gingival groove which represents the level of cemento-
enamel junction adjacent to the tooth (Newman et al., 2011) – Figure 1. 
The gingival sulcus is the narrow space between the normal gingiva and the 
tooth surface. It extends from the free gingival margin coronally to the junctional 
epithelium apically. The normal depth of sulcus ranges between 0.5 to 3 mm with an 
average of 1.8 mm. More than 3 mm depth should be considered as a pathologic 
periodontal pocket (Miller, 2012) - Figure 1. 
The gingiva is firmly attached to the underlying alveolar bone that extends 
apically from the gingival grove to the mucogingival junction. Stippling is the main 
feature of this part and it is defined as small depressions that can be clearly seen on 
the surface and gives the appearance of orange peel. The width of the attached 
gingiva varies according to the physiologic age and the location of the tooth in the 
oral cavity - whether it is an anterior or posterior, maxillary or mandibular location 
(Newman et al., 2011, Palumbo, 2011). 
 
Microscopic anatomy of gingiva 
The oral mucosa is composed of overlying epithelium and underlining 
connective tissue - the lamina propria. In free gingiva – the tissue that surrounds the 
tooth producing a cuff or collar of gingiva measured from the margin of the attached 
gingiva extending around the tooth at a width of ca. 1.5 mm, the epithelium is 
differentiated as follows: oral epithelium which faces the oral cavity; sulcular 
epithelium which is located in tooth side but not in contact to tooth surface; and  
33 
 
 
Figure 1: Anatomy of periodontium.  
Modified from (Niemiec, 2012). 
 
finally, the junctional epithelium which forms the connection between gingiva and 
tooth. The junctional epithelium is the base of the sulcus (Lang and Lindhe, 2015) - 
Figure 1. 
The junctional epithelial cells are characterised by wide intercellular spaces 
acting as semi-permeable barrier and this facilitate the invasion of bacteria and their 
by-products into the tissue. In addition, it facilitates the passage of leukocytes (e.g. 
neutrophils) and immune components (e.g. complement), enzymes, and gingival 
cervical fluid (GCF) into gingival sulcus (Avery, 2011). This oral epithelium is a 
keratinised, stratified and squamous which is divided into four layers according to 
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the degree of differentiation of keratin producing cells. These four layers represent 
themselves as: stratum basale, stratum spinosum, stratum granulosum, and the 
stratum corneum (Palumbo, 2011). 
 
1.1.1.2  Periodontal ligament (PDL) 
The PDL is a specialised connective tissue that occupies the space between 
the root cementum and the alveolar bone. It is referred to as the lamina dura in 
radiographic analysis. Its width ranges between 0.15 mm to 0.25 mm. There are 
many vital functions of PDL. It acts as a cell reservoir for tissue homeostasis, repair 
and regeneration; as a sensory receptor required for accurate locating of the jaws 
during mastication; and as a supporting tissue for teeth in their place in the socket to 
permit them to withstand the extensive masticatory forces and distribute this force to 
the alveolar bone. In addition, the PDL is important in preventing the fusion and 
mineralisation of root cementum – the surface layer of the tooth root , with the 
surrounding bone by producing matrix gla protein – a vitamin-K-dependent protein 
containing γ-carboxyglutamatci acid (Gla) residues (Nanci and Bosshardt, 2006). 
 
Components of PDL 
The PDL consists of cells and extracellular components. The cell population 
is a heterogeneous and comprises fibroblasts, osteoblasts, cementoblasts, epithelial 
cell rests of Malassez and undifferentiated mesenchymal cells (Tomokiyo et al., 
2008). The extracellular compartment is composed of well-defined collagen fibre 
bundles embedded in a ground substance which is amorphous background material 
(Nanci and Bosshardt, 2006). In the PDL there are three different types of fibre: 
elastic fibres, elaunin, and oxytalan fibres. The main constituents of the ground 
substance are glycosaminoglycans, glycoproteins and glycolipids (Miller, 2012). 
Fibroblasts are the major cells of PDL. Although all fibroblasts look similar 
under the microscope, heterogeneity of the cell populations occurs between different 
connective tissues and within the same connective tissue. The periodontal ligament 
fibroblasts (PDLFs) are characterised by the rapid turnover of their extracellular 
compartment, specifically collagen (Miller, 2012). PDLFs are large cells with an 
extensive cytoplasm enclosing organelles related to protein synthesis and secretion. 
Reflecting the physical and hydrostatic pressure demands placed on the cells, PDLFs 
have a well-developed cytoskeleton and display numerous adherence and gap 
35 
 
junctions. The collagen fibrils in bundles of the periodontal ligament are constantly 
being remodelled by PDLFs due to the capability of PDLFs to simultaneously 
synthesize and degrade collagen (Nanci and Bosshardt, 2006). 
Epithelial cells in PDL are called the epithelial cell rests of Malassez (ERM) 
which are fragments of Hertwig’s epithelial root sheath the main progenitor of root 
formation. ERM occur adjacent to the cementum as a collection of cells and forming 
an epithelial network. The functional roles of the ERM are not completely 
understood and they may participate in periodontal repair and regeneration (Oka et 
al., 2012, Xiong et al., 2012). 
A further important cellular constituent of PDL is the undifferentiated 
mesenchymal cell - progenitor cells of the PDL. In wound healing, the PDL donates 
cells for its own repair and to repair missing bone and cementum. Recently, from the 
human PDL, cells with stem cell features have been recognised and isolated (Maeda 
et al., 2012). 
The major fibrils of the PDL are comprised of collagen-I, -III, and -XII. The 
single PDL fibrils have a comparatively smaller average width than tendon collagen 
fibrils, a difference assumed to reflect the short half-life of ligament collagen, and 
therefore less time for fibrillar assembly. Most of collagen fibrils in PDL are 
organised in definite and distinct fibre bundles which are called principal fibres. 
Every bundle resembles a joined cord; individual strands are continually remodelled 
whereas the whole fibre preserves its architecture and function. In this way, the fibre 
bundles have ability to adapt to the persistent stresses applied on them. The ends of 
collagen fibre bundles are implanted in cementum or bone. The implanted portion is 
named as Sharpey’s fibres (Beertsen et al., 1997). Fibre bundles of PDL are 
illustrated in Figure 1 and 2. 
There are also elastic fibres of the PDL. Three types of elastic fibres are 
present: elastic fibres, elaunin and oxytalan. Elastic fibres are comprised mainly of 
elsatin, elaunin – a deposition of elastin between oxytalan fibres, and oxytalan fibres 
– bundles of microfibrils composed of fibrillin-1 and fibrillin-2 crosslinked by 
transglutaminase. Oxytalan and elaunin fibres are associated with the gingival 
ligament (Newman et al., 2011). 
Oxytalan fibres run in vertical direction from the cementum surface, making 
a three-dimensional branching meshwork that surroundings the root and ends in the 
apical arteries, veins, and lymphatics. Even though their role has not been completely 
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determined, they are assumed to adjust vascular flow with regard to tooth function. It 
is found that oxytalan fibres are thickened under stretching (Tsuruga et al., 2009). 
Non-collagenous matrix proteins are also found in the PDL. Numerous non-
collagenous matrix proteins, formed locally by occupier cells or transported by the 
blood flow, are present. These contain alkaline phosphatase (Oortgiesen et al., 2012), 
proteoglycans and glycoproteins as undulin, tenascin, and fibronectin (LeBlanc and 
Reisz, 2013). There is also extrafibrillar matrix or ground substance. It is amorphous 
matrix and has a substantial effect on the capacity of the tooth to tolerate stress. 
Ground substance increases in tissue fluids in areas of inflammation and injury 
(Nanci and Bosshardt, 2006). 
 
 
Figure 2: Periodontal ligament fibres groups. 
This consists of two main groups: gingival fibre groups and the principal fibre 
groups. The principal fibre groups of the periodontal ligament are: oblique fibres - 
running from alveolar bone to tooth; apical fibres - radiating from the apex of the 
tooth to the adjacent alveolar bone; horizontal fibres - running from the cementum 
to the adjacent alveolar bone; and inter-radicular fibres - between the roots of 
multi-rooted teeth, running from the root to the adjacent alveolar bone. Modified 
from (Niemiec, 2012). 
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Periodontal ligament fibroblasts (PDLFs) - characteristics, physiological 
functions and interaction with the extracellular matrix 
Periodontal ligament fibroblasts originate from the ectomesenchyme of the 
dental papilla. Fibroblasts are the predominant cell type in the periodontium 
(Beertsen et al., 1997). Viewed under electronic microscope, PDLFs have many 
cytoplasmic organelles - Golgi complexes, rough endoplasmic reticulum, 
mitochondria and secretory vesicles (Miller, 2012). PDLFs are connected by 
numerous types of junctions including gap and adherence junctions. PDLFs differ 
from other connective tissues cells in many aspects (Beertsen et al., 1997). The 
heterogeneity of PDLFs is based on the diversity of synthetic products, rate of 
synthesis, response to regulatory molecules and cellular turnover rates (Miller, 2012). 
PDLFs are oriented parallel to collagen fibres in longitudinal section. However, they 
may display a stellate appearance in cross-section. This orientation of PDLFs is 
caused by the cytoplasmic processes of PDLFs separating individual bundles of 
collagen fibres (Beertsen et al., 1997) - Figure 3. 
 
 
Figure 3: The orientation of fibroblasts in the periodontium. 
A Longitudinal section shows parallel orientation of PDLFs to collagen fibres. B 
Cross-section shows the stellate appearance of PDLFs as the cytoplasmic processes 
separating bundles of collagen (Modified from (Beertsen et al., 1997). 
 
Cell migration is an important function that has been detected in the 
periodontal ligament. It was observed in many cases including constantly erupting 
teeth, normal teeth function and PDL wound healing. PDLFs are relatively rich in 
cytoplasmic microfilament systems that are crucial for contraction and movement. 
Cell signalling pathways controlling the direction of migration and contractile 
actions are unknown. Structural polarity could be responsible for the directed 
migration of fibroblasts as the nucleus is usually in the trailing part of the cell, and 
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the Golgi complex and centrioles region are in front of the nucleus towards the 
leading edge of the cell, as is seen in migratory neutrophils (Beertsen et al., 1997). 
PDLFs produce and maintain normal levels of ground substance. This forms 
the extracellular matrix by producing many components, including fibrous 
components such as collagen and elastin and non-fibrous components such as 
proteoglycans and glycoproteins (Miller, 2012). Characteristically, PDLFs have high 
alkaline phosphatase activity. Alkaline phosphatase is involved in phosphate 
metabolism, mineralization processes and acellular cementum creation. It is found 
along the PDLFs outer plasma membrane face. The extracellular collagenous fibre 
framework contains 10% of alkaline phosphatase. It is not known why the PDL does 
not undergo calcification in regular function in presence of the high expression of 
alkaline phosphatase activity. Periodontium regeneration is sustained by PDLFs 
proliferation after injury (Beertsen et al., 1997). 
 
1.1.1.3 Cementum  
Cementum is defined as the rigid, avascular connective tissue that covers the 
roots of teeth. It grabs the principal PDL fibres. The cementum composition is 
similar to composition of the bone. Cementum contains approximately 50% 
inorganic material, mostly hydroxyapatite, and 50% organic matter and water by 
weight. Two variants of cementum are recognised according to the source of the 
collagen fibres of the matrix and the presence or the absence of cells within 
cementum (Phillips, 2012). Acellular cementum is usually situated from the 
cementum-enamel junction (cervical region) to the root. It has a very slow 
developing rate. It is called acellular because it does not incorporate cells (Phillips, 
2012), whereas, cellular cementum is found along the apical third of the tips of the 
roots and in furcation areas, branching point of the tooth root, in multi-rooted teeth. 
Cellular cementum is involved in repair of resorptive defects and root fractures. The 
cells involved, cementoblasts, are collagen-producing; when entrapped in lacunae 
within the matrix there are called cementocytes. Cementocytes are the characteristic 
components of cellular cementum (Phillips, 2012). 
 
1.1.1.4 Alveolar bone 
The alveolar process, or projections, is the bone of the jaw that holds the 
sockets, or alveoli, of the teeth. The development of alveolar process occurs at the 
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same time with the teeth development and eruption. It consists of outer cortical plates 
of compact bone, a central spongiosa, and bone lining the alveolus, or alveolar bone - 
Figures 1 and 2. The alveolar bone referred as bundle bone since it allows attachment 
of the periodontal ligament fibre bundles (Newman et al., 2011).  
The alveolar bone is continuously remodelled as the tooth is constantly 
moving during mastication. Subsequently, alveolar bone must react to the functional 
demand positioned on it by the mastication forces. The process of remodelling of 
alveolar bone is similar to the remodelling of other types of bone. However, alveolar 
bone is unique because it turns over more rapidly than other bone processes. During 
the movement of the tooth, the force is distributed on the socket wall which result in 
bone resorption on one side of the tooth socket and balanced by formation of bone on 
the opposite side (Nanci and Bosshardt, 2006). In the case of tooth loss, the alveolar 
bone disappears (Trombelli et al., 2008). 
 
1.1.2 Periodontal diseases 
Periodontal disease is the inflammation and/or infection caused by dental 
plaque accumulation that destroys the tooth supporting tissues including gingiva, 
periodontal ligament, and tooth socket – the alveolar bone (Taylor and Borgnakke, 
2008). Dental plaque is a soft pale-yellow sticky biofilm that develops naturally on 
the tooth surfaces. Plaque is made of bacteria, mucus, and food debris that deposit on 
the visible parts of the teeth and it is one of the most common causes of tooth decays. 
If plaque is not removed regularly, it hardens to form dental calculus, or tartar which 
is trapped at the tooth cervix (Selwitz et al., 2007). As a result of plaque and calculus 
accumulation, an irritation and inflammation of periodontal tissues occur due to acids 
resulting from degradation of fermentable sugars by bacteria (Lakschevitz et al., 
2011). 
 
1.1.2.1 Gingivitis 
Gingivitis is defined simply as the inflammation of gingiva – Figure 4. It is a 
disease that affects the periodontium. Gingivitis is caused by continuous plaque 
accumulation on the surfaces of teeth. It shows the same clinical signs as any other 
soft tissue inflammation such as enlarged gingival outlines because of oedema or 
fibrosis, redness or bluish-redness, elevated temperature of sulcus, bleeding with 
probing and increased gingival exudate. However, these signs are not associated with 
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any periodontal attachment loss (Igic et al., 2012, Lang et al., 2009, Kasaj and 
Willershausen, 2013). Gingivitis is confined only to gingival tissue and it can be 
reversed once the cause is removed. If left untreated, gingivitis can progress to 
periodontitis (Igic et al., 2012). 
 
 
Figure 4: Periodontal dental diseases progression. 
A. It shows the progression of periodontal pocket depth through the stages of the 
diseases. B. It shows the gradual recession of gum tissues that caused by periodontal 
inflammation. C. It shows X-rays in the space between the teeth, the supporting 
tissue gradually disappears as the disease progress. Modified from (Baker, 2000). 
 
Classification of periodontal diseases is controversial issue. Many dental 
health experts suggest classification according to criteria such as etiologic factors, 
pathologic changes or clinical manifestations (van der Velden, 2005). One of the 
recommended classifications is based on the major causative factor of dental plaque. 
This classification categorizes gingivitis into two types: plaque-induced gingivitis, 
and plaque-induced gingivitis modified by particular systemic factors. These 
systemic factors include the following: hormonal imbalance – such as puberty, 
menstrual cycle and pregnancy; systemic drugs - anticonvulsants, immune-
suppressants and calcium channel blockers; systemic diseases – such as diabetes and 
leukaemia; and malnutrition (Highfield, 2009). 
 
 
41 
 
1.1.2.2 Periodontitis  
Periodontitis is one of the most common inflammatory diseases that affect the 
oral cavity. Periodontitis is a highly prevalent but largely hidden oral disease. It 
affects the quality of life negatively. In addition, it has been found that 15% of adults 
complain of sever periodontitis and about 40-60% have moderate periodontitis 
(O'Dowd et al., 2010). It is characterised by destroying the supporting structures of 
the tooth, or periodontium (Suvan et al., 2015, Preshaw et al., 2013) – Figure 4. In 
periodontitis, a destruction of periodontal ligament collagen fibres and alveolar bone 
resorption occurs along with a progressing attachment loss. Subsequently, a 
periodontal pocket is formed between the tooth and the gingiva. Periodontal pocket 
can be assessed by periodontal probe as it is difficult to be assessed visually 
(Borgnakke and Genco, 2015, Preshaw et al., 2013) – Figure 5. 
 
 
Figure 5: The periodontium in health and disease. 
A. In health, the alveolar bone crest comes within 1 mm of the height of the 
cemento-enamel junction of the tooth. Gingival fibres connect the gingival soft tissue 
to the cementum of the tooth root, and periodontal ligament fibres connect the 
alveolar bone and cementum. B. In periodontal disease, Gram-negative bacterial 
infection occurs subgingivally. Soft tissue damage produces attachment loss and loss 
of the periodontal ligament fibres, deepening the sulcus into a periodontal pocket. 
Bone resorption lowers the height of the alveolar bone crest is called horizontal bone 
loss, and bone resorption moves the bone surface away from the tooth root is called 
vertical bone loss. Modified from (Baker, 2000). 
 
 
42 
 
Classification of the severity of periodontitis relates to the severe loss of 
periodontal ligament fibres, the so called clinical attachment loss (Wiebe and 
Putnins, 2000). According to the American Academy of Periodontology, the severity 
of periodontitis is classified as follows: mild, or early periodontitis when the tissue 
loss is approximately 1–2 mm; moderate periodontitis when the tissue loss is 
approximately 3–4 mm; and severe, or advanced periodontitis when the tissue loss is 
more than 5 mm (Wiebe and Putnins, 2000). Classification also relates to: the extent 
of the disease, the severity of the disease per tooth, the age of the patient and the 
clinical characteristics (van der Velden, 2005). Periodontitis classification is also 
affected by the same systemic factors which affect the classification of gingivitis 
with adding the genetic disorders such as familial and cyclic neutropenia (Highfield, 
2009). Severe periodontitis is characterised by gingival erythema, gingival oedema, 
gingival bleeding, gingival recession, teeth mobility, drifting of teeth, discharge from 
periodontal pockets and teeth loss (Newman et al., 2011, (Smith et al., 2010). Tissue 
destruction in periodontitis is irreversible even if the progression of the disease is 
very slow (Borgnakke and Genco, 2015). Periodontitis is not painful and is often 
asymptomatic in its early stage. Thus, the condition progresses while the patient is 
unaware until the tooth mobility occurs. 
The migration of the junctional epithelium (JE) alongside the root surface is 
considered one of the major changes found in tooth root structure in periodontitis. 
This causes changes in periodontium such as creation of gingival pocket and long 
junctional epithelium – Figure 5. Many functional changes accompany this structural 
modification. For example, the direction of crevicular exudate flow and neutrophil 
migration across the epithelium changes significantly as the free surface of the 
epithelium is now displaced from the sulcus bottom to the root surface. In addition, 
the free surface increases in size and is consequently exposed to more bacterial 
plaque. (Nanci and Bosshardt, 2006). 
 
1.1.2.3 Pathology of periodontitis 
Periodontitis is associated with mainly anaerobic gram-negative oral infection 
which cause gingival inflammation, damage of periodontal tissues, loss of alveolar 
bone, and eventual exfoliation of teeth in advanced cases (Liljenberg et al., 1994). 
Multiple strains of bacteria are considered the main etiological mediators of 
periodontitis. Lipopolysaccharides (LPS) or endotoxins found in the outer membrane 
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of gram-negative bacteria elicit strong immune responses in human subjects. The 
LPS inflammatory response is a key mediator of periodontitis (Offenbacher, 1996). 
LPS will be discussed in details later in this project. 
 
History of the pathogenesis of periodontal disease 
In early fifties, the interest in understanding the nature, classification and 
severity of periodontal diseases was started (Russell, 1956). In the mid-1960s, the 
modern era of the pathogenesis, prevention, and treatment of periodontal diseases 
began with human and animal experimental evidence indicating the key role of 
bacteria in the beginning of gingivitis and periodontitis (Lindhe et al., 1973, Slots, 
1979). This led to the concept of pathogenesis mediated by bacterial infection as 
causative periodontal disease. This model involved bacterial plaque biofilm as the 
primary, direct cause in the development of periodontitis and led to the rejection of 
former concepts that involved non-bacterial factors, such as trauma from occlusion, 
systemic conditions, and diet. This theory of the key role of bacteria dramatically 
improved the prevention and treatment of periodontitis by targeting the bacteria with 
suitable antibodies. However, features included within the simple concept were for 
example, the hypothesis that bacterial plaque mass was the contributing factor and 
that bacterial products, such as collagenases, directly cause tissue destruction 
(Kornman, 2008). During the 1970s and early 1980s, research built on the simple 
concept of bacterial causation leading to great improvements in knowledge and 
understanding. Specific gram-negative, anaerobic or microaerophilic bacteria were 
implicated in the causation of periodontitis (Theilade, 1986), and the protective and 
destructive roles of the immune-inflammatory responses were defined in health and 
disease (Seymour, 1987). 
By the 1980s the role of polymorphonuclear neutrophils (PMNs) in 
periodontal destruction in humans became widely accepted (Genco et al., 1986). 
Additionally, there was improvement in understanding that some clinical disease 
patterns or phenotypes had distinguishing bacteria and host responses. The extensive 
research over the mid-1980s directed to critical modifications in the pathogenesis 
theory. 
In the late 1980s, the interaction of bacteria with host immune response with 
disease progression was investigated. Related connective tissue and bone damage 
was produced mainly by activated tissue mechanisms, such as those mediated by 
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matrix metalloproteinases, interleukin-1 and prostaglandins. The most important 
feature of the 1980s models is that a difference was now obvious between the role of 
the microbial challenge and immune-inflammatory mechanisms in the pathogenesis 
of periodontal disease. From 1985 - 1995 there was increased consideration that 
marked variations in host responses and clinical expression of disease occurred. In 
spite of a strong and reproducible correlation between plaque deposition and 
gingivitis development, the relationship was less clear on a patient-to-patient analysis 
and at different sites within the same patient. Epidemiological studies suggested 
exposure to plaque deposition for long periods caused periodontitis – with evidence 
gained from longitudinal studies in animal models and clinical investigations 
(Kornman, 2008). In a study in beagle dogs, plaque deposition was related with 
development of periodontitis; however, two of eight dogs did not develop 
periodontitis, regardless of substantial plaque and calculus deposition and extensive 
gingivitis (Lindhe et al., 1975). There was an unusual series of reports on 
longitudinal studies of tea plantation workers in Sri Lanka (Loe et al., 1978, Loe et 
al., 1986). Initially reports described failure to keep teeth clean regularly led to the 
development of extensive gingivitis and periodontitis of varying severity (Loe et al., 
1978, Löe et al., 1978). Further analysis showed there were three different population 
subsets in relation to bacterial deposition-induced periodontitis development: all 
groups had poor oral hygiene and gingivitis but subsets developed no/minimal, 
moderate or severe periodontitis (Loe et al., 1986). 
Further complexity to theoretical models of periodontitis was added when the 
effect of genetic polymorphism on the development and severity of periodontal 
disease emerged. Genetic effects were estimated to account for approximately 30% - 
60% of the variability in the clinical severity of periodontitis (Corey et al., 1993, 
Michalowicz et al., 1991b). Twin studies revealed that greater variability in the risk 
for periodontal disease was found in dizygotic twins compared to monozygotic 
twins, assuming a similar home environment within families (Michalowicz et al., 
1991a, Michalowicz et al., 2000). Genetic polymorphism is an important influence 
on individual risk of periodontal disease and its severity, and also relatedly host 
response to bacterial infection (Kornman et al., 1997). 
In 1997, a new revised model of periodontitis emerged which accounted for 
engagement with key risk factors (Page and Kornman, 1997). In this model, bacterial 
products activated the host immune-inflammatory mechanisms. The initiation of the 
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host response induces soluble and cellular components of the host immune response 
to counter the microbial challenge in the gingival sulcus: induced expression of 
antibodies and recruitment and activation of PMNs. Furthermore, cytokines and 
prostaglandins, along with matrix metalloproteinases stimulated through the host 
response, may cause damage to connective tissue and bone and assume the disease 
clinical presentation (Kornman, 2008). Whilst the 1997 model of periodontal disease 
remains relevant today, there have been improvements in understanding about 
periodontal disease and related revisions of the model of pathogenesis. 
One of the initial revisions came with recognition that microbial periodontal 
pathogens change in response to ecological alteration of the dental plaque. For 
example, change of diet to foods of different texture and low pH may lead to 
repopulation of dental plaques with bacteria with anaerobic and aciduric physiology 
(Socransky et al., 1998, Ximénez‐Fyvie et al., 2000). Following this, several studies 
showed certain diseases, such as diabetes, genotype, and smoking, contribute 
strongly to the individual patient variance in the susceptibility to periodontitis. For 
example, in a recent study of young adults aged 26 - 32 years, ca. 70% new cases of 
periodontitis were smokers (Thomson et al., 2007). Finally, studies have defined the 
relationship between periodontitis and other diseases, such as cardiovascular disease, 
and clarified such interactions through bacterial seeding of dental plaques, studies of 
common inflammatory mechanisms and/or common modifying factors (Beck et al., 
2000, Southerland et al., 2006). Recently, further advances were made in bacterial 
and immune-inflammatory mechanisms in periodontitis (Yamazaki et al., 2001, 
Popadiak et al., 2007). 
 
1.1.3 Risk factors for periodontitis  
1.1.3.1 Non-modifiable risk factors 
Genetic factors 
Although bacterial infection is the main etiologic mediator of periodontal 
disease, studies of identical twins found that 50% of the variability to periodontal 
disease is associated with host factors (Michalowicz et al., 2000). Indigenous and 
relatively isolated populations were also found to develop different characteristics of 
periodontal disease (Dowsett et al., 2001, Ronderos et al., 2001). 
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Host response 
It is thought that pathogenesis in periodontal disease is caused by a 
dysfunctional immune response to bacterial infection rather than the damaging 
effects of bacterial pathogens directly (Van Dyke and Serhan, 2003). In localized 
aggressive periodontitis, it has been proposed that activated neutrophils mediate most 
of the tissue destruction detected (Van Dyke and Serhan, 2003). IL-1 genes (IL-1A 
and IL-1B) polymorphisms are related to periodontitis with particular IL-1 genotypes 
associated with the presence of pathogenic microorganisms (Socransky et al., 2000) 
to an increased risk of periodontitis in non-smokers and smokers (Meisel et al., 2002, 
Meisel et al., 2003). There is a potential relationship between IL-1 genotype and 
periodontal health in diabetics (Guzman et al., 2003). Currently, there is no definitive 
IL-1 genotype that confers sensitivity of individuals to high risk for periodontal 
disease. Current evidence suggests interactions of IL-1 genotypes with smoking and 
diabetes increase risk of periodontal disease (Van Dyke and Dave, 2005). 
 
Aging  
In ageing the collagen synthesis and the number of connective tissue cells are 
decreased. In addition, decrease in the number of PDLFs and related functional 
activities such as mitosis and biosynthetic activities occur. There is also a decrease in 
the formation of organic matrix and vascularization (Farias Gomes et al., 2010). 
Severe gingivitis is commonly seen in older adults with larger numbers of 
inflammatory cells – characterised by increased B cells and decreased PMNs, 
suggesting that the immunological response quality can be affected by aging (Farias 
Gomes et al., 2010). Biochemical, immunological and physiological changes 
occurring with aging may contribute to periodontal tissue damage in elderly people. 
However, the extent of aging effect on periodontal tissues is not well known and the 
periodontal tissue damage may arise as a consequence of other influences such as 
environmental factors, systemic diseases, medications and social modifications 
(Farias Gomes et al., 2010, Guiglia et al., 2010, Van Dyke and Dave, 2005). 
According to Van Dyke and Dave (2005), aging is not a risk factor for periodontal 
disease and rather tissue deterioration found in periodontal tissues of elderly people 
is a combination of that due to ageing and periodontal disease (Van Dyke and Dave, 
2005). 
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1.1.3.2 Modifiable risk factors 
Renal disease 
Renal disease is an influential factor in periodontal disease. Some treatments 
for renal disease, such as calcium channel blockers and cyclosporine, are associated 
with increased risk of gingival enlargements. There is no clear evidence, however, 
that risk of periodontitis increases with renal failure (Proctor et al., 2005) although 
the prevalence of periodontitis in patients with renal disease was higher than in 
healthy subjects (Ioannidou and Swede, 2011, Ioannidou et al., 2011). There was 
increased serum C-reactive protein (CRP) in patients with periodontitis and renal 
disease, suggesting that periodontitis may contribute to the systemic inflammatory 
burden in renal disease cases (Ioannidou and Swede, 2011, Ioannidou et al., 2011, 
Chen et al., 2015) 
 
Smoking  
Smoking increases the risk of developing periodontitis and its severity 
(Pihlstrom et al., 2005). Smoking causes vasoconstriction of the blood vessels of 
periodontal tissues decreasing the blood flow (Zee, 2009). Recently, it was found that 
the immune response to pathogens in periodontal tissue is altered by tobacco use, 
especially tobacco smoking. Peripheral blood mononuclear phagocytes are increased 
but their function is compromised, diminishing activity against pathogens in the oral 
tissue and increasing risk of developing periodontal disease (Fokkema, 2012). 
 
Obesity and overweight  
There was a positive strong relationship between body mass index and 
diagnosis of periodontitis in an age-matched case–control study. This relationship 
was independent of gender, ethnicity, smoking status and dental plaque levels. 
Obesity was independently related to periodontitis when judged by a comprehensive, 
full-mouth clinical periodontal evaluation. Overweight and obese individuals have a 
greater risk of getting periodontitis in comparison with those who are within the 
category of BMI normal (Suvan et al., 2015). 
 
Diabetes  
The prevalence of periodontitis increases among patients with diabetes – type 
1 and type 2. Poorly controlled hyperglycaemia in patients with diabetes tends to 
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cause more severe form of periodontitis than in non-diabetic subjects (Chang and 
Lim, 2012). It is thought that the systemic changes caused by diabetes reduce the 
host resistance to periodontal tissue breakdown. This alteration in host response may 
not be reversed by glycaemic control (Pacios et al., 2012). Additionally, it has been 
found that the long duration of diabetes with complications like retinopathy and 
nephropathy are correlated with worsening of periodontal states (Borgnakke and 
Genco, 2015, Preshaw et al., 2013). 
 
1.2 Diabetes  
1.2.1 Types of diabetes 
1.2.1.1 Type 1 diabetes mellitus  
Type 1 diabetes (T1DM) is due to absolute insufficiency of insulin 
production with little or no insulin being secreted (Holt et al., 2011). T1DM accounts 
for ca. 5-10% of diabetes cases globally (Haller et al., 2005). Approximately 10% of 
adults and 14% of children in UK with diabetes mellitus have T1DM. The 
prevalence of T1DM in children is 1 per 700-1000 and they are diagnosed in 
adolescence. Approximately 85% of patients with T1DM have no previous first-
degree family history. However, the risk of getting the disease in cases of first degree 
relative increase to 15 times comparing with general population (IDF, 2015). The 
cause of T1DM autoimmune disease is still unidentified. The occurrence is mainly 
common in ages; 4-6 years and 10-14 years. The incidence rate reduces at time of 
puberty and is noticed to be stable between 15-29 years of age (Haller et al., 2005). 
Many large studies have been performed to characterise the incidence of 
T1DM - for example, in the period 1990-1999, the WHO multinational project for 
childhood diabetes (DIAMOND study) and a collaborative European study 
(EURODIAB ACE) (Eurodiab, 2000, Karvonen et al., 2000).They found a 
geographical variation in the incidence of T1DM with highest incidence in  
Scandinavian and Mediterranean populations compared to oriental and equatorial 
populations (Karvonen et al., 2000). Although there was high genetic homogeneity in 
Scandinavian countries, T1DM incidence rates varied from 45 per 100,000 in 
Finland to 28 in Sweden and 20 in Denmark (Ali, 2010). A role of vitamin D levels 
and ultraviolet (UV) exposure was suggested in explanation of the strong North-
South gradient in the incidence of T1DM and the fact that vitamin D is an immune 
regulator (Mohr et al., 2008). Some exceptions are Kuwait, Puerto Rico and Sardinia 
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- countries exposed to sun with high T1DM incidence, and Lithuania in the Northern 
latitude with low prevalence of T1DM. From these exceptions, it has suggested that 
vitamin D levels or sun exposure cannot be the only explanation of variation in the 
disease prevalence (Ali, 2010). 
The incidence of diabetes in some studies showed seasonality (Willis et al., 
2002, Levy-Marchal et al., 1995, Green and Patterson, 2001, Svensson et al., 2009). 
There are other studies where the seasonal influence was not found (Ye et al., 1998, 
Kida et al., 2000) which might have been masked by the genetic and environmental 
factors. Furthermore, no gender preference was noticed in T1DM (Gale and 
Gillespie, 2001). 
 
Genetic factors 
The etiology of T1DM is variable. In some individuals, the main cause can be 
various susceptibility genes such as human leukocyte antigen (HLA), insulin gene, 
protein tyrosine phosphatase non-receptor type 22 (PTPN22), interleukin 2 receptor 
alpha (IL2Ra), and cytotoxic t-lymphocyte antigen 4 (CTLA4) (Van Belle et al., 
2011). Several gene loci are discovered to be linked with the risk of autoimmune 
T1DM. The major histocompatibility complex (MHC) or human leukocyte antigen 
(HLA) on chromosome 6, mainly at DR3/4 and DQ regions, is the genomic region 
that has the strongest association with risk of T1DM. The DR-DQ haplotype can be 
either influencing to or protecting against T1DM. For instance, the HLA DR3/4-
DQ2/8 recognised as a high risk genotype for T1DM is found in more than 30% of 
children with T1DM but in only 2.3% of all new-borns in Colorado (Ali, 2010). The 
DR2 haplotype appears to be protective as it is found in 20% of the total population 
but only in 1% of the immune-mediated diabetes (Frohlich-Reiterer et al., 2008). 
Furthermore, other non-HLA gene loci have been suggested to be participated in 
T1DM risk: for example, the insulin gene IDDM2, the lymphoid tyrosine 
phosphatase gene PTPN22, the cytotoxic T lymphocyte associated-4 gene, the 
interleukin-2 receptor, the interferon-induced helicase (IFIH1) gene and the vitamin 
D 1 alpha hydroxylase gene CYP27B1 (Bennett and Todd, 1996, Bottini et al., 2004, 
Nistico et al., 1996, Lowe et al., 2007, Smyth et al., 2006, Bailey et al., 2007). 
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Environmental factors 
Other triggers for T1DM could be environmental such as Cow's milk or 
enteroviruses such as coxsackieviruses (Van Belle et al., 2011). There is an increase 
in prevalence of T1DM in most populations, the monozygotic twins’ discordance for 
the disease and the seasonality of T1DM occurrence all propose that environmental 
factors may have a role in the risk of T1DM. Several studies have indicated the role 
of viral infections in T1DM multiuse pathogenesis by direct demolition of β-cells or 
encouraging the release of islet antigens. In contrast, the hygiene hypothesis 
proposed a promising defending role of infectious agents against autoimmune 
mediated diabetes, even though this remedy lacks of enough clinical evidences. In 
addition, dietary factors have been involved in association with the risk of T1DM, for 
instance bovine protein, omega-3 fatty acids and several vitamins, environmental 
chemicals, and psychological stress, even if these theories are not convincing at 
meantime and needs additional investigation (Ali, 2010). 
 
Pathogenesis of type 1 diabetes mellitus  
T1DM is affected by autoimmune destruction of pancreatic beta-cells. 
Exogenous insulin administration is compulsory for survival. Pathogenesis is caused 
by cellular and humoral autoimmune response that generates destructive autoimmune 
antibodies. These are produced by macrophages and T lymphocytes and used against 
several antigens of beta-cells (Mallone and van Endert, 2008, Holt et al., 2011). 
Histologic appearance of insulitis with infiltration of the islets of Langerhans by 
immune cells containing T and B lymphocytes, monocytes/macrophages, and natural 
killer cells were detected in the pancreas of newly diagnosed T1DM patients (Gepts 
and Lecompte, 1981, Hanninen et al., 1992). Autoimmune antibodies cause beta-cell 
degradation: formation of autoimmune antibodies leads to beta-cell destruction. This 
causes inflammatory lesions in the pancreas with mononuclear cell infiltration of 
islets and decrease beta-cells mass, followed by diminished insulin production. 
Subsequently, many signs start to occur such as gradual reduction in the acute insulin 
response to circulatory glucose burden, impaired oral glucose tolerance and fasting 
hyperglycaemia (Holt et al., 2011, Eisenbarth, 1986). This is called ‘autoimmune’ 
T1DM. However, in some cases, insulin-dependent state without provable 
autoantibodies can be diagnosed. This is termed ‘idiopathic’ type 1 diabetes mellitus 
(Seino et al., 2010). It generally exists in African-Caribbean subjects and is 
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characterised by insulinopenia and/or ketoacidosis. The function of beta-cells may 
improve and normoglycaemia may be regained (Leu and Zonszein, 2010). The 
number and intensity of the autoantibodies in addition to genetic susceptibility and 
environmental triggers are influence the possibility of clinical T1DM development 
and progression (Ali, 2010). 
T1DM can be either asymptomatic or mildly symptomatic; the majority is 
diagnosed with severe hyperglycaemia and/or ketoacidosis as a result of the fast 
development of the disease from β-cell destruction. After diagnosis of some T1DM 
patients, they show a short period when insulin treatment is not required. This could 
be caused by a transient recovery of β-cell function when achieving normoglycaemia 
(Martin et al., 1992). When the disease is diagnosed, however, patients usually lose 
all residual β-cell function within 1-3 years of diagnosis which necessitates 
exogenous insulin administration for survival (Ali, 2010). 
The common clinical symptoms of type 1 diabetes noticed before diagnosis 
are: polyuria, polydipsia, abdominal pain and weight loss. Ketonuria and acidosis 
were identified in more than 75% and 40% of the cases respectively. In the younger 
age group, ketonuria and acidosis were significantly more frequent (Roche et al., 
2005). 
 
1.2.1.2 Type 2 diabetes mellitus  
Type 2 diabetes mellitus (T2DM) has become an epidemic disease in the last 
decade. 91% of people with diabetes have T2DM (IDF, 2015). T2DM is mostly 
diagnosed at an age over 40 years because of a long period of an asymptomatic 
hyperglycaemic condition (Stumvoll et al., 2005). Patients with T2DM are 
characterised by insulin resistance or relative insulin insufficiency, which commonly 
do not need insulin for survival at start of the disease but may need insulin later once 
dietary control and other medications failures. Ketoacidosis is not common in T2DM 
and is generally limited to illness-triggered stress as infections. The risk factors for 
the development of T2DM is heterogeneous such as age, obesity, lack of exercise 
and genetic predisposition, however, exact aetiology remains unclear (ADA, 2015). 
The “common” type 2 diabetes has a multifactorial pathogenesis triggered by 
modifications in several gene products (Stumvoll et al., 2005). 
 
 
52 
 
Environmental and genetic risk factors 
Insulin resistance is an early sign for T2DM. It is associated with obesity, 
sedentary lifestyle and unhealthy diet. Obesity itself is a major independent risk 
factor for T2DM. Central obesity which revealed by the waist-hip ratio is 
significantly related with insulin resistance and has been presented as predictor of 
T2DM in several studies (Narayan et al., 2007, Grundy, 2000, Groop, 1999). 
Although lifestyle and overeating are the main causes of T2DM, genetic 
components also contribute to its pathogenesis. Genome-wide association studies 
have recognised multiple susceptibility gene loci for T2DM. Risk for T2DM increase 
2.4 fold in cases of positive family history. Approximately 15–25% of the first-
degree relatives of patients with T2DM have impaired glucose tolerance or diabetes. 
For subjects with one parent with T2DM, the lifetime risk of developing T2DM also 
is 38%. If the two parents have T2DM, the risk of developing T2DM by the age of 
60 years is approximately 60% (Stumvoll et al., 2005). 
Genetic mutations associated with T2DM are in high-affinity beta-cell 
sulphonylurea receptor 1 (SUR-1), glucose transporter isoform-2 (GLUT-2), 
glycogen synthase (GYS1) (Stumvoll et al., 2005), calpain-10 (CAPN10), potassium 
inward-rectifier 6.2 (KCJN11), peroxisome proliferator-activated receptor γ (PPAR 
γ), insulin receptor substrate-1 (IRS1), and others (Stumvoll et al., 2005). 
 
Pathogenesis of type 2 diabetes mellitus 
T2DM is insidious where clinical symptoms develop more slowly that for 
T1DM. Approximately 30% of the T2DM population is undiagnosed. Many T2DM 
patients suffer from vascular complications at time of diagnosis as a result of tissue 
damages by significant hyperglycaemia for 5-10 years before diagnosis (Fonseca and 
John-Kalarickal, 2010). 
In T2DM there may be abnormalities of insulin action, insulin secretion or 
both. Epidemiological and clinical studies propose that T2DM is most commonly 
started with insulin resistance in the majority of population. Before the onset of 
T2DM, fasting glucose and glucose tolerance stay normal with increased response of 
fasting insulin and glucose-stimulated insulin. The latter resituates for insulin 
resistance. Impaired glucose tolerance (IGT) progresses and increased fasting and 
postprandial insulin levels try to recompense for insulin resistance (Thies et al., 1990, 
Cusi et al., 2000). Pancreatic β-cell function decreases steadily over time and 
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approaching increased hyperglycaemia diagnostic for diabetes. Contributing to this 
there is probably diminished metabolism and/or sensing of glucose, imperfect 
stimulatory molecules and amyloid deposition (Thies et al., 1990, Cusi et al., 2000). 
Mechanisms thought to contribute to this are: increased non-esterified fatty acids, 
inflammatory cytokines, adipokines, and mitochondrial dysfunction for insulin 
resistance, and glucotoxicity, lipotoxicity, and amyloid formation for beta-cell 
dysfunction. 
Mechanisms of insulin resistance have been investigated. The insulin receptor 
substrates IRS-1 and IRS-2 are essential mediators in insulin signalling. Impaired 
IRS-1 phosphorylation in response to insulin was discovered in muscle tissues and 
adipocytes of T2DM patients. Phosphoinositide-3(PI3)-kinase, which contributes to 
the insulin-stimulated translocation of a glucose transporter GLUT-4 and glycogen 
synthase activation, is stimulated by binding to tyrosine phosphorylated IRS-1 and 
IRS-2. The activity of PI3-kinase was decreased in muscle of T2DM patients, (Thies 
et al., 1990, Cusi et al., 2000). Additional proposed mechanisms of insulin resistance 
are through the glucose transport system. Insulin stimulates glucose transport by 
stimulating the trafficking of GLUT4 from intracellular location to plasma 
membrane in tissues as adipocytes, skeletal muscle and cardiac muscle. Although the 
expression of GLUT4 is normal, decreased translocation of GLUT4 to the plasma 
membrane was found in patients with T2DM – suggesting impaired cell signalling 
for GLUT4 translocation (Kelley et al., 1996, Kruszynska and Olefsky, 1996). 
Hyperglycaemia develops as a result of progressive loss of β-cell function. 
Usually this is accompanied by other metabolic abnormalities such as increased 
lipolysis and gluconeogenic precursors, lactate, pyruvate, alanine and glycerol. 
Increased lipolysis produces raised levels of fasting and postprandial plasma free 
fatty acid (FFA) and hepatic VLDL. Increased plasma FFA and hyperglycaemia are 
found when T2DM is established which further aggravate insulin resistance. 
Skeletal muscle, liver and adipose tissue are the most important insulin-
targeting tissues in the body. Defective insulin action and/or secretion on these 
tissues in T2DM drives metabolic disturbances such as decreased insulin-stimulated 
skeletal muscle glucose uptake, overproduction of hepatic glucose, and impaired 
suppression of plasma glucagon and adipocyte lipolysis, leading to fasting and 
postprandial hyperglycaemia (Fonseca and John-Kalarickal, 2010). 
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1.2.1.3 Other types of diabetes 
There are several rarer forms of diabetes. Maturity onset diabetes of the 
young (MODY) is characterised by a group of disorders associated with monogenetic 
mutations affecting β-cell function or glucose sensing. Six genetic loci on various 
chromosomes have been recognised (Fajans et al., 2001). The main features of 
MODY are early onset (commonly before 25 years), family history of diabetes, slight 
hyperglycaemia and less chronic complications.   
Genetic mutations of the insulin receptor lead to abnormal insulin action, 
causing hyperinsulinemia, hyperglycaemia and severe diabetes. Examples of this 
syndrome are: Leprechaunism and the Rabson-Mendenhall syndrome. These two 
syndromes have autosomal recessive inheritance (Longo et al., 2002). Injuries to 
pancreas such as pancreatitis, infection, trauma, pancreatectomy, and pancreatic 
cancer lead to diabetes if the damage to the pancreas is extensive. Extensive damage 
to β-cells and blocking of insulin secretion can caused by cystic fibrosis and 
hemochromatosis. Diabetes can be induced by drugs, hormones and toxins by 
interfering with insulin secretion or action. For example, Nicotinic acid and 
glucocorticoids disturb insulin action. Viral infections including coxsackievirus B, 
cytomegalovirus, adenovirus and mumps are assumed to prompt hyperglycaemia by 
damaging β-cells (Karjalainen et al., 1988, Pak et al., 1988). Additionally, some 
genetic syndromes including Down syndrome and Wolfram syndrome have been 
related with increased occurrence of diabetes. The etiology of the disturbance in 
glucose homeostasis in these diverse unrelated syndromes is still unclear (Triplitt et 
al., 2015). 
 
1.2.1.4 Gestational diabetes mellitus (GDM) 
Gestational diabetes mellitus is glucose intolerance immediately before or 
during pregnancy. Approximately 90% of all mothers with diabetes in pregnancy are 
of the GDM type (Engelgau et al., 1995). The incidence of GDM is approximately 8-
9% of all pregnancies. Even though most of GDM terminates with delivery, the 
disease could continue after pregnancy. Glucose intolerance may happen before the 
start or at the beginning of pregnancy (Triplitt et al., 2015). In GDM, insulin 
resistance is initiated by interfering of pregnancy hormones with unidentified 
aetiology. GDM increases the possibility of new-born death and stillbirth, and having 
diabetes in future life. There are many risk factors of GDM such as obesity, history 
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of diabetes in the family, treatment of infertility, repetitive urinary tract infections, 
large size of infant, unclear neonatal death, pre-eclampsia, former GDM, and 
advanced maternal age (Bener et al., 2011). 
 
1.2.1.5 Other diabetes complications 
Complications of diabetes mellitus are microvascular disease (nephropathy, 
neuropathy and retinopathy) and increased risk of cardiovascular disease (CVD) and 
cerebrovascular disease. Patients with T2DM have 2 – 4 times greater risk of CVD 
than non-diabetic subjects (Stumvoll et al., 2005). Microvascular complications of 
diabetes may lead to blindness in advanced diabetic retinopathy, end stage renal 
failure in diabetic nephropathy, and sensory loss and nerve dysfunction in arms and 
legs with associated tissue damage in diabetic neuropathy such as ulcerated veins, 
gangrene and amputations (Donnelly et al., 2000). 
 
1.3 Periodontitis in diabetes   
1.3.1 Association of diabetes with periodontitis 
Diabetes is a major risk factor for periodontitis (Salvi et al., 2008, Borgnakke 
and Genco, 2015). Risk of periodontitis is increased 3-fold in patients with diabetes 
compared with healthy subjects (Mealey and Ocampo, 2007). The glycaemic control 
status is vital in determining increased risk. For instance, in the US National Health 
and Nutrition Examination Survey (NHANES) III, patients with diabetes and HbA1c 
>9% had a higher incidence of severe periodontitis after correcting for age, ethnicity, 
education, sex and smoking (Tsai et al., 2002). The importance of diabetes as a risk 
factor for periodontitis emerged in the 1990s in a number of cross-sectional and 
longitudinal studies examining the Pima Indian population. The incidence of 
periodontitis were higher in Pima Indians who had T2DM compared with healthy 
subjects (Taylor et al., 1998, Nelson et al., 1990, Emrich et al., 1991, Borgnakke and 
Genco, 2015). T1DM also increases risk of periodontitis. Approximately 10% of 
children (<18 years) with T1DM had greater attachment loss and bone loss compared 
with healthy controls, regardless of similar plaque scores (Cianciola et al., 1982). In a 
study includes 350 diabetic children (6 – 18 years old) vs 350 non-diabetic controls, 
the proportion of periodontal sites with sign of periodontitis was greater in the 
children with diabetes (Lalla et al., 2007). 
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One of the parameters frequently used to measure periodontal health is the 
attachment loss. Patients with poorly controlled T1DM or T2DM have poor 
periodontal health with increased attachment loss, bleeding from gums and increased 
tooth pocket depth (Mealey, 2000, Arrieta-Blanco et al., 2002). Other diabetes-
associated factors influential contributing to tooth loss are: (1) duration of diabetes 
(Papapanou, 1996, Sandberg et al., 2000); and (2) presence of other complications 
(retinopathy, neuropathy, nephropathy and cardiovascular disease) (Borgnakke and 
Genco, 2015, Mealey and Ocampo, 2007, Chang and Lim, 2012). Some subjects 
with well-controlled diabetes still suffer from periodontal problems, indicating that 
diabetes-induced periodontal changes are not readily prevented with current 
treatments for glycemic control (Iacopino, 2001, Chang and Lim, 2012). 
 
1.3.2 Factors contributing to development of periodontitis in patients with 
diabetes 
1.3.2.1 Lipopolysaccharide (LPS), infection, pro-inflammatory mediators and 
polymorphnuclear neutrophils  
LPS is one of the components of the cell wall of gram-negative anaerobic 
bacteria. LPS is a complex glycolipid. It stimulates the expression of pro-
inflammatory cytokines, for instance interleukins IL-1β and IL-6, prostaglandin E2 
(PGE2) and TNF-α, in macrophages and PDL cells. Cytokines then disturb the 
function of PDL cells by stimulating the production of matrix metalloproteases 
(MMPs), such as MMP-1, in PDL cells. MMP-1 is a major proteolytic enzyme, 
which cleaves natural type I and type III collagens, proposing its forceful 
contribution to PDL structure destruction (Maeda et al., 2012, Hatipoglu et al., 
2015). In patients with diabetes with periodontitis, the elevation of many pro-
inflammatory mediators was detected. These pro-inflammatory mediators include IL-
1β, IL-6, prostaglandin E2 (PGE2), TNF-α, receptor activator of nuclear factor κB 
ligand (RANKL), matrix metalloproteinases (MMPs; particularly MMP-8, MMP-9 
and MMP-13), T cell regulatory cytokines (e.g. IL-12, IL-18) and the chemokines 
(Preshaw et al., 2013). The nature of the inflammatory response among individuals is 
heterogeneous and is influenced by genetic, epigenetic and environmental factors. 
However, the pattern and rate of disease progression is determined by sum total of 
the inflammatory response in the periodontal tissues (Preshaw et al., 2013). 
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Patients with diabetes are usually more susceptible to severe infections than 
the non-diabetic individuals. Also, the severity of infections increases in the 
existence of diabetes. There is impaired host defence cell function, especially 
polymorphnuclear leukocyte and vascular changes in diabetic subjects (Mealey, 
1999). Defects in polymorphonuclear neutrophil (PMN) activity such as impaired 
chemotaxis and phagocytosis are found in patients with diabetes. This is increased 
retention of PMNs in the periodontal tissue which increases the likelihood of tissue 
destruction by sustained release of MMPs and reactive oxygen species (ROS) 
(Mealey, 1999, Preshaw et al., 2013). 
Acute viral and bacterial infections, especially those which continue for more 
than one month, increase insulin resistance in non-diabetic subjects. Furthermore, 
people who have periodontitis show an elevated levels of circulating pro-
inflammatory cytokines which involve in increasing insulin resistance (Mealey and 
Oates, 2006, Lu et al., 2015, Mealey, 1999). Diabetic patients who have periodontitis 
had 6-fold higher risk of impaired glycaemic status compared to diabetic patients 
without periodontitis. Effective periodontal therapy such as scaling, root planning, 
localized gingivectomy and extraction of hopeless teeth adjunct with systemic 
tetracycline antibiotic therapy may improve glycaemic control and decreased HbA1c 
(Mealey and Oates, 2006). 
  
1.3.2.2 Collagen metabolism 
Collagen homeostasis, synthesis and maturation are significantly affected by 
glucose level in the body. In patients with diabetes, there is a decrease in the collagen 
production with an increase in collagenase activity in gingival tissues. Gingival 
cervical fluid (GCF) collagenase activity was increased in patients with diabetes. 
This increase was inhibited by tetracycline despite the fact that collagenase is 
originated from PMNs and its production is not influenced by bacteria (Mealey, 
1999). 
Oral and extra oral diabetes-induced collagen abnormalities, such as a large 
decrease in synthesis and solubility of collagen in gingiva, skin and bone, and 
increased hydroxyproline excretion in urine - an amino acid marker of collagen 
degradation – have been found in diabetes. This suggest that the diabetes increases 
the breakdown of newly formed collagen in various connective tissues through the 
body (Golub et al., 1983). Increased GCF collagenase activity and decreased gingival 
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fibroblast collagen synthesis in diabetic patients have been detected. It was found 
that PMNs is the major cellular source of the increased collagenase activity in the 
GCF of patients with T1DM. PDLFs may also contribute to increased collagenase. 
Fibroblasts and other cells such as chondroblasts secrete the neutrophil collagenase - 
MMP8 (Ryan et al., 2003). MMP8 expression is inhibited by tetracycline although 
the production is not mediated by responses to bacteria (Mealey, 1999). 
 
1.3.2.3 Wound healing 
Wound healing is a cellular response to injury and includes activation of 
keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. These cell 
types release many growth factors and cytokines which are needed to organize and 
maintain healing. More than 100 known physiologic factors participate in wound 
healing insufficiencies in patients with diabetes. These include: impairment of 
production of growth factors, response of angiogenic factors, function of 
macrophages, accumulation of collagen, function of epidermal barrier, quantity of 
granulation tissue, migration and proliferation of keratinocyte and fibroblast, number 
of epidermal nerves, bone healing, and imbalance between the ECM components 
accumulation and their remodeling by MMPs (Brem and Tomic-Canic, 2007).  
The normal acute wound healing is directed and preserved through multiple 
cell responsive factors, such as cytokines (including transforming growth factor beta 
(TGF-beta)), and chemokines (IL-10), released by keratinocytes, fibroblasts, 
endothelial cells, macrophages, and platelets. In wound-induced hypoxia, vascular 
endothelial growth factor (VEGF) released by macrophages, fibroblasts, and 
epithelial cells enhances the phosphorylation and activation of nitric oxide synthase 
(eNOS) in the bone marrow, causing an increase in nitric oxide (NO) levels, which 
prompts the mobilization of bone marrow endothelial progenitor cells (EPCs) to the 
circulation. The chemokine stromal cell–derived factor–1α (SDF-1α) direct these 
EPCs to the injury site, where they contribute in neovasculogenesis (Brem and 
Tomic-Canic, 2007). Gallagher et al. showed that in diabetic mice, eNOS 
phosphorylation in the bone marrow is compromised which directly restricts EPC 
mobilization from the bone marrow into the circulation. In addition, they found that 
SDF-1α expression is diminished in epithelial cells and myofibroblasts in the wound 
of diabetic, which inhibits EPC homing to wounds and thus confines wound healing. 
Furthermore, they show that hyperoxia in wound tissue with hyperbaric oxygen 
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therapy triggered increased NOS, increasing levels of NO and improved mobilization 
of EPC to the circulation. Though, administration of SDF-1α locally was essential to 
direct these cells to the wound site. This suggested that hyperbaric oxygen therapy 
with administration of SDF-1α provides an option of treatment to stimulate diabetic 
wound healing alone or in presence of current clinical protocols (Gallagher et al., 
2007). 
Impaired oral wound healing is a common problem in patients with diabetes. 
This is a result of the fibroblast dysfunction - the primary reparative cell in the 
periodontium (Willershausen‐Zönnchen et al., 1991). Additionally, the collagen 
which is formed by fibroblasts is vulnerable to rapid degradation by MMPs and the 
production of MMPs is increased in diabetes (Golub et al., 1998). Accordingly, 
periodontal wound healing reacts poorly to chronic microbial stimuli in diabetes, 
causing increased bone loss and attachment loss (Mealey, 2006). 
 
1.3.2.4 Oxidative Stress 
The definition of oxidative stress is an imbalance of formation of reactive 
oxygen species (ROS) and antioxidants in favour of the former leading to cell and 
tissue damage. Increased formation of ROS occurs in diabetes through mitochondrial 
dysfunction, activation of NADPH oxidases and uncoupling of NO synthases (Bullon 
et al., 2009, Wright et al., 2006). There is an increase in the evidences which suggest 
that there is a strong relation between hyperglycemia, oxidative stress and diabetic 
complications. Increase in blood glucose levels cause overproduction of ROS by the 
mitochondria electron transport chain. In addition, high reactivity of ROS cause 
modification of DNA and protein and peroxidation of lipid (Piconi et al., 2003). 
It was found that periodontitis is associated with oxidative stress and 
worsened by poor glycaemic status in patients with diabetes (Allen et al., 2011). 
ROS and oxidative stress are found up-regulated in the liver and adipose tissues of 
diabetic mice. In addition, ROS formation started before the elevation of TNF-α and 
FFA. Thus, reduction in antioxidant defence may lead to insulin resistance and 
insulin sensitivity improved by antioxidants (Bruce et al., 2003, Ceriello, 2000). 
Dysregulation of the oxidative balance by increased formation of ROS by PMN and 
metabolism in hyperglycaemia may contribute to periodontitis (Bullon et al., 2009). 
A recent study of chronic periodontitis found low-grade inflammation and systemic 
oxidative stress with decreased antioxidant capacity (Bullon et al., 2014). 
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1.3.3 Periodontitis and insulin resistance 
Recently, there is an emphasis directed to the effect of chronic subclinical 
inflammation of periodontitis and insulin resistance on initiating and developing type 
2 diabetes. As the oral infection is the main trigger of the inflammation, this leads to 
increase cytokine production. This causes insulin resistance lead to changes resulting 
in type 2 diabetes (Kim and Amar, 2006, Mealey and Oates, 2006, Preshaw et al., 
2013). 
 
1.3.4 Other oral manifestations of diabetes mellitus 
In addition to periodontal diseases, there are many other oral manifestations 
of diabetes mellitus such as the decrease of salivary secretions or xerostomia, the 
enlargement of parotid gland and the increase of glucose level in gingival cervical 
fluid (GCF). Xerostomia can cause the feeling of burning mouth and tongue and 
increase the susceptibility of developing infection by opportunistic microorganisms 
such as Candida albicans. The elevation of glucose level in GCF may lead to 
alteration in plaque microflora and enhance the development of periodontal diseases 
and dental decays. These manifestations are frequently related to uncontrolled 
diabetes (Mealey, 1999). 
 
1.3.5 Pathogenic mechanisms linking diabetes and periodontitis 
Periodontitis is a chronic inflammatory disease in which inflammation in the 
periodontal tissues is caused by the long-term existence of the subgingival biofilm 
(dental plaque). The inflammatory response is recognised by alteration in the 
secretion of host-derived mediators of inflammation and tissue breakdown. Most 
studies recognised inflammatory mediators include IL-1β, IL-6, prostaglandin E2 
(PGE2), TNF-α, receptor activator of nuclear factor κB ligand (RANKL), and the 
matrix metalloproteinases (MMPs; principally MMP-8, MMP-9 and MMP-13), as 
well as T cell regulatory cytokines (e.g. IL-12, IL-18) and the chemokines (Preshaw 
and Taylor, 2011). In periodontal pathogenesis, the complexity of cytokine networks 
is becoming progressively apparent, and it is obvious that there is significant 
heterogeneity in the inflammatory response nature between individuals. This 
heterogeneity is also influenced by genetic, epigenetic and environmental factors. 
The sum total of the inflammatory response in the periodontal tissues defines the 
form and rate of disease progress (Kinane et al., 2011). 
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Diabetes is characterised with hyperglycaemic state and this has several 
deleterious effects. It increases the formation of irreversible advance glycation end 
products (AGEs) and the expression of their signalling receptor RAGE. This relation, 
in turn, causes dysfunction of the immune cell, alteration of phenotype and function 
of other key cells in the periodontium, and imbalance of cytokine with increased 
generation of certain pro-inflammatory cytokines (Yan et al., 2009). Additionally, 
hyperglycaemia involved in increased levels of ROS and a state of oxidative stress, 
both directly and indirectly through the AGE/RAGE axis (will be discussed in details 
later in this project in section 1.4.5), stimulating quantitative and qualitative shifts in 
cytokine profiles (Bullon et al. 2009). Fourthermore, hyperglycaemia may modifies 
the RANKL/osteoprotegerin (OPG), again directly and indirectly via the 
AGE/RAGE axis, tipping the balance towards enhanced inflammation and 
destruction (Santos et al., 2010, Vieira Ribeiro et al., 2011). All the above, 
accompanied by the effects of ecological shifts in the subgingival biofilm and the 
circulating adipokines produced because of diabetes-associated adiposity and 
dyslipidaemia, direct this vicious cycle of cellular malfunction and inflammation - 
Figure 6. This cause loss of equilibrium where increased periodontal tissue 
destruction and impaired repair process, leading to accelerated and severe 
periodontitis (Taylor et al., 2015). 
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Figure 6: Explanation of potential mechanisms participated in the pathogenesis 
of periodontitis in diabetes. 
Essentially, several connotations between different components in the figure are 
bidirectional, for instance, the pro-inflammatory state promote the generation of 
AGEs, ROS, and adipokines, elevated the RANKL/OPG ratio and helps pathogenic 
subgingival bacteria thrive. It is also essential to note the following; a) the quantity 
and quality of evidence supporting the various pathways varies, and b) even though 
the aim is to describe the major mechanisms and networks in the literature, other 
pathways and links between the various elements shown do exist, but cannot simply 
be illustrated in a single schematic. Finally, the processes outlined are possibly 
changed by several other factors, such as genetics, age, smoking, stress, all of which 
may contribute significantly to inter-individual variations in disease experience. 
Adopted from (Taylor et al., 2015). 
 
1.3.6 Inflammation 
Both T1DM and T2DM are associated with increased levels of systemic 
markers of inflammation (Dandona, 2004). Microvascular and macrovascular 
complications are partly driven by low-grade inflammation. Hyperglycaemia 
activates multiple pathways that increase inflammation, oxidative stress and 
apoptosis (Brownlee, 2005). In diabetes and obesity, there is elevation in serum 
levels of IL-6 and TNF-α. Future occurrence of T2DM is predicted by serum levels 
of IL-6 and C-reactive protein (CRP). There is an association with elevation of CRP 
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level and insulin resistance, T2DM and CVD. The main inducers of acute-phase 
proteins and CRP are TNF-α and IL-6. These both impair insulin signalling which 
potentially contributing to insulin resistance (Preshaw et al., 2013). In patients with 
periodontitis, serum levels of IL-6 and CRP are also elevated, with IL-6 levels 
associating with the degree of disease (Paraskevas et al., 2008). Periodontal disease 
may be exacerbated by the systemic low-grade inflammation of the diabetic state. In 
addition, adipokines and the proinflammatory properties of leptin may contribute to 
periodontal inflammation in obese subjects and patients with T2DM (Preshaw et al., 
2007). Diabetes causes increased inflammation in periodontal tissues. For example, 
GCF, a fluid exudate that flows from the gingival margins, contains increased PGE2 
and IL-1β in patients with T1DM with gingivitis or periodontitis compared with non-
diabetic subjects with periodontal disease (Salvi et al., 1997). Patients with T2DM 
and poor glycaemic control, HbA1c >8%, had higher IL-1β in GCF compared with 
patients with T2DM and HbA1c <8%. Both HbA1c and plasma glucose concentration 
were independently linked to increased IL-1β level in GCF (Engebretson et al., 
2004). 
When exposed to LPS, greater levels of TNF-α, IL-1β and PGE2 were 
produced from monocytes of patients with T1DM compared with monocytes from 
non-diabetic subjects. There is increased TNF-α in T2DM and extends the 
inflammatory reaction to Porphyromonas gingivalis (a periodontal pathogen 
normally found in the biofilm of patients with advanced periodontitis) (Naguib et al., 
2004). Treatment of periodontal diseases showed a significant decrease in serum 
levels of inflammatory mediators, such as IL-6, TNF-α, CRP and MMPs, in patients 
with and without diabetes (O'Connell et al., 2008). 
 
1.3.7 Biochemical mechanisms of periodontitis 
1.3.7.1 Inflamatory signaling 
Multiple pro-inflammatory cytokines are involved in the periodontitis 
immunopathology. Some of the most important cell signalling molecules involved in 
periodontium destruction are triggered by responses to TNF-α and IL-1β. These 
cytokines are increased in diseased periodontal sites throughout periods of active 
disease and tissue destruction. Furthermore, they are considerably decreased after 
periodontal treatment and return to the healthy tissues state (Iacopino, 2001). 
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IL-1β facilitates many processes, including recruitment of inflammatory cells, 
degranulation of PMNs, synthesis of inflammatory mediators PGE and MMPs, 
inhibition of collagen synthesis, and activation of both T and B lymphocytes. TNF-α 
is a major inducer of cell apoptosis, resorption of bone, secretion of MMPs, 
expression of intercellular adhesion molecule (ICAM), and production of IL-6. Once 
IL-6 produced, it promotes osteoclasts formation, osteoclastic bone resorption, and 
T-cell differentiation (Iacopino, 2001). 
Increased serum proinflammatory cytokine levels occur in periodontitis. It 
has been hypothesized that periodontitis-induced proinflammatory cytokines 
elevations such as IL-1β and TNF-α. This elevation in cytokines can show a 
significant role in progress of many systemic diseases. Therefore, advanced 
periodontitis patients may be considered as systemically compromised even in the 
absence of obvious clinical symptoms of disease (Iacopino, 2001). 
Destruction of the periodontal tissue detected in periodontitis is host-
mediated by releasing pro-inflammatory cytokines. The pro-inflammatory cytokines 
are released by local tissues and immune cells as a response to the bacterial 
fragments, immunogenic factors and metabolites, specifically LPS. Key cell 
signalling by LPS is mediated by binding of CD14 and the Toll-like receptor-4 
(TLR4) (Cohen, 2002) – Figure 7 .  
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Figure 7: Cell-surface recognition of lipopolysaccharide (LPS).  
From (Cohen, 2002). LPS is sensed via an LPS-binding protein (LBP)–LPS complex 
and then signalling through the Toll-like receptor 4 (TLR4)–MD-2 complex. Other 
cell surface molecules also sense LPS: macrophage scavenger receptor (MSR), 
CD11b/CD18 and ion channels. Intracellularly, TLR domain, TIR (Toll/IL-1 
receptor homology domain), binds to IRAK (IL-1 receptor-associated kinase) 
facilitated by two adapter proteins, MyD88 (myeloid differentiation protein 88) and 
TIRAP (TIR domain containing adapter protein; also called MyD88-adapter-like 
protein or Mal), and inhibited by a third protein Tollip (Toll-interacting protein) 
(Cohen, 2002). 
 
The mechanisms mediating inflammation driven periodontal ligament cell 
cytokine and chemokine expression are as follows. LPS binds to its receptor, TLR4, 
and this complex controls gene transcription of cytokine and chemokine genes 
through adaptor proteins and transcription factors (Dauphinee and Karsan, 2005, 
Covert, 2005). TLR4 signalling includes myeloid differentiation protein 88 (MyD88) 
-dependent and -independent pathways causing stimulation of nuclear factor-kappa-
B (NF-kB). The MyD88-independent signalling includes stimulation of the adaptor 
molecule TRAM, which procedures a complex with TRIF. Then, this complex binds 
the adaptor protein tumor necrosis factor receptor associated factor-6 (TRAF6), 
causing stimulation of NF-kB. Both the MyD88-dependent and -independent 
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activation of NF-kB prompts inflammatory genes expression. Therefore, NF-kB is a 
promising drug target for anti-inflammatory treatment. In a murine periodontal 
ligament cell line, Patil et al have displayed that Actinobacillus 
actinomycetemcomitans- and Escherichia coli-derived LPS induced IL-6 expression 
is dependent on multiple MAPK pathways, invloving ERK and c-jun N-terminal 
kinase (JNK), representing that many intracellular signalling pathways control 
periodontal ligament cell cytokine gene activity (Patil et al., 2006, Jönsson et al., 
2011). 
 
1.4 Glycation 
1.4.1 Definition of glycation 
Glycation is the non-enzymatic reaction of sugars or related derivatives with 
proteins, nucleic acid and basic phospholipids. In this project, I focus on glycation of 
proteins in physiological systems. Protein glycation occurs by a sequence of 
successive and parallel reactions known as the Maillard reaction (Rabbani and 
Thornalley, 2012b). Early stage glycation adducts are those formed by reaction of 
glucose and other monosaccharides with N-terminal and lysine residue side-chain 
amino groups to form initially a Schiff’s base intermediate which then undergoes a 
slow rearrangement, Amadori rearrangement, to from a ketoamine or Amadori 
product. For glycation of proteins by glucose, the Amadori products are Nα(1-
deoxyfructos-yl)amino acid  and Nε(1-deoxyfructos-yl)lysine residues; these are 
often called trivially fructosyl-amino acid or fructosyl-lysine residues. These adducts 
may undergo reverse reaction, enzymatic repair initiated and catalysed by 
fructosamine 3-phosphokinase or slowly degrade to form stable end-stage products  
called advanced glycation endproducts (AGEs) (Rabbani and Thornalley, 2008a) 
(Rabbani and Thornalley, 2012a). α-Oxoaldehydes or dicarbonyls present in 
physiological systems such as methylglyoxal (MG), glyoxal and 3-deoxyglucosone 
(3-DG) react with proteins directly to form AGEs (Rabbani and Thornalley, 2008a) 
(Rabbani and Thornalley, 2012b). They react predominantly with arginine side-chain 
guanidino groups to form hydroimidazolone adducts. 
Protein glycation leads to structural distortion, change in ionisation status and 
functional change or inactivation of proteins and thereby mediates cell and tissue 
dysfunction. The steady-state level of protein glycation is usually ≤ 5% of protein 
substrate and thereby may impact little on protein function. When the modified 
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protein has a different pathogenic function - for example increased binding of MG-
modified low-density lipoprotein (LDL) to arterial walls or markedly decreased 
affinity of MG-modified collagen IV for surface integrin proteins of endothelial cells 
– then it is particularly insidious. Also, when glycation accelerates the degradation of 
proteins, it effectively decreases the half-life of the protein substrate and if there is no 
compensatory increase in protein synthesis then the steady-state concentration of the 
unglycated will decrease. By such mechanisms, glycation affects the concentrations 
of also unglycated proteins. Therefore, it is possibly that protein glycation may 
produce cell and tissue dysfunction, impairing normal physiological function and 
contributing to disease. For this reason, glycation is termed a type of protein damage 
(Thornalley and Rabbani, 2011b, Rabbani and Thornalley, 2015).  
 
1.4.2 Historical background of glycation 
In 1908, Arthur Robert Ling developed a process involving thermal drying of 
proteins with sugars, which produced a coloured and flavoured mixtures. He termed 
referred to the formation of browning pigments after heating the glucose with 
asparagine (Ling, 1908). These were the first documented adducts formed between 
amino acids and glucose. Louise Camille Maillard (1912) – considered the founder 
of glycation research - studied the reaction between glucose and glycine on heating. 
He suggested that brown pigments produced, melanoidins, were formed by an initial 
reaction between amines and saccharides that produced Schiff’s base adducts. The 
name given to this reaction and related parallel and sequential reaction is the 
“Maillard reaction”. 
In 1913, the glyoxalase system was discovered. It is an important system 
catalysing MG to D-lactate in physiological systems (Dakin and Dudley, 1913, 
Neuberg, 1913). 
Between 1925 and 1931, Mario Amadori discovered that the condensation of 
D-glucose with aromatic amines p-phentidine, p-anisidine or p-toluidine form two 
different structure of isomers which were not anomers (Amadori, 1929a). He found 
one of the isomers is more liable to hydrolysis and vulnerable to decomposition on 
standing in the solid state in air. He identified this as N-glycosylamine. Conversely, 
he incorrectly assumed that the Schiff’s base was the more stable isomer, 
overlooking its resistance to hydrolysis by acid (Amadori, 1929b). Then, Kuhn and 
Dansi (1936) stated that the stable isomer was the product of a molecular 
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rearrangement instead of a Schiff’s base. They also confirmed Amadori finding 
about the labile isomer, the N-substituted glycosylamine (Kuhn R and Dansi A, 
1936). In 1937 Kuhn and Wegand found the structure of the stable isomer. It is the 
unbranched N-substituted 1-amino-1-deoxy-2-ketose (Kuhn R, 1937). Later, the 
reaction was called the Amadori rearrangement, involving the reaction of aldoses 
with amines. In 1953, Hodge suggested that formation of a Schiff’s base followed by 
Amadori rearrangement is involved in the initial stages of the Maillard reaction. In 
addition, He suggested enolisation, oxidation and fragmentation reactions are 
contributed in fructosamine degradation to glucosone and other adducts (Hodge, 
1953). 
In 1958, Allan et al. described the first observation of glycation of a protein 
in vivo. They found a glycated variant of haemoglobin, HbA1c, identifying it as a 
negatively charged component of human blood cell haemoglobin (Allen et al., 1958). 
Bookchin and Gallop (1968) studied glycated haemoglobin and described its 
elevation in diabetes (Bookchin and Gallop, 1968). Bunn et al (1975) described 
reactions which explain the creation of glycated haemoglobin (Bunn et al., 1975). In 
1976, Anthony Cerami and his colleagues suggested the use of glycated haemoglobin 
HbA1c as an indicator for the glycaemic control in patients with diabetes (Peterson et 
al., 1977). The value of HbA1c is now a common clinical diagnostic marker of 
glycaemic control in diabetic patients (ADA, 2015). 
Anet in 1960 described the degradation of a fructosamine (N,N-
difructosylglycine) to 3-deoxyglucosone (Anet, 1960). Kato successfully isolated 
3DG and 3-deoxypentosone from the browning reactions of amine with glucose and 
ribose (Kato, 1960, Kato et al., 1988). In biological systems, the reactive α-
oxoaldehydes are essential precursors of formation of glycation adducts (Nass et al., 
2014).  
Bonsignore in 1973 reported the first indication of formation of MG by non-
enzymatic degradation of triosephosphates to MG under physiological conditions and 
the degradation of glyceraldehyde-3-phosphate to MG (Bonsignore et al., 1973). In 
1977, Takahashi described the reaction between amino-acids and glyoxal derivatives 
containing glyoxal and MG. Then, arginine was identified as the main amino acid 
altered and hydroimidazolone was one molecular structure suggested for adducts. 
However, no analytical data was presented to prove the suggestion (Takahashi, 
1977). Later, the formation of hydroimidazolone adducts was confirmed. Then, 
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hydroimidazolones in the physiological systems and some foods found to be a 
principal AGE (Thornalley et al., 2003b, Henle et al., 1994). The formation of α-
oxoaldehydes by fragmentation of saccharide moiety early in the Maillard reaction, 
this evidence was provided by Hayashi and Namiki (1980). This is called the Namiki 
pathway of the Maillard reaction, involving the formation of glyoxal and MG by 
saccharide fragmentation (Hayashi and Namki, 1980, Rabbani et al., 2010). 
Dicarbonyls are also formed by monosaccharide auto-oxidation as the slow oxidative 
degradation of monosaccharides under physiological conditions to form the 
respective α-oxoaldehydes and hydrogen peroxide (Wolff et al., 1984). 
Nakayama et al (1980) defined the formation of 6-(2-formyl-5-
hydroxymethylpyrrol-1-yl)-L-norleucine from 3-DG and lysyl residues in proteins 
known as AGE – pyrraline (Nakayama et al., 1980). 
A product formed by degradation of Amadori product, 2-(2-furoyl)-4(5)-(2-
furanyl)-1H-imidazole (FFI), was reported in 1984, (Pongor et al., 1984). This was 
later found to be an artefact – formed in pre-analytic processing (Obayashi et al., 
1996). 
The phrase “advanced glycation endproducts” (AGEs) was first used in 1986 
by Cerami to refer them as “brown fluorescent pigments which cross link proteins” 
(Cerami, 1986). Brownlee and his colleagues found elevated collagen cross-linking 
in the arterial walls of diabetic rats and related fluorescence features of AGE 
compounds. The nucleophilic hydrazine derivative, aminoguanidine – later given the 
trademark name (PimagedineTM ) - was studied as a prototype AGE inhibitor and 
diabetes-induced protein cross-linking (Brownlee et al., 1986). 
Baynes and co-workers described the formation of Nε(carboxymethyl)lysine 
(CML) and erythronic acid from degradation of proteins glycated by glucose and 
later the presence of both compounds in human urinary metabolite was reported 
(Ahmed et al., 1986). CML is also formed by the reaction of lysine residues with 
ascorbate and glyoxal formed in lipid peroxidation (Thorpe and Baynes, 2002). 
Thornalley (1988) presented evidence of link between hyperglycaemia in 
diabetes, elevated flux of formation and concentration of MG and its potential 
involvement as main pathway causing the appearance of diabetic vascular 
complications (Thornalley, 1988) and reported 3 – 5 fold increase in MG 
concentration in blood samples of patients with T1DM and T2DM (McLellan et al., 
1994a). In 2001 Brownlee included glycation by MG one of the major metabolic 
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pathways involved in the appearance of diabetic vascular complications (Brownlee, 
2001). Between 1994 and 1998, clinical trials (ACTION I and ACTION II) for the 
avoidance of obvious nephropathy were conducted using the AGE inhibitor 
PimagedineTM. However, due to safety reasons and obvious absence of efficacy these 
trials were later terminated (Thornalley, 2003c).  
In 1989, Sell and Monnier discovered an acid stable fluorescent compound 
formed by the glycation of collagen and called it pentosidine (Sell and Monnier, 
1989). Pentosidine is a crosslink formed by a pentose moiety with lysine and 
arginine residues (Sell and Monnier, 1989). 
Horiuchi and Kurokawa (1991) discovered the enzymatic metabolism of 
fructosamine adduct. It was reported that the fructosyl-amino acid oxidase catalysed 
the transformation of fructosyl-amino acids to free amino acid, glucosone and 
hydrogen peroxide (Horiuchi and Kurokawa, 1991). Later, Delpierre et al. (2000) 
discovered an enzyme that catalysed the phosphorylation of fructosamine and 
fructosamine residues forming fructosamine-3-phosphate (F3P). This enzyme called 
fructosamine 3-kinase. F3P fragments spontaneously resulting in de-glycation and 
repair of early glycated proteins.  
Schmidt et al (1992) identified a cell surface protein that bound proteins 
highly modified by AGEs prepared in vitro. This was called an AGE receptor and 
was initially found in bovine lung endothelial cells and had a sequence molecular 
mass of 42 kDa (Schmidt et al., 1992). This is the best recognised AGE receptor 
called the receptor for advanced glycosylation end products (RAGE). 
In 1996, Cerami et al. proposed the concept of AGE breakers, which were 
defined as compounds that may cleave glycation-derived crosslinks and reverse one 
of the damaging of glycation associated with ageing and disease. N-
phenacylthiazolium bromide (PTB) was the prototype compound (Vasan et al., 
1996). This and associated analogues had stability problems and the claimed 
complete breaking of crosslinks was rather slowing of the putative AGE breaker 
reaction by spontaneous degradation of PTB and acidification of incubations and cell 
cultures (Thornalley and Minhas, 1999, Price et al., 2001). 
Shipanova and his colleagues (1997) identified argpyrimidine - a 
fluorescence AGE formed from MG (Shipanova et al., 1997). Vlassara and co-
workers (1997) suggested the term “glycotoxins” to refer to highly reactive AGE 
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intermediates and created a series of current studies, assessing the physiological 
effects on AGEs in diet on health (Koschinsky et al., 1997). 
Since 2000, there is a marked advances in glycation – particularly in relation 
to improved quantitation of  glycation adducts and free adducts by stable isotopic 
dilution analysis LC-MS/MS (Thornalley et al., 2003b, Thornalley et al., 2010). 
Application of high resolution mass spectrometry proteomics was identified proteins 
susceptible to glycation by glucose and by MG (Rabbani and Thornalley, 2014a, 
Zhang et al., 2007, Schmidt et al., 2015). Pre-clinical models with genetically 
controlled increased exposure to glycation – F3K knockout mice and glyoxalase 1 
(Glo1)-deficient mice (da-Cunha et al., 2006, El-Osta et al., 2008), and decreased 
glycation exposure – Glo1 transgenic mice (Inagi et al., 2002), have been developed 
and employed in studies of glycation in health and disease. The concept of 
“dicarbonyl stress” has emerged defined as the abnormal accumulation of dicarbonyl 
metabolites leading to increased protein and DNA modification contributing to cell 
and tissue dysfunction in ageing and disease. This explains the involvement of 
dicarbonyl glycation in health decline in ageing and in disease – particularly diabetes 
and its vascular complications, CVD, renal failure, schizophrenia, Parkinson’s 
disease, carcinogenesis and mechanisms of action of anticancer drugs and Glo1 
overexpression in multi-drug resistance – reviewed in (Rabbani and Thornalley, 
2015) 
The concept of AGE receptors has been well-investigated and role in health 
and disease has been best developed for RAGE. Even its involvement in responses to 
glycated porteins has been questioned and non-glycation ligands considered to be 
major phsyiological agonists. The link of RAGE to glycation was further 
complicated by suggestion that activaion of RAGE is linked to downregulation of 
Glo1, increasing sensitivity to dicarbonyl stress (Thornalley, 2007).  
Roles for glycation in ageing, obesity and chronic disease have been 
advanced – particularly for diabetic complications (Ahmed et al., 2005a), renal 
failure (Agalou, 2005, Miyata et al., 2001), cardiovascular diseases, Alzheimer’s, 
uremia, g (Ahmed et al., 2004, Chen et al., 2004, Rabbani et al., 2010), arthritis and 
cirrhosis (Ahmed et al., 2004), schizophrenia (Arai et al., 2010, Hambsch et al., 
2010) Parkinson’s disease (Kurz et al., 2010), carcinogenesis (Zender et al., 2008) 
and multidrug resistance (Santarius et al., 2010, Thornalley et al., 2010). 
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Treatments emerging from glycation research are dicarbonyl scavengers and 
Glo1 inducers. Treatments under current investigation are pyridoxamine as a 
dicarbonyl scavenger and small molecule Glo1 inducers (Lewis et al., 2012, Rabbani 
et al., 2014b) such as sulforaphane (Xue et al., 2012a) trans- resveratrol and 
hesperetin (Xue et al., 2016). 
  
1.4.3 Molecular structures of advanced glycation end-products 
AGEs are a heterogeneous collection of complex compounds (Thornalley et 
al., 2003b, Rabbani and Thornalley, 2008b). Examples are shown in Figure 8.  
 
 
Figure 8: Protein glycation, oxidation and nitration adduct residues in 
physiological systems. 
(a) Early glycation adducts - FL and Nα-(1-deoxy-D-fructos-1yl) amino acid 
residues. Advanced glycation endproducts: (b). Hydroimidazolones, (c). Monolysyl 
(d). Fluorophores, AGEs, (e). Non-fluorescent crosslinks, (f). Oxidation marker and 
(g). Nitration marker. From (Thornalley and Rabbani, 2014). 
 
1.4.4 Biochemical and physiological effects of protein glycation 
Glycation of proteins in physiological systems is generally minimal; that is, 
typically 0.5 – 10% proteins have one glycation adduct residue. Formation of FL 
residues increases steric demand on the immediate environment of the glycation site 
but does not change side positive charge (Röper et al., 1983). Formation of CML and 
CEL residues has a moderate increase in steric demand on the immediate 
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environment of the glycation and also adds a negative charge whilst preserving side 
chain positive charge. Hydroimidazolone formation increases steric demand and 
causes loss of positive charge. Arginine-derived hydroimidazolone formation is 
damaging because arginine residues have the highest probability of all amino acid 
residues types to be located at a functional site in a protein and loss of positive 
charge produces loss of functional interaction (Rabbani and Thornalley, 2012c). 
Functionally important arginine residues are also typically those reactive towards 
glycation as they are located at surface domains with polarisable electronic charge 
(Rabbani and Thornalley, 2012c). 
Susceptible sites for lysine and arginine glycation are thought to be those 
with activating positive and negatively charge amino acid residues close, 3 – 4 
residues distant, in the primary sequence but this has to be confirmed experimentally 
(Rabbani and Thornalley, 2012c). Protein glycation therefore usually causes minor 
loss of function of proteins. The physiological consequence of this is particularly 
important where this change in function of a minor fraction of total protein has a 
major physiological effect. Examples are: 
 (i) AGE modification of the integrin binding sites of vascular type IV 
collagen leading to endothelial cell detachment, exposure of the subendothelium and 
increased risk of thrombus formation (Dobler et al., 2006, Yamagishi et al., 2005). 
(ii) AGE damage of mitochondrial proteins leading to increased ROS leakage 
from the mitochondria and increased oxidative stress (Morcos et al., 2008). 
(iii) modification of the neural voltage gate sodium channels by 
methylglyoxal causing hyperalgesia in diabetic neuropathy (Bierhaus et al., 2012). 
 (iv) glycation of plasminogen in diabetes leading to reduction in plasmin 
generation and function (Ajjan, et. al, 2013), and 
(v) methylglyoxal modification of LDL producing atherogenic small dense 
LDL (Rabbani et al., 2011). 
(vii) methylglyoxal modification of HDL producing decrease concentration in 
plasma and loss of function of HDL (Godfrey et al., 2014). 
A further effect of protein glycation is formation of non-sulfhydryl crosslinks. 
AGE-mediated cross-linking of proteins leads to decreased protein solubility and 
susceptibility to enzymatic digestion (Schnider and Kohn, 1981) which is particularly 
important when affected proteins such as connective tissues and extracellular matrix 
sustain such damage that leads to changes in their mechanical and structural 
74 
 
properties - increased rigidity and thickening of the capillary basement membrane. 
These changes are associated with ageing (Lee, 1993, Cardenas-Leon et al., 2008). 
Glycation inhibits the formation of soluble collagen fibrils in vitro and it does so 
without denaturing the collagen molecules. This was found to be accompanied by a 
decrease in lysyl oxidase-catalysed crosslink formation (Lien, et. al, 1984, Oliveira, 
et. al, 2011). X-Ray diffraction indicated that glycation caused an increase in 
intermolecular spacing in the collagen fibril, resulting in progressive expansion of 
the molecular packing and ultimate loss of the lattice structure (Tanaka et al., 1988, 
Brownlee, 2001). In contrast, glycation of insoluble tendon collagen resulted in the 
formation of intermolecular cross-links, leading to increased collagen rigidity (Kent, 
et. al, 1985, Couppé, et. al. 2009). This difference of effect of glycation may be due 
to the greater proximity of the peptide chains in tendon collagen, which are tightly 
cross-linked and susceptible to further cross-linking by glycation. 
 
1.4.5 Receptor of advanced glycation end products (RAGE) 
The observation of cell activation and dysfunction following exposure of 
cultured cells to proteins highly modified by AGEs led to the hypothesis of cell 
surface receptors that bind specifically AGE-modified proteins or AGE receptors – 
reviewed in (Thornalley, 1998a). Studies were often misleading for physiological 
function, however, because glycation proteins prepared in vitro had ca. 38 - 52 
adducts per mol protein substrate and contained aggregates whereas proteins 
glycated in vivo are minimally modified with rarely more than one glycation adduct 
per mol protein and are not aggregated (Matsumoto et al., 2000, Westwood and 
Thornalley, 1995). Highly glycated proteins prepared in vitro have markedly 
different physiological interactions. For example, albumin glycated highly by 
glucose in vivo containing ca. 40 molar equivalents of glycation adducts had a 
plasma half-life of 1.2 h in rats and was mainly cleared from circulation in the liver 
(Matsumoto et al., 2000); whereas albumin glycated minimally glycated to the level 
found in diabetes had a half-life in rats of 47 h - similar to un-glycated albumin and 
is metabolized in the kidney and elsewhere by normal routes of albumin catabolism 
(Johnson et al., 1991) and analysis of glycation adduct content of plasma protein in 
blood flow into and out of the liver in human subjects gave no indication of glycated 
protein removal in the liver (Ahmed et al., 2004). This has prompted a reappraisal of 
putative AGE receptors. Proposed AGE receptors 1, 2 and 3 and scavenger receptors 
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are unlikely to have an AGE receptor function in vivo – as discussed (Ahmed and 
Thornalley, 2007). A further putative AGE receptor is RAGE. 
RAGE is a cell surface receptor and has a well-substantiated role in vascular 
cell dysfunction (Schmidt et al., 1995, Yonekura et al., 2003, Chavakis et al., 2003). 
It is a member of the immunoglobulin superfamily of proteins and structurally has an 
extracellular V-shaped domain of 320 amino acids with two N-linked 
oligosaccharides, a membrane spanning domain of 21 amino acids and a short 
cytoplasmic domain of 41 amino acids. The V domain is responsible for most 
extracellular ligand binding. For intracellular signalling, the cytoplasmic tail is 
assumed to be essential and possibly mediate cellular migration (Sparvero et al., 
2009). RAGE is associated with advance host responses in many pathological 
conditions such as diabetes, chronic inflammation, tumours, and neurodegenerative 
disorders (Sparvero et al., 2009). 
Recent research indicated binding of albumin minimally modified with MG 
occurs to the V-domain of the RAGE with a binding constant KD of 800 nM. There is 
a competitive binding by MG-H1 and related hydroimidazolone isomer-containing 
peptides which suggests MG-H1 is specifically recognised (Xue et al., 2014). In 
plasma of healthy human subjects, the concentration of MG-H1-albumin is ca. 4.5 
μM (Ahmed et al., 2005b). In human monocytes in vivo, the RAGE protein copy 
number is 37,000 per cell (Hou et al., 2004), equivalent to a concentration of  ca. 130 
nM. Therefore, it is expected that RAGE be always saturated with MG-modified 
protein ligand which suggests this binding may be non-productive for activation of 
signal transduction. Recently, some studies indicate heparan sulfate-RAGE 
complexes are essential for mediating signal transduction (Xu et al., 2013) and 
heparan sulfate may decrease binding affinity for MG-modified protein such that 
there is limited binding in healthy subjects. In addition, RAGE has high affinity 
homophilic binding with KD of 470 nM facilitating cell-cell interaction. This 
decreases  the availability of the cellular RAGE for AGE-modified protein binding 
(Sessa et al., 2014). 
RAGE was isolated initially from endothelial cells of bovine lung (Neeper et 
al., 1992). Human microvascular pericytes, endothelial cells and other cells express 
splice variants of RAGE: N-terminal truncated, C-terminal truncated and full length 
forms; only the latter two bound AGE-modified protein (Yonekura et al., 2003). The 
endogenous secreted C-terminal truncated RAGE, called endogenous secreted RAGE 
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(esRAGE), lacks the cytoplasmic and transmembrane domains of RAGE and is 
expressed in several human tissues (Cheng et al., 2005). Recombinant DNA 
techniques were used to produce a similar C-terminal truncated RAGE called soluble 
RAGE (sRAGE) (Park et al., 1998). esRAGE and sRAGE act as decoy receptors for 
RAGE ligands endogenously and experimentally, respectively, and thereby influence 
RAGE-ligand interactions and signalling. RAGE transgenic and knockout mice have 
provided functional genomic models to identify roles of RAGE in several disease 
states – particularly where an inflammatory mechanism is involved:  atherosclerosis 
(Sakaguchi et al., 2003), sepsis (Liliensiek et al., 2004) and others - Figures 9 and10.  
 
 
Figure 9: RAGE signal transduction pathways.  
The engagement of RAGE stimulates the activation of a diverse array of signalling 
cascades, including mitogen activated protein kinases (MAPK), such as extracellular 
regulated (ERK)-1/2, p38 and c-Jun N-terminal kinase (JNK), Jak/STAT, 
phosphoinositol 3-kinase (PI3K), and members of the Rho GTPase signaling 
pathway (Cdc42 and Rac-1). RAGE activation may enhance the generation of ROS 
by activating NAD(P)H oxidase. RAGE-dependent responses converge to the 
activation of nuclear transcription factors, including nuclear factor (NF)-kB, and 
consequent target gene transcription. Other abbreviations: MCP-1 monocyte 
chemoattractant protein-1, mDia-1 mammalian Diaphanous-1, PKC protein kinase C, 
SR scavenger receptor. From (Vazzana et al., 2009). 
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Figure 10: Soluble RAGE isoforms.  
sRAGE consists in an heterogeneous population, comprising at least different 
isoforms: (1) the extracellular RAGE shedded form the surface receptor by the action 
of membrane-associated metalloproteinases (MMPs), such as ADAM-10 and MMP-
9; (2) esRAGE, arising from RAGE pre-mRNA alternative splicing and characterised 
by a specific C-terminal sequence. Spanning the ligand-binding domain, sRAGE 
probably acts as a decoy for ligands, thus competitively inhibiting the engagement of 
cell-surface RAGE and other RAGE-ligand receptors. From (Vazzana et al., 2009). 
 
The ligand(s) activating RAGE in vivo are less certain. It was initially thought 
that AGEs were the main activating ligands for RAGE. However, ligand binding 
activity is limited to only proteins highly-modified by AGEs and aggregated. Such 
proteins are rarely found in tissue and physiological fluids – but they are found in 
thermally processed foods and are ingested. Non-AGE ligands of RAGE are most 
likely agonist in vivo: high mobility group box-1 protein (HMGB1/amphoterin), and 
members of the S100/calgranulin protein family. RAGE binds members of the 
S100/calgranulin group of proteins: S100A12 (EN-RAGE) and S100b (Hofmann et 
al., 1999). Currently, cell activation by S100A12 and S100b appears to be a likely 
important function of RAGE in vivo – reviewed in (Thornalley, 2007). Activation of 
RAGE is linked to activation of the Ras/NF-kB signalling pathway (Yan et al. 1994, 
Huttunen, and Rauvala 1999). 
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1.4.6 Evidence for RAGE regulation of Glo1 
The association of RAGE went a substantial revision following the work of 
Bierhaus and colleagues who found engagement of RAGE was associated with 
decreased expression of glyoxalase I (Glo1) (Bierhaus, 2006). Bierhaus found that 
induction of diabetes in wild-type mice decreased the expression of Glo1 whereas the 
induction of diabetes in RAGE (–/–) mice did not. Decreased Glo1 expression causes 
increased protein glycation (Thornalley, 2003b). The mechanistic interpretation of 
the association of RAGE expression and AGEs in tissues may, therefore, require 
reappraisal. The co-localization of RAGE and AGEs may be due to RAGE activation 
by S100 proteins (or other non-AGE agonists) decreasing the local expression of 
Glo1 and thereby increasing the local formation of AGEs. The functional role of 
decreasing Glo1 activity and increasing protein glycation by RAGE activation is not 
yet clear. This may be part of an inflammatory response leading to labelling proteins 
with dicarbonyl-derived hydroimidazolone AGE residues and directing these 
proteins to the proteasome for destruction. Methylglyoxal modification of proteins is 
thought to target proteins for proteasomal destruction (Du et al., 2006). If correct, 
this will link AGE formation to removal and destruction of proteins, at least for 
intracellular proteins – a “twist” or re-interpretation of the role originally attributed 
to the formation of AGE modified proteins by Cerami (Cerami, 1986). 
The mechanism of down regulation of Glo1 expression by RAGE is 
unknown. It may occur by activation of NF-kB which then conflicts and blocks with 
signalling of transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2, 
or Nrf2) (Liu et al., 2008). Nrf2 regulates basal and inducible expression of Glo1 
(Xue et al., 2012a) - Figure 11. 
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Figure 11: Model for down regulation of glyoxalase 1 by receptor for advanced 
glycation endproduct (RAGE). 
 (a.) Structure of RAGE and soluble RAGE (sRAGE). Key: V – variable region; C 
and C’ conserved structural domains. (b.) RAGE signalling for down regulation of 
glyoxalase 1 (Xue et al., 2012a). 
 
1.4.7 Evidence of involvement of glycation and RAGE in periodontal disease 
The hyperglycaemic state of diabetes accelerates destruction of periodontal 
tissue. This destruction is caused by malfunction of polymorphonuclear leukocytes, 
changing of collagen metabolism and vascular permeability, reducing the viability 
and differentiation potential of cells within periodontium and shifting composition of 
microflora. In addition, hyperglycaemia increases the creation and accumulation of 
AGEs in plasma and tissues by oxidation and non-enzymatic glycation of proteins. 
AGEs can cause modification of matrix molecules cross-linking, impairment of the 
growth factors efficiency, elevation of oxidative stress in diabetic conditions, and 
exaggeration of inflammation significantly through interaction with the cellular 
RAGE (Chang et al., 2013). It has been found that glycation of collagen-I and 
fibronectin in PDL altered the PDL behaviour including reduction in cell migration 
which could contribute in impaired periodontal wound healing in diabetic individuals 
(Murillo et al., 2008). 
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Chang, et. al, (2012) found slight elevations of AGEs and RAGE with no 
histologic destruction in periodontium of animals with diabetes and without 
periodontitis. However, periodontal destruction in mice with diabetes and 
periodontitis was aggressive with evidence of AGE accumulation and increased 
RAGE expression. In addition, in healthy animals with periodontitis, increased AGEs 
and RAGE expression were found. The presence of the AGE-RAGE axis without 
diabetes implies that it is involved in the regulation of inflammation (Chang et al., 
2013). 
RAGE was found to be expressed in PDLF (Hasegawa, 2008). Hasegawa 
stimulated PDLF cells with HMGB1, with or without anti-RAGE, TLR2 and TLR4 
antibodies, to measure IL-6 and IL-11 production using an enzyme-linked 
immunosorbent assay and mRNA expression was quantified by real-time PCR. 
PDLF cells expressed RAGE, TLR2 and TLR4 mRNA and production of IL-6 and 
IL-11 were augmented in PDLF cells stimulated with HMGB1. Hasegawa conclude 
that PDLF cells produce IL-6 and IL-11 in response to HMGB1 via RAGE, TLR2 
and TLR4 (Hasegawa, 2008). 
 RAGE has a significant role in model periodontal disease. S100 proteins may 
be the most important activators and inflammatory mediators acting via RAGE in 
vivo. S100 has been proposed as important in periodontal disease and this may bind 
RAGE in PDL (Lalla et al., 2000). S100B was found to down regulate Glo1 in wild 
type fibroblasts cells but not in fibroblasts from RAGE knockout mice (Bierhaus et 
al., 2005a). 
 
1.5 The Glyoxalase system 
1.5.1 Enzymatic defence against glycation 
The major enzymatic defence against MG glycation in physiological systems 
is provided by the glyoxalase system -Figure 12. 
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Figure 12: The Glyoxalase system and its metabolites.  
From (Xue et al., 2011) 
 
1.5.1.1 Glyoxalase system - definition and function 
The glyoxalase system catalyses the metabolism of methylglyoxal (MG) to 
D-lactate via the intermediate S-D-lactoylglutathione. The glyoxalase system 
consists of two enzymes, glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2) and a catalytic 
amount of reduced glutathione (GSH). The glyoxalase system is found in the cytosol 
or intracellular fluid of mammalian cells. It is present in animals, plants, bacteria, 
fungi and protoctista (Xue et al., 2011). The detoxification process of glyoxalase 
system contains two sequential reactions which follows the non-enzymatic 
construction of hemithioacetal from the MG CH3COCHO reaction with GSH. 
Primarily, Glo1 influences the formation of S-D-lactoylglutathione CH3CH(OH)CO-
SG from the hemithioacetal.  
CH3COCHO  +  GSH   ⇌   CH3COCH(OH)-SG  CH3CH(OH)CO-SG  
For the methylglyoxal-glutathione hemithioacetal and human Glo1, the KM is 
71-130 M and the kcat is 7-11 x 104 min-1. Secondly, Glo 2 catalyses S-D-
lactoylglutathione to D-lactate and GSH. GSH will be consumed in the Glo1-
catalyses reaction in the next circle (Xue et al., 2011). 
CH3CH(OH)CO-SG + H2O  CH3CH(OH)CO2- + H+ + GSH  
MG is the main physiological substrate for Glo1. MG significantly 
accumulates when Glo1 is suppressed in situ by decrease of GSH and in presence of 
cell permeable Glo1 inhibitors (Thornalley, 1993, Abordo et al., 1999, Thornalley et 
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al., 1996). Glyoxal, hydroxypyruvaldehyde HOCH2COCHO and 4,5-doxovalerate H-
COCOCH2CH2CO2H are other substrates for Glo1 (Thornalley, 1993, Abordo et al., 
1999, Thornalley et al., 1996, Thornalley, 1998c). The activity of Glo1 prevents the 
increase of these reactive -oxoaldehydes and thus inhibits -oxoaldehyde-mediated 
glycation reactions (Shinohara et al., 1998). Therefore, Glo1 is a main anti-glycation 
defence enzyme (Thornalley, 2003b, Thornalley, 2003a). 
 
1.5.1.2 Histological development of glyoxalase system 
The glyoxalase system was discovered in 1913 as an enzymatic system in 
physiological systems which catalysed the conversion of methylglyoxal to lactate 
(Neuberg, 1913, Dakin and Dudley, 1913). Later, the stereospecific formation of D-
lactate appeared. Racker revealed in 1951 the presence of two consecutive steps 
catalysed by Glo1 and Glo2 were involved in the enzymatic system (Racker, 1951). 
Later in 1954, Racker proposed that D-lactate was the terminal product of 
metabolism of MG by glyoxalase system rather than L-lactate (Racker, 1954). 
Ekwall and Mannervik confirmed this later in 1974 (Ekwall and Mannervik, 1973). 
In 1960, studies on human arterial tissue showed decrease Glo1 activity with age 
(Kirk, 1960), which probably related with increased risk of cardiovascular disease 
with ageing. 
Takahashi (1977) reported arginine-directed protein glycation by MG –  the 
principal adduct found later to be a hydroimidazolone forming hydroimidazolone 
MG-H1 (Ahmed et al., 2002). In 1988, it was revealed that MG formation was 
increased in red blood cells incubated in high glucose concentrations in vitro 
(Thornalley, 1988). Thornalley and Atkins found an increase in Glo1 activity in 
STZ-induced diabetic and obese mice in 1989 (Atkins and Thornally, 1989). Then, 
Thornalley and his colleagues also noticed increased concentrations of MG, S-D-
lactoylglutathione and D-lactate in patients with diabetes as compared to healthy 
controls (Thornalley et al., 1989). 
In 1991, Wilson and his co-workers showed that Glo1 gene was a genetic 
factor related to body mass index (Wilson et al., 1991). Glo1 later was recognized as 
part of the human obesity genome. 
In 1993, Philips and Thornalley measured the formation rate of the 
triosephosphates - GA3P and DHAP, under physiological conditions by using a 
specific MG assay. They found that ca. 0.1% glucotriose flux degraded to MG under 
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physiological conditions and this was the main source of MG formation in 
mammalian metabolism (Philips and Thornalley, 1993). In 1994, it was reported by 
Lo et al. that MG is a potent glycating agent forming AGEs (Lo et al., 1994b). In 
addition, it was shown that aminoguanidine was an effective MG scavenger and 
inhibited AGE formation to inhibit development of vascular complication of diabetes 
(Lo et al., 1994a). 
In 1998, Shinohara reported a decrease in the accumulation of MG and 
associated AGEs as a consequence of overexpression of Glo1 in endothelial cells in 
vitro (Shinohara et al., 1998). In 1999, Abordo et al. described the accumulation of 
MG in cultured cells was linked with oxidative stress (Abordo et al., 1999). In the 
same year Beisswenger et al. reported a decrease in plasma concentration of MG in 
patients with T2DM receiving metformin therapy (Beisswenger et al., 1999). 
Ranganathan et al. (1999) reported on GLO1 gene promoter analysis and 
revealed an insulin response element, displaying a possible association between 
expression of Glo1 and dysfunctions in diabetes (Ranganathan et al., 1999). 
From 1989 to 2003, there were several studies describing a decrease in Glo1 
and Glo2 activities and increase in MG and glyoxal derived AGEs with age in human 
and mouse tissues and cells (McLellan and Thornalley, 1989, Dunn et al., 1989, 
Dunn et al., 1991, Haik Jr et al., 1994, Ahmed et al., 1997, Sharma-Luthra and Kale, 
1994). Pamplona et al. (2002) found a decrease in the MG-derived CEL residues in 
mitochondria of rat heart in case of long term caloric restriction (Pamplona et al., 
2002). In 2003, Thornalley et al. developed stable isotopic dilution analysis LC-
MS/MS methods for specific and sensitive measurement of MG-derived AGEs and 
found that MG-derived hydroimidazolone the major quantitative AGE in 
physiological systems (Thornalley et al., 2003b). 
In 2006 Redon and his colleagues constructed a copy number variation 
(CNV) map. Glo1 was noticed to be positioned in one of the CNV regions (Redon et 
al., 2006). This was followed in 2009 by the finding that the non-transcribed region 
of Glo1 gene was a significant site of CNV in the genome of the mouse causing 4-
fold alterations in expression of Glo1 (Cahan et al., 2009). In 2007 Zender et al. 
found in a genome-wide study of tumour suppressor genes that Glo1 was one of only 
14 genes with tumour suppressor activity, likely linked to suppression of mutagenic 
MG-derived nucleotide AGEs, MGdG and CEdG  (Zender et al., 2008, Thornalley et 
al., 2010). In 2008 Morcos et al. showed for the first time that Glo1 is a gene 
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influential on lifespan or “vitagene”. Overexpression of Glo1 in Caenorhabditis 
elegans increased median and maximum lifespan by ca. 30% and silencing of Glo1 
decreased lifespan by ca. 50% (Morcos et al., 2008). 
In 2010, it was shown by Brouwers with his co-workers that Glo1 over-
expression inhibited oxidative stress and endothelium dependent vaso-relaxation 
impairment in mesenteric arteries of diabetic rats. This implied to MG elevation in 
the diabetic state in initiation of vascular dysfunction and oxidative stress (Brouwers 
et al., 2010, Brouwers et al., 2011). Thornalley et al. presented that the major 
markers of physiological damage to genome is MG-derived DNA imidazopurinone 
MGdG adducts which are linked to DNA instability and mutagenesis in vivo 
(Thornalley et al., 2010). Santarius et al. discovered amplification of the GLO1 gene 
in human tumors. In 520 human tumours, amplification of Glo1 was noticed in ca. 
8% with majority in breast cancer, 19%, small cell lung cancer (SCLC) 16% and 
non-small cell lung cancer (NSCLC) 11%. Glo1 amplification linked to increased 
Glo1 expression and multidrug resistance (Santarius et al., 2010). 
In 2012, Xue et al. described the presence of a regulatory antioxidant-
response element (ARE) in the 5’-untranslated region of exon 1 of the mammalian 
Glo1 gene. Transcription factor nuclear factor-erythroid 2 p45 subunit related factor 
2 (Nrf2) binds to this ARE and increases basal and inducible expression of Glo1 
(Xue et al., 2012a). Small molecule Nrf2 activators and Glo1 inducers are now 
providing the basis for development of Glo1 inducer functional foods to sustain 
healthy ageing and Glo1 inducer pharmaceuticals for treatment of vascular 
complications of diabetes and other diseases linked to dicarbonyl stress (Rabbani et 
al., 2014b). 
 
1.5.1.3 Glyoxalase 1 - molecular properties, genetics and human polymorphism 
Expression and activity of Glo1 is found in all human tissues. In fetal tissues, 
the specific activity of Glo1 is ca. 3 times higher than of similar adult tissues. In 
human tissues and blood cells there is approximately 0.2 μg Glo1 per gram of protein 
(Larsen et al., 1985). 
The human GLO1 gene is located on chromosome 6 at band number 21.2. 
GLO1 gene is ~12.0kb in length and contains 6 exons and 5 introns (Gale and Grant, 
2004). Expression of human GLO1 occurs at a diallelic genetic locus with alleles 
GLO1 and GLO2 in heterozygotes. These two alleles encodes for two related subunits 
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in heterozygotes. The enzyme of human Glo1 is a dimeric protein with 3 allozymes 
in heterozygotes designated as Glo1 1-1, Glo1 1-2 and Glo1 2-2. All allozymes have 
a molecular mass of 46 kDa (gel filtration) or 42 kDa (sequence), contain two zinc 
ions (one per subunit) and isoelectric point pI values of 4.8 - 5.1. Glo1 allozymes 
have unique charge densities and/or molecular shapes and may be resolved by ion 
exchange chromatography and non-denaturing gel electrophoresis resolved Glo1 
allozymes (McLellan and Thornalley, 1991, Schimandle and Vander Jagt, 1979). 
Glo1 alleles are inherited in a simple co-dominant manner with the presence of 
characteristic expression of the phenotype (Thornalley, 2003b). The Glo1 
translational product of human encloses 184 amino acids. There is a difference in 
amino acid sequence in the expression products of the two Glo1 alleles, only at 
position 111. There is an alanine residue in subunit Glo1-A, and there is a glutamic 
acid residue in subunit Glo1-E (Kim et al., 1995). 
In post-translational processing, the N-terminal Met of Glo1 is removed and 
the N-terminal Ala is acetylated. Further phosphorylation and acetylation gives rise 
to several forms of differing pI (Xue et al., 2011). There is a vicinal disulphide 
bridge between cysteine residues 19 and 20. Cysteine-139 and cysteine-61 may also 
form of an intra-molecular disulphide. There is a mixed disulphide with glutathione 
on cysteine-139. N-terminal acetylation and C19/C20 disulphide formation did not 
affect Glo1 activity whereas glutathionylation on C139 strongly inhibited Glo1 
activity in vitro (Birkenmeier et al., 2010). S-Nitrosylation by nitric oxide (NO) of 
Glo1 occurs on cysteine-139. C19 and C20 presence is important on S-nitrosylation 
which occurred on the acidic, α-form of Glo1 (De Hemptinne et al., 2007). The basic 
and reduced form of Glo1 is the NO-responsive, without intramolecular disulfide 
bonding (De Hemptinne et al., 2007). Glo1 is a substrate for calcium, calmodulin-
dependent protein kinase II (CaMKII). Mainly but not exclusively, phosphorylation 
of Glo1 occurred on Thr-107 on the basic, reduced and NO-responsive form 
(Santarius et al., 2010, de Hemptinne et al., 2009, Xue et al., 2011, Birkenmeier et 
al., 2010).  
The GLO1 promoter region contains binding sites for regulatory elements: 
insulin response element (IRE), metal responsive element (MRE) and glucocorticoid 
responsive element (GRE), positioned from -842 to -848bp, -647 to-654bp and -363 
to -368bp respectively (Ranganathan et al., 1999), and activating enhancer binding 
protein 2 alpha (AP-2 alpha - also known as TFAP2A) positioned from -24 to -32 
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(Orso et al., 2010), E2F – binding to transcription factor E2F4 (Conboy et al., 2007) 
and ARE-1 positioned from -10 to -19, ARE-2 from -252 to -261 and ARE-3 from -
1051 to -1060 (Xue et al., 2012a) – Figure 13. Glo1 was induced by oxidative stress 
in nematode Onchocerca volvulus, however the mechanism is still unidentified 
(Sommer et al., 2001) but may occur via the nematode orthologue of Nrf2. 
 
 
Figure 13: Human GLO1 gene structure.  
A. Representation of human GLO1 gene (Yellow: promoter region, Pink: exon, 
Orange: untranslated region (UTR), Blue: regulatory elements). B. Promoter 
sequence of human GLO1 with positions of regulatory elements. 
 
The crystal structure of human Glo1 in complex with competitive inhibitor S-
benzylglutathione was determined using isomorphous replacement and 4-fold 
molecular averaging to 2.2 Å resolution (Cameron et al., 1997) – Figure 14. Each 
monomer consisted of two, structurally equivalent domains connected by a 20 
connection of residue and anteceded by a long arm of N-terminal. The active site was 
located at the interface of the dimer, with the inhibitor and essential Zn2+ ion 
interacting with side chains from both subunits. The binding site of the zinc ions 
involved two residues from each subunit which are structurally equivalent from each 
domain: Gln-33A, Glu-99A, His-126B, Glu-172B plus two water molecules in 
octahedral coordination. (Cameron et al., 1997, Cameron et al., 1999a, Thornalley, 
2003b).  
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Figure 14: Glyoxalase 1 crystal structure.  
Provided by Prof Paul Thornalley. 
 
 
The catalytic mechanism suggested for the Glo1 reaction includes base-
catalysed shielded proton transfer from C1 to C2 of the active site bound 
hemithioacetal. This creates an ene-diol intermediate with rapid, stereospecific 
reprotonisation and ketonisation to form the thioester product. The hemithioacetal 
forms are R- and S-forms. They are bound in the active site of Glo1 and are therein 
deprotonated; the subsequent reprotonation of the putative ene-diol intermediate 
happens stereo-specifically to produce the R-2-hydroxyacylglutathione derivative. 
Glu-172 and Glu-99 are the catalytic base for the S-substrate enantiomer and the R-
substrate enantiomer respectively. These reaction mechanism produces a cis-ene-diol 
intermediate coordinated directly to the Zn2+ ion. This then is deprotonated to a cis-
ene-diolate by Glu-172 which then reprotonates C2 stereo-specifically to create the 
product of R-2-hydroxyacylglutathione (Himo and Siegbahn, 2001). Glyoxal, 
methylglyoxal and hydroxypyruvaldehyde formed S-glycolylglutathione, S-D-
lactoylglutathione and S-L-glyceroylglutathione by glyoxalase I respectively. They 
are hydrolysed by glyoxalase II respectively to glycolate, D-lactate and L-glycerate 
(Clelland and Thornalley, 1991). 
Glo1 of other mammalian species has similar molecular characteristics to 
those of the human enzyme. Glo1 enzymes of mammalian, bacterial and plant origins 
are usually dimeric. However, Glo1 of yeast is a monomer of 32 and 37 kDa for 
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Saccharomyces cerevisae and Schizosaccharomyces pombe, respectively. These 
monomers have two copies of a segment corresponding to the monomer of Glo1 in 
humans. The sequence identity of Glo1 of human with Glo1 of bacterial 
Pseudomonas putida is 55% and with Glo1 of yeast Saccharomyces cerevisiae 
among residues 1-182 and 183-326 is 47% (Thornalley, 2003b). This may suggest 
that different origins of Glo1 may have arisen by divergent evolution from a common 
ancestor (Xue et al., 2011). 
 
1.5.1.4 Glyoxalase 2 - molecular properties, genetics and human polymorphism 
Glyoxalase 2 (Glo2) activity occurs in all cells of eukaryotic and prokaryotic 
organisms (Thornalley, 1993). Glo2 has been identified in yeast - Saccharomyces 
cerevisiae and Hansenula mrakii (Murata et al., 1986, Inoue and Kimura, 1992), 
protozoans - malaria parasite plasmodium falciparium (Vander Jagt, 1993) and 
Leishmania braziliensis (Darling and Blum, 1988), helminths including cestodes, 
digeneans and nematodes (Brophy et al., 1990, Pemberton and Barrett, 1989) and 
fungus; Candida albicans (Talesa et al., 1989). 
There are two major forms of human Glo2: isoform 1 which is the 
mitochondrial form and its molecular mass 33,806 Da (sequence) and isoelectric 
point of 8.3 (predicted) and the isoform 2 which is the cytosolic form and its 
molecular mass 29,200 Da (SDS-PAGE; sequence 28,860 Da) and isoelectric point 
of 8.3 (Allen et al., 1993a, Ridderstrom et al., 1996, Cordell et al., 2004). Glo2 is a 
thiolesterase and has extensive substrate specificity for glutathione thiol esters 
favourably with S-2-hydroxyacylglutathione derivatives (Thornalley, 1991).  
The cytosolic Glo2 of human contains two domains: a four-layered β 
sandwich and a mostly α-helical domain. The active site consist of a binuclear metal 
ion-binding site inclosing zinc (II) and iron (II) ions and a substrate-binding site 
covering the domain interface (Xue et al 2011). Additionally, there is a hydroxide ion 
attached to both metal ions and is located at 2.9 Å from the carbonyl carbon of the 
substrate in a site that may perform as the nucleophile during catalysis (Cameron et 
al., 1999b). The binding of metal ion in Glo2 is important for activity (Dragani et al., 
1999, Limphong et al., 2009). The hydrolysis rate of S-D-lactoylglutathione to GSH 
and D-lactate catalysed by Glo2 followed Michaelis-Menten kinetics where the kcat 
and KM values were estimated as 727 s
-1 and 146 µM respectively (Allen et al., 
1993a). Acetylation of Glo2 is found at lys-229 (Choudhary et al., 2009). 
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The gene of human Glo2 is hydroxyacylglutathione hydrolase (HAGH). It is 
situated on chromosome 16 in region 16p13.3. Glo2 genetic polymorphism is 
extremely rare. Usually, only one phenotype- HAGH1 is expressed. Also, a rare 
second form named HAGH2 has been detected (Thornalley, 1993). The gene of Glo2 
consists of 10 exons and is transcribed to two different mRNA species from 9 and 10 
exons, respectively. The 9-exon-derived transcript encodes both the mitochondrial 
and cytosolic Glo2 forms. The Glo2 targeted to mitochondria originates from an 
AUG codon in the mRNA sequence, and cytosolic Glo2 is produced by internal 
ribosome entry at a downstream AUG codon. The 10-exon derived transcript 
contains an in-frame termination codon among the two initiating AUG codons and 
only encodes the cytosolic Glo2. The glyoxalase II form of mitochondria is directed 
to the mitochondrial matrix (Cordell et al., 2004). 
 
1.5.1.5 D-Lactate 
L-Lactate is the main stereoisomer of lactate made in the human intermediary 
metabolism (Drury and Wick 1965). D-Lactate is the other enantiomer which is 
generally about 1-5% of the L-lactate concentration in plasma. D-Lactate of 
exogenous sources is found at relatively high concentration in fermented food; for 
example, yogurt, sauerkraut and pickles. Furthermore, in the gut, D-lactate is 
absorbed from microbial fermentation (Mortensen et al., 1991, Hove, 1998, 
Ewaschuk et al., 2005, De Vrese and Barth, 1991). D-Lactate is formed 
endogenously in intermediary metabolism by the glyoxalase pathway and 
metabolised by 2-hydroxyacid dehydrogenase to pyruvate (Thornalley, 1993). In 
humans, D-lactate is well metabolised, however, it has higher fractional renal 
clearance than L-lactate (Connor et al., 1983). Infusion of D-lactate in humans at 1.0-
1.3 mmol sodium D-lactate/kg/hr lead to nearly 90% of the D-lactate to metabolised 
whereas the residual 10% is excreted in urine (Oh et al., 1985). The D-lactate 
metabolism is reduced to nearly 75% of the overall clearance with higher infusion 
rates of 3.0-4.6 mmol/kg/hr (Oh et al., 1985). Its concentrations in blood plasma rises 
approximately 2-3 fold after meal and exercise (Ohmori and Iwamoto, 1988, Kondoh 
et al., 1992b). Permeability of D-lactate to cell membranes occurs via transporters, 
the inorganic anion exchange system and the specific lactate transporter, and also by 
ionic diffusion. Excretion of D-lactate occurs mainly in urine and with minor 
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excretions in stool and sweat (Oh et al., 1985, Kondoh et al., 1992b, Kondoh et al., 
1992a). 
Increased D-lactate can be used as an indicator of the elevated flux of 
formation of MG in cells where D-lactate is unable to metabolised; for example, red 
blood cells and lens fibre cells (Thornalley, 1993). D-lactate concentration increases 
in median of cultures of endothelial cells and red blood cells when cultured in high 
glucose conditions, and in plasma and urine of STZ-induced diabetic rats and 
patients with diabetes (Thornalley, 1988, Phillips and Thornalley, 1993, Karachalias 
N, 2005, McLellan et al., 1994a). The D-lactate levels in plasma in healthy adults is 
approximately 2 – 20 nM (Thornalley, 1988, Phillips and Thornalley, 1993, 
Karachalias N, 2005, McLellan et al., 1994a). Higher values may be reached when 
the analytical method does not avoid even limited racemisation of L-lactate which is 
normally existing in >100 folds excess over D-lactate (De Vrese and Barth, 1991, 
McLellan et al., 1992, Ohmori and Iwamoto, 1988, Brandt et al., 1980). 
Endpoint enzymatic assay is used for measuring D-lactate with either 
absorbance or fluorescence detection of NADH formed in presence of D-lactic 
dehydrogenase. The amount of D-lactate in the sample is equivalent to the amount of 
NADH formed from NAD+ at endpoint, occurring concomitant with oxidation of D-
lactate to pyruvate (McLellan et al., 1992). In addition, D-lactate may be detected 
from the amount of pyruvate formed where pyruvate is detected after derivatisation 
with 1,2-diaminobenzene to 2-hydroxy-3-methylquinoxaline by high performance 
phase liquid chromatography (HPLC) with fluorescent detection (Ohmori and 
Iwamoto, 1988, Ohmori et al., 1991). 
 
1.5.1.6 S-D-Lactoylglutathione 
S-D-Lactoylglutathione is a physiological intermediate of the glyoxalase 
system. It is formed from the hemithioacetal adduct of MG and GSH in a reaction 
catalysed by Glo1. Then, in the reaction catalysed by Glo2, S-D-Lactoylglutathione is 
hydrolysed to GSH and D-lactate (McLellan et al., 1993). 
MeCOCHO + GSH ⇌ MeCOCH(OH)-SG     
Glyoxalase 1       MeCH(OH)CO-SG 
S-D-Lactoylglutathione is formed in the cytosol of cells and does not freely 
cross membranes of the cell. However, when it leaks from cells by the GSH 
conjugate transporter, γ-glutamyltransferase - found on the external surface of 
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plasma membrane of cells - cleaves S-D-lactoylglutathione to S-D-
lactoylcysteinylglycine. Then, S-D-lactoylcysteinylglycine rearranges to N-D-
lactoylcysteinylglycine spontaneously (Tate, 1975) and this may be cleaved by 
dipeptidase to N-D-lactoylcysteine. 
In the 1980s, Thornalley and his colleagues found remarkable biological 
properties of S-D-lactoylglutathione added to cells in culture i.e. in the extracellular 
compartment. They revealed that S-D-lactoylglutathione prompted toxicity and 
growth arrest in human leukaemia cells in vitro (Thornalley and Tisdale, 1988). 
Moreover, in human neutrophils, S-D-Lactoylglutathione influence the percentage of 
stimulus-activated granule secretion, where at low concentrations it potentiated 
secretion (2 - 5µM) and while at higher concentrations (100 µM - 5mM) it inhibited 
secretion (Thornalley et al., 1990). These effects were found to be mediated by N-D-
lactoylcysteine which enters cells by passive diffusion as it has a major solution 
species which is unionised. It is an inhibitor of dihydro-oratase of the de novo 
pyrimidine synthesis pathway. Inhibition of pyrimidine synthesis accounted for the 
anticancer activity of S-D-lactoylglutathione and all the effects of granule secretion 
through effects of metabolic channelling of pyrimidine metabolites into nucleotide 
conjugates influencing cell signalling for degranulation (Edwards et al., 1993, 
Edwards and Thornalley, 1994, Edwards et al., 1996). 
 
1.5.1.7 Non-glyoxalase detoxification of MG 
When the glyoxalase system is impaired or inhibited, glyoxal is metabolised 
to glycolaldehyde by aldoketo reductase (AKR) isozymes 1B1 (aldose reductase), 
1B3 and MG is metabolised to mainly hydroxyacetone by 1B8 and AKR isozymes 
1A4, 1B1 and 1B3 (Baba et al., 2009). Metabolism of glyoxal and MG by AKR 1B1 
probably occurs mainly in the renal medulla where high expression of AKR 1B1 
outcompetes Glo1 (Larsen et al., 1985, Nishimura et al., 1993). Concentrations of 
glyoxal and MG may be elevated in renal failure as a result of impaired Glo1 
activity. Glo1 activity in renal and vascular cell may be reduced in renal failure by 
many factors including decreased concentration of GSH in oxidative stress, 
decreased Glo1 expression and glutathionylation of Glo1. Expression of Glo1 may 
be reduced by stimulation of RAGE and by suppression of signalling by Nrf2. Glo1 
and AKRs 1A4, 1B1, 1B3 and 1B8 are ARE-linked genes with basal and inducible 
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expression controlled by Nrf2 (Xue et al., 2012a, Kwak et al., 2003, MacLeod et al., 
2009, Nishinaka and Yabe-Nishimura, 2005, Thimmulappa et al., 2002). 
Aldehyde dehydrogenase may also contribute in the degradation of MG in case 
of impairment or absence of the glyoxalase system. MG is oxidized to pyruvate by 
methylglyoxal dehydrogenase in an NAD+ dependent reaction (Nemet et al., 2006). 
There are more than 17 known functional aldehyde dehydrogenase genes (Vander Jagt 
and Hunsaker, 2003). The most significant genes: aldehyde dehydrogenase 1 (ALDH1), 
aldehyde dehydrogenase 2 (ALDH2) and aldehyde dehydrogenase 3 (ALDH3). They 
commonly show wide specificity and detoxify many aldehydes in humans (Vander Jagt 
et al., 2001). Unhydrated aldehydes are the preferred substrates of these genes (Vander 
Jagt et al., 2001, Nemet et al., 2006). Consequently, MG-a fully hydrated α-
oxoaldehyde- is not readily reduced by ALDH1 and ALDH2 (Vander Jagt et al., 2001, 
Nemet et al., 2006, Izaguirre et al., 1998). 
 
1.5.2 Regulation of Glo1 gene expression 
Initial Glo1 inhibitors were developed based on GSH conjugates which were 
Glo1 substrate analogues. S-bromobenzylglutathione was a prototype of Glo1 
inhibitor. Other Glo1 inhibitors include S-p-bromobenzylglutathione, Bis[(S-N-4-
chlorophenyl-N-hydroxycarbamoyl)glutathione-hexa(β-alanyl)] suberate diamide, γ-
Glutamyl-γ-(N-4-bromophenyl-N-hydroxycarbamoyl)glutamylglycine and S-p-
bromobenzylglutathione cyclopentyl diester. Methotrexate, anti-cancer drug known 
as amethopterin, was a weak inhibitor of Glo1 (Thornalley and Rabbani, 2011a). 
Glo1 expression and activity may be decreased in some abnormal physiological 
conditions. Glo1 activity was decreased in the sciatic nerves of STZ-induced diabetic 
mice causing diabetic neuropathy (Stoyanov et al., 2007). This was related to the 
RAGE activation in diabetic mice with knock-out RAGE, Glo1 down regulation and 
development of diabetic neuropathy did not occur (Stoyanov et al., 2007). 
Neuropathy was re-established in RAGE knockout mice by dosing mice with a cell 
permeable Glo1 inhibitor, S-p-bromobenzylglutathione cyclopentyl diester 
(SpBrBzGSHCp2) (Stoyanov et al., 2007). This implicated RAGE mediated down 
regulation of Glo1 in diabetic neuropathy and may increase MG concentration in 
development of neuropathy. Other mechanisms of Glo1 expression suppression in 
diabetes may be through hypertonic stress as mouse embryonic stem cells revealed 
reduced expression of Glo1 in hypertonic stress (Mao et al., 2008).  
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Glo1 found to be induced by small molecule inducers (Lewis et al., 2012, 
Rabbani et al., 2014b) such as sulforaphane (Xue et al., 2012a) trans- resveratrol and 
hesperetin (Xue et al., 2016). It has recently been shown that basal and inducible 
expression of Glo1 is regulated by Nrf2 by binding to a functional ARE (Xue et al., 
2012a). Inflammatory signalling of LPS and TNFα may contribute to obesity and 
insulin resistance (Cani et al., 2007). In the nucleus and cytosol of macrophages, LPS 
inflammatory signalling stimulate the expression of Glo1 via the Tol-4 receptor (Du et 
al., 2010). RAGE and LPS activate pro-inflammatory signalling through NF-kB. It 
may thereby represses the Nrf2/ARE pathway: p65 of the NF-kB  pathway deprives 
CREB-binding protein from Nrf2 and thereby suppresses Nrf2-activated 
transcriptional activity (Liu et al., 2008) – including Glo1 expression. NF-kB 
signalling activated by TNF-α may also produce competition with Nrf2 for CREB-
binding protein and down regulate expression of Glo1 – Figure 15. This and other 
mechanisms could drive decrease of Glo1 expression by inflammatory signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15; Receptor for advanced glycation endproduct (RAGE).  
Proposed signalling for conflict with Nrf2. 
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1.5.3 Copy number variation of GLO1 gene 
There is a newly recognised source of genetic diversity which is copy number 
variations (CNV). It defined as segregating duplications and deletions in the DNA 
which caused by genetic diversity and may result in increased susceptibility to 
specific diseases (Williams IV et al., 2009). Approximately 75% of CNV is found at 
a frequency of less than 3% in human populations, suggesting a stochastic origin and 
maintenance of most of this variation (Hastings et al., 2009). Some CNVs maybe 
more prevalent, however, GLO1 CNV increase was common to all three tissues 
examined - hypothalamus, hematopoietic and adipose (Cahan et al., 2009).  
 Williams et al. analysed gene copy number in mice strain using a Hidden 
Markov Model (HMM) approach and Affymetrix exon arrays. This assigns 
probabilities to hybridisation probes for three states: duplicated, deleted or ground, 
relative to the B6 reference strain. They identified the GLO1 locus as a hotspot for 
CNV in mice with particular strains undergoing duplications (Williams IV et al., 
2009). Presence of the duplication is related with 4-fold increased in GLO1 
expression (Williams IV et al., 2009, Cahan et al., 2009).  
Furthermore, GLO1 CNV was found in the human genome (Redon et al., 
2006). Redon et al. constructed a first-generation CNV map of the human genome by 
investigating 270 subjects from four populations with ancestry in Europe, Africa or 
Asia. A total of 1,447 CNV regions were detected covering 12% of the genome. The 
only gene found in a copied region of ca. 122 kb was GLO1. There were 5 copy 
number increases, suggesting a normal GLO1 CNV prevalence ca. 2% (Redon et al., 
2006). GLO1 CNV was confirmed in the human population (Wong et al., 2007) and 
also found in other primates (Perry et al., 2008). 
 
1.5.4 Glyoxalase 1 - a critical role in enzymatic defence against glycation 
Glycation of proteins leads to protein modification which can cause structural 
derangement, impaired function and loss of side chain charge. Increase of the 
glycation adducts have been associated to chronic diseases. In physiological systems, 
glycation of protein is prevented and repaired by elements of the enzymatic defence 
against glycation. The concept of this enzymatic defence against glycation was 
established by Thornalley in 2003 and includes activities of enzymes that prevent the 
glycation adducts formation and also repair sites of early glycation (Thornalley, 
2003b, Thornalley, 2003a). These include Glo1, aldehyde reductase, aldehyde 
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dehydrogenase, amadoriase and fructosamine 3-kinase. Detoxification of reactive α-
oxoaldehydes - specifically MG, glyoxal and 3-DG - is performed by Glo1, aldehyde 
reductases and aldehyde dehydrogenase. Fructosamine 3-kinase catalyse the removal 
of fructosamine glycation adducts which formed by glucose protein glycation. The 
enzymatic defence against glycation decreases the damage to the proteome. 
However, it does not totally prevent it as glycation of proteins, nucleotides and basic 
phospholipids still occurs but it is suppressed to a low tolerable level (Thornalley, 
2003b). In disease states, such as diabetes and chronic and acute renal failure, the 
enzymatic defence against glycation is overwhelmed and hence glycation adducts 
increase. Glo1 is the major defence against glycation by MG and glyoxal. The 
decline of Glo1 expression with age may contribute to the development of ageing 
and ageing associated disease (Morcos et al., 2005).  
 
1.5.5 Glyoxalase inhibitors 
Chemical inhibitors of Glo1 and Glo2 have been applied experimentally to 
observe the effects of endogenous elevation in dicarbonyls. Earlier studies revealed 
that glutathione thioether S-conjugate are substrate analogue inhibitors of Glo1 and 
may find use as anticancer drugs (Vince and Daluge, 1971, Vince et al., 1971). Early 
studies failed to demonstrate antitumour activity of  glutathione thioether S-
conjugates because prodrug modifications are required to facilate cell permeability 
and stabilise them from degreadation in the extracellular compartment. Inhibitors of 
Glo1 and Glo2 were developed by Lo and Thornalley (1992). Substrate analogue 
inhibitors of Glo1 had some residual inhibitory activity towards Glo1 (Bush and 
Norton, 1985). The problem of cell permeability and extracellular stability of 
glutathione thioether S-conjugates was solved by Lo and Thornalley who prepared 
diester derivataives. Glutathione thioether S-conjugate diesters, such as the prototype 
Glo1 cell permeable inhibitor S-p-bromobenzylglutathione cyclopenyl diester 
(BrBzGSHCp2), were permeable to cells as they have a major solution species which 
is unionised and were also stable in the extracellular compartment as esterified 
glutathion derivatives are poor substrates for γ-glutamyl transferase. Once inside 
cells, glutathione thioether S-conjugate diesters are de-esterified by cell non-specific 
esterase and the Glo1 inhibitor is produced and trapped in the cell cytosol wherein 
lies the Glo1 receptor (Thornalley, 2003b). The effects of different S-conjugates of 
glutathione on growth and viability of cells were examined (Lo and Thornalley, 
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1992). This showed that unesterfied inhibitors probably did not enter cells and are 
degraded and no cytotoxicity was found. Ester derivatives were found to be 
unaffected to cleavage by the enzyme γ-glutamyltransferase and so more capable to 
enter cells, where the ester groups would be cleaved, representing the inhibitor in 
active form. Accordingly, BrBzGSHCp2 was found to be a cell permeable inhibitor 
of Glo1 appropriate for use in cell based trials and also proposed to be of use in 
inhibiting tumour growth and prompting apoptosis (Thornalley et al., 1996). 
 
1.6 Dicarbonyls 
1.6.1 Dicarbonyl stress 
Dicarbonyl stress is the abnormal accumulation of α-oxoaldehyde metabolites 
causing increased protein and DNA modification leading to cell and tissue 
dysfunction. This contributes to cell and tissue dysfunction in ageing and disease 
(Rabbani and Thornalley, 2014b). There are many examples including the elevation 
of MG in ageing plants, elevation of MG-protein modification in ageing human lens, 
elevation of plasma and tissue concentration of MG in diabetes, and elevation of 
MG, glyoxal, 3-DG concentrations and other dicarbonyls in renal failure (Rabbani 
and Thornalley, 2015). Dicarbonyl stress is a result of an imbalance between the 
formation of dicarbonyl metabolites and the enzymatic metabolism of them and also 
by increased exposure to exogenous dicarbonyls (Mingzhan et al., 2012). Normal 
levels of glyoxal, MG and 3-DG in human plasma are 50 - 150 nM and 1 - 4 μM in 
plant and mammalian cells. When dicarbonyl concentrations increase beyond this, 
dicarbonyl stress arises and contributes to impaired health and disease (Rabbani and 
Thornalley, 2015) 
 
1.6.2 Dicarbonyl glycation and protein damage 
1.6.2.1 Physiological dicarbonyl and historical aspects 
Dicarbonyl compounds are intermediates of the Maillard reaction. The 
complexity of the Maillard reaction appears from multiple fragmentation reactions of 
sugar moiety, creating branch points in the reaction network. Saccharides may suffer 
dehydration, oxidation and fragmentation reactions before attaching to an amine 
substrate and therefore many equivalent reaction pathways may happen. Moreover, 
there are reactive dicarbonyls in the physiological systems. These reactive 
dicarbonyls – particularly α-oxoaldehydes - are important reactive intermediates of 
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Maillard reaction as they redirect minor but important part of the flux of glycation 
reaction intermediates to form AGEs on functional arginine residues (Thornalley, 
2005). 
In 1898, Pinkus discovered degradation of glucose to reactive α-
oxoaldehydes. Since then their contribution to glycation in physiological systems and 
food has been extensively investigated. α-Oxoaldehydes are important saccharide 
derivatives as they make major quantitative and functional contributions in 
physiological systems. α-Oxoaldehydes are potent glycating agents, being 200 - 
20,000 times more reactive than glucose and form AGEs directly. For example, 
incubation of human plasma ex vivo at 37 oC with 1 µM [14C]MG led to complete and 
irreversible binding of MG to plasma protein within 24 h (Thornalley, 2005). 
Dicarbonyl concentrations in physiological systems are 10,000 - 50,000 times lower 
than glucose. Nevertheless, reactive dicarbonyls remain important AGEs precursors. 
MG, glyoxal and 3-DG are the main dicarbonyls – Figure 16. The most important 
dicarbonyl is MG as it has high reactivity, relatively high flux of formation in vivo 
and undergoes glycation directed mostly but not exclusively to functional arginine 
residues to form the most quantitatively predominant AGE, MG-H1 (Thornalley, 
2005). An example of MG modification of protein is glycation of mitochondrial 
proteins. Glycation of mitochondrial protein by MG was associated with increased 
ROS and protein damage by oxidation and nitration (Thornalley, 2008). 
 
 
Figure 16: Physiological dicarbonyl metabolites. 
 
1.6.2.2 Metabolic sources and reactions 
MG is formed in vivo by non-enzymatic elimination of phosphate from the 
triosephosphates - glyceraldehyde-3-phosphate (GA3P) and 
dihydroxyacetonephosphate (DHAP) (Philips and Thornalley, 1993). GA3P is more 
reactive than DHAP in degradation to MG but this is countered by the concentration 
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ratio of DHAP/GA3P in cells in situ such that the contributions of GA3P and DHAP 
degradation to MG formation are similar (Philips and Thornalley, 1993). 
Triosephosphates are intermediates of anaerobic glycolysis (Embden-Meyerhof 
pathway) and also gluconeogenesis and glyceroneogenesis pathways – the latter is 
increased in obesity by cycling of triglycerides and free fatty acids from the liver to 
adipose tissue. MG is also formed by cytochrome E4502 E1-catalysed oxidation of 
acetone from ketone bodies, degradation of threonine via aminoacetone, degradation 
of monosaccharides and by degradation of proteins glycated by glucose (Thornalley, 
2005). 
There are three forms of MG in aqueous solution under physiological 
settings: dihydrate CH3C(OH)2CH(OH)2 (28%), monohydrate CH3COCH(OH)2  
(71%) and the reactive unhydrated form CH3COCHO (1%) (Rabbani and Thornalley, 
2012a). MG reacts with arginine residues to produce the quantitatively dominant 
AGE which is known in physiological systems as MG-H1 (Thornalley et al., 2003b, 
Ahmed et al., 2005a) and a minor fluorescent AGE argpyrimidine. There are other 
minor adducts formed with lysine residues and arginine and lysine residues: CEL, 
MOLD and MODIC (Ahmed et al., 2005a, Thornalley et al., 2003b). Increase of 
glucose level cause increased MG production in cultured endothelial cells (Shinohara 
et al., 1998, Queisser et al., 2010, Dobler et al., 2006), rats (Queisser et al., 2010) and 
human subjects with prediabetes and diabetes (Beisswenger et al., 2001). Cellular 
glucose uptake is controlled by GLUT1 receptors in endothelial cells; increased 
glucose uptake by GLUT1 leads to cytosolic hyperglycaemia and increased glucose 
metabolism (Dobler et al., 2006). This increases flux of MG formation. Decrease in 
Glo1 activity also occurs (Phillips et al., 1993, McLellan et al., 1994a) and this 
synergises with increased MG flux to increase the concentration of MG (Rabbani et 
al., 2014b). When MG concentration increases, the rate of formation and steady-state 
concentration of AGEs (Dobler et al., 2006), apoptosis of retinal pericytes (Liu et al., 
2004a) and oxidative stress is enhanced (Rabbani and Thornalley, 2008a). AGE 
formation is induced by MG leads to modification of protein which can cause 
structural derangement, impaired function and loss of side chain charge (Thornalley, 
2008). Some MG protein modifications studied includes: human serum albumin 
(Ahmed et al., 2005c), haemoglobin (Chen et al., 2005), vascular basement 
membrane of type IV collagen (Dobler et al., 2006), low density lipoproteins (LDL) 
(Rabbani et al., 2010, Rabbani et al., 2011) and high density lipoproteins (HDL) 
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(Godfrey et al., 2014). There are several pathological changes increased such as: 
angiopoietin-2 transcription (Yao et al., 2007), increased superoxide formation 
(Rosca et al., 2005), and alteration of fibroblast activity (Giardino et al., 1994). 
Physiological formation of glyoxal occurs by auto-oxidation of glucose and by 
lipid peroxidation (Thornalley, 2005). Glyoxal targets arginine and lysine protein 
residues to form hydroimidazolone G-H1, CMA, CML, GOLD and GODIC (Nangia-
Makker et al., 1993, Lo et al., 1994b). Protein glycation by glyoxal also causes 
structural distortion and functional impairment. 
3-DG is a glucose and fructosamine derived α-oxoaldehyde and glycating 
agent. It is ca. 100-fold less reactive than MG. 3-DG reacts with lysine and arginine 
proteins residues to form particular AGEs – hydroimidazolones 3DG-H1 and 
associated structural isomers and pyrraline (Beisswenger et al., 2003, Thornalley et 
al., 2003b). The enzymatic activity of fructosamine-3-kinase (F3K) is a major source 
for 3-DG. F3K phosphorylates fructoselysine to 3-phospho fructoselysine which 
degrades spontaneously to lysine, phosphate and 3-DG (Thornalley, 2005, 
Beisswenger et al., 2003). Raised levels of 3-DG have been found with diabetes 
(Beisswenger et al., 2003). Important association has been found between increased 
3-DG concentrations and glomerular hyperfiltration and diabetic nephropathy 
(Beisswenger et al., 2003). High levels of 3DG-H were found in the kidneys of 
diabetic patients and animals (Niwa et al., 1996, Karachalias et al., 2010). 
Additionally, 3-DG causes foetal malformation which is a feature of diabetic 
embryopathy (Eriksson et al., 1998). 
 
1.6.3 DNA glycation by dicarbonyls 
DNA has susceptibility to glycation by MG and glyoxal. Deoxyguanosine 
(dG) is the most reactive nucleotide towards dicarbonyl glycation under 
physiological conditions. The main nucleotide AGEs include imidazopurinone 
derivatives 3-(2ʹ-deoxyribosyl)-6,7-dihydro-6,7-dihydroxyimidazo[2,3-b]purin-
9(8)one (GdG) derivative of glyoxal and 3-(2ʹ-deoxyribosyl)-6,7-dihydro-6,7-
dihydroxy-6-methylimidazo[2,3-b]purin-9(8)one (MGdG) derivative of MG 
(Thornalley et al., 2010). There are other adducts formed by glyoxal including: N2-
carboxymethyl-deoxyguanosine (CMdG) and 5-glycolyldeoxycytidine (gdC). A 
further minor adduct formed by MG is N2-(1-carboxyethyl)-deoxyguanosine (CEdG) 
(Thornalley et al., 2010). These are nucleotide AGEs. DNA glycation is related to 
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mutagenesis, DNA strand breaks and cytotoxicity (Thornalley, 1999). Nucleotide 
excision repair (NER) suppress glycation of nucleotide and its detrimental effects 
(Murata-Kamiya et al., 1998, Murata-Kamiya et al., 1999, Pischetsrieder et al., 
1999). Mutation by MG-derived nucleotide AGEs leading to carcinogenesis may 
underlie why Glo1 is considered a tumour suppressor protein (Zender et al., 2008). 
 
1.6.4 Measurement of dicarbonyls 
A problem in this research area is to perform a reliable estimation of the MG 
and glyoxal concentrations in physiological systems. MG and glyoxal may be 
produced by degradation of monosaccharides, glycated proteins, glycolytic 
intermediates and derivatising agents during pre-analytic processing. Therefore, 
physiological concentrations of MG and glyoxal have often been overestimated. 
Chemical derivatisation of α-oxoaldehydes is important for required assay 
sensitivity. Best methods have been: (i) derivatisation with 1,2-diaminobenzene and 
gas chromatography with mass spectrometric detection (GC-MS) (Beisswenger et al., 
1999), and (ii) liquid chromatography with tandem mass spectrometric detection 
(LC-MS/MS) with stable isotopic dilution analysis (Dobler et al., 2006, Kurz et al., 
2011). A reference protocol has been published (Rabbani and Thornalley, 2014c). 
The concentrations of MG and glyoxal in human blood plasma are in between 100 – 
120 nM and cellular concentrations of MG (1 – 5 µM) and glyoxal (0.1 – 1 µM) 
(Dobler et al., 2006, Kurz et al., 2011). This is corroborated by independent 
predictions from metabolic models of MG glycation (Rabbani and Thornalley, 
2014c). Failure to control interferences during sample processing has led to 10 – 
1000-fold overestimates. 
Following from this, experiments to study effects of glyoxal and MG on 
cultured cells and tissues have used concentrations 10- 1000- fold higher than found 
physiologically. These are likely to be only applicable for acute intoxication and 
cytotoxicity. The use of MG at millimolar concentrations to show insulin signalling 
impairment, for example, is of unlikely physiological relevance (Riboulet-Chavey et 
al., 2006). Extreme overestimates of MG concentration lead to exaggeration of the 
physiological and toxicological role of MG in physiological setting and thus to the 
uncertainty of the health risks posed by endogenous exposure to MG in aging and 
disease, in healthcare products (such as thermally sterilized dialysis fluids), in foods 
and beverages, and in the environment. A well-validated reference protocol for MG 
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assay and systems modelling corroboration of estimates will hopefully decrease risk 
of overestimation in the future (Rabbani and Thornalley, 2014c). 
 
1.6.5 Dicarbonyl proteome 
Proteins vulnerable to glycation by dicarbonyls with associated functional 
impairment are called as the 'dicarbonyl proteome' (DCP) (Rabbani and Thornalley, 
2008b). Proteomic applications have been conducted to recognise the DCP (Ahmed 
et al., 2005c, Dobler et al., 2006). Proteins include albumin (Ahmed et al., 2005c), 
haemoglobin (Chen et al., 2005), type IV collagen (Dobler et al., 2006), LDL 
(Rabbani et al., 2011), HDL (Godfrey et al., 2014), co-repressor protein sina3A (Yao 
et al., 2007), αA lens crystallin (Gangadhariah et al., 2010), HIFIα co-activator 
protein p300 (Thangarajah et al., 2009) and 20S proteome subunits (Queisser et al., 
2010) are recognised to be susceptible to MG glycation and hotspot sites for 
modification by MG within them have been identified. 
In human serum albumin, MG produced hotspot modification of Arg-410 in 
vitro and in vivo (Ahmed et al., 2005c). Arg-410 is located in the drug-binding site II 
and the active site of albumin-associated esterase activity. The MG-H1 residue 
formed inhibited drug binding and esterase activity. 
MG modified vascular basement membrane collagen-IV, forming MG-H1 
residues at hotspot modifications sites in arginine-glycine-aspartate (RGD) glycine-
phenylalanine-hydroxyproline-glycine-glutamate-arginine (GFOGER) integrin 
binding sites of collagen (Dobler et al., 2006). This caused detachment of endothelial 
cells, anoikis and decreased angiogenesis. MG modification of collagen-IV in vivo 
likely contributes to the increased number of circulating endothelial cells found in 
diabetes and renal failure which is a risk predictor of CVD. 
MG reacts with lipoproteins, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL). LDL minimally modified by MG (MGmin-LDL) contained mostly 
hydroimidazolone MG-H1 and accounted for 3 – 10% LDL in vivo. MGmin-LDL had 
decreased particle size, increased binding to proteoglycans and increased aggregation 
in vitro. Cell culture studies showed that MGmin-LDL was bound by the LDL 
receptor but not by the scavenger receptor, and had increased binding affinity for cell 
surface heparan sulfate-containing proteoglycan. Radiotracer studies in rats showed 
that MGmin-LDL had similar fractional clearance rate in plasma to unmodified LDL 
but increased partitioning onto the aortal wall. Mass spectrometry peptide mapping 
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identified the arginine hotspot site of apolipoprotein B100 modification in MGmin-
LDL. A computed structural model predicted that methylglyoxal modification of 
apolipoprotein B100 induces distortion, increasing exposure of the N-terminal 
proteoglycan binding domain on the surface of LDL. Methylglyoxal modification of 
LDL forms small, dense LDL with increased atherogenicity. This non-oxidative 
process may explain escalation of cardiovascular risk in diabetes and renal failure, 
and resistance of early stage atherosclerosis to antioxidant therapy. Quantitation of 
methylglyoxal-modified LDL may improve cardiovascular disease risk models 
and therapeutics to decrease methylglyoxal may improve preventive treatment of 
cardiovascular disease (Rabbani et al., 2011). 
MG-modified HDL was also found in vivo. Major fractions of HDL were 
isolated from healthy human subjects and patients with T2DM and fractions 
modified by MG and related dicarbonyl metabolites quantified. HDL modified by 
MG and related dicarbonyl metabolites accounted for 2.6% HDL and increased to 
4.5% in patients with T2DM. HDL fractions were glycated by MG to minimum 
extent in vitro and molecular, functional and physiological characteristics 
determined. MG modification induced re-structuring of the HDL particles, 
decreasing stability and plasma half-life in vivo. It occurred at sites of apolipoprotein 
A-1 linked to membrane fusion, intramolecular bonding and ligand binding. Kinetic 
modelling of methylglyoxal modification of HDL predicted a negative correlation of 
plasma HDL-C with methylglyoxal-modified HDL which could be validated 
clinically. It also predicted dicarbonyl modification produces 2 - 6% decrease in total 
plasma HDL and 5 - 13% decrease in functional HDL clinically. MG modification of 
HDL may accelerate HDL degradation and impairs its functionality in vivo, likely 
contributing to increased risk of cardiovascular disease (Godfrey et al., 2014). 
Recent application of high resolution mass spectrometry proteomics has 
attempted to identify globally the dicarbonyl proteome. In pilot studies using 
nanoflow liquid chromatography-Orbitrap FusionTM mass spectrometry with peptide 
HCD fragmentation, we analysed cytosolic protein extracts of human aortic 
endothelial cells in primary culture. In control samples, cell cytosolic protein had a 
total MG-H1 residue content of ca. 0.4 mmol/mol arg measured by LC-MS/MS 
analysis of exhaustive enzymatic digests; while in tryptic digests, Orbitrap Fusion 
analysis detected 1027 proteins of which 12 contained MG-H1 or MG-derived 
dihydroxyimidazolidine residues. After incubation of cytosolic protein extracts with 
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exogenous MG to increase the MG-H1 content ca. 20-fold, we then detected total 
MG-H1 residue content of ca. 8 mmol/mol arg and identified 1366 proteins of which 
344 now contained MG-H1 or MG-derived dihydroxyimidazolidine residues 
(Rabbani and Thornalley, 2014a). In a recent report (Schmidt et al., 2015), plasma 
digests were analysed by nanoflow chromatography-LTQ Orbitrap XL ETD mass 
spectrometry and tryptic peptides scanned for m/z 152.1 and 166.1 indicative of 
glyoxal and MG modified proteins. Forty-four peptides representing 42 proteins were 
annotated. Arginine modifications were mostly represented by glyoxal-derived 
hydroimidazolones (34 peptides/39 sites) and MG-derived dihydroxyimidazolidine  
(8 peptides/8 sites) and MG-H1 (14 peptides/14 sites). Use of high temperature and 
pH processing in this study may have compromised the outcome; many glyoxal 
modified proteins were detected whereas LC-MS/MS analysis typically shows very 
low amounts of glyoxal-derived-AGEs, hydroimidazolone and Nω-
carboxymethylarginine, in plasma protein (Ahmed et al., 2005b). 
Protein modification by MG is damaging because it is directed to arginine 
residues and arginine residues have the highest probability of any amino acid residue 
to be located at functional sites in proteins - sites of protein-protein, enzyme-
substrate or protein nucleotide interaction (Gallet et al., 2000). MG modification 
causes loss of charge of the arginine residue and functional inactivation of the 
protein. MG modification tends to be directed to functional arginine residues because 
the accessibility and depolarisability of the electronic charge that confers the 
functional role is also activates the residue for MG modification (Rabbani and 
Thornalley, 2014a). 
 
1.6.6 Clinical implications of dicarbonyls 
Reactive dicarbonyls and the related glycation adducts with nucleotides and 
proteins are implicated in ageing and number of pathological processes and diseases 
such as diabetes, tumourigenesis and multi-drug resistance, and neurodegenerative 
diseases (Brownlee, 2005, Kuhla et al., 2005, Morcos et al., 2008, Rabbani et al., 
2011, Thornalley, 2008). 
 
1.6.7 Repair of glycated proteins 
The main early stage glycation adduct of glucose, FL, can be de-glycated. 
Therefore, glycated proteins can be repaired by a pathway catalysed by fructosamine 
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3-kinase (Delpierre et al., 2000, Pascal et al., 2009). However, currently there is no 
recognised de-glycation mechanism for hydroimidazolone-modified proteins 
(Rabbani and Thornalley, 2012c). Proteins having hydroimidazolone adducts contain 
distorted and damaged structures and possibly as a result are directed to the 
proteosome for proteolysis (Dobler et al., 2006, Hernebring et al., 2006). MG-H1 
free adducts are thereby released from proteins for urinary excretion. MG-H1 free 
adducts are found in plasma and urine in both laboratory rodents and human subject 
(Karachalias et al., 2010, Thornalley et al., 2003a). 
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1.7 Project-specific background 
1.7.1 Measurement of protein glycation, oxidation and nitration 
1.7.1.1 Advances in measurement of protein glycation, oxidation and nitration 
adducts 
The analysis of protein glycation, oxidation and nitration adducts involves  
the detection and quantitation of trace amounts (fmol – pmol) of multiple glycated, 
oxidised and nitrated amino acids with the presence of 103 - 106 fold excess of 
associated unmodified amino acids. This provides a profound challenge for the 
analytical methodology employed. Many adducts are also unstable in pre-analytic 
processing at high pH and temperature. Protein glycation, oxidation and nitration 
adducts have been analysed by immunoassay (Wu and Steward, 1991, Yamamoto et 
al., 1989) and fluorescence (Vishwanath et al., 1986). The gold standard reference 
method for quantification is stable isotopic dilution analysis LC-MS/MS. 
 
1.7.1.2 Immunoassay 
Immunoassays were used initially for quantifying protein glycation, oxidation 
and nitration adduct analytes. Immunoassays have good analytical performance for 
specific and high affinity binding for peptide and protein analytes. However, there 
may be poor and insufficient antigen specificity in detection of protein glycation, 
oxidation and nitration adducts. For example, monoclonal antibody 6D12 was 
initially thought to bind CML residues specifically but later it was revealed that it 
binds both CML and CEL residues; indeed, it binds CEL preferentially over than 
CML (Ikeda et al., 1996, Koito et al., 2004). There are other interferences in pre-
analytic processing of immunoassays: introduction of analyte into the assay matrix in 
blocking proteins to reduce non-specific binding of the antibody, creation of analyte 
during sample processing and effects of complex sample matrix on antibody 
function. Examples of interferences include: use of physiological proteins as 
blocking proteins which contain protein glycation, oxidation and nitration adduct 
residues – this may be avoided by use of synthetic polyamino acids lacking amino 
acid residue substrates of glycation, oxidation and nitration adducts (Rabbani et al., 
2011), processing samples having FL residues at high pH for CML measurement 
where CML residues are formed from FL residues during the high pH processing 
step, and use of AGE immunoassays for food analysis when calibration, development 
and validation of the immunoassay was performed in a diluted plasma or serum 
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sample matrix. Thus, immunoassays have frequently given variable and 
overestimated values of analyte content and poor reproducibility. Nevertheless, 
immunoassays have analytical advantages: assessment of spatial localisation of 
antigen in immunohistochemistry, high throughput and relatively low cost. 
Therefore, if immunoassays can be validated and corroborated to LC-MS/MS 
reference methods they stay a very valuable analytical source. 
 
1.7.1.3 Fluorescence 
Assays based on fluorescence are limited to the minor number of protein 
glycation and oxidation adduct analytes that are fluorescent. A chromatographic 
resolution step is required for quantitative measurement. AGEs have been measured 
by “total AGE fluorescence”, determining fluorescence with excitation and emission 
wavelengths of 350 nm and 450 nm, respectively (Šebeková et al., 2001). Later, the 
method of measuring total AGE fluorescence has been improved to detect low 
molecular mass AGE peptides or free adducts (Thomas et al., 2004, Wróbel et al., 
1997). These methods have several analytical difficulties: (1) the major quantitative 
AGEs are not fluorescent and hence are not detected (Rabbani and Thornalley, 
2009), (2) the oxidative adduct and fluorophore, N-formylkynurenine cause 
significant interference (Buxton and Guilbault, 1974), and (3) there are different 
fluorophores contribute to the global measure of fluorescence each with a different 
specific fluorescence, therefore, no quantitation can be achieved – Table1. Estimates 
of “total AGE fluorescence” provide a qualitative measure of damage made by both 
glycation and oxidation adduct fluorophores. 
Oxidation of tryptophan produces fluorophores NFK and kynurenine 
(Fukunaga et al., 1982). Interaction of proteins with the lipid peroxidation product 
malondialdehyde produces fluorophores such as 3,5-diformyl-1,4-dihydropyridin-4-
yl-pyridinium derivatives (Yamada et al., 2001) and related crosslinks (Itakura et al., 
1996). These and other compounds such as retinoid derivatives in retinal tissue 
(Eldred and Lasky, 1993, Sparrow et al., 1999) may contribute to the fluorescence of 
the ageing pigment “lipofuscin” – although the mixture of fluorophores is complex 
(Li et al., 2006).  
 
 
107 
 
Table 1: Fluorophores associated with protein damage by glycation and 
oxidation. 
Fluorophore Structure 
Fluorescence 
characteristics: 
λexcitation, 
λemission 
Reference 
Glycation 
Pentosidine 
 
335 nm, 385 nm 
(Sell and 
Monnier, 1989) 
Argpyrimidine 
 
320 nm, 385 nm 
(Shipanova et 
al., 1997) 
Vesperlysine A 
(LM-1) 
 
345 nm, 405 nm 
(Tessier et al., 
1999) 
“AGE 
fluorescence” 
Multiple 350 nm, 440 nm 
(Monnier et al., 
1984) 
Oxidation 
N-
Formylkynureni
ne 
 
325 nm, 434 nm 
(Fukunaga et 
al., 1982) 
Kynurenine 
 
365 nm, 480 nm 
(Fukunaga et 
al., 1982) 
2-Amino-6-(3,5-
diformyl-1,4-
dihydro-4-
methyl-pyridin-
1-yl)hexanoic 
acid 
 
387 nm, 455 nm 
(Yamada et al., 
2001) 
“Fluorescent 
oxidation 
products” 
Multiple fluorophores 360 nm, 430 nm 
(Shimasaki, 
1994) 
Lipofuscin Multiple fluorophores 
340 – 390 nm, 
430 – 490 nm 
(Li et al., 2006, 
Sohal, 1981) 
Modified from (Xue, 2009).  
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1.7.1.4 Stable isotopic dilution analysis liquid chromatography with tandem 
mass spectrometric detection (LC- MS/MS) 
Isotopic dilution analysis liquid chromatography with tandem mass 
spectrometric detection (LC-MS/MS) is the gold standard reference method used for 
analysis of protein glycation, oxidation and nitration adducts - as described 
(Thornalley et al., 2003b). Protein glycation, oxidation and nitration adduct residues 
in protein samples can be determined after exhaustive enzymatic hydrolysis. Protein 
glycation, oxidation and nitration free adducts are determined in ultrafiltrate of 
physiological fluids, typically prepared using a 3 kDa or 12 kDa cut-off microspin 
filter. This technology was developed in our group and many research teams are now 
using it. Other techniques – especially immunoassay - are useful for high sample 
throughput but the protocol and use in a particular sample matrix should be 
corroborated to the reference LC- MS/MS method before use. Ultra-high 
performance liquid chromatography with tandem mass spectrometric detection 
(UPLC-MS/MS) and robotic automation of enzymatic hydrolysis techniques are now 
used. Some examples of protein glycation, oxidation and nitration adducts markers 
by isotopic dilution analysis LC-MS/MS are illustrated in Table 2.  
 
Table 2: Protein glycation, oxidation and nitration adducts markers determined 
by stable isotopic analysis LC-MS/MS 
Analyte group Analyte 
Early glycation adduct FL 
Advance glycation adduct AGEs 
 
Hydroimidazolones MG-H1, G-H1, 3DG-H 
Monolysyl AGEs CEL, CML, pyrraline 
Imidazolium AGEs MOLD, GOLD, DOLD 
Fluorescent AGEs Pentosidine, argpyrimidine 
Other Nδ-carboxymethylarginine 
 
S-carboxymethylcysteine, ornithine 
Oxidation adducts 
MetSO, dityrosine, NFK, 
alpha-aminoadipic semialdehyde, glutamic 
semialdehyde 
Nitration adducts 3-NT 
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1.7.2 Therapeutic approaches to counter dicarbonyl stress 
Investigational therapeutic interventions to counter dicarbonyl stress have 
mainly been based on scavenging by chemical agents. Aminoguanidine or 
PimagedineTM is a dicarbonyl scavenger that inhibits AGE formation (Thornalley, 
2003c). The first report of use of aminoguanidine was by Brownlee et al. to suppress 
AGE formation in diabetes-induced arterial wall protein crosslinking (Brownlee et 
al., 1986). Aminoguanidine reacts with dicarbonyls such as glyoxal, MG and 3-DG 
and produce 3-amino-1,2,4-triazine derivatives (Thornalley et al., 2000). It was 
evaluated as a potential therapeutic agent for vascular complications of diabetes. 
However the clinical use of aminoguanidine was halted due to toxicity and poor 
clinical efficacy (Thornalley, 2003c). Dicarbonyl scavengers require high intrinsic 
chemical reactivity and hence toxicity may be expected. 
Other dicarbonyl scavengers under development are N-terminal 2,3-diamino-
propionic acid peptides (Sasaki et al., 2009), 3,3-dimethyl-D-cysteine (Wondrak et 
al., 2002), functionalised polymer beads with dicarbonyl scavenging has been 
proposed for dialysis fluid (Yamamoto et al., 2007) and phenacylthiazolium 
compounds (Ferguson et al., 1999). The latter compound exhibited a further problem 
of reactive scavengers – it was unstable in aqueous solution and degraded with 
acidification of cell cultures used in experimental evaluations (Thornalley and 
Minhas, 1999). 
Supplementation with high dose of thiamine and related derivatives may 
decrease MG formation by activating the reductive pentosephosphate pathway and 
suppressing triosephosphate concentrations. Increased oxidative pentosephosphate 
pathway activity increases NADPH formation to sustain activities of aldoketo 
reductases and indirectly preserve Glo1 activity by GSH reductase activity and GSH 
levels. Supplementation with high dose of thiamine prevented and reversed early-
stage diabetic nephropathy in experimental and clinical diabetes (Babaei-Jadidi et al., 
2003, Rabbani et al., 2009). S-Benzoylthiamine-monophosphate (Benfotiamine) 
supplementation in experimental peritoneal fluid decreased peritoneal fibrosis, 
markers of inflammation and neovascularisation causing improvements in 
characteristics of peritoneal transport (Kihm et al., 2011). These beneficial effects 
may be related to decrease of dicarbonyl stress (Babaei-Jadidi et al., 2003). 
Metformin, or N,N-dimethylbiguanide, is a extensively recommended drug 
for the treatment of type 2 diabetes and other metabolic syndromes. Moreover, 
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metformin shows antioxidant properties and it has been exhibited in neurogenesis, 
spatial memory formation and reduce the risk of Parkinson’s disease (Solís-Calero et 
al., 2015). Previously, it has been suggested that metformin scavenges α-dicarbonyl 
compounds and inhibiting the subsequent creation of AGEs. Metformin reacted with 
MG and glyoxal and led to triazepinone derivatives formation (Ruggiero-Lopez et 
al., 1999) and more recently hydroimidazolone derivatives (Kinsky et al., 2016)– 
although the amounts of adducts formed are too low to account for marked 
suppression of plasma MG concentration. Thornalley and co-worker investigated the 
kinetics of reaction of metformin with MG and concluded that it is not kinetically 
competent to be an effective MG scavenger in vivo (Battah et al., 2002)– this 
corroborates with the findings of low levels of MG adducts. Metformin has the 
advantage of as drug which is safe and a good tolerability profile (Solís-Calero et al., 
2015).  
A recent advances in approaches to decline dicarbonyls is the potential use of 
Nrf2 activators that may stimulate expression of Glo1, aldoketo reductase and 
aldehyde dehydrogenase isozymes to enhance the metabolism of dicarbonyls (Xue et 
al., 2012a). Methyl 2-cyano-3,12-dioxo-oleana-1,9(11)dien-28-oate (Bardoxolone 
methyl) recently shows benefits for treatment of diabetic patients with stage 3-4 renal 
disease (GFR= 20-45 ml/min/1.73m2 of body surface area) (Pergola et al., 2011). 
However, bardoxolone methyl is a weak inducer of Glo1 expression (Xue et al., 
2012a). Its development was halted due to adverse effects (Chin et al., 2014). Small 
molecule activators of Nrf2 increase expression of different ARE-linked gene subsets 
(Xue et al., 2015a, Xue et al., 2015c)- likely due to the ability of Nrf2 activators to 
recruit the requisite accessory proteins and increase nuclear concentration of 
functionally active Nrf2 to the level required for increased expression of the ARE-
linked gene of interest. A specific functional screen for GLO1-ARE transcriptional 
activation was therefore required. Thus developing of Glo1 inducers to enhance 
dicarbonyls metabolism is required. Dicarbonyls metabolism by Glo1 inducers as a 
pharmacologic strategy for therapeutic intervention has a superior advantage over 
other methods like chemical scavenging. Resveratrol (RSV) was found to be a Glo1 
inducer (Chen et al., 2012). 
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1.7.3 Resveratrol 
RSV (3,5,4'-trihydroxylstilbene; RSV) is a natural polyphenol with 2 
aromatic rings linked by a methylene bridge (Baur and Sinclair, 2006). It exists in 
two geometric isomer forms - trans (tRSV) and the cis (cis-RSV) isomers; inter-
conversion of trans- to cis- isomer is promoted by exposure to UV light (Constant, 
1997). Normally, RSV is found in grapes, red wine, certain other red berries, 
Japanese knotweed, peanuts, roots of rhubarb and other plants from trace to mg/g 
contents. RSV content increases 2 - 10 fold when grapes are exposed to UV light 
(Shakibaei et al., 2009) - Table 3. tRSV is the major form found naturally in plants 
and has the significant biological activity. It is a phytoallexin that defends plants 
against fungal infection – such as the grey mould fungus Botrytis cinerea. RSV was 
discovered in 1940 as a phenolic element of the medicinal herb hellebore-Veratrum 
grandiflorum (Takaoka, 1940). In 1992, Siemann and Creasy suggested RSV may 
have a role in the cardioprotective effects of red wine (Siemann and Creasy, 1992). It 
is considered to be one of the wine components which responsible for the French 
paradox. The French paradox is the phenomena of low mortality related to coronary 
heart disease despite a lifestyle containing a high-fat diet and smoking (Yu et al., 
2012). The skin and seeds of grape varieties Vitis vinifera, Labrusca, and Muscadine 
may contain 50-100 µg RSV per gram fresh weight and the concentration in wine 
varies between 0.1 to 14 mg/l for red wine and from 0.04 to 3.5 mg/l for white wine 
(with the greatest concentrations observed in wines from Pinot noir grapes) (Mark et 
al., 2005, Pervaiz, 2003, Lekli et al., 2010). Subsequently, RSV has been widely 
studied and claims of protective effects against a variety of chronic diseases - mainly 
cardiovascular atherosclerosis, cancer, diabetes and hypertension (Bradamante et al., 
2004, Jang et al., 1997, Fröjdö et al., 2008, Baur and Sinclair, 2006). A large number 
of pharmacological targets for RSV have been claimed - Table 4. Most potent 
activity is found for tRSV.  
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Table 3: Dietary sources of tRSV 
Source tRSV content Comments 
Red wines 0.1-14.3 mg l-1 
cis-RSV, trans-piceid* and cis-piceid* also 
present, typically at slightly lower 
concentrations 
White wines <0.1–2.1 mg l-1 
Generally tRSV found at concentrations of 
<0.1 mg l-1, exceptions include Swiss, 
Portuguese and German Riesling wines, cis-
RSV, trans-piceid and cis-piceid also 
present 
Ports and sherries 
Generally <0.1 
mg l-1 
  
Grapes 0.16–3.54 g g-1 
Contents are similar for wine or table 
grapes, and black or white grapes. trans-
Piceid is predominant at concentrations of 
1.5–7.3 g g-1 
Dry grape skins 
24.1 g g-1 
(average) 
trans-Piceid and cis-piceid found at 
concentrations of 42.19 g g-1 and 92.33 g 
g-1, respectively 
Red grape juices 
0.50 mg l –1 
(average) 
trans-Piceid, cis-piceid and cis-RSV found 
at concentrations of 3.38 mg l-1, 0.79 mg l-1 
and 0.06 mg l-1, respectively 
White grape 
juices 
0.05 mg l-1 
(average) 
trans-Piceid and cis-piceid found at 
concentrations of 0.18 mg l-1 and 0.26 mg l-
1, respectively 
Cranberry raw 
juice 
0.2 mg l-1 
cis-RSV also found at a concentration of 
0.03 mg l-1 
Blueberries 
Up to 32 ng g-
1 
  
Bilberries 
Up to 16 ng g-
1 
  
Other Vaccinium 
berries 
7–5,900 ng g-1 
(dry sample) 
Highest concentrations in lingonberries 
Peanuts 0.02–1.92 g g-1   
Roasted peanuts 0.055 g g-1   
Boiled peanuts 5.1 g g-1   
Peanut butters 
0.3–0.4 g g-1 
(average) 
trans-Piceid also found at a concentration of 
0.13 g g-1 
100% Natural 
peanut butters 
0.65 g g-1 
(average) 
trans-Piceid also found at a concentration of 
0.14 g g-1 
Pistachios 0.09–1.67 g g-1   
Groundnuts 
(Arachis 
hypogaea) 
ND   
Rhubarb ND   
Hops 0.5–1 g g-1 
trans-Piceid and cis-piceid found at 
concentrations of 2–9 g g-1 and 0.9–6 g g-
1, respectively 
Itadori 
(Polygonum 
0.68 mg l-1 
trans-Piceid also found at a concentration of 
9.1 mg l-1 
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cuspidatum) tea 
Herbal 
Veratrum (Lily) ND   
Cassia 
quinquangulata 
ND   
Gnetum klossii ND   
Polygonum 
cuspidatum 
0.524 mg g-1 
trans-Piceid also found at a concentration of 
1.65 mg g-1 
Rhubarb (Rheum 
rhaponticum) dry 
root 
3.9 mg g-1   
Yucca schidigera 
bark 
ND   
Modified from (Baur and Sinclair, 2006). 
*Piceid, stilbenoid glucoside, is the major resveratrol derivative in grape juices 
(Romero-Pérez et al., 1999). 
 
Table 4: Molecular targets of tRSV  
Modified from (Aggarwal and Shishodia, 2006). 
 
Target  Effect 
Metabolism and Aging 
Sirtuin-1 (Sirt1) , AMP-activated protein kinase 
(AMPK) , Glucose transporter (GLUT-4) ,  PDEs , 
Cytokines 
Transforming growth factor β2 (TGFβ2) ,  
Transforming growth factor α (TGFα) , Epidermal 
growth factor (EGF) ,  Tumour necrosis factor (TNF) 
, Interleukin (IL)-1β , Interleukin (IL)-6 , Vascular 
epithelial growth factor (VEGF) , Insulin like growth 
factor 1 receptor (IGF-1R) .   
Transcription Factors 
Activator protein-1 (AP-1) , Nuclear factor-kappa B 
(NF-κB) , Beta catenin (β-catenin) , Early growth 
response (erg)-1 , Androgen receptor (AR) . 
Cell Cycle Proteins 
Cyclin D1 , Retinoblastoma (Rb) , Cyclin A , 
Cyclin-dependent kinase (cdk)-2 , Cyclin B1 , 
P21CIp1/WAF1  , P27kip1  . 
Invasion and Metastasis 
Cyclooxygenase (COX)-2 , 5-Lipoxgenase (5-LOX) , 
Inducible nitric oxide synthase (iNOS) , Vascular cell 
adhesion molecules (VCAM-1) , Intercellular adhesion 
molecule (ICAM-1) , Tissue factor , 
NADPH:quinone oxidoreductase (NQO)-1 . 
Apoptosis FasL , Bax , Bel-2 , Surviving , P53 . 
Kinases 
Protein kinase C (PKC) , Syk , Protein kinase D 
(PKD) , Casein kinase II (CKII) , Extracellular 
signal-regulated kinase (ERK) ½ . 
Others 
Ribonucleotide reductase, DNA polymerase, 
CYP1A1, Nonsteroidal anti-inflammatory drug-
activated gene (NAG-1) . 
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Pharmacological mechanisms of action of tRSV in vivo are controversial 
because many cell-based studies in vitro have studied response to 10 – 50 µM tRSV 
and the upper limit of plasma concentration in human subjects is 2 µM (Boocock et 
al., 2007). Not the least of the concerns is the apparent activation of SIRT1 by tRSV 
has an EC50 of 22 µM (Lakshminarasimhan et al., 2013). This has led to the proposal 
that the basis for the apparent “activation” of SIRT1 by tRSV in vivo is through 
effects on increased availability of NAD+ co-factor rather than direct activation of 
SIRT1 enzyme (Cantó et al., 2009).  
 
1.7.3.1 Effect of tRSV on diabetes 
Anti-diabetic effects of tRSV 
Management of T2DM focuses on three main features of metabolic 
regulating: glycaemic control, protection of pancreatic β-cells and improvement of 
insulin action for T2DM. 
 
Glycaemic control 
Studies of Zucker obese rats treated orally with 5 mg/kg/day tRSV showed a 
modest decrease in blood glucose: 6.1 mM versus 7.1 mM (Lekli et al., 2008). In 
ob/ob obese mice, oral doses of 5 and 15 mg/kg/day tRSV were ineffective and 50 
mg/kg/day tRSV decreased blood glucose from ca. 14 mM to ca. 10 mM (Sharma et 
al., 2011). In STZ-diabetic rats and milder insulinopenic STZ-nicotinamide diabetic 
rats, orally administered 0.75 mg/kg/day tRSV decreased plasma glucose by 30 – 
50% (Su et al., 2006). Thirunavukkarasu et al. found similar effects in STZ-diabetic 
rats with oral 2.5 mg/kg/day tRSV and Palsamy and Subramanian, 2008 found 
similar effects in STZ-nicotinamide-diabetic rats with oral 5 mg/kg/day tRSV. 
Moreover, reduced levels of glycosylated haemoglobin (HbA1C) was detected in 
tRSV treated diabetic rats. This suggests prolonged reduction of glycaemia (Palsamy 
and Subramanian, 2010, Palsamy and Subramanian, 2008). Key enzymes of 
carbohydrate metabolism (hexokinase, glucose-6-phosphatase, fructose-1,6-
bisphosphatase, glucose-6-phosphate dehydrogenase, glycogen synthase and 
glycogen phosphorylase, pyruvate kinase and lactate dehydrogenase) were increased 
in kidney and liver of STZ-nicotinamde diabetic rats treated with oral 2.5 mg/kg/day 
tRSV (Palsamy and Subramanian, 2009).   
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In contrast, Silan reported more modest decrease in blood glucose by ca. 10% 
with i.p. administration of 5 mg/kg/day tRSV to STZ-diabetic rats (Silan, 2008). 
Also Schmatz et al. (2009a,b) found no decrease in blood glucose of STZ diabetic 
rats with i.p. administration of 10 and 20 mg/kg/day. It appears that in obese and 
chemically-induced diabetes tRSV is less effective when administered i.p. rather than 
orally (Schmatz et al., 2009b, Schmatz et al., 2009a).   
tRSV has also been studied in the prevention of chemically-induced diabetes 
where tRSV administration is initiated soon after STZ injection. The protection 
against insulinopenic activity depends on how soon after STZ injection the tRSV 
treatment is initiated; the longer the delay, the weaker the effect of tRSV – showing 
that tRSV is improving blood glucose by disturbing the toxicity of STZ to pancreatic 
beta-cells. In mild diabetes model of STZ-nicotinamide, the anti-hyperglycaemic 
effect of tRSV may relate to a stimulatory effect on intracellular glucose transport. 
Increased glucose uptake in cells including hepatocytes, adipocytes, and skeletal 
muscle cells isolated from STZ induced diabetic rats was found to be enhanced in the 
absence of insulin. This suggests that the anti-hyperglycaemic effect of tRSV may be 
insulin independent (Su et al., 2006). Studies on models of diabetic rat displayed 
amplified expression of GLUT-4 with tRSV treatment (Penumathsa et al., 2008, Chi 
et al., 2007).  
 
Enhancement of insulin action 
There are a number of animal studies which have proposed tRSV as a 
beneficial compound for improving insulin action in T2DM. Baur and his colleagues 
(2006) revealed that when high fat diet mice were administered orally 22 mg/kg/day 
tRSV there was improved insulin sensitivity (Baur et al., 2006). Furthermore, fasting 
and random insulin and glucose levels in plasma were decreased as compared to high 
fat diet fed mice without tRSV. Stimulation of phosphorylated AMP-activated 
protein kinase (AMPK), a metabolic controller that stimulates insulin sensitivity and 
fatty acid oxidation, by tRSV was suggested as the mechanism of action – finding 
evidence for phosphorylation and two downstream indicators of activity-
phosphorylation of acetyl-CoA carboxylase at Ser79 and reduced expression of fatty 
acid synthase (Baur et al., 2006). Related findings of decreased plasma insulin in 
tRSV treated high fat diet-fed mice were also noticed by other research groups: 
Lagouge et al. with an oral dose of 200 – 400 mg/kg tRSV, Sun et al. with oral dose 
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of 2.5 mg/kg tRSV and Um et al. with an oral dose of 400 mg/kg tRSV (Lagouge et 
al., 2006, Sun et al., 2007, Um et al., 2010). The higher doses of tRSV used are not 
clinically translatable and benefits of tRSV clinically have not been confirmed in 
meta-analysis of clinical studies (Liu et al., 2014). 
Oral treatment of genetically obese, hyperphagic, diabetic KKAy mice with 2 
and 4 mg/kg/day tRSV improved insulin resistance, and oral treatment of genetically 
obese Zucker rats with 10 mg/kg tRSV per day prevented insulin resistance but not 
obesity (Lagouge et al., 2006, Chen et al., 2012, Rivera et al., 2009). Several studies 
in mice and rats have reported anti-obesity effects: Sprague-Dawley rats given 6, 30 
or 60 mg/kg/day tRSV showed no, 24% and 19% decrease in body fat, respectively; 
Wistar rats fed orally 100 mg/kg/day tRSV had decreased body weight; mice fed 
orally 400 mg/kg/day tRSV had decreased body weight (Macarulla et al., 2009, Um 
et al., 2010, Shang et al., 2008, Rocha et al., 2009). Anti-obesity effects of tRSV are 
only apparent at very high doses that are not clinically translatable and tolerable 
(Vang et al., 2011).    
Treatment with tRSV has been claimed to produce effects similar to those 
induced by caloric restriction - such as decreased age-related cardiac dysfunction, 
decrease in blood glucose levels and inhibition of gene expression profiles related 
with cardiac and skeletal muscle ageing. tRSV dosing of mice decrease in signs of 
aging - including decreased albuminuria, inflammation and apoptosis in the vascular 
endothelium, increased aortic elasticity, reduced cataract formation, greater motor 
coordination, and preserved bone mineral density. This achieved, however, at doses 
of 100 – 400 mg/kg/day (Pearson et al., 2008). A lower dose of tRSV, 4.9 mg/kg/day 
orally, initiated in middle age (14 months old mice) led to change in gene expression 
similar to caloric restriction (CR) without decrease in body weight found with CR. 
(Barger et al., 2008, Pearson et al., 2008). 
In vitro studies have presented similar effects but there in vivo relevance is 
doubtful because of high supraphysiological concentrations. tRSV (6 – 50 µM) 
treatment of rat adipocytes showed decreased ATP content, decreased accumulation 
of triglyceride, decreased lipogenesis and decreased lipolytic response to 
epinephrine, and ES (62.5 – 250 µM) treatment of rat adipocytes decreased leptin 
secretion (Szkudelska et al., 2011, Szkudelska et al., 2009). Human adipocytes  
cultured with conjugated linoleic acid and 10, 25 and 50 µM tRSV had decreased 
insulin resistance, increased insulin-stimulated glucose transport and reduced 
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inflammation when compared to cells exposed to conjugated linoleic acid only 
(Kennedy et al., 2009). This was proposed to be caused by decrease of cellular stress, 
prevention of activation of extracellular signal related kinase, inhibition of 
inflammatory gene expression, increase in peroxisome proliferator-activated receptor 
γ (PPAR- γ) activity (Szkudelska et al., 2011, Szkudelska et al., 2009). 
AMPK and Sirt-1 activation have been connected to tRSV induced 
enhancement in insulin action. There were several studies on animals which 
demonstrated the activation of AMPK and Sirt-1 by tRSV (Baur et al., 2006, 
Lagouge et al., 2006, Lee et al., 2009, Shang et al., 2008, Hausenblas et al., 2015). In 
AMPK deficient high fat diet mice, tRSV was unsuccessful in decreasing body fat 
and improving insulin action. Sirtuins participate in NAD(+)-dependent protein 
deacetylation and are key controllers of transcription, apoptosis, metabolism, and 
aging (Um et al., 2010). Seven human sirtuins (SIRT1-7) are found, and Sirt1 has 
been involved significantly as a mediator of the pathways downstream of calorie 
restriction that have been presented to defer the onset and decrease the occurrence of 
age-related diseases such as type 2 diabetes (Pacholec et al., 2010, Baur et al., 2006). 
Sirt1 action is directed to histone proteins in addition to several transcription factors 
such as p53, the forkhead box protein (FOXO) family, PPAR-γ, co-activator 1α and 
PPAR gamma coactivator-1alpha (PGC-1α). Sirt1 enhances function of 
mitochondria, induces genes for mitochondrial and fatty acid oxidation and increases 
potential of mitochondrial membrane (Lagouge et al., 2006). In human endothelial 
cells in vitro, 10 – 100 µM tRSV increased the mRNA expression of Sirt1 (Kao et 
al., 2010). In a different study, 3 – 30  µM tRSV human coronary artery endothelial 
cells presented up-regulation of MnSOD expression and increased cellular levels of 
GSH in a concentration dependent manner (Ungvari et al., 2009). These effects were 
diminished by knocking down Sirt1 and mimicked by Sirt1 overexpression-
presenting the action of tRSV via Sirt1 activation. However, the thought of tRSV 
being the main activator of Sirt1 was challenged recently (Dolinsky and Dyck, 2011, 
Pacholec et al., 2010). Therefore, even though the exact tRSV mechanism of action 
is uncertain, it has a significant role in improving insulin action. 
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Protection of β-cells 
In T2DM, hyperglycaemia occurs in the presence of hyperinsulinemia – 
insulin resistance leading to increased glucose concentration drives the pancreas to 
secret a compensatory release of insulin. Prolonged overstimulation of β-cells lead to 
their exhaustion and degradation causing inadequate insulin secretion (Hansen et al., 
2004). Normally, glucose-induced insulin secretion is mediated by a sequence of 
actions: intracellular glucose transport by GLUT2 transporter, glucose metabolism 
by oxidative glycolysis, hyperpolarisation of inner mitochondrial membrane, 
increased formation of ATP, increased ATP/ADP ratio, closure of the ATP-sensitive 
potassium channels, depolarisation of plasma membrane, opening of voltage-
operated Ca2+ channels and increase in cytosolic Ca2+. The increase in cytosolic 
Ca2+ activates secretion of insulin. Constant insulin-secretory response is preserved 
by intensifying signal generation in the β-cells (Henquin, 2000, Maechler, 2002). In 
rat pancreatic islets, treatment with 1 – 100 µM tRSV caused increased L-lactate, 
reduced oxidation of glucose, diminished hyperpolarisation of the inner 
mitochondrial membrane and decreased levels of ATP (Szkudelski, 2007). Since the 
ATP/ADP ratio is important for insulin secretion, reduced formation of ATP with 
tRSV led to decreased secretion of insulin from the pancreatic islets. However, 
insulin secretion inhibition by tRSV was noticed to be reversible and were not 
because permanent changes in the β-cells (Kennedy et al., 2009, Szkudelski, 2006). 
Inhibition of insulin secretion by tRSV may decrease β-cells degradation as a 
consequence of their chronic overstimulation but this hypothesis needs confirmation 
and requires further investigation. 
Other mechanisms activated by tRSV may protect pancreas islets. When 
isolated pancreatic islets of rat were exposed to cytokines, there was increased DNA 
binding of NF-κB, increased production of NO and expression of eNOS (Lee et al., 
2009). Conversely, when treated with 10 and 50 µM tRSV all these damaging effects 
were inhibited. Moreover, the viability of islets exposed to cytokines and tRSV was 
increased and compared to ones exposed only to cytokines. tRSV was found to repair 
β-cells secretory function; disturbed by cytokine action. Furthermore, the reduction 
in glucose induced insulin secretion as a consequence of cytokine exposure was 
restored completely after pre-treated the pancreatic islets with tRSV. These 
concentrations of tRSV, however, are not achievable clinically. 
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The protective role of tRSV from cytokine action on pancreatic β-cells was 
also present in experimental animals. In rat models of experimental diabetes, oral 
tRSV administration decreased plasma TNF-α, IL-1β and IL-16 as compared to non 
tRSV treated diabetic rats (Palsamy and Subramanian, 2010). 
tRSV has been proposed to inhibit diabetes through its anti-oxidant effects.  
Beta-cells are more vulnerable to oxidative damage as a result of significantly lower 
anti-oxidant defence as compared to other cells (Lenzen, 2008). Levels of lipid 
peroxides, hydroperoxides and protein carbonyls were increased in STZ-induced 
diabetic rats, compared to controls (Palsamy and Subramanian, 2010). Activities of 
antioxidant enzymes, including superoxide dismutase, catalase, GSH, peroxidase and 
glutathione-S-transferase were decreased in the diabetic rats. These were corrected 
by tRSV treatment. Oxidative stress is considered to be a key factor causing β-cell 
dysfunction in T2DM (Robertson, 2006). 
 
1.7.3.2 Role of tRSV in diabetic cardiovascular complications 
Several studies had suggested protective effects of tRSV on the vasculature 
and heart in experimental diabetes. STZ-diabetic rats treated i.p. with 0.75 mg/kg 
tRSV 3 times daily had decreased thickening of vascular wall, the deposition/cross-
linking of collagen, and vascular permeability as compared to the untreated diabetic 
rodents (Jing et al., 2010). Vascular smooth muscle cells of the tRSV-treated rats 
were showed less proliferation, lower NF-κB, and extracellular-signal-regulated 
kinases (Erk1/2) activation and diminished proliferation. Additionally, tRSV was 
found to decrease expression of RAGE in diabetic rats (Jing et al., 2010) and 
improve the vasorelaxant ability of the diabetic aorta (Silan, 2008). tRSV-induced 
decreased RAGE and NF-κB signalling pathway may suppress DM-induced 
vasculopathy (Jing et al., 2010). 
In STZ-induced diabetic rats, tRSV presented cardio-protective effects on the 
myocardium by up-regulation of thioredoxin, NO, heme-oxygenase, and VEGF 
(Thirunavukkarasu et al., 2007). Also, 10 mg/kg/day tRSV was found to restore 
normal vascular function and prevent oxidative stress in T1DM in rats via increasing 
eNOS (Arrick et al., 2011). Moreover, tRSV enhanced left ventricular diastolic 
relaxation in diabetes by stopping TNF-α-induced NF-κB activation, consequently 
inhibiting the expression and activation of NADPH oxidase along with increasing 
eNOS (Zhang et al., 2010). Therefore, tRSV protects against cardiac dysfunction in 
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diabetes via preventing oxidative stress and improving NO availability. The positive 
effects of tRSV have been related with Sirt1 activation. tRSV activates Sirt1 which 
improves the expression of sarcoplasmic calcium ATPase (SERCA2a) and cardiac 
function in diabetic mice (Sulaiman et al., 2010). tRSV (10 µM) increased 
mitochondrial content in endothelial cells by Sirt1 activation and eNOS up-
regulation; tRSV (20 mg/kg/day) produced a similar response in aortas of db/db 
diabetic mice (Csiszar et al., 2009). The heart in diabetes is also vulnerable to 
ischemia-reperfusion injury. tRSV has also been considered for its capability to 
protect the diabetic heart from ischemia- reperfusion injury. In Zucker obese rats, 
oral 5 mg/kg/day tRSV decreased in cardiac apoptosis in ischemia-reperfused hearts 
in presence or absence of glucose uptake (Lekli et al., 2008).  
 
1.7.3.3 Role of tRSV in other diabetic complications 
The effect of tRSV has been studied in other diabetic complications including 
nephropathy, retinopathy and neuropathy. To assess the effect of tRSV on diabetic 
nephropathy, db/db mice were treated with 20 mg/ kg/day of resveratrol for 12 
weeks. The results showed a decrease in albuminuria, improvement in the glomerular 
matrix expansion and inflammation. tRSV also increased the phosphorylation of 
AMPK and the activation of SIRT1–PGC-1α signalling in db/db mice (Kim et al., 
2013b). In STZ induced diabetic rats with nephropathy, treatment with tRSV (20 
μmol/l) increased activity of FoxO1 and a significantly up regulated the expression 
of AdipoR1- down-regulation of AdipoR1 is a cause of diabetic nephropathy (Ji et 
al., 2014). Wu and his colleagues also found that tRSV has protective effects against 
diabetic nephropathy by modifying the SIRT1/FOXO1 pathway. Their findings 
showed that activity of FOXO1 is decreased, with a parallel decrease in the catalase 
expression, a FOXO1 target gene, and expression of SIRT1 reduced in the renal 
cortex of STZ induced diabetic rats, improving renal oxidative stress (Wu et al., 
2012). Palsamy and Subramanian found that tRSV (5 mg/kg orally for 30 days) 
resulted in normalization of the clearance of creatinine and the plasma levels of 
adiponectin, C-peptide, and renal oxidative stress and inflammation in STZ 
nicotinamide induced diabetic rats. Furthermore, tRSV treatment ameliorated the 
antioxidant enzymes [superoxide dismutase (SOD), catalase, glutathione peroxidase 
(GPx), glutathione-S-transferase (GST), and glutathione reductase (GR)] dysfunction 
and decreased levels of vitamin C, vitamin E and reduced glutathione (GSH) in 
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diabetic nephropathy. Moreover, they found that the expression levels of Nrf2 and its 
downstream enzyme, involving 𝛾-glutamyl cysteine synthase (GCS), m-GST, and 
hemoxygenase-1 (HO-1) were significantly reduced in the renal tissues of diabetic 
rats (Palsamy and Subramanian, 2011) and tRSV corrected this. Zhang et al. reported 
that high levels of glucose increased mesangial cell proliferation and fibronectin 
expression through the c-Jun N-terminal kinase JNK/NF-𝜅B/NADPH oxidase/ROS 
pathway, which was inhibited by tRSV (5 µM; 10 µM) in vitro (Zhang et al., 2012). 
Few studies were conducted to investigate the effect of tRSV on diabetic 
retinopathy. Soufi et al. reported that oral administration of tRSV (5 mg/kg/day) for 
four-month in STZ induced diabetic rat significantly alleviated hyperglycaemia, 
weight loss, enhancement of oxidative markers, lipid peroxidation index. tRSV also 
improved oxidized to reduced glutathione ratio, and superoxide dismutase activity in 
both blood and retinas of the diabetic rats. Furthermore, tRSV treatment to diabetic 
rat reduced the increased levels of retinas NF-κB activity and apoptosis rate (Soufi et 
al., 2012). Ciddi and Dodda found that in sugar-induced lens opacity model, tRSV 
(10 μg/ml) displayed a significant protective effect inhibiting opacification and 
polyols formation in cattle lens (Ciddi and Dodda, 2014). 
The diabetic neuropathy caused mainly by oxidative stress, AGE formation, 
lipid peroxidation (Vinik, 2008). Using of tRSV in diabetic neuropathy as a potent 
antioxidant was established by Kumar et al. STZ induced diabetic rats developed 
neuropathy assessed by reduction in motor nerve conduction velocity (MNCV), 
nerve blood flow (NBF) and increased thermal hyperalgesia. After 2-week of 
treatment with tRSV (10 and 20 mg/kg), it significantly ameliorated the alterations in 
MNCV, NBF, and hyperalgesia. In addition, tRSV reduced enhanced levels of 
malondialdehyde (MDA), peroxynitrite and increased the catalase levels in diabetic 
rats. This study suggested the potential of tRSV as a treatment of diabetic 
neuropathy, its protective effect may be mediated by reducing oxidative stress 
(Kumar et al., 2007). Another study investigated whether combination of tRSV and 
4-amino 1,8 naphthalimide (4-ANI) is effective in the development of diabetic 
neuropathy. STZ induced diabetic rats were treated for 2 weeks with tRSV (10 
mg/kg) and 4-ANI (3 mg/kg). Combination of tRSV and 4-ANI enhanced nerve 
conduction and nerve blood flow and improved diabetic neuropathic pain (Sharma et 
al., 2009). STZ induced diabetic rats were treated for 2 weeks with tRSV (10 and 20 
mg/kg). The results showed that tRSV decreased the expression of p65 and IκB-α in 
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treated rats. In addition, tRSV ameliorated the elevated levels of TNF-α, IL-6 and 
COX-2. These findings suggest that tRSV also prevent neuropathy through  
inhibiting NF-κB activity and inflammation apart from its antioxidant effect (Kumar 
and Sharma, 2010). 
 
1.7.3.4 Role of trans-resveratrol in periodontal diseases 
tRSV has an antioxidant and anti-inflammatory properties which can decrease 
oxidative stress and inflammation. Direct scavenging of ROS is unlikely to explain 
these effects as tRSV and cis-RSV have equal direct scavenging activity of ROS but 
tRSV has more potent effects in physiological systems. Antioxidants activities of 
tRSV are, therefore, likely due to indirect effects of inducing increased expression of 
antioxidant enzymes. There are few studies were conducted to identify the effect of 
tRSV on counteract the periodontal tissue breakdown in inflammatory status. A 
recent study found that administration to rats of tRSV, 10 mg/kg/day by gavage for 
30 days – 19 days before induction of periodontitis and 11 days after, decreased 
periodontal tissue breakdown and alveolar bone loss; periodontitis was induced by 
cotton ligature in a cervical position secured sub-marginally. Lower levels of IL-17 
were found in the tRSV treatment group but no change in IL-1β and IL-4 levels were 
found (Casati et al., 2013). 
 Tamaki and his colleagues studied tRSV-containing extracts from the 
melinjo plant. Oral dose of 10 mg/kg/day limited alveolar bone loss in ligature-
induced periodontitis and activated the SIRT1/AMPK and the Nrf2/antioxidant 
defence pathways in inflamed gingival tissues. Additionally, tRSV-containing 
extracts intake decreased urinary levels of 8-hydroxydeoxyguanosine and dityrosine, 
serum nitrite/nitrate and nitrotyrosine, and proinflammatory cytokines. Hence, oral 
administration of tRSV-containing extracts may suppress the development of 
ligature-induced periodontitis and enhance systemic oxidative and nitrosative stress 
(Tamaki et al., 2014). 
The effects of tRSV on human gingival fibroblasts (HGFs) in vitro under 
oxidative stress prompted by hydrogen peroxide were studied. tRSV (25 – 75 µM) 
improved cell proliferation under oxidative stress. Moreover, tRSV was effective at 
preventing ROS production. HGFs treated with tRSV (50 µM) up-regulated 
collagen-I gene transcription after 3 h and continued for 24 h (Orihuela-Campos et 
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al., 2015). It is doubtful if these effects of supraphysiological concentrations of tRSV 
can be translated in vivo. 
Recently, it is found that tRSV given after induction of periodontitis by daily 
subcutaneous injection to rats at a dose of 5 mg/kg body weight for 2 weeks 
protected from periodontal tissue breakdown by inhibiting inflammatory responses 
and by stimulating antioxidant defence systems. The effect of tRSV on HGF growth 
and variability in vitro was studied. tRSV increased growth at 25 – 100 µM and 
decreased growth and viability at >100 µM (Bhattarai et al., 2016). 
 
1.7.4 Hesperetin 
Hesperetin (HSP) is a member of a group of phenolic compounds called 
flavanones – derivatives of a core 2,3-dihydro-2-phenylchromen-4-one structure. 
Flavanones originated from plants and are used as traditional remedies (Sun et al., 
2013). HSP closely-related to the glycoside derivative, hesperidin (hesperetin 7-
rutinoside, hesperetin 6-O-α-L-rhamnosyl-D-glucose), found in oranges and other 
citrus fruits (Khan and Dangles, 2014). Hesperidin was first extracted from citrus peel 
by the French chemist Lebreton (Pietta, 2000). 
Hesperidin is found particularly lemon, limes and sweet oranges (Khan and 
Dangles, 2014). Hesperidin is absorbed poorly after de-glycosylation by gut bacteria 
in the small intestine and colon which likely contributes to high variability of 
exposure to HSP from the diet. HSP, however, is absorbed efficiently without enteral 
metabolism (Kanaze et al., 2007). The concentration of HSP and hesperidin (mostly 
the latter) in a typical serving of commercial orange juice was ca. 22 mg per 100 ml 
(Erlund et al., 2001) but specific varieties of citrus fruits may have levels 10 – 20 
fold higher (Khan and Dangles, 2014). HSP is absorbed effectively, metabolised to 
glucuronide and sulfate derivatives and excreted in urine. Conjugates of hesperetin 
are widely detected in urine of clinical studies as markers of consumption of oranges, 
orange juice or related citrus fruits. The peak plasma concentration of HSP achieved 
in healthy subjects after bolus dose of 135 mg was 2.7 μM (Erlund et al., 2001); cf. 
peak plasma concentration of HSP after consumption of one litre of orange juice, 1.3 
μM. The plasma half-life of HSP in healthy people is 1.3 – 2.2 h (Erlund et al., 
2001). HSP is an approximately equal mixture of R- and S-stereoisomers with 
similar pharmacokinetic properties (Lévèques et al., 2012). 
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There was no adverse effects of dosing with 135 mg HSP per day in healthy 
adults (Kanaze et al., 2007). HSP is considered extremely safe (Garg et al., 2001); 
the LD50 of hesperetin in rats was estimated to be >2000 mg/kg (Vaeth, 2006). In 
mouse embryonic stem cells in culture there was no effect of HSP on cell viability up 
to and including 100 μM (Choi et al., 2006). Hesperidin can be fully deglycosylated 
to HSP by hesperidin 6-O-α-L-rhamnosyl-β-D-glucosidase – which has been recently 
isolated and cloned from bacteria (Neher et al., 2015) and by chemical processing 
(Seitz and Wingard Jr, 1978). 
 
1.7.4.1 Antioxidant properties of hesperetin 
Flavanones have several biological properties, including antioxidant, 
anticancer, cancer chemopreventive, and anti-inflammatory properties (Harborne and 
Williams, 2000). Garg et al. reviewed the physicochemical and biological activities 
of Hesperidin and HSP, concluding they displayed antioxidant, anti-inflammatory, 
anticarcinogenic, and antiallergic properties (Garg et al., 2001). However, most of 
these studies use high concentration of HSP (50 µM) in vitro to identify benefits of 
this flavanone such as anti-obesity (Kim et al., 2013a). In addition, large number of 
studies have been published describing its new pharmacological activities, molecular 
targets, and mechanisms of action (Romano et al., 2013, Chiba et al., 2014). Recent 
findings show that the antioxidant activity of Hesperidin includes free radical 
scavenging activity and increased antioxidant cellular defences via the ERK/Nrf2 
signalling pathway but has very weak activity (Chen et al., 2010a, Elavarasan et al., 
2012). Recent research on flavonoids has focused on the protective properties of 
Hesperidin and HSP against several oxidants, such as peroxynitrite and hydrogen 
peroxide, and several other chemicals and toxins that cause damage to tissues via 
oxidative stress or other mechanisms (Kamaraj et al., 2010, Kalpana et al., 2009, 
Shrivastava et al., 2013). 
The antioxidant properties of Hesperidin and HSP are achieved by at least 
two mechanisms: direct radical scavenging and augmenting cellular antioxidant 
defences. Studies have shown that Hesperidin and HSP have ability to neutralise 
reactive oxygen species (ROS), including superoxide anions, hydroxyl radicals, 
peroxynitrite, and nitric oxide radicals (Garg et al., 2001, Kim et al., 2004, Wilmsen 
et al., 2005, Choi, 2008). Wilmsen et al. incubated suspensions of yeast S. cereyisiae 
cells contain 2 x106 cells/ml with and without Hesperidin (25 and 50 µM) and 
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stressing agents (1 mM) for 6 h at 28 °C. Hesperidin increased activities of catalase 
and superoxide dismutase (Wilmsen et al., 2005). Choi (2008) administrated HSP to 
mice in which oxidative stress had been induced by dimethylbenz(a)anthracene 
(DMBA). HSP was administered orally to two of the three groups at 10 and 
50 mg/kg body weight for 5 weeks (Choi, 2008). Thiobarbituric acid reactive 
substances (TBARS) and carbonyl content were measured as biomarkers of lipid 
peroxidation and protein oxidation, respectively. Treatment with HSP resulted in a 
normal level of lipid peroxidation in DMBA-treated groups, representing the 
protective effects of HSP. Hesperidin and HSP decreased tissue damage induced by 
hydrogen peroxide, peroxynitrite, CCl4, nicotine, DMBA, cadmium, LPS, 
acetaminophen, tert-butyl hydroperoxide, technetium (99m Tc, a radioactive 
element), gamma radiation, cyclophosphamide, benzo[α]pyrene, and acrylonitrile 
(neurotoxin) (Ahmad et al., 2012, Arafa et al., 2009, Balakrishnan and Menon, 
2007b, Balakrishnan and Menon, 2007a, Chen et al., 2010b, Sahu et al., 2013, 
Hosseinimehr et al., 2009)  
 
1.7.4.2 Role of hesperetin in glycation 
There are few publications on the effects of Hesperidin and HSP on early 
glycation and AGEs. Li et al. reported an in vitro inhibitory effect of Hesperidin and 
HSP against glycation reaction when RNase was incubated with MG (100 mM) and 
bovine serum albumin (BSA) was incubated with glucose (100 mM) (Li et al., 
2012a, Li et al., 2012b). These results are not translatable in physiological system 
and the study also suffers with technical flaws.  
 
1.7.4.3 Anti-inflammatory effects of hesperetin 
Flavanone have been used for their anti-inflammatory properties as either 
simple plant extracts or purified flavanone fractions (Kang et al., 2011, Ramelet, 
2001). There are many in vitro and in vivo studies have been conducted to investigate 
Hesperidin and HSP (1 mM) ability in decreasing the inflammatory reactions. Wei et 
al., administrated Hesperidin orally at 5, 10 and 30 mg/kg to mouse allergic asthma 
model where the mice were sensitized and challenged by 100 µg of ovalbumin 
(OVA) to induce chronic airway inflammation and airway remodelling. The 
administration of Hesperidin significantly lowering the number of infiltrating 
inflammatory cells and Th2 cytokines in bronchoalveolar lavage (BAL) fluid 
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compared with the OVA-induced group of mice. Hesperidin decreased OVA-specific 
IgE serum levels (Wei et al., 2012). Yeh and his colleges used Hesperidin to 
investigate its modulation of lung local immune responses. Mice were treated with 
intratracheal LPS (100 μg) 30 min before Hesperidin oral administration (200 
mg/kg). After 4 and 24 h, proinflammatory (TNF-α, IL-1β, IL-6), anti-inflammatory 
(IL-10, IL-4, IL-12) cytokines, chemokines (KC, MCP-1 and MIP-2), total cell 
counts, nitric oxide production, and proteins were measured in bronchoalveolar 
lavage fluid. The results showed that Hesperidin downregulate the LPS-increased 
expression of TNF-α, IL-1 α, IL-6, KC, MIP-2, MCP-1, and IL-12. Also, it enhanced 
the production of IL-4, IL-10 (Yeh et al., 2007). In the OVA-induced inflammation 
model, levels of cytokines such as IL-4 in BAL fluid increased more than in LPS-
induced inflammation models (Wei et al., 2012, Yeh et al., 2007). Therefore, 
flavanone immunomodulatory effects may translate to immunosuppression in the 
OVA model but immunopotentiation in the LPS model (Wei et al., 2012, Yeh et al., 
2007). Hesperidin has been proposed as a food supplement to treat complication of 
obesity but it did not improve glycaemic control nor insulin resistance in overweight 
and obese subjects (Rizza et al., 2011). Table 5 presents the anti-inflammatory effects 
of Hesperidin, HSP and related compounds. 
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Table 5: The anti-inflammatory effects of Hesperidin, HSP and related compounds. 
Study model Compound (s) Major findings References 
LPS-stimulated 
RAW 264.7 cells 
Hesperidin (30 μM)  Prostaglandin E2 (PGE2) 
(Sakata et al., 
2003) 
Flavonoid mixture (nobiletin, naringin, and Hesperidin) 
(10, 50, 100 and 150 μg/ml) 
 COX-2 and iNOS at both the 
protein and mRNA levels in a dose-
dependent manner and probably via 
blocking NF-κB and the MAPK 
signaling pathway. 
(Kang et al., 
2011) 
Hesperidin and HSP and other flavonoids (10 -100 µM)  NO,  COX-1 and  COX-2. 
(Lee and Kim, 
2010) 
LPS-stimulated 
RAW 264.7 and 
A7r5 cells 
Hesperidin and HSP (40 – 100 µM) and HSP metabolites 
(2.5 - 20 μM)  
 iNOS and COX-2  
(Yang et al., 
2011) 
H2O2-stimulated 
rat endothelial 
cells 
HSP glucuronide metabolites, i.e. HSP-7G and HSP-3′G  
(100 µM) 
 ICAM-1 and MCP-1  
(Yamamoto et 
al., 2013) 
HMC-1 cells, a 
human mast cell 
line 
Hesperidin (0.1 mg/ml) and Citrus unshiu peel water 
extract (1 mg/ml) 
 Inflammatory cytokine, HIF-1α and 
 extracellular signal-regulated kinase 
(ERK) phosphorylation. 
(Choi et al., 
2007) 
Human 
umbilical vein 
endothelial cells 
(HUVECs) 
Hesperidin and other active compounds were extracted 
from P. trifoliata (Rutaceae) (1 -50 µM) 
 TNF-α-induced VCAM-1 protein 
expression. 
(Nizamutdinova 
et al., 2008) 
 
Rat model of 
rheumatoid 
arthritis, AA 
Hesperidin (40, 80 and 160 mg/ kg) 
 IL-1β, IL-6, TNF-α and  IL-10 
secretion from synoviocytes.  T-
lymphocyte proliferation and  IL-2 
production. 
(Li et al., 2008, 
Li et al., 2010) 
 
7,3′-dimethoxy HSP (20, 40, and 80 mg/ kg)  TNF-α, IL-1β, IL-6.  (Li et al., 2012c, 
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antiapoptotic Bcl-2 expression and  
pro-apoptotic Bax expression. 
Li et al., 2012b, 
Li et al., 2012a) 
Murine OVA-
induced airway 
inflammation 
Hesperidin (5, 10 and 30 mg/kg) 
 B cell-dependent production of 
OVA-specific IgE.  OVA-induced 
total cell and  cytokines such as IL-
4, IL-5, and IL-13 in bronchoalveolar 
lavage fluid (BALF). 
(Wei et al., 
2012, Kim et al., 
2011) 
 
Xylene-induced 
ear oedema 
Hesperidin and HSP (150 and 75 mg/kg respectively)  Ear swelling in this model 
(Rotelli et al., 
2003) 
Rat air pouch 
model of 
inflammation 
Hesperidin (50 mg/kg) and naringin (30 mg/kg)  
 Lipid peroxidation,  superoxide 
dismutase (SOD),  catalase (CAT), 
 reduced glutathione (GSH) and  
NO in tissue. 
(Jain and 
Parmar, 2011) 
Murine dextran 
sulfate sodium-
induced 
ulcerative colitis 
Hesperidin (10, 40 and 80 mg/kg)  IL-6  (Xu et al., 2009) 
Murine LPS-
induced acute 
lung 
inflammation 
model 
Hesperidin (200 mg/kg) 
 TNF-α, IL-1β, IL-6, and MCP-1, 
and  anti-inflammatory cytokines 
such as IL-4 and IL-10 by its 
immunomodulatory effect.  
(Yeh et al., 
2007) 
Healthy human 
beings 
Orange juice (500 ml daily) and Hesperidin (292 mg in a 
capsule) 
No marked effect on leukocyte 
activation, cytokine production (IL-2 
and IL-4), or NK-cell lytic activity. 
(Perche et al., 
2014) 
Modified from (Parhiz et al., 2015). 
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1.7.5 Proteomics 
Proteomics is one focus of study in post-genomic science where all proteins 
in the whole or fractional proteome are detected, post-translational modifications 
(PTMs) and turnover are studied. Proteomics studies can thereby address the amount 
of gene products from gene expression in cells under basal and experimentally 
manipulated states and study interactions and subcellular distributions of proteins. 
Proteomics has thereby helped define protein composition of organelles, systematic 
explanation of protein-protein interactions and the large-scale mapping of PTMs – 
especially protein phosphorylation - as response to a stimulus. It is allied with gene 
expression studies measuring whole transcriptome mRNA levels, translational rates 
and turnover in 'transcriptomics' using oligonucleotide chips, and all metabolites in 
samples in metabolomics studies (Ong and Mann, 2005). 
The term 'proteomics' was initially used to describe studies using two-
dimensional gel electrophoresis (2-DE) of proteins with following gel excision of 
protein spots and protein identification by mass spectrometry – usually after limited 
proteolysis by trypsin. In 2-DE experiments, the pattern of staining of proteins from 
two samples revealed changes of up or down regulation of protein subsets. Staining 
of proteins was used to determine relative amounts of each protein within the 
sample. Limitations of the 2-DE approach are low resolution and bias against 
membrane proteins. The dynamic range of protein detection was also limited and 
could not accommodate the 7 - 12 orders of magnitude within a biological sample. 
Consequently, 2-DE gel studies have been superseded by nanoflow liquid 
chromatography-high resolution mass spectrometry (MS) in proteomics studies 
(Anderson and Anderson, 1998, Aebersold and Mann, 2003). 
The principal workflow in MS proteomics sample analysis involves limited 
proteolysis by trypsin and/or lys-C to digest proteins to peptides (Fang et al., 2002), 
partial resolution of peptides by nanoflow liquid chromatography and detection and 
fragmentation of peptides by positive ion electrospray ionisation mass spectrometer. 
Subsequent fragment ion series mass spectra, MSn spectra, are employed to sequence 
peptides and identification the protein(s) from which they were derived. 
Bioinformatics analysis tools are required for data analysis and threshold criteria for 
protein identification have been set by consensus. A minimum of two unique 
peptides are required for protein identification. Excellent detection and identification 
of protein-specific peptides approve their existence within the sample. Nevertheless, 
  
130 
 
inability to identify or detect a peptide does not certainly mean that the protein is 
absent, as the peptides possibly be under the threshold of recognition. As a result, the 
Boolean nature of MS protein identification schemes (present or absent by set 
threshold criteria) delivers an inadequate picture of protein abundance in a sample. 
Sensitive MS-based proteomic methods simply recognise 1000s of proteins in each 
samples but robust quantitation is challenging (Aebersold and Mann, 2003) 
Quantitative data of protein have two forms: the absolute amount of the 
protein in the sample or the relative change in the amount of protein between two 
conditions. Absolute quantification is the measurement of the amount of the 
substance under investigation; for example, ng ml−1 of a protein or the copy number 
of a protein per cell. In relative quantification, the amount of a substance is measured 
in relative to another measure of the same substance, for example a fold change of 
protein abundance caused by drug treatment. Theoretically, absolute quantification 
includes relative comparisons; if the absolute amounts of the proteins are identified 
in two samples, their comparative ratios can be easily calculated (Ong and Mann, 
2005, Sadygov et al., 2004). 
 Protein identification scores from commonly used algorithms (e.g. Mascot) 
cannot be used for quantitative measure of protein abundance. Rather quantitation is 
based on 'protein abundance indices' (PAIs). In order to low to high level of surety of 
quantitation, an initial approach is based on the number of peptides used in protein 
detection: this increases with increasing the amount of protein, and a greater protein 
will produce more quantifiable peptides than a low abundance protein. This is a 
simple PAI approach in which the number of observed peptides is normalized to the 
number of observable peptides for the protein in question (Rappsilber et al., 2002, 
Sanders et al., 2002). Ishihama et al. have detected that the relationship between the 
number of peptides detected and the amount of protein within a given sample is 
logarithmic, producing the concept of an exponentially modified PAI (emPAI) 
(Ishihama et al., 2005). 
A range of experimental techniques and related protocols have been 
developed for protein isolation, separation, digestion, enrichment, depletion, 
identification and absolute and relative quantification of proteins. Currently, there 
are two main approaches to quantify protein by LC-MS/MS one including chemical 
labelling and the other one is label free (Wong and Cagney, 2010). 
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1.7.5.1 Labelling-based quantification 
Most quantitative proteomic approaches depend on the samples labelling 
from different conditions with stable isotopes (2H, 13C, 15N, 18O) and a subsequent 
quantitative analysis by mass spectrometry with deduction of analyte amount by 
stable isotopic dilution analysis. Isotopic labelling is achieved by metabolic, 
chemical or enzymatic labelling. Methods applying stable-isotope labelling include: 
stable isotope labelling by amino acids in cell culture (SILAC), stable isotope 
labelling of mammals (SILAM), isotope-coded affinity tags (ICAT), isotope-coded 
protein labelling (ICPL), isobaric tags for relative and absolute quantification 
(iTRAQ), tandem mass tags (TMT), isobaric peptide termini labelling (IPTL), 
dimethyl labelling as well as several variants of these techniques. Interbatch 
coefficients of variation by this method are typically <10% (Megger et al., 2013). 
 
1.7.5.2 Label-free quantification 
Label-free quantitative approaches of proteomics can be divided into two 
different strategies of quantification that are briefly described in the following. The 
first approach is called spectral counting and involves a counting and a comparison 
of the number of fragment-ion spectra (MS/MS) attained for peptides of a certain 
protein. Because of the experimental findings that the number of tandem mass 
spectra of a specific peptide increases with an increasing amount of the equivalent 
protein, a relative proteins quantification between different samples is possible (Liu 
et al., 2004b). However, as the quantification in this method depend on a simple 
counting of resultant spectra rather than on quantifying physical data, the spectral 
counting method is debateable (Bantscheff et al., 2007, Bantscheff et al., 2012). 
Nevertheless, spectral counting is extensively employed and was more developed 
over the years. For instance, improved approaches of spectral counting have been 
reported that take into consideration aspects inducing the number of spectral counts, 
such as physicochemical properties of peptides and the lengths of the corresponding 
proteins. These approaches are identified as absolute protein expression (APEX) (Lu 
et al., 2007) and normalized spectral abundance factor (NSAF) (Florens et al., 2006, 
Zybailov et al., 2006). Recently, normalized spectral index (SIN) was presented 
which associates three MS abundance features, specifically peptide count, spectral 
count and fragment-ion intensity. This approach has revealed to eradicate 
discrepancies between measurements of replicate and permits quantitative 
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reproducibility and significant quantification in replicate MS measurements (Griffin 
et al., 2010). 
The second approach of label-free quantitative proteomics measures the 
chromatographic peak areas of peptide precursor ions (molecular ions) - also called 
mass spectrometric signal strengths. Depending on the chromatographic technique 
(e.g. reversed-phase liquid chromatography), the peptides are separated according to 
their specific physical properties (e.g. hydrophobicity, charge) and are then ionized 
and identified by mass spectrometric analysis. In acquiring the mass spectrum, each 
peptide of a specific mass/charge ratio creates one mono-isotopic mass peak. The 
intensity of this peak as a function of the retention time can be visualized in an 
extracted ion chromatogram (XIC) and the area under the curve (AUC) can be 
determined. The areas of chromatographic peaks have been found to associate 
linearly in a wide range with the abundance of protein which makes their 
measurement achievable for quantitative studies (Bondarenko et al., 2002, Chelius 
and Bondarenko, 2002). This approach is straightforward and very convenient; 
however to achieve reliable results numerous experimental and technical features 
have to be considered. Additionally, raw LC–MS data produced in the experiments 
have to be post-processed (e.g. detection of features, alignment of retention times, 
normalization of MS intensities, peak picking, and noise reduction) for quantitative 
analysis (Megger et al., 2013). Interbatch coefficients of variation by this method are 
typically ≥30% (Megger et al., 2013). 
 
1.7.5.3 Sample preparation, purification and separation for label-free 
quantification 
Proteomic analysis may be made for different sample types varying from 
body fluids (e.g. serum, plasma, urine, bile) to cell lines or isolated cell types and 
tissue samples (Megger et al., 2013). Cell lysis, protein isolation and digestion is 
then performed. Cell lysis buffers and conditions are chosen depending on the whole 
or fractional proteome to be investigated e.g. membrane proteins, organelle proteins, 
cytosolic proteins, extracellular proteins and others (Shevchenko et al., 2012). 
Digestion protocols involve trypsin and /or lys-C or other proteases 
(Wiśniewski et al., 2009). Trypsin is the most prevalent protease used in mass 
spectrometry as a result of its high proteolytic activity and cleavage specificity. 
However, trypsin has certain weaknesses, which is incomplete digestion. 
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Furthermore, trypsin activity is resisted by tightly folded proteins and inhibited by 
many reagents used in protein preparation (Saveliev et al., 2013). Lys-C overcomes 
the proteolytic resistance of tightly folded proteins and cleaves lysine sites with 
exceptional efficiency and specificity. Supplementing trypsin with Lys-C overcomes 
trypsin weaknesses (Saveliev et al., 2013). Additionally, spin columns are 
progressively used for sample purification (Antharavally et al., 2011) and 
corresponding on-filter digestion procedures are also available (Shevchenko et al., 
2012). In-solution digestion procedures for small sample amounts were developed by 
Vékey and co-workers (Turiák et al., 2011). 
Determination of total protein concentration in samples is also vital, 
particularly in the case of label-free quantification. Protein determination after 
extraction of protein from a sample is mandatory to check the successful protein 
isolation and to deduce the amount of protease required in the digestion step 
(Megger et al., 2013). Protein content may be determined by colorimetric methods,  
such as Bradford (Bradford, 1976), bicinchoninic acid (BCA) (Smith et al., 1985), 
biuret, Lowry (Lowry et al., 1951) or Popov assay (Popov et al., 1974). 
Alternatively, concentration of protein can be determined by amino acid analysis 
(Tyler, 2000). 
Peptides achieved from a tryptic digestion are partially resolved by reversed-
phase liquid chromatography (RP-LC) prior to and hyphenated with mass-
spectrometric analysis. For label-free quantitative analysis by peptide ion intensities, 
the reproducibility of this stage is important (Megger et al., 2013). To confirm 
chromatographic reproducibility within a label-free study, it is advantageous to use 
an internal standard containing stable-isotope coded peptides. The retention times of 
these standard peptides can be used to observe the performance of LC–MS over a 
period of time and can be used as landmarks for the chromatographic alignment 
through following data analysis. Sickmann et al. obtained an internal standard of 
synthetic stable-isotope coded peptides that can act to assess several parameters on 
LC and MS level (Burkhart et al., 2011). 
Several high-resolution mass analysers have been used for label-free 
proteomics analyses: time-of-flight (TOF), Fourier transform ion cyclotron 
resonance (FT-ICR) or Orbitrap analysers (Panchaud et al., 2008, Aebersold and 
Mann, 2003). 
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Bioinformatics and biostatistical tools have become necessary to handle and 
interpret the massive amount of data created in a single proteomic analysis. Useful 
open-source software is available (Megger et al., 2013). The dominant mass analyser 
used in proteomics studies is currently the Orbitrap mass spectrometer, mainly 
because of its high mass resolution, relatively easy analysis of output data and 
applicability to multiple types of peptide fragmentation (collision-induced 
dissociation CID, electron-transfer dissociation ETD and higher-energy collisional 
dissociation HCD).   
 
1.7.6 Human periodontal ligament fibroblasts 
Primary cultures of mammalian cells provide good similarity with tissue in 
vivo although they have limited growth potential and life span (Khojasteh et al., 
2010). 
 
1.7.6.1 Collection of hPDLFs 
Primary hPDLFs collection techniques were described in 1985 by 
Ragnarsson and co-workers. Clinically healthy pre-molars or third molars were 
extracted. They are washed with sterile phosphate buffer saline (PBS) three times. 
The gingival attachment is carefully removed by surgical sharp scalpel. The crown is 
dipped in a 5.25% sodium hypochlorite solution for 2 min to eliminate bacteria and 
any remaining gingival cells. Each tooth is placed in sterile 15 ml centrifuge tube 
with 5 ml 0.125% trypsin and 0.1% collagenase and incubated at 37 ᴼC for one hour. 
After incubation, the tooth was removed and the tube was centrifuged at 100 g for 2 
min and cells collected by centrifugation. Cell were washed in complete medium 
(MEM, 10% FBS, containing 50 µg /ml gentamicin, 3 µg /ml fungazone) and plated 
into 60-mM culture dishes. The cells are incubated and replenished everyday with 
complete medium (Ragnarsson et al., 1985). 
Another further technique was based on obtaining PDL explants by scraping 
the middle third of the root surface using a sterile surgical blade. Care was applied to 
avoid contamination from gingival or periapical granulation tissues. Then the 
explanted PDL is rinsed in sterile phosphate buffer saline (PBS) containing 2% 
penicillin–streptomycin solution (100 U/ml and 100 μg/ml). Next, the cells are 
sterilized in biopsy media: Dulbecco's Modified Eagle's Medium (DMEM) with 
glucose (4500 mg/ml), 10% foetal bovine serum (FBS), 2% penicillin–streptomycin, 
  
135 
 
250 μg/ml gentamicin sulfate and 2.5 μg/ml amphotericin B (Chou et al., 2002, 
Khojasteh et al., 2010, Somerman et al., 1990, Nizam et al., 2014) . 
 
1.7.6.2 Separation of fibroblasts and epithelial cells 
The periodontal ligament fibroblasts cells start to grow out from the explants 
within about ten days (Jönsson et al., 2011). When confluence is obtained, the cells 
are subcultured by differential trypsinisation. The dishes are rinsed with PBS and the 
cells are removed with 0.15% trypsin. The removal of cells should be closely 
observed by phase microscopy. The trypsin will remove the fibroblasts earlier and 
faster than the epithelial cells. The early and late removed cell are collected 
separately and plated into clean culture dishes (Ragnarsson et al., 1985). 
 
1.7.6.3 Characteristic of primary hPDLFs 
The teeth used for collecting explants are generally extracted for orthodontic 
reasons from subjects between 12 and 18 years of age. The hPDLFs viability is high, 
probably because of the fact that the cells originate from young and healthy 
individuals. After passage, the cells are re-seeded and then used for experimentations 
in passages two to eight. It was found that in passages 3 to 5, cells respond in a 
similar way to stimulation with hormones and growth promoters (Jönsson et al., 
2005). This suggests that their phenotype is preserved, even though some osteogenic 
markers such as alkaline phosphatase activity, have been shown to be reduced at 
later (passage 6) compared with earlier passages (Itaya et al., 2009). Cell viability 
decreases beyond passage 7 which suggest that the periodontal ligament fibroblasts 
then undergo senescence (Jönsson et al., 2011). 
 
1.7.7 Human periodontal ligament fibroblasts as a model for periodontitis 
Periodontal ligament fibroblasts are used in research to investigate 
inflammation, disease process and tissue breakdown in periodontal diseases. Human 
periodontal ligament fibroblasts (hPDLFs) have an important role in modulating the 
inflammatory process in periodontium (Özdemir et al., 2014). 
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1.7.7.1 Inflammation promoters enhance hPDLFs cytokine and chemokine 
mRNA and protein production 
In addition to their fibroblast and osteoblast-like properties, hPDLFs have 
functional characteristics comparable to those of leukocytes and leukocyte-derived 
cells such as macrophages involved in essential immunity (Özdemir et al., 2014). 
hPDLFs express and secrete cytokines and chemokines in response to stimulation of 
inflammation promoter – Table 6. The cytokine and chemokine transcript and 
protein levels were found low or below the level of detection in unstimulated 
hPDLFs but they increase markedly with stimulation by inflammation promoters, 
such as bacterial lipopolysaccharide (LPS) (Jönsson et al., 2011). LPS prompts 
cytokine production in human gingival fibroblasts (HGFs) (Souza et al., 2010, 
Almasri et al., 2007). This suggests that hPDLFs and HGFs work together to 
promote proinflammatory actions. 
Cytokine and chemokine production by hPDLFs was detected in response to 
stimulation with 1 ng/ml to 10 ng/ml LPS (Jönsson et al., 2008, Jönsson et al., 2009). 
LPS prompted hPDLFs cytokine/chemokine expression, was detected within hours 
but also after several days (3–21 day) of treatment. This is presenting that both acute 
and long-term stimulation with inflammation promoters stimulate cell-signalling 
pathways causing cytokine/chemokine production (Jönsson et al., 2008). 
Inflammation promoter-induced cytokine and chemokine production is 
detected in hPDLFs in passages 3 to 5. This is found in both acute (24 hour) and 
chronic (3–21 day) LPS stimulation responses (Jönsson et al., 2008). 
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Table 6: A review of papers presenting data on pro-inflammatory stimulus-
induced cytokine/chemokine expression in hPDLFs. 
Proinflammatory 
stimulus 
Cytokine/ 
chemokine 
Transcript/protein 
level 
Reference 
Escherichia coli LPS IL-6, MCP-1 Protein (Jönsson et al., 2008) 
E. coli LPS GROα mRNA and protein (Jönsson et al., 2009) 
TNF-α IL-6 Protein (Okada et al., 1997) 
Porphyromonas 
gingivalis, 
P. intermedia 
IL-1β, IL-6, 
IL-8 
mRNA 
(Yamamoto et al., 
2006) 
P. endodontalis LPS IL-6 mRNA and protein (Ogura et al., 1994) 
Actinobacillus 
actionomycetem-
comitans LPS, E. coli 
LPS 
IL-1β, IL-6, 
IL-8 
mRNA and protein (Agarwal et al., 1998) 
E. coli LPS 
TNFα, IL-1β, 
IL-6, 
RANKL 
mRNA and protein (Shu et al., 2008) 
P. gingivalis LPS, 
E. coli LPS 
IL-6, IL-8 mRNA and protein (Yamaji et al., 1995) 
Streptococcus 
mutans 
IL-6, IL-8 Protein 
(Engels-Deutsch et 
al., 2003) 
TNFα, IL-1β MCP-1 mRNA and protein (Ozaki et al., 1996) 
Reactive oxygen 
species (H2O2) 
IL-8 mRNA and protein (Lee et al., 2008) 
P. gingivalis LPS IL-6 Protein 
(Morandini et al., 
2010) 
E. coli LPS IL-1β, TNFα mRNA (Wada et al., 2004) 
Adapted from (Jönsson et al., 2011). 
 
Leptin has powerful effects on immunity and inflammation. Recent evidence 
suggests a role of leptin in periodontitis as judged by the effect of leptin on the level 
of serum interleukin IL-1β, IL-6, and TNF-α, as well as clinical markers of 
periodontal breakdown (Zimmermann et al., 2013, Meng et al., 2015). Li and co-
workers (2015) studied this in hPDLFs. High dose of leptin can induce the 
expression of mRNA and protein of IL-6 and IL-8 in hPDLFs through binding with 
obesity related leptin receptor-b (OBRb) and triggering different intracellular 
signalling pathways (Li et al., 2015). 
In hPDLFs, IL-17 upregulated the production of IL-6 and MMP-1 
sequentially. IL-6/sIL-6R (soluble IL-6 receptor) may improve the effects of IL-1β 
on MMP-1 production. IL-17 likely induces MMP-1 production directly and also 
indirectly by stimulating IL-6 production, thus causing in the degradation of 
collagens in the PDL (Shibata et al., 2014). 
  
138 
 
The effect of high mobility group box 1 (HMGB1) on cultured hPDLFs was 
investigated. hPDLFs expressed RAGE, TLR2 and TLR4 mRNA. Production and 
mRNA expression of IL-6 and IL-11 were increased in hPDLFs cells stimulated with 
HMGB1. Furthermore, they were inhibited by anti-RAGE, TLR2 and TLR4 
antibodies. This suggested that hPDLFs cells produce IL-6 and IL-11 in response to 
HMGB1 via RAGE, TLR2 and TLR4 (Hasegawa, 2008). A further study conducted 
to investigate the effects of different concentrations of high glucose on apoptosis in 
hPDLFs and the potential mechanisms involved. hPDLFs were cultured and 
subjected to glucose of different concentration (5.5, 15, 25, and 35 mM) for 
24 hours. The data show that high glucose prompts a concentration- and caspase-3-
dependent increase of apoptosis in hPDLFs in vitro. Stimulation of caspase-3 
triggered by high glucose is independent of Fas/FasL signalling pathways system. A 
mechanism for the regulation of hPDLFs apoptosis by high glucose was proposed 
(Liu et al., 2013). 
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1.8 Aims and objectives 
In this project I hypothesised that increased concentration of MG is produced 
in hPDLFs by exogenous MG, hyperglycaemia associated with diabetes and 
inflammatory signalling leading to increased extracellular matrix modification 
causing human PDL fibroblast (hPDLFs) dysfunction and extracellular matrix 
detachment. The aim of this study is to test this hypothesis and characterise the 
activity of glyoxalase system and the influence of dicarbonyls on hPDLFs growth 
and function in vitro – including under stress of high glucose concentration as a 
model of hyperglycaemia in diabetes. The major experimental model for this 
hPDLFs cells in primary culture. This is a widely used cell culture model of 
mechanisms of cell dysfunction and injury leading to periodontitis (Mariotti and 
Cochran, 1990). hPDLFs are key cells mediating dysfunction in periodontitis in 
diabetes (Somerman et al., 1990). 
 
Objective 1: To characterise the glyoxalase system and dicarbonyl metabolism 
in hPDLFs cells in vitro and dicarbonyl stress induced by high glucose 
concentration 
There is no previous research on the glyoxalase system and the associated 
dicarbonyl metabolism in hPDLFs or related cell lines. There was a report describing 
increased MG in gingival crevicular fluid (GCF) of subjects with periodontitis but 
since the study estimated MG in “pmol per site” without assessment of site volume, 
it is not clear what the concentration of MG was nor if the change in periodontitis 
relates to a change in concentration (Kashket et al., 2003). If the GCF volume was < 
1 μl, as is usual (Teles et al., 2010), MG estimates were > 100 μM which is typically 
of profound overestimates of MG (Rabbani and Thornalley, 2014c). There is 
emerging evidence that dicarbonyl stress contributes to pathogenesis in inflammation 
and diabetes. Therefore, it is important to characterise the glyoxalase enzymatic 
system using well-validated analytical techniques in a relevant cell type, hPDLFs 
cells, and assess how it response to stress of inflammatory stimuli and high glucose 
concentration. 
To achieve this objective, hPDLFs cells will be used as a model in which to 
characterise the glyoxalase system in both low concentration of glucose, 8 mM, and 
high concentration of glucose, 25 mM. The glyoxalase enzymes activities and the 
associated metabolites concentrations, dicarbonyls, D-lactate and glutathione, will be 
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measured. The glyoxalase pathway flux will be measured and the glucose 
consumption will be used to estimate the proportional flux from triosephosphates in 
cells cultured in low and high glucose. Cellular protein will be examined for damage 
marker adducts to identify whether exposure to higher concentrations of glucose has 
an influence on the level of cellular protein damage. In hPDLFs model, dicarbonyls, 
glutathione and cell thiols will be determined, as well as the RNA expression of 
glyoxalase 1 to characterise alterations in dicarbonyl metabolism and hPDLFs 
function. 
 
Objective 2: To study the effect of Glo1 inducers on the formation and 
metabolism of methylglyoxal in hyperglycaemia in hPDLFs in vitro and cell 
function 
High glucose concentration in hyperglycaemia associated with diabetes and 
downregulation of Glo1 expression in inflammation is likely to cause dicarbonyl 
stress in hPDLFs lead to cell dysfunction and contribute to periodontal disease. The 
most effective strategy to counter this is to increase the expression of Glo1. This may 
be achieved through the functional ARE and activators of Nrf2 which induce Glo1 
(Xue et al., 2012a). 
To achieve this objective, the effect of recently discovered small molecule 
Glo1 inducers on the formation and metabolism of MG will be studied in hPDLFs. 
Glo1 inducers have been screened from libraries of dietary bioactive compounds 
known to activate transcription factor Nrf2 and may thereby increase Glo1 
expression through Nrf2 binding to a functional antioxidant response element (Xue 
et al., 2012a). This was done on a commercailisation project in the host research 
team. The best Glo1 induction was achived with a binary, 2-compound co-
formulation. This has been applied in this project. Levels of glyoxalase 1 activity, 
protein, mRNA expression and concentration of dicarbonyls and protein damage 
markers will be determined in cell extracts to assess the effect of Glo1 inducers on 
production of dicarbonyls and the markers of protein damage and the impact on cell 
function in high glucose. Levels of glucose consumption, D-lactate and L-lactate 
production will be measured in medium obtained from same culture. Glutathione and 
cell thiols will be determined to characterise changes in dicarbonyl metabolism and 
hPDLFs function.  
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The functional activity of hPDLFs may be changed in dicarbonyl stress. One 
target for dicarbonyl glycation affecting functionality is modification of RGD and 
GFOGER integrin binding sites by MG and detachment of hPDLFs from collagen-I 
in the extracellular matrix; cf. detachment of endothelial from collagen type IV 
modified by MG (Dobler et al., 2006). The sites of modification were specific 
arginine residues within integrin binding sites, essential for cell-ECM binding in 
both endothelial cells and periodontal cells. To achieve this objective hPDLFs cells 
will be cultured on control and MG-modified collagen-I coated plates and adhesive 
ability will be assessed colorimetrically. Then, the effect of Glo1 inducer on the 
attachment ability of hPDLFs to collagen will be determined.  
 
Objective 3: To study the dysfunction of hPDLFs exposed to AGE-modified 
proteins in vitro 
hPDLFs have been shown to activate RAGE which is thought to bind 
proteins highly modified by AGEs (Neeper et al., 1992, Kislinger et al., 1999) – 
although there is concern whether it binds proteins modified minimally by AGEs 
found in cells and tissues of physiological systems (Thornalley, 2007, Buetler et al., 
2008, Thornalley, 1998b). If AGE-modified proteins bind and activate RAGE in 
hPDLFs it may lead to activation of the NF-kB system, inflammatory signalling and 
tissue cell dysfunction. It has also been claimed that RAGE activation down 
regulates Glo1 (Bierhaus et al., 2005a) – although this has to be further confirmed. 
This would produce and exacerbate dicarbonyl stress in hPDLFs. 
To achieve this objective, the effect of human serum albumin glycated to low 
and high extent by CML (CMLmin-HSA and CML-HSA), albumin glycated by 
glucose to form FL and a mixture of glucose-derived AGEs and unglycated albumin 
as control will be prepared in vitro. Then, hPDLFs will be treated with the modified 
human serum albumin and activation of NF-kB and Glo1 activity and expression in 
hPDLFs in vitro will be investigated.  
 
Objective 4: To study the mechanism of down regulation of glyoxalase protein 
in hPDLFs in vitro 
When endothelial cells and other cells are incubated in high glucose 
concentration and develop dicarbonyl stress (Dobler et al., 2006), a contributing 
factor is decrease in activity of Go1 protein. If this occurs in hPDLFs the mechanism 
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of Glo1 down regulation will be investigated. Assay of Glo1 mRNA, protein and 
activity will be performed to assess if the loss of Glo1 activity is due to decreased 
expression, increased degradation or inhibitory PTM. Glo1 is a target for acetylation 
(Li et al., 2012) and deacetylation by sirtuins (Rauh et al., 2013). In addition, tRSV 
corrects decreased SIRT1 activity in cells exposed to high glucose concentration in 
vitro (Mortuza et al., 2013). Sirtuin are protein deacetylases - mediated deacetylation 
reaction by coupling lysine deacetylation to NAD hydrolysis (Guarente, 2013). To 
further pursue this objective, I will investigate putative acetylation and other PTMs 
of Glo1 in hPDLFs by high resolution mass spectrometry proteomics and 
immunoblotting. I will assess if there is a link between Glo1 acetylation and Glo1 
protein content, as may occur in acetylation-directed ubiquitination (Xiong and 
Guan, 2012). I will also investigate sirt1 and sirt2 protein level and mRNA 
expression in hPDLFs incubated in low and high glucose concentrations with or 
without Glo1 inducers. In addition, the effect of deacetylase inhibitors and activators 
on Glo1 activity and mRNA expression level in hPDLFs incubated in low and high 
glucose will be determined. 
 
Objective 5: To study the dicarbonyl proteome in the cytosol of hPDLFs 
incubated in low and high glucose in vitro 
Dysfunction of hPDLFs in dicarbonyl stress is mediated by protein 
modification by MG and related dicarbonyls. MG is formed and accumulates in the 
cell cytoplasm where it modify proteins. Change in the total level of the major MG-
derived AGE, MG-H1, in cytosolic extracts of cell protein has been determined in 
Objective 1. To identify which proteins suffer MG-H1 modification, I will apply 
high resolution mass spectrometry proteomics analysis to cytosolic extracts of cell 
protein from hPDLFs cultured in low (8 mM) and high (25 mM) glucose for three 
days. I will use as positive control a cytosolic extract of cell protein from hPDLFs 
that has been incubated in cell-free system with exogenous MG to increase MG-H1 
content ca. 10-fold. Samples were prepared for proteomic analysis, mass 
spectrometric analysis performed on a nanoflow-Orbitrap platform and unmodified 
and MG-H1-modified proteins identified by MS/MS sequencing. Data analysis will 
include bioinformatics pathway analysis to assess which metabolic pathways in the 
cell cytosol are most sensitive to dicarbonyl stress.   
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Objective 6: To characterise glycation, oxidation and nitration adduct residue 
content of plasma protein of healthy people, patient with periodontitis and 
patients with periodontitis and end stage renal disease 
To achieve this objective, plasma will be collected from healthy people as 
control subjects, patient with periodontitis and patients with periodontitis and 
chronic kidney disease (CKD) stage 3 or 4. All of the latter group also had diabetes 
mellitus. The glycation, oxidation and nitration adduct residue content of plasma 
protein was determined by stable isotopic dilution analysis LC-MS/MS.  
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2. Materials and Methods 
2.1 Materials 
2.1.1 Cells and tissues 
Primary human periodontal ligament fibroblasts (hPDLFs) were purchased 
from ScienCell, Carlsbad, USA; cat. no. 2630. hPDLFs were isolated from human 
periodontal tissue of healthy individuals which is located between the cementum of 
the teeth and the alveolar bone of the mandible. 
 
2.1.2 Cell culture reagents 
Primary hPDLFs were maintained in Modified Eagles Medium (MEM) (cat. 
no. M8042, ScienCell) supplemented with 10% Foetal Bovine Serum (FBS) and 
penicillin-streptomycin (cat. nos. F7524 and P0781 respectively; Sigma Aldrich, 
Gillingham, Dorset UK) and L-glutamine (200 mM solution; cat. no. 25030-024, 
Gibco Life Technology, Paisley, UK). Tissue culture grade plastic polystyrene T75 
flasks was purchased from Fisher Scientific (Nunclone™, Loughborough, UK). 
Trypsin/EDTA (0.25%; a solution, sterile-filtered, containing 2.5 g porcine trypsin 
and 0.2 g EDTA. 4Na+ per liter of Hanks’ Balanced Salt Solution with phenol red) 
was purchased from Invitrogen Life Technologies (Paisley, UK; cat. no. 25200-072). 
Trypan blue dye was purchased from Sigma Aldrich (cat. no. 302643). 
 
2.1.3 Enzymes, substrates, cofactors, and consumables 
Proteases, peptidases, D-lactic dehydrogenase, L-lactic dehydrogenase and 
other enzymes were purchased from Sigma-Aldrich. L-Lactic dehydrogenase (EC 
1.1.1.27) was from bovine heart, type III with activity of ≥ 500 units/mg protein. D-
Lactic dehydrogenase (EC 1.1.1.28), lyophilised powder, was from Staphylococcus 
epidermidis and had activity of ≥ 80 units/mg protein. Pepsin (EC 3.4.23.1) was 
from porcine stomach mucosa with a specific activity of 3460 units/mg protein (1 
unit hydrolysed haemoglobin with an increase in A280 of 0.001 AU per min of 
trichloroacetic acid-soluble products, at pH 2 and 37 oC); prolidase (EC 3.4.13.9) 
was from porcine kidney and had a specific activity of 145 units/mg protein, where 1 
unit of activity hydrolyses 1.0 μmol of Gly-Pro per min, at pH 8 at 40 oC; leucine 
aminopeptidase (EC 3.4.11.2), type VI, was from porcine kidney microsomes with a 
specific activity of 22 units/mg protein (1 unit of activity hydrolysed 1.0 mol of L-
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leucine-p-nitroanilide to L-leucine and p-nitroaniline per min at pH 7.2 and 37 oC);  
pronase E (EC 3.4.24.31), type XIV, was from bacterial Streptomyces griseus with a 
specific activity of 4.4 units/mg protein (1 unit of activity hydrolysed casein forming 
1.0 mmol of tyrosine per min at pH 7.5 and 37 oC); and collagenase (EC.3.4.24.3) 
was from bacterial clostridium histolyticum with specific activity of 125 Collagen 
Digestion Unit (CDU)/mg protein (CDU definition – one unit liberates peptides from 
collagen equivalent in ninhydrin colour to 1.0 μmol L-leucine in 5 h at pH 7.4 at 37 
°C in the presence of calcium ions).  
 
2.1.4 Primers and antibodies 
Primers 
Glo1 and β-actin primers were designed using OligoPerfectTM designer 
software and purchased from Invitrogen. Primers for SIRT1, SIRT2, COL1, COL3 
and COL12 genes were purchased from Sigma Aldrich (Gillingham, Dorset, UK).  
Primers were used to amplify cDNA for mRNA of GLO1, β-actin, SIRT1, SIRT2, 
COL1, COL3 and COL12 are summarised in Table 7. 
 
Table 7: The primers sequences used for amplification 
Primers Forward Reverse 
GLO1 5'-ATGCGACCCAGAGTTACCAC-3' 5'-CCAGGCCTTTCATTTTACCA-3' 
ACTB 5'-GGACTTCGAGCAAGAGATGG-3' 5'-AGCACTGTGTTGGCGTACAG-3' 
SIRT1 5′-AGGATAGAGCCTCACATGCAA-3′ 5′-TCGAGGATCTGTGCCAATCATA-3′ 
SIRT2 5′-ATCCCCGACTTTCGCTCTC-3′ 5′- GGTTGGCTTGAACTGCCCA -3′ 
CLO1 5' GTGCTAAAGGTGCCAATGGT-3' 5'- ACCAGGTTCACCGCTGTTAC-3' 
CLO3 5'- CCAGGAGCTAACGGTCTCAG-3' 5'- CAGGGTTTCCATCTCTTCCA-3' 
CLO12 5'- CTCCTTGGGCATTAAAGCTG-3' 5'- GCTTCCAATTCTGAGCGAAC-3' 
 
Antibodies 
Anti-Glo1 rabbit polyclonal antibody (cat. no. H00002739-D01) used for 
immunoprecipitation experiments was purchased from VWR International Ltd 
(Lutterworth, UK). Monoclonal anti-Glo1 antibody produced in rat (cat. no. 
SAB4200193), anti-rabbit IgG antibody (cat. no. A9169), anti-mouse IgG antibody 
(cat. no. A9917) and anti-rat IgG antibody (cat. no. B7139) were purchased from 
Sigma-Aldrich. Anti-β-actin mouse monoclonal antibody (cat. no. ab6276) and anti-
acetyl lysine rabbit polyclonal antibody (cat. no. ab80178) were purchased from 
  
146 
 
Abcam (U.K). Anti-SIRT1 (cat. no. ab32441) and anti-SIRT2 (cat. no. ab51023) 
rabbit monoclonal antibodies were purchased from Abcam (U.K).   
 
2.1.5 Other analytical reagents 
Methanol, acetonitrile, isopropanol (IPA) and tetrahydrofuran (THF) (all 
HPLC grade) were purchased from Fisher Scientific. Trifluoroacetic acid (TFA, ≥ 
99% HPLC grade), Trifluoroacetic acid (TCA, BioUltra, ≥ 99.5%) and formic acid 
(FA, ≥ 98%) were purchased from Sigma-Aldrich. All other reagents, salts, acids and 
bases for buffers were analytical grade reagents and purchased from Sigma-Aldrich 
and Fisher Scientific. D-Lactate, D-glucose, reduced glutathione (GSH) and glycine 
were purchased from Sigma-Aldrich. Methylglyoxal (MG) for cell culture was 
prepared by the hydrolysis of methylglyoxal dimethylacetal in dilute sulphuric acid 
and purified by fractional distillation under reduced pressure, as previously described 
(McLellan and Thornalley, 1992)  
Human serum albumin solution (ZenalbTM 20; 200 g/l of which >95% is 
human albumin, endotoxin free) was purchased from Bio Products Laboratory 
Limited (Hertfordshire, UK). Nicotinamide adenine dinucleotide, oxidised form, 
(NAD+; cat. no. N6522), aminoguanidine hydrochloride (cat. no. 369494), D-lactic 
acid (cat. no. L0625), L-lactic acid (cat. no. L6402) pyruvate (cat. no. P2256), and 
glyoxal (cat. no. 43612; 40% aqueous solution) were purchased from Sigma-Aldrich. 
Lipopolysaccharides, LPS (cat. no. L6143; from Salmonella enterica serotype 
typhimurium, γ-irradiated), tumour necrosis factor-α, TNF-α (cat. no. T0157) – 
human recombinant, expressed in yeast and had activity of ≥2 × 107 U/mg, buffered 
aqueous solution, were purchased from Sigma Aldrich. Trichostatin A (TSA), [R-
(E,E)]-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-
heptadienamide from Streptomyces species (cat. no. T8552), sirtuin-1 (SIRT1) 
inhibitor 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (EX-527; cat. no. 
E7034), and sirtuin-2 (SIRT2) inhibitor 2-cyano-3-[5-(2,5-dichlorophenyl)-2-
furanyl]-N-5-quinolinyl-2-propenamide (AGK2; cat. no. A8231), were purchased 
from Sigma Aldrich.  
 
2.1.6 Other consumables 
Sodium phosphate monobasic (cat. no. 71505), hydrochloric acid (analytical 
grade, 1 N; HCl) (cat. no. H1758) bovine serum albumin, EDTA, triton-X100, 
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Tween-20, diethylenetriaminepentaacetic acid (DETAPAC) (cat. no. D6518), 
mannitol and trans-resveratrol (tRSV, cat. no. R5010), ammonium persulphate (ACS 
reagent grade, cat. no. 248614), N,N,N’,N’-tetramethylethylene-1,2-diamine 
(TEMED, ≥ 99% electrophoresis grade), β-mercaptoethanol, 3',3'',5',5''- 
tetrabromophenol sulfonphthalein sodium salt (bromophenol blue, electrophoresis 
grade) were purchased from Sigma-Aldrich. Protease inhibitor cocktail (cat.no. 
04693159001) and phosphatase inhibitor cocktail (cat. no. 04906845001) tablets 
were purchased from Roche Diagnostics (Mannheim, Germany). 10 x RIPA lysis 
buffer (cat. no. 20-188) (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic 
acid, 10% NP-40, 10 mM EDTA) was purchased from Millipore, UK. Coomassie 
Brilliant Blue G-250 (analytical grade) and hydrazine hydrate (cat. no. 18412) was 
purchased from Fluka (Poole, Dorset, UK). Tris(hydroxymethyl)aminomethane 
(Tris), Tris-HCl base, perchloric acid, sodium chloride and potassium bicarbonate 
were purchased from Fisher Scientific (Loughborough, UK). 
The 10 x premixed electrophoresis Tris-glycine buffer (cat. no. 1610732; 1 x 
dilution contains 25 mM Tris, 192 mM glycine, pH 8.3), 10 x Tris-buffered-saline 
TBS (cat. no. 1706435 ; 1 x dilution gives 20 mM Tris, 500 mM NaCl, pH 7.4), 
Criterion™ TGX™ stain-free gel 4–20% precast polyacrylamide gel (cat. no. 
3450412, 3450418, 3450426), Trans-Blot® Turbo™ PVDF pre-cut blotting transfer 
pack (cat. no. 1704157), including filter paper, buffer, polyvinyl difluoride (PVDF) 
membrane for use with Trans-Blot Turbo transfer system (cat. no. 1704155) were 
purchased from Bio-Rad (Hertfordshire, UK). Photographic film was purchased 
from GE Healthcare (Little Chalfont, UK). SpectroTM multicolor broad range protein 
ladder (10-260 kDa, for 4 – 20% Tris-glycine SDS-PAGE), enhanced 
chemiluminescence (ECL) reagent kit (cat. no. 32106) and sodium dodecyl sulphate 
(SDS) (cat. no. 28312B) were purchased from Fisher Scientific.  
Concentrated protein assay dye and reagents for Bradford assay (cat. no. 
5000201) and DC assay (cat. no. 5000111) were purchased from Bio-Rad 
Laboratories. BCA protein assay was purchased from Fisher Scientific. 
Microplate U bottom polystyrene 96-well Sterilin plate, HPLC vials, inserts 
and plastic supports, caps and microspin filters “Spin-X” (0.2 µm pore size) were 
purchased from Fisher Scientific. Amicon ultrafiltration microcentrifuge tubes and 
filter inserts (0.5 ml, 3 kDa and 10 kDa cut-off) were purchased from Merck-
Millipore (Watford, UK). 
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2.1.7 Analytical and preparative kits 
The glucose assay kit - hexokinase method (cat. no. GAHK20) - was 
purchased from Sigma-Aldrich. The RNAse mini kit (cat .no. 74106) was from 
Qiagen, UK. Nuclear extraction kit (cat. no. 40010) and TransAM® Flexi NF-ĸB p65 
kits (cat. no. ab133128) were purchased from Abcam as UK supplier of products for 
Active Motif (La Hulpe, Belgium). Pierce™ Limulus Amebocyte Lysate (LAL) 
chromogenic endotoxin quantitation kit (cat. no. 88282), Direct magnetic IP/Co-IP 
kit and Dynabeads® Protein G immunoprecipitation kit (cat. no. 10007D) were 
purchased from Fisher Scientific (Loughborough, UK). CytoSelect™ 48-well cell 
adhesion assay (collagen I, colorimetric) (cat. no. CBA-052) was purchased from 
Cambridge Bioscience Ltd (Cambridge, UK).  
 
2.1.8 Chromatographic materials 
For dicarbonyl assay the column-BEH C18, 1.7 µm particle size column (100 
x 2.1 mm) fitted with a (5 x 2.1mm) pre-column was purchased from Waters 
(Elstree, Herts, UK). The two columns used for protein damage markers and 
glutathione analysis - 5 µm particle size HypercarbTM columns (column 1, 2.1 x 50 
mm; and column 2, 2.1 mm x 250 mm) were purchased from Fisher Scientific. 
Analytical microcentrifuge tube filter inserts (0.2 m) were purchased from Alltech 
Associates Applied Science Ltd (Carnforth, Lancs, U.K.). For proteomics analysis 
the column used  was: an Acclaim PepMap ODS µ-precolumn cartridge, 300 µm i.d. 
x 5 mm,  5 μm particle size, 100 Å pore size, fitted to an Acclaim PepMap ODS 
RSLC 75 µm i.d. x 50 cm, 2 µm particle size, 100 Å pore size main column (Thermo 
Scientific). 
 
2.1.9 Analytical standards 
2.1.9.1 Calibration standards for protein glycation, oxidation and nitration 
adduct analysis 
The standards for protein damage markers were prepared by current and 
previous members of host research team, as described previously (Thornalley et al., 
2003b, Ahmed et al., 2003). [guanidino-15N2]-L-Arginine, 4,4,5,5-[
2H4]L-lysine and 
[13C6]L-lysine, [methyl-
2H3]-L-methionine and ring-[
2H4]-L-tyrosine (all >98% 
isotopic purity) were purchased from Cambridge Isotope Laboratories (Andover, 
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MA, USA). [guanidino-15N2]MG-H1, [guanidino-
15N2]3DG-H and [guanidino-
15N2]G-H1 were prepared in house from [guanidino-
15N2]-L-arginine after 
conversion to the Nα-t-butoxycarbonyl derivative (Thornalley et al., 2003b, Meldal 
and Kindtler, 1986). [2H8]MOLD was prepared from 4,4,5,5-[
2H4]-L-lysine after 
conversion to the Nα-formyl derivative (Finot and Mauron, 1969). [13C6]CEL, 
[13C6]CML and [
13C6]pentosidine were prepared from [
13C6]-L-lysine after 
conversion to the Nα-formyl derivative. The synthetic methods for the preparation, 
puriﬁcation and characterisation of all AGE calibration standards were as described 
for their non-isotopically substituted analogues (Ahmed et al., 2003). [methyl-
2H3]MetSO was prepared from [methyl-
2H3]-L-methionine, and [
2H6]dityrosine and 
[2H3]3-nitrotyrosine (3-NT) were prepared from ring-[
2H4]-L-tyrosine, using 
previously described methods (Lapp and Dunn, 1955, Huggins et al., 1993, 
Sokolovsky et al., 1966). 
 
2.1.9.2 Dicarbonyl calibration standards 
Glyoxal (40% aqueous solution) from Sigma-Aldrich was used without 
purification. High purity MG and 3-deoxyglucosone (3-DG) were prepared in-house 
by the host research team. MG was prepared as mentioned before and described by 
McLellan (McLellan and Thornalley, 1992). 3-DG was prepared from glucose and 
toluidine by method of Madson and Feather (Madson and Feather, 1981) with 
modifications described by Henle and Bachmann (Henle and Bachmann, 1996). The 
concentration of stock solutions of dicarbonyls was calibrated by conversion to 
1,2,4-triazine derivatives by incubation with aminoguanidine hydrochloride and 
spectrophotometric detection, deducing concentrations of the 1,2,4-triazine 
derivatives and thereby dicarbonyl precursors from known extinction coefficients 
(Thornalley et al., 2000). 
 
2.1.10 Instrumentation 
A Nikon Eclipse TE2000-S inverted microscope (Kingston-Upon-Thames 
Surrey, U.K.) was used to view cells and record micrographs. Neubauer 
haemacytometer was used for cell counting (Model no. 0630410, Marienfeld-
Superior, Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany). A 
FLUOstar OPTIMA microplate reader from BMG Labtech (Aylesbury, U.K) was 
used for microplate spectrophotometry and fluorimetry. Other spectrophotometry 
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was performed with UVICON UV/VIS spectrophotometer (Northstar Scientific 
Limited, Leds, U.K.). The Vibra-Cell sonicator, used to disrupt cells, was from 
Jencons Scientific (Leighton Buzzard, UK). A Criterion™ Cell electrophoresis 
chamber (Model no. 1656020), Trans-Blot® Turbo™ Transfer System (Model no. 
170-4155) and PowerPac™ Basic Power Supply (Model no. 164-5050) were 
purchased from Bio-Rad. Applied BiosystemsTM 7500 Real-time PCR machine was 
from Life Technologies. Quantification of RNA stock solutions was performed using 
a ND-1000 Nanodrop spectrophotometer (Nanodrop, Wilmington, USA). A gel 
imaging system for fluorescence and chemiluminescence, G:BOX Chemi XX6 system, 
was purchased from Syngene (Cambridge,UK). 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis 
was performed using two different instruments from Waters (Manchester, U.K.): (i) 
an AcquityTM UPLC system with a Quattro Premier XE tandem mass spectrometer, 
and (ii) and an AcquityTM UPLC system with a Xevo-TQS tandem mass 
spectrometer. Enzymatic hydrolysis was performed using a CTC-PAL Automation 
System (CTC-Analytics, Zwingen, Switzerland). The centrifugal evaporator was a 
Savant Instruments SpeedVac (Thermo Scientific, Waltham MA). For high 
resolution mass spectrometry proteomics analysis, The UltiMate® 3000 RSLCnano 
LC system was used coupled with Thermo Orbitrap Fusion mass spectrometer 
(Thermo Scientific). 
 
2.1.11 Software 
Microplate assays were analysed using Optima software version 2.10 R2 
(BMG Labtech). Real-time PCR analysis was performed using 7500 Fast System 
Software version 1.4.0. ImageQuant densitometry software (GE Healthcare Life 
Sciences, Amersham, U.K.) was used for quantification of Western blot protein 
levels. RNA primers were designed using the OligoPerfectTM design tool (Invitrogen 
Life Technologies). Masslynx software, version 4.1 (Waters), was used to integrate 
the tandem mass spectrometry metabolomics data. The proteomics raw data was 
processed using Proteome Discoverer (version 1.4.0.288, Thermo Scientific), 
Progenesis QITM (Nonlinear Dynamics, Newcastle upon Tyne, U.K.) and ScaffoldTM 
version 4.4.3 (Proteome Software, Portland, Oregon, USA). Molecular ion 
fragmentation mass spectra, MS2, were searched with SEQUEST and Mascot engine 
against a human protein database, Uniprot (http://www.uniprot.org June-July 2015). 
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The programme EnzFitter (Biosoft, Cambridge, U.K.) was used for non-linear 
regression in data fitting to dose-response curves. 
 
2.2 Cell culture methods 
2.2.1 Human periodontal fibroblasts cells culture 
hPDLFs cells were maintained in Modified Eagles Medium (MEM) 
supplemented with L-alanyl-L-glutamine (2 mM), 10% FBS and 100 Units/ml 
penicillin and 100 µg/ml streptomycin at 37 oC under aseptic conditions and an 
atmosphere of air/5% carbon dioxide/100% humidity. Cells were passaged 
approximately every 3 days with a seeding density of ca. 5,000 cells/cm2. Cells were 
harvested using 0.25% trypsin-EDTA, subsequently neutralised by addition of 
culture media. For experiments performed in low and high glucose conditions, 
culture media was supplemented with β-D-glucose to a final concentration of 8 mM 
and 25 mM using a concentrated sterile aqueous stock solution of β-D-glucose. 
Unless stated otherwise, all experimental cultures were performed for 3 days on cells 
between passages 3 and 5. Cells were collected by trypsinisation and sedimentation 
by centrifugation; and media samples were centrifuged prior to storage to sediment 
any detached cells. Cell and media samples were stored at – 80 oC until subsequent 
analysis. Cell viability was ≥ 98% at the start of all experiments determined using 
Trypan blue dye exclusion. 
 
2.2.2 Cell culture experimentation 
Assessment of human periodontal fibroblasts viability 
Primary hPDLFs were cultured in 6 well plates (5000 cells/cm²) in triplicate 
in MEM media supplemented with three different glucose concentrations (5.5 mM, 
8.0 mM and 25.0 mM). Total cell number and viable cell number was counted every 
day for 6 days and a cell growth curve constructed.  
 
The effect of exogenous methylglyoxal on hPDLFs growth – dose-response 
study 
Primary hPDLFs were cultured in low glucose concentration (8 mM) in 6 
well plates at a cell density of 5000 cells/cm² in triplicate. In the second day of 
culturing the cells, the cells were incubated in fresh media containing 8 mM glucose 
with variable MG concentrations, 0, 25, 50, 100 and 200 μM MG, for 2 days. Cells 
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were counted after 48 h using a Neubauer haemocytometer. Viable and non-viable 
cell numbers were recorded to produce a MG concentration-response curve. Data 
were fitted to the dose-response equation V=100 × (GC50)
n / ((GC50)
n + ([MG])n) 
where V is the viable cell number as a percentage of control cultures without MG, 
GC50 is the median growth inhibitory concentration value, [MG] is the concentration 
of MG and n is the logistic regression coefficient (also known as the Hill 
coefficient). Experimental data of V and [MG] were fitted by non-linear regression 
of V on [MG] using the programme EnzFitter solving for GC50 and n. 
 
Effect of methylglyoxal on hPDLFs growth – time course study 
Primary hPDLFs were cultured at a cell density of 5000 cells/cm2 in 6-well 
plates in MEM in low and high glucose concentration, 8 mM and 25 mM 
respectively, in triplicate. After 24 h, the cells were incubated in fresh media with 8 
mM or 25 mM glucose and with and without 200 μM MG. The number of viable and 
non-viable cells were counted every day for three days. 
 
Characterisation of glyoxalase system and dicarbonyls metabolism in hPDLFs 
in model hyperglycaemia 
Primary hPDLFs cells were cultured in MEM in low and high glucose 
concentration, 8 mM and 25 mM respectively, for 3 days in triplicate. Cell extracts 
were analysed for Glo1 activity, total protein, MG-H1 residue content of cell protein 
and MG concentration. Medium was analysed for concentrations of glucose, MG, 
MG-H1 free adduct and D-lactate.  
 
Effect of Glo1 inducers on the glyoxalase system and dicarbonyl metabolism in 
hPDLFs in vitro 
Primary hPDLFs cells were cultured in MEM with low and high glucose 
concentration, 8 mM and 25 mM respectively, with and without tRSV (10 µM), HSP 
(10 µM) or tRSV+HSP (tRSV, 10 µM and HSP, 10 µM) for 3 days in triplicate. 
Cells were analysed for Glo1 activity, protein and mRNA, MG and cell protein MG-
H1 residue content. Medium was analysed for concentrations of glucose, MG, MG-
H1 free adduct and D-lactate. Aldose reductase and MG reductase activities were 
also measured. The attachment of hPDLFs to collagen-I was also measured (see 
below). 
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Glo1 half-life experiment 
Primary hPDLFs cells were cultured in MEM with low and high glucose 
concentration, 8 mM and 25 mM respectively, in 6 well plates. After 24 h, fresh 
MEM was added to each well with cycloheximide (CHX, 10 µM) and with and 
without tRSV (10 µM) for 2 days in triplicate. Cell viability test was assessed. Cell 
protein extracts were analysed for Glo1 protein content after a further 24, 48 and 72 
h. 
 
Glo1 acetylation 
Primary hPDLFs cells were cultured in MEM with low and high glucose 
concentration, 8 mM and 25 mM respectively, with and without tRSV (10 µM). 
Glo1 protein was pulled down by immunoprecipitation technique and the acetylation 
of Glo1 protein was detected by immunoblotting method. 
Primary hPDLFs cells were cultured in MEM with low glucose and high 
glucose concentration, 8 mM and 25 mM respectively. After 24 h, fresh MEM was 
added to each flask with and without SIRT1 inhibitor EX 527 (100 nM), SIRT2 
inhibitor AGK2 (4 µM) or class I and II mammalian histone deacetylase inhibitor 
TSA (300 nM) and incubated for a further 2 days in triplicate. Dose response curve 
was constructed. Cell viability was assessed. Cells were analysed for Glo1 activity 
and mRNA. 
 
Proteomics analysis of primary human periodontal fibroblasts 
Primary hPDLFs cells were cultured in MEM with low and high glucose 
concentration, 8 mM and 25 mM respectively, for 3 days in triplicate. A cytosolic 
protein extract was prepared and analysed by high resolution mass spectrometry 
proteomics – see below. 
 
Effect of highly glycated protein/RAGE interaction on inflammatory signalling 
and Glo1 expression in hPDLFs in vitro 
To assess if glycated protein activate inflammatory signalling activated in 
hPDLFs in vitro, cells were incubated for 3 days in triplicate in MEM with 8 mM 
glucose supplemented with various preparations of glycated protein: AGEmin-HSA, 
AGE-HSA, CMLmin-HSA and CML-HSA (50 µg/ml or 100 µg/ml final 
concentration). Low level of endotoxin in the glycated protein preparations had been 
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confirmed beforehand by measurement by Limulus Amebocyte Lysate (LAL) assay. 
Cell viability assessment was performed. Cells were analysed for Glo1 activity and 
Glo1 mRNA. Transcription factor p56/NFκB activation status was measured on 
nuclear extracts. 
 
2.2.3 Preparation of glycated derivatives of human serum albumin 
Aliquots of ZenalbTM HSA solution (250 μl, 20% w/v) were washed four 
times with sodium phosphate buffer (1.25 ml, 100 mM, pH 7.4) by diafiltration using 
microspin ultrafilters (10 kDa), centrifuged at 4000 g for 15 min and 4 oC under 
sterile conditions. Concentration of the washed HSA aliquots were determined by 
Bradford assay. 
 
2.2.3.1 Preparation of human serum albumin modified minimally and highly by 
glucose-derived glycation adducts (AGEmin-HSA and AGE-HSA, 
respectively) 
Minimally glycated HSA (AGEmin-HSA) was prepared by incubation of HSA 
(50 mg/ml) with β-D-glucose (40 mM) in sodium phosphate buffer (100 mM, pH 
7.4) at 37 oC for 5 weeks. Highly glycated HSA (AGE-HSA) was prepared by 
incubation of HSA (50 mg/ml) with β-D-glucose (1.67 M) in sodium phosphate 
buffer (100 mM, pH 7.4) at 37 oC for 60 days. These incubations were prepared and 
incubated under aseptic and endotoxin-free conditions. Unmodified HSA control was 
incubated without glucose and treated similarly. The modified protein was then 
dialysed against ammonium bicarbonate buffer (30 mM, pH 7.9) at 4 oC for 24 h. 
The modified protein was lyophilised to dryness and stored at -20 oC until use 
(Ahmed and Thornalley, 2002). 
 
2.2.3.2 Preparation of modified human serum albumin modified minimally and 
highly by Nᵋ-carboxymethyl-lysine residues (CMLmin-HSA and CML-
HSA, respectively) 
CMLmin-HSA was prepared by incubation of HSA (0.66 mM) with glyoxylic 
acid (2.15 mM) and sodium cyanoborohydride (56 mM in 200 mM sodium 
phosphate buffer, pH 7.8) at 37 oC for 24 h. CML-HSA was prepared by incubation 
of HSA (0.66 mM) with glyoxylic acid (21.5 mM) and sodium cyanoborohydride 
(56 mM in 200 mM sodium phosphate buffer, pH 7.8) at 37 oC for 24 h. The 
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modification experiments were performed under aseptic and endotoxin free 
conditions. The modified protein was dialysed against phosphate buffer saline 
(PBS), pH 7.4 and 4 oC, and stored at –20 oC (Ahmed and Thornalley, 2002). 
 
2.2.4 Effect of glycated human serum albumin on activation of NF-κB in 
hPDLFs in vitro 
2.2.4.1 Limulus amebocyte lysate LAL assay 
LPS may activate NF-kB in hPDLFs (Preshaw et al., 2013) and hence LPS 
contamination of glycated proteins is a potential interference in assessing activation 
of NF-κB in hPDLFs in vitro by glycated proteins. Glycated proteins were prepared 
form endotoxin-free HSA of clinical HSA infusion solutions and under aseptic 
conditions. Endotoxin content of the glycated HSA preparations was assessed by 
chromogenic LAL assay (Unger et al., 2014). The reporter chromophore of samples 
was measured in a microplate reader at 405 nm. A standard curve was created using 
the E. coli LPS standard from 0.1 – 1.0 endotoxin unit (EU) per ml. One EU is 
approximately equivalent to 100 pg endotoxin E. coli LPS – Figure 17.  
 
 
Figure 17: Calibration curve for E. coli endotoxin.  
Linear regression equation: Absorbance= (2.41 ± 0.08) x endotoxin (EU/ml) + 
(0.0339 ± 0.0403); R2 = 0.997; (n = 15). 
 
The assay microplate was maintained in a heating block for 10 min at 37 oC. 
An aliquot of blank, standard or test sample (50 µl) was added into the appropriate 
microplate well then covered with lid and incubated for 5 min at 37 oC. An aliquot of 
LAL was added (50 µl) to each well then microplate was covered by lid and gently 
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shacked for 10 s and incubated at 37 oC for 10 min. An aliquot of chromogenic 
substrate solution (100 µl) was then added to each well, samples mixed for 10 s and 
incubated at 37 oC for 6 min. Finally, an aliquot of stop reagent (25% (v/v) acetic 
acid, 50 µl) was added to each well and samples mixed for 10 s. The absorbance at 
405 nm of standard and test samples was recorded by microplate reader. 
 
2.2.4.2 Nuclear extraction protocol 
Principle of assay 
Nuclear extraction is the process of obtaining non-denatured and active 
proteins from nuclear compartment of the cell by using high-salt extraction method. 
The extracted nuclear proteins are used to monitor NF-kB activation (Singh et al., 
2012) 
 
Cell cultures 
hPDLFs were cultured at a cell density of 5000 cells/cm2  in T175 flasks in 
MEM with 8 mM glucose. After 24 h, the media was changed and the fresh media 
was added supplemented with glycated protein (AGEmin-HSA, AGE-HSA, CMLmin-
HSA or CML-HSA; 50 µg/ml or 100 µg/ml) and cell cultures continued for a further 
2 days. Cell pellets were then collected by as follow. The cells were washed by ice 
cold PBS/ phosphatase inhibitors (5ml) and was aspirated. Aliquot of ice cold PBS/ 
phosphatase inhibitors (3ml) was added to the cells (8 x 106) and cells were collected 
by scraping from culture flasks with cell lifter and transferred to pre-chilled 15ml 
conical tubes. Cell suspension was centrifuged for 5 min at 200 x g in a pre-cooled 
centrifuge at 4˚C and supernatant was removed. 
 
Nuclear extraction 
The cell pellet was gently resuspended in 1X hypotonic buffer (250 µl) by 
pipetting up and down and incubated on ice for 15 min. The cells were transferred 
into a pre-chilled microcentrifuge tube and an aliquot of NP40 detergent (10%, 25 
μl) was added. The homogenate was vortexed for 10 s then centrifuged (14,000 g, 1 
min, 4 oC). The supernatant was transferred and retained (cytosolic fraction). The 
nuclear pellet was re-suspended in complete cell extraction buffer (50 μl; 10 mM 
DTT (5 µl), lysis buffer (44.5 µl) and protease inhibitor cocktail (0.5 µl)) by 
pipetting the solution in and out of the pipette tip 5 times. The suspension was 
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incubated for 40 min on ice on a rocking platform shaker, 150 rpm, then vortexed for 
30 s. The suspension was centrifuged (10 min, 14,000 g, 4 °C) and the supernatant 
retained (nuclear fraction) and stored in -80 oC. The protein level in nuclear fraction 
was measured by the Bradford method.  
 
2.2.4.3 Assay of NF-κB system activation status 
The transcription factor nuclear factor κB (NF-κB) is a key transcriptional 
system for activation of a battery of pro-inflammatory genes (Ghosh and Hayden, 
2008). Measurement of NF-κB activation status in cells is an indicator of cell 
inflammation. Herein the TransAMTM activation assay is used (ActiveMotif, La 
Hulpe, Belgium). In NF-κB activation, the p50/p65 heterodimer moves into cell 
nucleus and binds NF-κB consensus motifs to activate inflammatory gene 
expression. The method involves adding a stimulated cell nuclear extract with 
biotinylated oligonucleotide NF-κB consensus motif to capture activated NF-κB 
binding. The binding reaction is then transferred to the wells of a 96-well 
streptavidin coated plate and is quantified using an antibody specific for the bound 
p50/p65 heterodimer. A second anti-IgG-horseradish peroxidase antibody is added to 
enable chromogenic detection in an ELISA protocol. The assay was performed with 
assay reagents and protocol provided by the manufacturer. 
An aliquot of nuclear extract of test samples (10 µg) and biotinylated 
oligonucleotide (1 pmol) were diluted to 50 µl with complete binding buffer in a 
microcentrifuge tube. For positive control, Jurkat nuclear extract (2 µl; 5 µg) and 
biotinylated oligonucleotide (1 pmol) were diluted to 50 µl in complete binding 
buffer. For blank assay, biotinylated oligonucleotideto (1 pmol) was diluted to 50 µl 
in complete binding buffer. Each tube was vortex mixed and incubated in room 
temperature for 30 min. An aliquot (50 µl) of the mixture was transferred in to the 
well on the 96-well streptavidin-coated assay plate. The plate was covered with 
adhesive cover and incubated for 1 h at room temperature with mild agitation. After 
incubation, each well was washed three times with 200 µl washing buffer. An aliquot 
(100 µl) diluted p50/p65 heterodimer antibody (1:1000) was added to each well, 
covered with adhesive cover and incubated for 1 h at room temperature without 
agitation. Each well was washed three times with 200 µl washing buffer and an 
aliquot of diluted anti-IgG-HRP antibody conjugate (100 µl; 1:1000) was added to 
each well, the plate was covered with adhesive cover and incubated for 1 h at room 
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temperature. The wells were washed three times with 200 µl washing buffer and an 
aliquot (100 µl) of developing solution was added to each well, incubated for 10 min 
at room temperature in the dark and then an aliquot (100 µl) of stop solution was 
added. The absorbance at 450 nm of wells was recorded. 
 
2.2.5 GLO1-ARE, mutant non-functional stable ARE and NQO1-ARE 
transfectant reporter cells lines 
These were produced by transfection of a pGL4.22[luc2CP/puro] reporter 
vector containing GLO1-ARE (ARE-1 from our previous notation), mutated 
functionally inactive GLO1-ARE (ARE1m, negative control) and quinone reductase 
ARE (NQO1-ARE) – a conventional ARE-related marker gene (Xue et al., 2012b, 
Xue et al., 2015b). Transfected HepG2 cells were selected with puromycin (1 
µg/ml). After culture for 3 weeks, puromycin-resistant cells were screened for 
luciferase activity after treatment with 4 µM SFN for 6 h. After validation of positive 
clones by measuring luciferase activity, the stable cell line was expanded in selection 
media and thereafter used in studies for screening of bioactive compounds and 
synergism. Briefly, stable transfectant cell lines were incubated with and without 
bioactive compounds and combination of tRSV and HSP (0.625 – 5.0 μM) for 6 h in 
MEM medium with 10% fetal calf serum and 2 mM glutamine under an atmosphere 
of 5% CO2 in air, 100% humidity and 37 
oC. This incubation period was optimum to 
judge initial rate of increase in transcriptional response in cells treated with 
compounds without increase in untreated controls. For the reporter assay, 100 µl Cell 
Culture Lysis Reagent (CCLR, Promega, Southampton, UK) was added to cell and 
shaken gently for 30 min. The mixture of cell lysate was centrifuged (12,000 g, 5 
min, 4 oC) and an aliquot (20 µl) of supernatant used in the reporter assay. The 
luciferase activity was determined using a Luciferase Assay System (Promega). The 
luciferase response is given in Relative Light Units (RLU). Data are corrected for 
blank response and normalised to the highest effect (100%) achieved with 10 μM 
tRSV. Data of normalised responses (blank = 0%, 10 μM tRSV = 100%) for varied 
bioactive concentrations are fitted by non-linear regression to a dose-response curve, 
E = Emax x [Bioactive]
n/(EC50
n + [Bioactive]n), solving for EC50 and n (logistic 
regression coefficient - also called the Hill coefficient). Nrf2-dependent 
transcriptional response was verified by siRNA silencing of Nrf2, as described (Xue 
et al., 2012b). This experiment was performed by the host research team. 
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2.2.6 Cell adhesion assay – unmodified collagen-I 
Primary hPDLFs were incubated with high and low glucose media in 
triplicate for 3 days with or without Glo1 inducers (i.e. tRSV, HSP or tRSV+HSP). 
Cells (0.1-1.0 x 106 cells/ml) were then suspended in serum free media containing 10 
µM of either tRSV, HSP or tRSV+HSP. An aliquot of cell suspension (150 μl) was 
added to each well of a 48-well plate where walls of the wells were coated with 
collagen-I (CytoSelect™ cell adhesion assay plate, Cambridge Bioscience Ltd). The 
plate was incubated at 37 °C for 3 h. All steps were performed under sterile 
conditions. The unattached cells were then carefully removed by aspirating the 
media. After washing the plate 5 times with PBS (250 μl), an aliquot of cell stain 
solution (200 μl, 0.5% (w/v) crystal violet, 30% (v/v) ethanol and 3% (w/v) 
formaldehyde) was added to fix and stain the attached cells and incubated for 10 min 
at room temperature. The stain solution was aspirated, and the plate was then washed 
5 times with deionized water (500 μl) and dried in air. Finally, an aliquot of 
extraction solution (200 μl, 10% (w/v) citric acid) was added to each well and 
incubated for 10 min on an orbital shaker to dissolve crystal violet stain. The 
absorbance of the wells at 595 nm was recorded. 
 
2.2.7 Cell adhesion assay – modified collagen 
Primary hPDLFs were incubated with 8 mM glucose and 25 mM glucose 
media for 3 days with or without tRSV, HSP or tRSV+HSP. The media from these 
cell cultures were then incubated for 3 h in 37 oC with or without aminoguanidine 
(500 µM) under sterile conditions. Aminoguanidine is a potent MG scavenger and 
derivatised MG completely in the time (Thornalley et al., 2000). An aliquot of these 
conditioned media samples (200 μl) was then added to the wells of a collagen-I 
adhesion plate and incubated for 24 h at 37 oC. The collagen-I plates were then 
washed 3 times with PBS (250 μl). hPDLFs cells grown under normal conditions (8 
mM glucose, 0.1-1.0 x 106 cells/ml ) were then added to wells of preconditioned 
collagen plate. The plates were incubated for 3 h at 37 oC. The unattached cells were 
then carefully removed by aspirating the media. After washing the plate 5 times with 
PBS (250 μl), an aliquot of cell stain solution (200 μl, 0.5% crystal violet, 30% 
ethanol and 3% formaldehyde) was added to fix and stain the attached cells and 
incubated for 10 min at room temperature. The stain solution was aspirated from the 
wells. The wells were washed 5 times with deionized water (500 μl) and left to dry 
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in air. Finally, an aliquot of extraction solution (200 μl, 10% citric acid) was added 
to each well and incubated for 10 min on an orbital shaker to dissolve crystal violet 
stain. The absorbance of the wells at 595 nm was recorded. 
 
2.3 Analytical methods 
2.3.1 Total protein assay 
2.3.1.1 Bradford method to measure total protein 
The concentration of protein in cell lysates was quantified by Bradford 
protein assay (Bradford, 1976, Compton and Jones, 1985). Stock solutions of bovine 
serum albumin (BSA) was calibrated by UV absorption spectrophotometry using the 
extinction coefficient at 279 nm for a 1% (10 mg/ml) solution; ε279 (1%) = 6.9 cm-1 
(Peters, 1962). Protein samples were diluted in the range 0.05 to 0.3 mg/ml. Test 
samples, BSA standards and blanks in triplicate (20 µl per well) were mixed with 
200 µl of Bradford reagent in a 96-well microplate and incubated for 15 min on a 
shaker at room temperature. Absorbance was read at 595 nm. The concentration of 
protein in test samples was calculated by interpolation of the calibration curve. 
 
2.3.1.2 Detergent compatible lowry method 
For immunoblotting and proteomics experiments, the detergent compatible 
assay (DC assay) was used to measure protein concentration of hPDLFs cell extracts 
containing 0.5% SDS (RIPA buffer). This is a colorimetric assay for detergent 
solubilised protein based on the Lowry assay (Lowry et al., 1951).  
 
2.3.2 Enzymatic activity assay 
2.3.2.1 Preparation of samples 
Primary hPDLFs cells were cultured under condition described above and 
then collected by trypsinisation, counted and sedimented by centrifugation (150 g, 5 
min). Cell pellets were washed with ice-cold PBS three times. The cell pellets (ca. 1 
x 10⁶ cells) were re-suspended in sodium phosphate buffer (10 mM, pH 7.0, 200 μl), 
sonicated on ice (110 W, 30 s) and the membranes sedimented by centrifugation 
(20,000 g, 30 min, 4 oC). The supernatant was retained and stored at -80 oC for later 
use as lysate in enzymatic activity assays. 
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2.3.2.2 Activity of Glo1 
The activity of Glo1 is assayed by measuring the initial rate of formation of 
S-D-lactoylglutathione from the MG-GSH hemithioacetal formed non-enzymatically 
from MG and GSH. The reaction is followed spectrophotometrically at 240 nm; 
Δε240 = 2.86 mM−1 cm−1 (Allen et al., 1993b). Hemithioacetal was prepared by pre-
incubation of MG (2 μmol) with GSH (2 μmol) at 37 °C for 10 min in sodium 
phosphate buffer (50 mM, pH 6.6, 980 μl). The cell lysate (20 μl) was added and the 
absorbance at 240 nm was monitored with time for 5 min. The activity of Glo1 was 
calculated from the initial increase in absorbance, corrected for buffer blank. Glo1 
activity is given in units per mg protein where one unit of Glo1 activity is the 
amount of enzyme which catalyses the formation of 1 μmol of S-D-
lactoylglutathione from the hemithioacetal substrate per minute under assay 
conditions (Allen et al., 1993b). The activity of Glo1 may be assayed in the presence 
of Glo2 because the high concentrations of the MG-GSH hemithioacetal used 
inhibits Glo2 activity (Uotila, 1973). 
 
2.3.2.3 Activity of glyoxalase 2 
The activity of Glo2 is determined by measuring the initial rate of hydrolysis 
of S-D-lactoylglutathione to GSH and D-lactate – Figure 18. The hydrolysis of S-D-
lactoylglutathione is followed spectrophotometrically at 240 nm for which 240 = - 
3.10 mM-1cm-1 (Clelland and Thornalley, 1991, Allen et al., 1993a). 
 S-D-lactoylglutathione (0.3 mM, 100 µl) was incubated in Tris/HCl (50 mM, 
pH 7.4, 850 µl) and 37 oC, and the cell lysate or lysate buffer for the blank (50 μl) 
was added and followed the absorbance at 240 nm for 5 min at 37 oC. The initial rate 
of change in absorbance was deduced. One unit of Glo2 activity equals the volume 
of enzyme that catalyses the hydrolysis of 1 µmol of S-D-lactoylglutathione per 
minute under assay conditions (Allen et al., 1993b). Cytosolic cell extracts were 
performed by sonication as described above. 
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Figure 18: The catalytic reactions of the glyoxalase system.  
From (Clugston et al., 2004). 
 
2.3.2.4 Methylglyoxal reductase activity 
NADPH-dependent aldoketo reductase provides an alternative metabolic fate 
for MG and converts it to hydroxyacetone. AKR isozymes 1A4, 1B1 (aldose 
reductase) and 1B3 metabolise MG (Baba et al., 2009). MG reductase activity is 
determined by measuring the initial rate of oxidation of NADPH by cell lysates in 
the presence of MG and NADPH, followed spectrophotometrically at 340 nm; Δε340 
= - 6.20 mM-1cm-1.   
                                        MG reductase 
CH3COCHO + NADPH + H+            →              CH3COCH2OH + NADP+ 
 
MG (1 mM) was incubated with NADPH (0.1 mM) in sodium phosphate 
buffer (50 mM pH 7.4 and 37 oC) and cell lysate, or lysate buffer for blank, added to 
a final volume of 1 ml. The solution was mixed by inversion and the absorbance at 
340 nm measured for 5 min. The activity of MG reductase is measured in units 
where one unit catalyses the reduction of 1 µmol of MG per min under assay 
conditions. 
 
2.3.2.5 Methylglyoxal dehydrogenase activity 
NAD+-dependent MG dehydrogenase converts methylglyoxal to pyruvate 
(Monder, 1967). The methylglyoxal dehydrogenase activity is determined by 
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measuring the initial rate of reduction of NAD+ by cell lysates in the presence of MG 
and NAD+, followed spectrophotometrically at 340 nm; Δε340 = 6.20 mM-1cm-1. 
                                        MG dehydrogenase 
CH3COCHO + NAD+ + H2O               →                CH3COCO2- + NADH + 2H+ 
 
Cell lysate, or lysate buffer for blanks, is added to MG (1 mM) and NAD+ 
(0.1 mM) in sodium phosphate buffer (50 mM, pH 7.4 and 37 oC) and the sample 
mixed well by inversion. The reaction was monitored for absorbance at 340 nm for 5 
min. The activity of MG dehydrogenase is measured in units where one unit 
catalyses the oxidation of 1 µmol of MG per minute under assay conditions. 
 
2.3.3 Total cell thiol assay 
The concentration of cell thiol – protein thiol + non-protein thiol (mainly 
GSH) – was determined by measuring the absorbance produced by the reaction of 
cell extract with 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB) or Ellman’s reagent.  
DTNB is reacts with thiols to from the yellow chromophore, 5-mercapto-2-
nitrobenzoic acid – Figure 19. 5-Mercapto-2-nitrobenzoic acid is detected by 
absorbance with λmax at 412 nm (Hansen et al., 2007, Hansen and Winther, 2009). It 
can also be monitored by a 405 nm, 10 nm bandwidth, filter on an absorbance mode 
microplate reader, as used herein.  
 
 
Figure 19: Reaction of DTNB with thiol R-SH. 
 
Cell cytosol extract was prepared by re-suspending ca. 1 x 10⁶ cells in 
sodium phosphate buffer (10 mM, pH 7.0), sonicating the cell suspension on ice 
(110 W, 30 s), and sedimenting the cell membranes by centrifugation (20,000 g, 30 
min, 4 °C). The supernatant was retained and stored at – 80 oC until analysis. An 
aliquot of DTNB solution (125 μl, 1 mM DTNB in 100 mM sodium phosphate 
buffer, pH 7.4, with 0.2 mM DETAPAC) was added to the wells (96-well 
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microplate) followed by distilled water (100 μl). Cell cytosol extract (25 μl) was then 
added to the well and the absorbance at 405 nm was monitored until a stable 
maximum value was reached – after 20 min. The absorbance increase at 405 nm was 
used to calculate the level of cellular thiols. Using GSH as an analytical standard 
thiol, the assay was calibrated in the range of 0 - 30 nmol GSH- Figure 20. 
 
 
Figure 20: Calibration curve for GSH. 
 Linear regression equation: A412 (A.U.) (0.037 ± 0.0003) x thiols (nmol) + (0.063 ± 
0.0047); R2 = 0.999 (n = 21). 
 
2.3.4 D-Glucose assay 
The glucose concentration in culture media was measured using 
commercially available an end-point enzymatic assay. Assay mixtures contained:  
1.5 mM NAD+, 1 mM ATP, 1 unit/ml hexokinase (HK) and 1 unit/ml glucose-6-
phosphate (G-6-P) dehydrogenase (Sigma Aldrich). The enzymatic basis of the assay 
is illustrated in - Figure 21. 
 
 
Figure 21: Detection of glucose via hexokinase (HK) and glucose-6-phosphate 
dehydrogenase. 
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Glucose is converted to 6-phosphogluconate via glucose-6-phosphate using 
hexokinase and glucose-6-phosphate dehydrogenase catalytic enzymes. The NADH 
formed in the reaction mixture is measured by absorbance at 340 nm. As equimolar 
amounts of glucose is phosphorylated in this reaction as NAD+ is reduced to NADH. 
The increase in absorbance at 340 nm is directly proportional to the concentration of 
NADH and hence to concentration of glucose in the sample. 
 
2.3.4.1 Preparation of sample 
A standard curve was constructed in the range of 0.25 – 1.50 mM glucose - 
Figure 22. An aliquot of standard or diluted sample (25 µl) was added to each well of 
a microplate then the assay reagent (225 µl) was added. The plate was incubated at 
room temperature for 15 min before the absorbance at 340 nm was read using a 
spectrophotometer.   
 
Figure 22: Calibration curve for D-glucose. 
 Linear regression equation: A340 (A.U.) = (0.479 ± 0.009) x D-glucose (mM) + 
(0.0008± 0.008); R2 = 0.996 (n = 21). 
 
2.3.5 Assay of D-lactate 
The flux of formation of D-lactate by hPDLFs was determined by measuring 
the concentration of D-lactate in the culture medium at baseline and end of the 
culture period. D-Lactate crosses cell membranes by the specific lactate transporter, 
the inorganic anion exchange system and by non-ionic passive diffusion. An end-
point enzymatic fluorometric assay was used (McLellan et al., 1992). D-lactate is 
converted to pyruvate by the enzyme D-lactic dehydrogenase. The enzymatic 
reaction occur during the incubation at 37 oC. The increase in NADH concentration 
is measured by fluorescence (excitation = 340 nm, emission = 460 nm). 
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 D-Lactate + NAD+                                  pyruvate + NADH 
 
2.3.5.1 Preparation of sample 
An aliquot of ice-cold perchloric acid (PCA) (1 ml, 0.6 M) was added to 
culture medium (500 μl) for deproteinisation. The mixture was vortexed and left on 
ice for 10 min to complete protein precipitation. The samples were centrifuged (7000 
g, 4 oC, 5 min) to sediment the protein precipitate. An aliquot of the supernatant (700 
µl) was neutralised to pH 7 by adding potassium bicarbonate (200 µl, 2 M), mixed 
and centrifuged again (7000 g, 4 oC, 10 min) to sediment the precipitate of potassium 
perchlorate. Samples were then saturated in CO2 and were degassed by placing in a 
centrifugal evaporator at room temperature for 5 min under reduced pressure (20 
mmHg). An aliquot of degassed deproteinised extract or D-lactate standard solution 
(100 µl) was added in duplicate to the 96-well black microplate containing glycine-
hydrazine buffer (100 µl; 1.2 M glycine, 0.5 M hydrazine hydrate, 2.5 mM 
DETAPAC, pH 9.2) and NAD+ (4 mM, 25 µl). The reaction was started on the 
addition of D-lactic dehydrogenase enzyme (25 µl, 250 units per ml). The microplate 
was incubated at 37 oC in the dark for 2 h. Each sample has its own control without 
the enzyme and used as a blank. The fluorescence of NADH was monitored at 
λexcitation 340 nm and λemission 460 nm. A standard curve for calibration was 
constructed in the range of 0 – 6 nmol D-lactate/ well – Figure 23. 
 
 
Figure 23: Calibration curve for D-lactate assay.  
Linear regression equation: Fluorescence (arb. units) = (7648 ± 88) x D-lactate 
(nmol) + (2523 ± 317); R2 = 0.999 (n = 21). 
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2.3.6 Assay of L-lactate 
The method to measure the concentration of L-lactate in culture medium was 
similar to that of D-lactate – see above. A standard curve was produced using L-
lactate standards and the enzyme L-lactate dehydrogenase was used instead of the D-
lactate dehydrogenase used for the D-lactate assay. The standard curve range was 
selected to ensure that the range used was linear and a time-course achieved to 
establish the optimal incubation length. Since cellular level of L-lactate is higher 
than D-lactate, media samples were diluted 10-fold with water to ensure that 
concentrations measured were within the standard curve range – Figure 24.  
 
 
Figure 24: Calibration curve for L-lactate. 
 Linear regression equation: Fluorescence = (4176 ± 178) x L-lactate (nmol) + (2919 
± 603); R2 = 0.991 (n = 21).  
 
2.3.7 Real-Time PCR quantitation 
The relative copy number of specific gene mRNA in hPDLFs cells was 
measured by real-time quantitative PCR. This method includes the extraction of 
mRNA with subsequent reverse transcription to cDNA. The cDNA is then quantified 
by measuring fluorescence in a PCR reaction. SYBR green dye was used to produce 
the fluorescence. This dye is highly fluorescent when bound to double-stranded 
DNA.  
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2.3.7.1 Primer design and testing 
Primers were designed using the OligoPerfectTM designer software by using 
mRNA and genomic DNA sequences found in the UCSC genome browser. Multiple 
primer pairs were designated for each gene. Amplicon length (optimal 100-150 bp) 
was considered and primers spanning exon-exon junctions were selected when 
possible. Dissociation plots were implemented for all primers to test performance. 
MgCl2 concentration was optimised when necessary. Example dissociation plots are 
shown in – Figure 25. Dissociation plots were constructed for each assay plate. This 
guaranteed that the primers performed constantly. 
 
    
Figure 25: Dissociation plots for primers. 
(A) GLO1 dissociation curve. (B) COL1 dissociation curve.    
 
2.3.7.2 RNA extraction and purification 
Sample preparation 
Primary hPDLFs cells were cultured in 8 mM glucose and 25 mM glucose 
with or without Glo1 inducers as described in cell culture section. After incubation 
for desired experimental period, RNA extracts of cells were prepared. 
Total RNA was extracted using the Qiagen RNeasy mini kit according to the 
manufacturer’s instructions. Briefly, the samples were lysed by addition of a lysis 
buffer (350 μl) containing β-mercaptoethanol and pipetting the suspension in and out 
of a pipette 10 times. The lysis buffer contained a high concentration of guanidine-
thiocyanate which acted as a chaotropic agent promoting cell lysis. Lysed samples 
were mixed with 70% (v/v) ethanol to improve binding conditions to the silica-based 
spin-column. The sample was washed with multiple buffers to eliminate impurities 
A. B. 
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and finally RNA was eluted by addition of RNAse-free water. The quality and 
concentration of RNA was determined spectrophotometrically using a NanoDrop 
1000 spectrophotometer. RNA sample (2 µl) was used to measure the concentration 
of RNA at A260, given that value of 1.0 at A260 is equal to 40 µg/ml of RNA. The 
quality of the RNA was determined by ratio between A260 and A280. Pure RNA was 
expected to give a ratio of 1.9 - 2.1. Each sample was diluted to 50 ng nucleic acid 
and concentration confirmed using NanoDrop 1000. 
 
2.3.7.3 Reverse transcription 
cDNA was synthesised from the RNA using reverse transcription. A total of 
0.2 μg RNA (12 µl in 20 µl reaction) from cells was annealed with oligo (dT) (1 µl) 
at 70 oC for 5 min before chilling on ice. Subsequently, 8 µl of master mix 
containing 10 U/μl RNase inhibitor (1 µl), 10 mM dNTPs (1 µl), 5 X Bioscript 
reaction buffer (4 µl) and Bioscript reverse transcriptase (1 µl) mix in nuclease-free 
water were added to each sample. Samples were heated at 42 oC for 60 min. The 
reaction was stopped by heating to 70 oC for 10 min. The synthesised cDNA was 
mixed with 40 µl (3 X dilution) of nuclease-free water and stored at –20 ºC repeated 
freeze-thawing was avoided before analysis. 
 
2.3.7.4 Analysis of gene mRNA expression by SYBR green 
This method was used to measure the expression of mRNA of specific genes 
and normalised to housekeeping gene. The mRNA was firstly transcribed to cDNA 
as described in previous section. The synthesised cDNA was used for standard and 
for analyses.  
 
2.3.7.5 Preparation of standards 
Samples with the highest mRNA concentration were used to create the 
standard curve. RNA volume (1 µg) was used to extract cDNA using the same 
method described formally. The formed cDNA was used to custom standards 0 - 
1000,000 pg using serial dilutions. A typical standard curve is shown in Figure 26. 
 
 
  
170 
 
 
Figure 26: RT-PCR calibration curve. 
Linear regression equation: Threshold cycle = (-3.748 ± 0.083) x log input amount of 
mRNA + (41.6 ± 0.447); R2 = 0.999 (n = 21). 
 
2.3.7.6 Data analysis 
In a clear 96 well plate, sample (2 µl) was mixed with Master Mix SYBR 
Green (10 µl), primer (0.5 µl) and nuclease free water (7.5 µl). Then, the plate was 
sealed and centrifuged for few seconds; mRNA expression was measured using a 
7500 Fast-Real time PCR machine. Plates were heated to 95 °C for 10 min to 
activate the hot-start DNA polymerase, 40 cycles of 95 °C x 15 s and 60 °C x 60 s. A 
standard curve of serially diluted pooled cDNA over the range 0 - 1000,000 pg was 
run alongside assay samples and used for quantification using β-actin as a reference 
gene. 
 
2.4 Immunoblotting for Glo1 
Expression level of Glo1 protein in primary hPDLFs was measured by 
Western blotting and normalised to β-actin. 
 
2.4.1 Sample preparations 
Primary hPDLFs were cultured in 8 mM glucose and 25 mM glucose with or 
without 10 μM tRSV, HSP or tRSV+HSP. After treatment, cells were trypsinised, 
washed and collected as described in cell culture section. Cell pellets were 
resuspended in RIPA buffer with phosphatase inhibitor and protease inhibitor and 
incubated on ice for 10 min. Cell lysate suspension was centrifuged (20,000 g, 30 
min, 4 oC) and supernatant was collected and stored at -80 oC until the analysis. 
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The protein concentration was measured by DC assay. According to DC 
assay readings, the protein samples were prepared for loading onto the gel wells. 
Loading buffer containing β-mercaptoethanol (4x Laemmli sample buffer, Bio-rad) 
and the protein samples were mixed to make the total concentration 20 μg. Samples 
were heated at 95 oC for 5 min to denature the protein and loaded onto the gel. 
 
2.4.2 Western blotting 
Cell protein extract (20 µg) was separated using 4–20% precast polyacrylamide 
gel (4-20% criterion™ TGX stain-free™ gel), gel was inserted into the Criterion 
electrophoresis cell (Bio-rad). Premixed electrophoresis buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS, pH 8.3) following 1 fold  dilution was poured into the 
electrophoresis cell to separate protein samples by SDS-PAGE. An aliquot of the 
prestained protein ladder (10 µl) and the test sample (15 µl) was loaded into the wells. 
Finally, samples were electrophoresed at 150 V for 1 h. 
The sandwich layer of semi-dry transfer consisted of paper, gel and 
membrane was prepared by using pre-cut blotting transfer pack that included filter 
paper, PVDF membrane. These were used with Trans-Blot Turbo transfer system 
(Bio-rad) to transfer proteins from gel to membrane – Figure 27. Semi-dry transfer 
was performed at 2.5A; 25V constant for 15 min. 
 
 
Figure 27: Gel and membrane setup for electrophoretic transfer (bio-rad).  
 
The transfer membrane was firstly blocked with 5% (w/v) dried milk protein 
in Tris-buffered saline with Tween-20 (TBS-T buffer; 150 mM NaCl, 10 mM 
Tris/HCl pH 7.6 and 0.05% Tween-20). The membrane was then probed using pre-
  
172 
 
determined concentrations of primary antibody (anti Glo1 rat, 1/3000; anti β-actin 
mouse, 1/1000) overnight in 4 oC in 1% (w/v) dried milk protein in TBS-T buffer. 
After blotting with primary antibody, the membrane was washed three times with 
TBS-T buffer for 10 min. Membrane was then probed with secondary antibody (anti-
rat, 1/10000; anti-mouse, 1/10000) at room temperature for 1 h followed by rinsing 
three times with TBS-T and developed with ECL reagent. Photographic image was 
taken by G:BOX Chemi systems (Syngene). The intensity of the Glo1 protein band 
was normalised to β-actin (protein loading control). Membranes was scanned and 
quantified with ImageQuant densitometry software. 
 
2.4.3 Immunoprecipitation (IP) 
2.4.3.1 Preparing cells for immunoprecipitation 
Cell pellets were suspended in 1x RIPA buffer, phosphatase inhibitor and 
protease inhibitor and incubated on ice for 10 min. Cell lysate suspension was 
centrifuged (20,000 g, 30 min, 4 oC). Supernatants were transferred to new 
microcentrifuge and stored at -80 oC until further analysis. 
 
2.4.3.2 Pre-clear lysate 
Pre-clear the lysate is a way to remove potentially reactive components from 
the cell lysate prior to the immunoprecipitation of desired protein to prevent a non-
specific binding of these components to the IP beads or antibody. Pre-clear the 
sample by passing the sample over the beads alone. Lysate was incubated with beads 
only for 1 h at 4 oC. Beads are then removed and discarded prior to the immune-
precipitation. The protein concentration of remaining lysate was measured by DC 
assay. 
 
2.4.3.3 Immunoprecipitation (IP) protocol 
Dynabeads G was re-suspended in the vial by vortexing for 30 s and aliquots 
(50 μl, 1.5 mg) were transferred to microcentrifuge tubes. Tubes were placed on the 
magnetic stand and the supernatants were removed. An aliquot of Glo1 rabbit 
antibody (5 μg) was added to the beads, diluted in TBS buffer (300 μl) and mixed. 
The beads and the antibody mixture were incubated with rotation for 10 min at room 
temperature to allow the Ab-conjugated Dynabeads to be formed. Aliquots of cell 
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lysate containing the required protein concentration (100 μg) of each sample were 
added to the Ab-conjugated Dynabeads. 
To immunoprecipitate the target antigen, the mixture was incubated at 4 oC 
with gentle end-over-end mixing overnight to form the immune complex. The next 
day, tubes were placed on the magnetic stand and the supernatant was discarded. The 
beads were washed with TBS buffer (200 μl) three times; after each wash, the 
supernatant was removed. 
An aliquot (5 μl) of SDS sample loading buffer containing β-mercaptoethanol 
in 4 x Laemmli sample buffer and TBS (15 µl) was added to the beads. The beads 
were incubated at 95 oC for 5 min then tubes were placed on the magnetic stand and 
eluents were collected. The samples were allowed to cool to room temperature 
before applying to SDS-PAGE gel. 
 
2.4.3.4 Western blotting for immunoprecipitate samples 
IP samples (20 μl) were separated using 8–16% Mini-PROTEAN® TGX™ 
gel using the Mini-ProteanR Tetra cell system (Bio-rad) as described above. 
Membranes were probed using pre-determined concentrations (rabbit, 1/1000) of 
anti-acetyl-lysine antibody (primary antibody) overnight in 4 oC in 1% milk in TBS-
T. Membranes were then probed with secondary antibody (anti-rabbit, 1/10000) at 
room temperature for 1 h and photographic image was taken by G:BOX Chemi 
systems (Syngene). 
 
2.4.3.5 Stripping of the membrane 
The membrane was incubated in a stripping buffer for 45 min at 37 oC on 
shaker. The membrane was washed with water then washed 3 times with TBS-T 
buffer for 10 min. The membrane was then blocked with 5% dried milk protein in 
TBS-T for 1 h. Membranes were then probed using pre-determined concentrations of 
anti-Glo1 (rat, 1/3000) antibody (primary antibody) overnight in 4 oC in 1% dried 
milk protein in TBS-T. After blotting with primary antibody the membranes were 
washed three times with TBS-T buffer for 10 min. Membrane was then probed with 
secondary antibody (anti-rat, 1/10000) at room temperature for 1 h. Membranes were 
washed three times with TBS-T and developed with ECL reagent and photographic 
image was taken by G:BOX Chemi systems (Syngene). Membrane was scanned and 
quantified with Image Quant densitometry software. 
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2.5 LC-MS/MS methodology 
2.5.1 Assay of protein glycation, oxidation and nitration adducts by LC-
MS/MS 
Protein glycation, oxidation and nitration adducts residues in cell protein 
were analysed by LC-MS/MS after exhaustive enzymatic hydrolysis, and free 
adducts in the media were quantified by stable isotopic dilution analysis liquid 
chromatography with tandem mass spectrometric detection (LC-MS/MS) (Rabbani 
et al., 2014a, Thornalley et al., 2003b). This is a gold standard technique with high 
specificity and sensitivity developed by the host team. 
Analytes tested were: early glycation adduct Nε-fructosyl-lysine (FL); AGEs 
Nε-(1-carboxyethyl)lysine (CEL), Nε-carboxymethyl-lysine (CML), 
hydroimidazolones derived from glyoxal (G-H1), MG (MG-H1) and 3-DG (3DG-H 
and related structural isomers), Nω-carboxymethyl-arginine (CMA), MG derived 
lysine dimer (MOLD) and oxidation adducts - methionine sulfoxide (MetSO), 
dityrosine (DT) and N-formylkynurenine (NFK); and nitration adduct 3-nitrotyrosine 
(3-NT).  
 
2.5.1.1 Sample preparation, filtration and washing 
An aliquot (300 μl) of cell culture medium from hPDLFs cultures was 
filtered by microspin ultrafiltration (3 kDa cut-off) at 14,000 g for 20 min at 4 ºC 
until around 200 µL of ultrafiltrate was collected and stored at -80 oC until further 
analysis. The hPDLFs cell lysate (100 μl) was washed by 4 cycles of concentration 
to 40 μL and dilution to 500 μl with water over microspin ultrafilter (10 kDa cut-off) 
at 4 oC. The protein concentration was determined by Bradford method. For the 
hydrolysis, an aliquot of washed protein sample containing 100 µg of protein was 
diluted to 20 µl with water in a glass vial and flushed with argon in preparation for 
enzymatic hydrolysis. 
 
2.5.1.2 Enzymatic hydrolysis of soluble protein 
The reagents and test samples were placed in a robotic processor (PAL 
HTS9, CTC Analytics, Switzerland) ready for automated enzymatic hydrolysis – 
Figure 28. All steps were performed under argon to inhibit the oxidative degradation 
of protein substrate. The processor was programmed to perform series of additions as 
follows: aliquots of 100 mM HCl (10 µl), pepsin solution (2 mg/ml in 20 mM HCl; 5 
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µl), and thymol solution (2 mg/ml in 20 mM HCl; 5 µl) were added, and the samples 
were incubated at 37 oC for 24 h. The samples were then neutralized and buffered at 
pH 7.4 by the addition of 12.5 µl 100 mM potassium phosphate buffer, pH 7.4, and 5 
µl 260 mM KOH. Pronase E solution (2 mg/ml in 10 mM KH2PO4, pH 7.4; 5 µl) and 
penicillin/streptomycin (1000 units/ml and 1 mg/ml respectively; 5 µl) was added, 
and the samples were incubated at 37 oC for 24 h. Finally, aminopeptidase solution 
(2 mg/ml in 10 mM KH2PO4, pH 7.4; 5 µl) and prolidase solution (2 mg/ml in 10 
mM KH2PO4, pH 7.4; 5 µl) were added, and the samples were incubated at 37 
oC for 
48 h. This gave the final enzymatic hydrolysate (77.5 µl) for the LC-MS/MS assay - 
Table 8. It is important that addition of reagents used should be in the correct order 
to prevent pH overshoot. Hydrolysed sample (5 µl) and water (20 µl) was mixed 
with internal standard mixture (25 µl) in HPLC vials to be analysed for protein 
glycation, oxidation and nitration adducts and related amino acids by LC-MS/MS. 
 
 
Figure 28: CTC PAL HTS9 processor 
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Table 8: Protocol for enzymatic hydrolysis of protein using CTC-PAL 
automated sample processor.  
Addition Volume added (μl) 
Day 0 
100 mM HCl 10.0 
Pepsin solution (2 mg/ ml) 5.0 
Thymol (1 mg/ml) 5.0 
Incubate for 24 hours at 37 ºC 
Day 1 
100 mM KH2PO4/K2HPO4 buffer, pH 7.4 12.5 
260 mM KOH 5.0 
Pronase E solution (2 mg/ml) 5.0 
Penicillin (100 units/ml) and streptomycin (1 mg/ml) 5.0 
Incubate for 24 h at 37 ºC 
Day 2 
Aminopeptidase solution (2 mg/ml) 5.0 
Prolidase solution (2 mg/ml) 5.0 
Incubate for 48 h at 37 ºC 
Adapted from (Rabbani et al., 2014a). 
 
2.5.1.3 Preparation of standard curve 
Standard curves for LC-MS/MS analysis were prepared in the range shown in 
Table 9, using a cocktail of normal and isotopic standards prepared as described in 
Tables 10. Seven calibration samples were prepared from 0 to 6 using stock 
calibration solutions with water. The solution (50 µl) was applied directly to LC-
MS/MS for detection of each analyte. Figure 29 shows typical calibration curves for 
arginine and MG-H1. 
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Table 9: Preparation of calibration standard solutions from cocktails of normal 
and stable isotopic standards for protein glycation assay, oxidation and 
nitration adduct residues of hPDLFs protein extracts.  
Cal no 
Normal standards 
solution (µl) 
Water 
(µl) 
Stable isotopic 
standard solution (µl) 
Total volume 
(µl) 
0 0.00 25.00 25 50 
1 1.25 23.75 25 50 
2 2.50 22.75 25 50 
3 6.25 18.75 25 50 
4 12.50 12.50 25 50 
5 18.75 6.25 25 50 
6 25.00 0.00 25 50 
 
Table 10: Analyte content of calibration standard solutions for protein 
glycation assay, oxidation and nitration adduct residues of hPDLFs protein 
extracts. 
Analytical standard (nmol) Internal  standard 
Cal no 0 1 2 3 4 5 6 (nmol) 
Lys  0 0.05 0.10 0.25 0.50 0.75 1.00 [13C6]Lys 0.25 
Arg  0 0.05 0.10 0.25 0.50 0.75 1.00 [15N2]Arg 0.25 
Met  0 0.05 0.10 0.25 0.50 0.75 1.00 [2H3]Met 0.25 
Tyr  0 0.01 0.02 0.05 0.10 0.15 0.20 [2H4]Tyr 0.1 
Trp  0 0.01 0.02 0.05 0.10 0.15 0.20 [15N2]Trp 0.05 
Analytical standard (pmol) Internal standard 
(pmol) Cal no 0 1 2 3 4 5 6 
FL 0 0.250 0.50 1.250 2.50 3.750 5.00 [2H4]FL 0.30 
Orn 0 0.125 0.25 0.625 1.25 1.875 2.50 [2H6]Orn 2.50 
G-H1 0 0.025 0.05 0.125 0.25 0.375 0.50 [15N2]G-H1 0.25 
MG-
H1 
0 0.125 0.25 0.625 1.25 1.875 2.50 [15N2]MG-H1 1.25 
3DG-H 0 0.125 0.25 0.625 1.25 1.875 2.50 [15N2]3DG-H 1.25 
CML 0 0.125 0.25 0.625 1.25 1.875 2.50 [13C6]CML 0.25 
CEL 0 0.025 0.05 0.125 0.25 0.375 0.50 [13C6]CEL 0.25 
CMA 0 0.025 0.05 0.125 0.25 0.375 0.50 [13C2]CMA 0.25 
MOLD 0 0.025 0.05 0.125 0.25 0.375 0.50 [2H8]MOLD 0.25 
MetSO 0 0.125 0.25 0.625 1.25 1.875 2.50 [2H3]MetSO 1.25 
DT 0 0.025 0.05 0.125 0.25 0.375 0.50 [2H6]DT 0.25 
3-NT 0 0.025 0.05 0.125 0.25 0.375 0.50 [3H2]3-NT 0.25 
NFK 0 0.025 0.05 0.125 0.25 0.375 0.50 [15N2]NFK 0.25 
     
  
178 
 
 
 
Figure 29: Typical calibration curves for arginine and MG-H1 in stable isotopic 
dilution analysis LC-MS/MS.  
A. Calibration curve of arginine. Linear regression equation: arg/[15N2]arg peak area 
ratio = (3.49 ± 0.02) x arg (nmol) + (0.028 ± 0.009); R² = 0.999 (n = 7). B. 
Calibration curve of MG-H1. Linear regression equation: MG-H1/[15N2]MG-H1 
peak area ratio = (0.934 ± 0.019) x MG-H1 (pmol) + (0.031± 0.025); R² = 0.998 (n = 
7). 
 
2.5.1.4 LC-MS/MS (Xevo-TQS system) conditions 
For chromatographic conditions of the LC-MS/MS analyses, two 5 µm 
particle size Hypercarb columns were used in series (column 1: 2.1 x 50 mm; and 
column 2: 2.1 mm x 250 mm). The mobile phase was: solvent A - 0.1% TFA in 
water, and solvent B - 0.1% TFA in 50% acetonitrile (ACN). Solvents for the post-
run method for column washing were: solvent A - 0.1% TFA in water, and solvent C 
- 0.1% TFA in 50% tetrahydrofuran (THF). The elution profiles for assay run and 
column washing and re-equilibration are given in Table 11. Flow from the column in 
the interval 4 to 35 min was directed to the MS/MS detector. Electrospray positive 
ionisation mass spectrometric multiple reaction monitoring (MRM) was used to 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.0 0.2 0.4 0.6 0.8 1.0
A
rg
/[
1
5
N
2
]A
rg
(P
e
a
k
  
a
re
a
 r
a
ti
o
) 
Arg (nmol)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 1 2 3
M
G
-H
1
/[
1
5
N
2
]M
G
-H
1
 
(P
e
a
k
  
a
re
a
 r
a
ti
o
) 
MG-H1 (pmol)
A. 
B. 
  
179 
 
detect all protein damage analytes. The ionisation source temperature and 
desolvation temperature were 120 °C and 350 °C, respectively. The cone gas and 
desolvation gas flow were 99 l/h and 901 l/h, respectively. Optimised molecular ion 
and fragment ion masses and collision energies for MRM detection are given in – 
Table 12. Masslynx software was used to integrate the chromatographic peaks. 
Analyte amounts were normalised to amount of related unmodified amino acid in 
protein hydrolysates to deduce content of glycation, oxidation and nitration adduct 
residues in hPDLFs cell protein and to volume to deduce concentrations of glycation, 
oxidation and nitration free adducts in culture media. A similar elution profile was 
used for the AcquityTM-Quattro Premier LC-MS/MS system. 
 
Table 11: Elution profile for stable isotopic dilution analysis liquid 
chromatography with tandem mass spectrometric detection analysis of protein 
glycation, nitration addaucts and oxidation (AcquityTM-Xevo-TQS system). 
Time (min) 
Flow rate 
(ml/min) 
Solvent A (%) Solvent B (%) Gradient 
0 0.2 100 0 ---- 
5 0.2 100 0 Isocratic 
8 0.2 97 3 Linear 
12 0.2 97 3 Isocratic 
15 0.2 83 17 Linear 
18 0.2 83 17 Isocratic 
24 0.2 20 80 Linear 
24 0.2 97 3 Immediate 
35 0.2 97 3 Isocratic 
Post-run 
0 0.4 0 100 ----- 
10 0.4 0 100 Isocratic 
20 0.2 0 100 Isocratic 
20 0.2 100 0 Immediate 
25 0.2 100 0 Isocratic 
40 0.4 100 0 Isocratic 
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Table 12: Chromatographic retention times and MRM detection conditions for 
detection of glycation, oxidation and nitration adducts by (LC-MS/MS) 
(AcquityTM-Xevo-TQS system). 
Analyte Rt (min) Molecular ion (Da) Fragment ion (Da) 
Lys 5.6 147.1 84.1 
[13C6]Lys 5.6 153.1 89.1 
Val 8.6 117.8 72.0 
[2H8]Val 8.6 125.8 80.0 
MetSO 8.7 166.1 56.2 
[2H3]MetSO 8.7 169.1 56.2 
3DG-H 11.7 319.1 70.1 
[15N2]3DG-H 11.7 321.1 70.1 
MG-H1 11.9 229.2 114.1 
[15N2]MG-H1 11.9 231.2 116.1 
CMA 12.3 233.1 70.1 
[13C2]CMA 12.3 235.1 70.1 
G-H1 12.7 215.2 100.1 
[15N2]G-H1 12.7 217.2 102.1 
MOLD 15.0 341.2 83.9 
[2H8]MOLD 15.0 349.2 87.9 
Tyr 18.4 182.9 137.0 
[2H4]Tyr 18.4 186.9 141 
NFK 23.7 237.1 191.1 
[15N2]NFK 23.7 239.1 193.1 
3-NT 23.4 227.1 181.1 
[2H3]3-NT 23.4 230.1 184.1 
Trp  23.7 205.1 158.8 
[15N2]Trp  23.7 205.1 160.8 
CML 32.1 205.1 84.1 
[13C6]CML 32.1 211.1 89.1 
FL 32.1 291.1 84.1 
[2H4]FL 32.1 295.1 88.1 
CEL 32.2 219.2 130.0 
[13C6]CEL 32.2 225.2 136.0 
Arg 32.2 176.2 70.1 
[15N2]Arg 32.2 178.2 70.1 
Met 32.2 150.0 104.0 
[2H3]Met 32.2 153.0 107.0 
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2.5.2 Assay of dicarbonyls by stable isotopic dilution analysis LC-MS/MS 
Methylglyoxal, glyoxal and 3-DG amount in cultured hPDLFs and media 
were determined by using 1,2-diaminobenzene for derivatisation and quantification 
of the subsequent quinoxaline compounds – Figure 30 – by stable isotopic dilution 
analysis LC-MS/MS (Rabbani and Thornalley, 2014c).         
 
 
Figure 30: Derivatisation used in the dicarbonyl assay. 
 
2.5.2.1 Sample preparation 
Primary hPDLFs were cultured in experimental conditions described 
previously. For sample collection for analysis of media, culture medium was 
removed, centrifuged (250 g, 5 min) to sediment any detached cells and the 
supernatant removed and stored at – 80 oC until analysis. For the cell samples, 
remaining medium was aspirated and the cells washed with a minimum volume of 
PBS to remove any residual media. Then, the cells were trypsinised, trypsin 
neutralised, and the detached cells were counted and pelleted by centrifugation (250 
g, 5 min). The supernatant was removed and cell pellets were frozen at -80 ºC 
immediately. 
For analysis of cell pellets, 10 µl of cold 20% trichloroacetic acid (TCA) 
containing 0.9% sodium chloride solution (NaCl) (TCA-saline) was added to cell 
pellets to de-proteinise the samples then samples were vortex mixed well. An aliquot 
of water (40 µl) was added. For media samples, an aliquot of culture medium (20 µl) 
was used, and 10 µl of TCA-saline and 20 µl of water were added. Subsequent 
preparation was similar for both sample types: an aliquot of 3% sodium azide in 
water (5 µl) was added to inhibit peroxidase activity and isotopic standard cocktail (5 
µl; 2 pmol stable isotopic dicarbonyl) then added to each sample. The samples were 
vortex mixed and centrifuged (6,000 g, 10 min, 4 °C). Supernatant (45 µl) was 
removed and added to 10 µl derivatisation agent solution (0.5 mM diaminobenzene 
in 200 mM HCl containing 0.5 mM DETAPAC). Samples and standards were kept 
  
182 
 
at room temperature in the dark for 4 h for derivatisation to quinoxaline adducts to 
go to completion and then analysed by LC-MS/MS. Standards (2 - 20 pmol) were 
derivatised at the same time with the samples for calibration of the analyte/internal 
standard response ratio. 
 
2.5.2.2 Preparation of calibration standards 
Cocktails of dicarbonyls which contain MG, glyoxal and 3DG at 800 nM and 
[13C]dicarbonyls at 400 nM were prepared and used to prepare standards over the 
range 2 - 20 pmol glyoxal, MG and 3-DG as shown in Table 13 and 14 and Figure 31. 
 
Table 13: Calibration standards for dicarbonyls 
Calibration 
no 
MG 
(pmol) 
Glyoxal 
(pmol) 
3-DG 
(pmol) 
Isotopic 
standard (IS) 
0 0 0 0 2 
1 2 2 2 2 
2 4 4 4 2 
3 8 8 8 2 
4 12 12 12 2 
5 16 16 16 2 
6 20 20 20 2 
 
Table 14: Preparation of calibration standards from stock solution 
Volume Added (µl) 
  
Cal0 Cal1 Cal2 Cal3 Cal4 Cal5 Cal6 
10%TCA-
0.9%NaCl 
10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Water 25.0 22.5 20.0 15.0 10.0 5.0 0.0 
3% Sodium azide 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Dicarbonyl 
standard 
(800pmol/ml) 
0.0 2.5 5.0 10.0 15.0 20.0 25.0 
[13C]Dicarbonyls 
(400 pmol/ml) 
5.0 5.0 5.0 5.0 5.0 5.0 5.0 
0.5 mM DB 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
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Figure 31: Standard curve for dicarbonyls. 
(A) Methylglyoxal. Regression equation: Peak area ratio = ((0.267 ± 0.008) x MG 
[pmol]) + (1.58 ± 0.09); R² = 0.996 (n = 7). (B) Glyoxal. Regression equation: Peak 
area ratio = ((0.062 ± 0.002)x glyoxal [pmol]) + (0.062 ± 0.017); R² = 0.997 (n = 7). 
(C) 3-DG. Regression equation: Peak area ratio = ((0.169 ± 0.005)x 3-DG [pmol]) + 
(-0.052 ± 0.056); R²= 0.996 (n = 7). 
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2.5.2.3 LC-MS/MS conditions 
LC was performed by using a reverse phase octadecylsilica (ODS) BEH C18, 
1.7 µm particle size column (100 x 2.1 mm) fitted with a 5 x 2.1 mm pre-column.  
The temperature of column was 30 °C. Solvents used were 0.1% TFA in water 
(solvent A) and 0.1% TFA in 50:50 acetonitrile (MeCN) in water (solvent B). The 
gradient used is displayed in Table 15 below. 
 
Table 15: The gradient used for dicarbonyl analysis on LC-MS/MS. 
Method phase 
Time  
(min) 
Flow rate  
(mL/min) 
Solvent A  
(%) 
Solvent B   
(%) 
Curve 
Analysis 0.0 0.2 100 0 0 
 10.0 0.2 0 100 Linear 
 15.0 0.2 0 100 Isocratic 
Re-
equilibration 
15.0 0.2 100 0  
 30.0 0.2 100 0 Isocratic 
 
Analysis was performed by using AcquityTM UPLC system with eluate 
directed into the electrospray source of a Quattro Premier XE tandem mass 
spectrometer. Optimised mass spectrometer settings were: capillary voltage was 0.6 
kV, ion source temperature 120 °C, desolvation gas temperature 350 °C and cone 
and desolvation gas flows 140 and 900 l/h respectively. Table 16 shows the 
optimised multiple reaction monitoring (MRM) conditions used in mass 
spectrometric detection, along with their retention times, cone voltage and collision 
energy. Data analysis was performed using MassLynx software. Calibration curves 
were constructed by plotting peak area ratio of analyte/isotopic standard against 
analyte concentration. 
 
Table 16: Optimised MRMs used for dicarbonyls analysis. 
Analyte 
Retention 
time (min) 
Parent ion 
(Da) 
Fragment 
ion (Da) 
Cone 
voltage (V) 
Collision 
energy (eV) 
MG 7.8 145.1 77.1 24 24 
Glyoxal 7.1 131.0 77.1 24 23 
3-DG 5.6 235.2 199.0 21 15 
[13C3]MG 7.8 148.1 77.1 24 24 
[13C2]glyoxal 7.1 133.0 77.1 24 23 
[13C6]3DG 5.6 241.2 205.0 21 15 
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2.5.3 Glutathione assay by LC-MS/MS 
The amount of reduced glutathione (GSH), oxidised glutathione (GSSG) and 
S-D-lactoylglutathione in cultured hPDLFs cells and media samples was measured 
by stable isotopic dilution analysis LC-MS/MS.   
 
2.5.3.1 Sample preparation 
Primary hPDLFs were cultured in 8 mM glucose and 25 mM glucose as 
described previously. After 3 days of incubation, the media was removed and cells 
were washed with PBS. Cells were trypsinised, counted and pelleted by 
centrifugation (150 g, 5 min). An aliquot (40 µl) of a solution including 10% TCA, 
0.15% NaCl and 0.25% sodium azide in water was added to each cell pellet sample. 
This solution aids in protein precipitation and acts as a preservative by inhibiting 
peroxidase enzymes. Samples were then centrifuged (20,000 g, 30 min, 4 oC) and 
supernatant (10 µl, equivalent to 0.5 million cells) was mixed with internal standard 
(10 µl), made up to 50 µl by the addition of 0.1% TFA (aq) and analysed by LC-
MS/MS for detection of each analyte.  
 
2.5.3.2 Preparation of calibration standards 
Stock solutions (1 mg/ml) of GSH hydrochloride and GSSG were prepared in 
water. Further dilutions of these stocks were made using 0.1% TFA (solvent A). 
Calibration standards were prepared for sample analysis over the range 100-8000 
pmol and 5-100 pmol for GSH and GSSG respectively - Table 17. Standards were 
prepared as shown in Table 18 and Figure 32. S-D-lactoylglutathione was not 
routinely included in calibration standards since the quantities in test samples were 
below the limit of detection for the assay. 
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Table 17: Standard curve concentrations. 
 
GSH 
(pmol) 
GSH IS 
(pmol) 
GSSG 
(pmol) 
GSSG IS 
(pmol) 
S1 0 100 0 25 
S2 200 100 5 25 
S3 400 100 10 25 
S4 1000 100 20 25 
S5 2000 100 50 25 
S6 4000 100 80 25 
S7 6000 100 100 25 
S8 8000 100 - - 
 
Table 18: Standard curve preparation. 
 
GSH (µl) GSSG (µl) 
0.1% TFA 
(µl) 
12.5% TCA 
(µl) 
IS cocktail 
(µl) 
S1 0 0 20 20 10 
S2 0.5 (400 µM) 2.5 (2 µM) 15 20 10 
S3 1.0 (400 µM) 5.0 (2 µM) 10 20 10 
S4 2.5 (400 µM) 10 (2 µM) 0 20 10 
S5 5.0 (400 µM) 5.0 (10 µM) 10 20 10 
S6 10 (400 µM) 8.0 (10 µM) 4 20 10 
S7 15 (400 µM) 10 (10 µM) 0 20 10 
S8 20 (400 µM) - - 20 10 
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Figure 32: Standard curve for glutathione.   
(A) GSH. Regression equation: Peak area ratio = ((0.015 ± 0.0003)x GSH [pmol]) ± 
(1.13± 1.30); R² = 0.997 (n = 8). (B) GSSG. Regression equation: Peak area ratio = 
((0.245± 0.004)x GSSG [pmol]) ± (-0.556 ± 0.231); R² = 0.998. (n=7).  
 
2.5.3.3 LC-MS/MS conditions 
GSH, GSSG and S-D-lactoylglutathione were detected in hPDLFs cells by 
LC-MS/MS. Two graphite Hypercarb HPLC columns were used in series (50 x 2.1 
mm and 250 x 2.1 mm, particle size 5 µm) with a column temperature of 30 oC.  
Solvents used were: 0.1% TFA in water (solvent A); 0.1% TFA in 50:50 MeCN 
(solvent B); and 0.1% TFA in 50% THF (solvent C). The gradients used during the 
run and post run are presented in Tables 19. 
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Table 19: Gradient used for glutathione assay on liquid chromatography with 
tandem mass spectrometric detection. 
Time (min) 
Flow rate 
(mL/min) 
Solvent A 
(%) 
Solvent B 
(%) 
Gradient 
Sample 
analysis 
    
0 0.2 100 0 0 
1 0.2 100 0 Isocratic 
15 0.2 40 60 Linear 
Column wash and re-equilibration 
0 0.4 0.0 100 --- 
10 0.4 0.0 100 Isocratic 
10 0.4 100 0 --- 
25 0.4 100 0 Isocratic 
 
 
LC-MS/MS was performed on the AcquityTM UPLC-Premier XE tandem 
mass spectrometer system, as described above. For mass spectrometric detection, the 
capillary voltage was 0.6 kV. The source ionisation temperature was 120 oC. The 
desolvation gas flow and cone gas flow was 549 l/h and 146 l/h. The optimised 
MRMs used for detection, along with their retention times, cone voltage and 
collision energy are given in Table 20. 
 
Table 20: Optimised MRMs used for glutathione assay. 
Analyte 
Retention 
time (min) 
Parent 
ion (Da) 
Fragment 
ion (Da) 
Cone 
voltage 
(V) 
Collision 
Energy 
(eV) 
GSH 11.7 308.16 179.1 30 13 
GSSG 11.7 613.20 483.7 52 18 
S-D-Lactoyl-
glutathione 
12.7 380.21 76.2 32 35 
[13C215N1]GSH 14.3 311.16 182.1 30 13 
[13C415N2]GSSG 14.4 619.20 489.7 52 18 
 
Data analysis was performed using MassLynx software. Calibration curves 
were constructed by plotting peak area ratio of analyte/isotopic standard against 
analyte concentration. Total glutathione levels were also calculated by formula: 
Total GSH = GSH + (2 x GSSG). Estimates of cellular GSH, GSSG and total GSH 
are given as nmol per million cells. 
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2.6 Statistical Analysis 
Experiments were performed using analysis in replicates of triplicates or 
greater. Difference between normally distributed experimental groups was tested 
using Student’s t-test assuming equal or unequal variance. The data generated here is 
normally distributed and assessment of statistical differences between two study 
groups were required. Therefore, t-test is applied in this assessments. Significance 
was defined as p≤0.05.   
 
2.7 Proteomics analysis of cytosolic protein 
hPDLFs were cultured in MEM with 8 mM glucose and 25 mM glucose for 3 
days. Lysate was prepared by sonication. Cell pellets were suspended in aliquots of 
10 mM sodium phosphate buffer, pH 7.0 (400 μl) and sonicated on ice (110 W, 30 
s). Samples were centrifuged (20,000 g, 30 min, 4 oC) to sediment membranes. The 
supernatant was transferred and stored at -80 oC until analysis. The protein 
concentration was measured using Bradford assay. Lysate (500 μg) was washed by 4 
cycles of concentration to 40 μl and dilution to 400 μl with water over microspin 
ultrafilter (10 kDa cut-off) at 4 oC. The final washed protein concentration 
determined by Bradford method. For a positive control sample of MG-modified 
proteins, cell protein (100 µg) was incubated with MG (467 µM) for 24 h at 37 oC – 
Figure 33. 
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              Figure 33: Proteome analysis of hPDLFs cell lysate. 
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2.7.1 Protocol of tryptic digestion of cytosolic protein 
To an aliquot of cytosolic protein extract (100 µg) was dissolved in 
dithiothreitol (6 l, 6 mM) and incubated at 37 oC in the dark for 30 min to reduce 
disulphide bonds in the protein. Then, thiol groups were modified by addition of 
iodoacetamide (5.9 µl, 10.8 mM) and incubated at 37 oC in the dark for 30 min. 
Residual iodoacetamide was quenched by further addition of dithiothreitol (5.9 l, 6 
mM) and incubated at 37 oC in the dark for 30 min. An aliquot of TPCK-treated 
trypsin (1 mg/ml, 5 µl) in 1 mM calcium chloride/500 mM ammonium bicarbonate, 
pH 8.0, was then added and the sample was incubated at 37 oC for 5 h in the dark. 
Finally, the reaction was stopped by adding 10% TFA (5 µl) in water. The sample 
was lyophilised to dryness to remove volatile salts and re-suspend in an aliquot (100 
µl) 0.1% formic acid in water and analysed by nanoflow liquid-chromatography-
Orbitrap mass spectrometry. 
 
2.7.2 Protocol of Lys-C-Trypsin protease digestion of cytosolic protein 
A Lys-C protease digestion protocol similar to the previous one for tryptic 
digestion was used; instead of adding TPCK-treated trypsin to the cytosolic protein, 
an aliquot of Lys-C protease (1 mg/ml, 5 µl) in 500 mM ammonium bicarbonate, pH 
8.0, was added and incubated for 1 h at 37 oC. Then TPCK-treated trypsin (1 mg/ml, 
5 µl) in 1 mM calcium chloride/500 mM ammonium bicarbonate, pH 8.0, was added 
and samples were incubated at 37 oC for 5 h in the dark. 
 
2.7.3 Peptide separation, protein identification and quantitation 
The processed cell lysate samples were submitted to the Mass Spectrometry 
and Proteomics Facility at Warwick University for a label-free proteomic 
quantitation analysis. Reversed phase nanoflow liquid chromatography- mass 
spectrometry for global protein identification was performed on an Orbitrap mass 
spectrometer equipped with a microspray source operating in positive ion mode. For 
proteomics analysis the column used was: an Acclaim PepMap µ-pre-column 
cartridge (trap), 300 µm i.d. x 5 mm, 5 μm particle size, 100 Å pore size, fitted to an 
Acclaim PepMap RSLC 75 µm i.d. x 50 cm, 2 µm particle size, 100 Å pore size 
main column (Thermo Scientific). It was installed on an Ultimate 3000 RSLCnano 
system (Dionex). An aliquot (5 µl) of each sample was injected. After injection, the 
peptides were eluted off of the trap onto the analytical column. Mobile phases were: 
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A - 0.1% formic acid in water, and B - 0.1% formic acid in acetonitrile. The flow rate 
was programmed at 0.3 µl/min. Mobile phase B was increased from 3% to 35% in 
125 to 220 min, depending on the complexity of the sample, in order to separate the 
peptides. Mobile phase B was then increased from 35% to 80% in 5 min before being 
brought back quickly to 3% in 1 min. The column was equilibrated at 3% of mobile 
phase B for 15 min before the next sample. Peptides were eluted directly (300 nl min-
1) via a Triversa Nanomate nanospray source (Advion Biosciences, NY) into a 
Thermo Orbitrap Fusion (Q-OT-qIT, Thermo Scientific) mass spectrometer. Survey 
scans of peptide precursors from 350 to 1500 m/z were performed at 120K resolution 
(at 200 m/z) with automatic gain control (AGC) 4 × 105. Precursor ions with charge 
state 2 - 7 were isolated (isolation at 1.6 Th [Thomson units; m/z =1] in the 
quadrupole) and subjected to high energy collision dissociation (HCD) 
fragmentation. The collusion-induced dissociation fragmentation energy was 
programmed to 35%. It was used rapid scan MS analysis in the ion trap, the AGC 
was set to 1 x 104 and the max injection time was 200 ms. Dynamic exclusion 
duration was set to 45 s with a 10 ppm tolerance around the selected precursor and its 
isotopes. Monoisotopic precursor selection was turned on. The instrument was run in 
top speed mode with 2 s cycles. Sequence information from the MS/MS data was 
managed by converting the raw (.raw) files into a merged file (.mgf) using 
MSConvert in ProteoWizard Toolkit (version 3.0.5759) (Kessner et al., 2008). The 
resulting .mgf files were searched, and the database was searched against protein 
sequence databases.  
 
2.7.4 Data analysis 
Database search. MS2 spectra were searched with Mascot engine (Matrix 
Science, version 2.5.0) against Homo sapiens database (http://www.uniprot.org/). 
Mascot was set up to search the human_uniprot_18June2015 database assuming the 
digestion enzyme trypsin to determine levels of false-positive peptide identifications, 
spectra were also searched against the corresponding reverse database, the common 
Repository of Adventitious Proteins Database 
(http://www.thegpm.org/cRAP/index.html). Search parameters for precursor mass 
and product ions tolerance were, respectively, ± 5 ppm and ± 0.8 Da, with allowance 
made for two missed trypsin cleavages, fixed modification of cysteine through 
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carbamidomethylation and methionine oxidation. Only fully tryptic peptide matches 
were allowed.  
Validation. Scaffold (version Scaffold 4.3.2, Proteome Software Inc.) was 
used to validate MS/MS based peptide and protein identifications from MS/MS 
sequencing results. Peptide identifications were accepted if they could be established 
at greater than 95.0% probability by the Scaffold Local FDR algorithm. Protein 
identifications were accepted if they could be established at greater than 95.0% 
probability and contained at least 3 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that 
contained similar peptides and could not be differentiated based on MS/MS analysis 
alone were grouped to satisfy the principles of parsimony. Proteins sharing 
significant peptide evidence were grouped into clusters. 
 
2.7.5 Protein function and ontology 
Protein ontology was evaluated using literature reports of protein roles as 
well as Web-based tools (http://www.reactome.org/) to identify functional annotation 
to characterise molecular functions and biologic processes that were used in 
reporting the potential relationships and interconnecting ontologies for proteins 
determined to show differential expression in hPDLFs.  
 
2.7.6 Statistical analyses 
The mean, standard deviation, confidence score and ANOVA test for all 
proteins were determined using the datasets of the three matched hPDLFs pellets 
using bioinformatics software and statistical program analysis by Progenesis QI for 
proteomics 2.0 (Nonlinear Dynamics, Newcastle upon Tyne. Algorithms for 
calculating protein probabilities from peptide probabilities were performed using 
Progenesis. A relative quantification of protein concentration was performed using 
non-conflicting peptides in Progenesis (see http://www.nonlinear.com/progenesis/qi-
for-proteomics/v2.0/faq/which-quantitation-method-should-i-choose-for-my-
experiment.aspx#relative-all for further details). Briefly, this method considers non 
conflicting peptides identified as part of the protein for quantification.  
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The following graphs show the experiment matrices calculated and visualised 
in Progenesis. The graph below shows mean abundance of peptides found in each 
experiment, identified peptide ions shown in yellow – Figure 34. Peptide ion 
abundance was calculated using the current experiment design. The levels of 
peptides identified was similar in both condition about 5% identified in LG and 4.8% 
in HG. Small decrease in peptide identification in HG suggests more peptide may 
have been glycated and not identified. Total and identified peptide ions are heavily 
skewed towards right in the histogram indicating that low abundance peptides were 
missed identifications and saturation at high abundance may compromise the 
accuracy of quantification. 
 
 
Figure 34: relative abundance of protein in low and high glucose hPDLFs 
proteomics samples. 
 Data are mean ± SD, n = 3. 
 
The efficiency of tryptic digestion was high – ca. 70% protein was digested, 
20% peptides contained one missed cleavage and ca. 2% peptides contained 2 missed 
cleavages. The mean number of missed cleavage per peptide ions by trypsin was 
very low in all preparations as indicated in the graph below – Figure 35. 
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Figure 35: The mean number of missed cleavage per peptide ions by trypsin. 
 
Figure 36 below shows the scan rate variation within the experimental 
condition run on the mass spectrometer. The variability between run was low 
indicating high quantification accuracy of the proteome concentration in low and 
high glucose.  
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Figure 36: The scan rate variation within the experimental condition run on the mass spectrometer. 
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2.8 Characterisation of protein glycation, oxidation and nitration markers in 
plasma of healthy people, periodontitis patients and periodontitis patients 
with Co-morbidities 
2.8.1 Study groups 
2.8.1.1 Control group 
Age- and gender-matched periodontally healthy control subjects (n =17, 11 
males and 6 females; mean age = 49 ± 6 years, range = 32–60 years) were recruited 
from staff of the University Hospital, Coventry and Warwickshire. Normal healthy 
control subjects were recruited with no history of periodontitis, diabetes or renal 
failure suggestive of any pathology. Venous blood samples were collected after 
consent was obtained from the subject. 
 
2.8.1.2 Periodontitis without any co-morbidity 
Samples of blood plasma used in this study came from ENERGISE study 
(NCT00952536). Subjects with chronic periodontitis from the placebo arm (n= 17, 9 
males and 7 females; mean age = 43 ± 11 years, range = 38–60 years) were recruited 
from patients referred to the periodontal department of Birmingham’s Dental 
Hospital (Birmingham, U.K.). Volunteers were both non-smokers and medically 
healthy by medical history questionnaire. Volunteers had chronic periodontitis as 
defined by a minimum of two sites per quadrant with pocketing or interproximal 
attachment loss of >6 mm and one-third radiographic bone loss. The exclusion 
criteria were: patients with aggressive disease, patients with physical or mental 
disability, pregnant women, patients whose medical history may place them at risk of 
complications from periodontal therapy (e.g. need for antibiotic prophylaxis, 
Warfarinised patients), patients taking long-term antimicrobial or anti-inflammatory 
drugs, patients unable to swallow capsules, patients unable to provide informed 
consent, current smokers (or within 5 years), patients taking regular vitamin 
supplementation (Chapple et al., 2012). The clinical characteristics of patients with 
periodontitis is presented in Table 21. 
 
2.8.1.3 Periodontitis with co-morbidities 
The plasma sample of patients with comorbidities such as chronic 
periodontitis, diabetes and chronic kidney disease (CKD) were from the RIISC 
(Renal impairment in secondary care) cohort (n = 5, 4 males and 1 female; mean age 
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= 58 ± 9 years, range = 52–74 years) were recruited at Birmingham Hospital NHS 
Trust. The inclusion criteria for these patients were: patients with, CKD stage 3 or 4, 
diabetes with a HbA1c at >58 mmols/mol and severe periodontitis as defined by 
Page and Eke (Page and Eke, 2007). 
Ethical approval for this work was sought and obtained from local ethics 
committees at Birmingham Hospital NHS Trust, Birmingham, U.K., South 
Birmingham Local Research Ethics Committee, U.K (the REC numbers are: 
10/H1207/109 and 10/H1207/6). The collection of samples from patients and healthy 
subjects with informed consent and use of them were approved by the NRES 
Committee West Midlands – South Birmingham (REC No: 13/WM/0097) and were 
conducted in accordance with the Declaration of Helsinki. The clinical characteristics 
of the study groups is presented in Table 21. 
 
Table 21: Clinical characteristics of healthy people and patients with 
periodontitis 
Clinical 
characteristics 
Control Periodontitis 
Co-morbidities and 
periodontitis 
N 16 17 5 
Age (yr) 43 ± 11 49 ± 6 58 ± 9 
Gender M/F 9/7 11/6 4/1 
Co-morbidities None None Diabetes, CKD 
eGFR 
(ml/min/1.72m2) 
None None 19 ± 10 
HbA1c (mmol/mol) None None 87.2 ± 25.9 
 
2.8.2 Plasma sample preparation, filtration, washing and delipidation 
Plasma (100 μl) was diluted 5-fold with water and washed by 4 cycles of 
concentration to 50 μl and dilution to 500 μl with water over a microspin ultrafilter 
(10 kDa cut-off) at 4 oC. The final washed protein (100 μl) was delipidated by 
extraction 3-times with an equal volume of water-saturated ether. Residual ether was 
removed in a centrifugal evaporator and protein concentration determined by 
Bradford method. Please see section 2.5.1 in material and methods for details. 
 
2.8.3 Hydrolysis of sample protein 
For the hydrolysis, an aliquot of washed protein sample containing 100 µg of 
protein was diluted to 20 µl with water in a glass vial and flushed with argon in 
preparation for enzymatic hydrolysis as described above in section 2.5.1. 
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2.8.4 Statistical Analysis 
Experiments were performed using analysis in replicates of triplicates or 
greater. Difference between normally distributed experimental groups was tested 
using Student’s t-test assuming equal or unequal variance. The data generated here is 
normally distributed and assessment of statistical differences between two study 
groups were required. Therefore, t-test is applied in this assessments. Significance 
was defined as p ≤ 0.05. Non-parametric data were analysed using Mann Whitney-U 
test (2 groups).  
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3. Results 
3.1 Characterisation of the glyoxalase system in human periodontal 
ligament fibroblasts in vitro 
3.1.1 Growth and viability of hPDLFs incubated in 5.5 mM, 8.0 mM and 
25.0 mM glucose in vitro 
Growth and viability of hPDLFs incubated in 5.5 mM, 8.0 mM and 25.0 
mM glucose was studied. The viable cell number increased progressively 
throughout the period of culture. At day 6 the viable cell number had increased 
from 0.048 x106 at seeding to: 1.35 ± 0.26 x106 cells in 5.5 mM glucose, 1.83 ± 
0.14 x106 cells in 8.0 mM glucose and 3.37 ± 0.17 x106 cells in 25.0 mM glucose. 
The cell viability, as judged by Trypan blue exclusion test, was > 98.5% in the 
three culture conditions. Cell growth curves were plotted of viable cell number 
against time over 6 days - Figure 37. The growth of hPDLFs was higher in 
medium containing 8.0 mM glucose and growth tended to slow beyond 3 days in 
5.5 mM glucose and 5 days in 8.0 mM glucose. The mean growth rate from day 1 
– day 3 was 27% higher in in 8.0 mM glucose, compared to in 5.5 mM glucose 
cultures. The rate of hPDLFs growth in 8.0 mM glucose and 25.0 mM glucose 
was similar until the day 5 when cell growth stopped in 8.0 mM glucose cultures 
and continued in 25.0 mM glucose.  
 
Figure 37: Growth curve of hPDLFs cells in media containing 5.5 mM, 8.0 
mM and 25.0 mM glucose in vitro.  
Primary hPDLFs cells (5000 cells/cm2) were incubated in MEM media with 10% 
FBS and the glucose concentrations indicated for 6 days. Data are mean ± SD (n = 
3). Key: 5.5 mM glucose         , 8.0 mM glucose,         and 25.0 mM glucose      . 
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To further examine hPDLFs growth kinetics, the growth curves are shown 
with log transformation of cell number estimates. This shows that the rate of cell 
growth was highest from day 1 to day 2 when the doubling time was ca. 0.43 – 
0.47 days. Beyond this, in all culture conditions the rate of cell growth slowed 
progressively until stopping at day 5 for cultures with 5.5 mM and 8.0 mM 
glucose with slow, extended growth to day 6 occurring in cultures with 25.0 mM 
glucose – Figure 38. In subsequent sub-cultures of these hPDLFs cell growth was 
stimulated again, suggesting that the slowing of cell growth was linked to 
depletion of nutrients rather than a cumulative cell doubling limited growth – 
known as the Hayflick limit (Effros and Walford, 1984). In subsequent 
experiments hPDLFs sub-cultured and grown for up to 3 days were used where 
mean population doubling time was: 5.5 mM glucose, 0.69 ± 0.10 days, 8.0 mM 
glucose, 0.63 ± 0.08 days, and 25.0 mM glucose, 0.61 ± 0.08 days (n = 12).  
 
 
Figure 38: Growth curve of hPDLFs cells in media containing 5.5 mM, 8.0 
mM and 25.0 mM glucose in vitro – logarithm transformation of cell number.    
Log2 transformation. Primary hPDLFs cells (5000 cells/cm
2) were incubated in 
MEM media with 10% FBS and the glucose concentration indicated for 6 days. 
Data are mean ± SD (n = 3). Key: 5.5 mM glucose          , 8.0 mM glucose        , 
and 25.0 mM glucose         . 
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conditions. The 5.5 mM glucose culture was not used so that hPDLFs with similar 
growth rate were compared in LG and HG conditions. Moreover, the normal 
salivary glucose level in a healthy subject is ca. 8.0 mM glucose and in patients 
with diabetes is typically ca. 25.0 mM (Aydin, 2007). Primary hPDLFs were 
maintained in 8.0 mM glucose and 25.0 mM glucose for three days without 
change of medium. 
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3.2 Characterisation of the glyoxalase system of hPDLFs incubated in 
high and low glucose concentration conditions in vitro 
3.2.1 The activity of glyoxalase 1 and glyoxalase 2 of hPDLFs cells 
incubated in high glucose concentration in vitro 
Activities of Glo1 and Glo2 were measured in hPDLFs cells incubated in 
low glucose and high glucose concentrations. The activity of Glo1 in low glucose 
culture was 985 ± 148 mU per mg protein (n = 5). This was decreased ca. 45% 
after 3 days incubation under high glucose conditions (P<0.001) – Table 22 and 
Figure 39. The activity of Glo2 in low glucose culture was 4.20 ± 2.71 mU per mg 
protein (n = 5). This was not changed after 3 days incubation under high glucose 
conditions – Table 22 and Figure 39. 
 
 
 
 
 
     
 
 
 
 
 
 
Figure 39: Enzymatic activities of the glyoxalase system in hPDLFs cells in 
vitro.  
Activities of (A) Glo1, (B) Glo2 in hPDLFs cells were cultured in medium 
containing low glucose concentration (8 mM) and high glucose concentration (25 
mM) for 3 days. Data are mean ± SD (n = 5). Significance: * and ***, P<0.05 and 
P<0.001, respectively (t-test) with respect to low glucose control.  
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3.2.2 Glyoxalase 1 protein content of hPDLFs cells incubated in low and 
high glucose concentration in vitro 
The level of the Glo1 protein in the hPDLFs cells cultured in low and high 
glucose conditions was determined by Western blotting. Glo1 proteins was 
decreased by ca. 19% in high glucose cultured cells, compared to low glucose 
cultured controls – Figure 40.  
                                                              
Figure 40: Glyoxalase 1 protein content of hPDLFs incubated in high glucose 
concentration in vitro.  
(A) Glo1 protein blot, (B) Glo1 protein blot interpretation. hPDLFs were cultured 
in medium containing 8 mM and 25 mM glucose for 3 days. Data are mean ± SD 
(n = 4). Significance: * P<0.05 (t-test) with respect to low glucose control. Key: 
LG, low glucose concentration (8 mM); HG, high glucose concentration (25 mM). 
 
3.2.3 Glyoxalase 1 gene expression in hPDLFs incubated in high glucose 
concentration in vitro 
Expression of Glo1 of hPDLFs cells incubated in low and high glucose 
conditions was measured by RT-PCR. There was no significant change in the 
Glo1 gene expression in hPDLFs cultured in low and high glucose. This suggests 
that the high glucose may affect the Glo1 protein stability and functionality either 
by modification by reactive dicarbonyls and followed by acetylation leading to 
proteasomal degradation or inactivation by glycation damage to the catalytic site. 
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Table 22: Values of Glo1 and Glo2 activity and GLO1 gene expression in 
hPDLFs cells incubated in media contains high and low glucose in vitro 
Analyte LG HG 
Glo1 activity (mU/mg protein) 985 ± 148    534 ± 129*** 
Glo2 activity (mU/mg protein) 4.20 ± 2.71   5.40 ± 1.25 
GLO1 mRNA 
(normalized to β-actin mRNA) 
0.792 ± 0.002 0.791 ± 0.003 
Data are mean ± SD, n = 5. Significance: ***, P<0.001 (t-test) respectively, with 
respect to low glucose control. 
 
3.2.4 Dicarbonyl concentration in hPDLFs cells incubated in low and 
high glucose concentrations in vitro 
High glucose concentration decreased Glo1 activity in hPDLFs and hence 
it is likely that dicarbonyl stress is induced under these conditions. This was 
investigated by assay of the levels of MG, glyoxal and 3-DG in cell culture 
medium and hPDLFs cells following culture for 3 days in medium containing 8 
mM glucose and 25 mM glucose. MG concentration of the medium and MG 
content of cells was increased significantly by ca. 60% and 41%, respectively, in 
the high glucose conditions, compared to low glucose control (P<0.01). The 
concentration of 3-DG in the medium was increased 4-fold (P<0.001) and the cell 
content of 3-DG was increased 3-fold (P<0.001) in the high glucose conditions, 
compared to low glucose control. Glyoxal level did not change with high glucose 
treatment in the cell and medium – Figure 41 and Table 23.  
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Figure 41: Effect of high glucose concentration on cellular content and 
medium concentration of dicarbonyl levels in hPDLFs in vitro.  
hPDLFs were cultured in medium containing 8 mM and 25 mM glucose for 3 
days. (A) Cellular MG. (B) MG in culture medium. (C) Cellular 3-DG. (D) 3-DG 
in culture medium. Data are mean ± SD, n = 5. Significance: ** and ***, P<0.01 
and P<0.001, respectively (t-test), with respect to low glucose control. Key: LG, 
low glucose (8 mM); HG, high glucose (25 mM). 
 
Table 23: Effect of high glucose concentration on dicarbonyls assay 
measurement in hPDLFs cells and medium in vitro 
Human 
PDLFs 
(pmol/10⁶cells) 
  Methylglyoxal Glyoxal 3-DG 
LG 7.59 ± 0.53 9.11 ± 1.45 0.949 ± 0.128 
HG 10.7 ± 1.5** 9.04 ± 1.24 3.70 ± 0.56*** 
Media 
(nM) 
     
LG 257 ± 47 909 ± 81 382 ± 61 
HG 410 ± 58** 1028 ± 118 1562 ± 121*** 
Data are mean ± SD, n = 5. Significance: ** and ***, P<0.01 and P<0.001, 
respectively (t-test), with respect to low glucose control. Key: LG, low glucose (8 
mM); HG, high glucose (25 mM). 
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3.2.5 Flux of formation of D-lactate and concentration of L-lactate in 
hPDLFs cells cultured in low and high glucose conditions in vitro 
The flux of D-lactate produced by human cells often approximates to flux 
of MG formation as >99% of MG formed is metabolised by the glyoxalase 
system, metabolism of D-lactate by human cells is often limited and in cultured 
cells the only source of D-lactate is the glyoxalase system (Rabbani and 
Thornalley, 2012c). To establish if D-lactate is metabolised in the hPDLFs, D-
lactate was measured in culture medium of hPDLFs with and without addition of 
exogenous D-lactate (10 nmol). Media alone was also analysed for D-lactate with 
or without exogenous D-lactate. D-Lactate concentration increased in the culture 
medium from baseline after culture for 3 days. Incubations of hPDLFs with added 
10 nmol D-lactate showed a similar increase and maintained the differential of + 
10 nmol after 3 days and set at baseline – Table 24. From this study it can be 
inferred that D-lactate was not metabolised significantly by hPDLFs cells in vitro 
under the conditions studied and accumulation of D-lactate in hPDLFs cultures is 
therefore a measure of flux of formation of MG. 
Primary hPDLFs cells were cultured in low and high glucose 
concentration for 3 days. The concentration of D-lactate was determined in the 
media samples collected on baseline and at day 3. The flux of D-lactate was 
determined by subtracting the amount of D-lactate at baseline from that at day 3 
and normalising to final cell number and days in culture – presenting D-lactate 
flux as nmol per million cells per day. The production of D-lactate was increased 
42% in hPDLFs cultured in high glucose, compare to low glucose (P<0.001) - 
Figure 42 and Table 25. This suggests that the flux of formation of MG in 
hPDLFs is increased in high glucose concentration conditions. 
L-Lactate is the terminal product of anaerobic glycolysis and it is readily 
metabolised. Similar measurement of the flux of L-lactate as for D-lactate above 
is a qualitative marker of glycolytic activity and underestimate of L-lactate 
formation since it is readily metabolised. Nevertheless, apparent L-lactate has 
been assumed to be qualitative marker of glycolytic activity (Forristal et al., 
2013). When apparent flux of L-lactate formation was measured over 3 days of 
hPDLFs cultured in high glucose concentration there was no significant change in 
  
208 
 
apparent flux of L-lactate formation, compared to low glucose control. As 
expected, apparent flux of L-lactate formation was markedly higher than the flux 
of D-lactate formation - Figure 42 and Table 25.  
 
Table 24: D-lactate metabolism in the hPDLFs  
D-Lactate production (nmol) 
Control media 5.67 ± 0.33 
Media + exogenous D-lactate (10 nmol) 15.6 ± 0.34  
Difference  9.88 ± 0.71 
Data are mean ± S.D, n = 3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Flux of formation of D-lactate and concentration of L-lactate in 
hPDLFs cells cultured in low and high glucose conditions in vitro.  
hPDLFs cells were cultured in medium containing 8 mM and 25 mM glucose for 
3 days. (A) D-lactate production in hPDLFs cells, (B) L-lactate production in 
hPDLFs cells. Data are mean ± S.D, n = 5. Significance: ***, P<0.001 (t-test) 
with respect to low glucose control. Key: LG, low glucose (8 mM); HG, high 
glucose (25 mM). 
 
3.2.6 Consumption of D-glucose by hPDLFs cells incubated in low and high 
glucose in vitro 
Net glucose consumption by hPDLFs may be readily assessed by 
measuring the decrease in glucose concentration in the culture medium over 3 
days. When glucose consumption was measured over 3 days of hPDLFs cultured 
in high glucose concentration there was a 93% increase in glucose consumption, 
compared to low glucose control (P<0.001) – Figure 43. Increased glucose 
metabolism through anaerobic glycolysis increases the flux of triosephosphate 
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formation and thereby the flux of MG formation. To assess if there is increased 
proportion of flux of glucotriose (2 x flux of glucose consumption) degrading to 
MG in high glucose conditions, the flux of D-lactate was calculated as a 
percentage of flux of glucotriose. The flux of formation of D-lactate as a 
percentage of flux of glucotriose was decreased ca. 24% in high glucose cultures, 
compared to low glucose control, suggesting that glucose may be diverted or 
consumed in other pathways e.g. pentosephosphate pathway in high glucose 
conditions - Figure 43 and Table 25. 
 
  
 
Figure 43: Consumption of D-glucose by hPDLFs cells incubated in high 
glucose in vitro.  
hPDLFs cells were cultured in medium containing 8 mM and 25 mM glucose for 
3 days. (A) D-Glucose consumption in hPDLFs cells. (B) Percentage flux of D-
lactate from glucotriose in hPDLFs cells. Data are mean ± SD, n = 5. 
Significance: *, P<0.05 and ***, P<0.001 (t-test) with respect to low glucose 
control. Key: LG, low glucose (8 mM); HG, high glucose (25 mM). 
 
Table 25: Values of different analytical assays performed on hPDLFs 
medium contains high and low glucose in vitro 
Culture Medium 
Analyte LG  HG  
L-Lactate production (nmol/day/10⁶ cells) 240 ± 33 261 ± 53 
D-Glucose consumption (μmol/day/10⁶ cells) 5.32 ± 0.50 10.3 ± 0.80*** 
D-Lactate production (nmol/day/10⁶ cells) 6.43 ± 0.81 9.15 ± 0.55** 
D-lactate flux (% Glucotriose) 0.059 ± 0.009 0.045 ± 0.004** 
Data are mean ± SD, n = 5. Significance: *, P<0.05, **, P<0.01 and ***, P<0.001 
(t-test) with respect to low glucose (control). Key: LG, low glucose (8 mM); HG, 
high glucose (25 mM). 
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3.2.7 Thiols and glutathione in hPDLFs cultured in low and high glucose 
conditions in vitro 
GSH is a cofactor in the glyoxalase system. The cellular contents of 
reduced and oxidised glutathione (GSH and GSSG) and total thiols were 
measured in hPDLFs cells following a 3 days culture supplemented with low and 
high glucose. The cell thiol level was increased ca. 24% in high glucose 
comparing with the control. Protein thiols were determined by subtracting GSH 
level from the samples. In low glucose cultures, the protein thiols content of 
hPDLFs was 16.0 ± 1.6 nmol/106 cells. Protein thiols were increased ca. 43% in 
hPDLFs cells with high glucose, compare to low glucose control (P<0.001) -
Figure 44 and Table 26. The levels of GSH and GSSG decreased with high 
glucose conditions by 22% and 24% respectively. Total glutathione levels were 
also calculated: Total GSH = GSH + (2 x GSSG). Total GSH level was decreased 
by 22% in high glucose compare to low glucose control - Figure 45 and Table 26. 
 
 
    
 
 
 
 
  
 
 
 
Figure 44: Effect of high glucose concentration on the total cell thiols in 
hPDLFs in vitro.  
hPDLFs cells were cultured in medium containing 8 mM and 25 mM glucose for 
3 days. (A) Total cell thiols. (B) Protein thiols. Data are mean ± SD, n = 5. 
Significance: ** and ***, P<0.01 and P<0.001, respectively (t-test) with respect to 
low glucose (control). Key: LG, low glucose (8 mM); HG, high glucose (25 mM). 
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Figure 45: Effect of high glucose concentration on the glutathione level in 
hPDLFs in vitro.  
hPDLFs cells were cultured in medium containing 8 mM and 25 mM glucose for 
3 days. (A) Reduced glutathione, (B) oxidized glutathione and (C) total 
glutathione. Data are mean ± SD, n = 5. Significance: * and ***, P<0.05, and 
P<0.001, respectively (t-test) with respect to low glucose (control). Key: LG, low 
glucose (8 mM); HG, high glucose (25 mM). 
 
Table 26: Effect of high glucose concentration on thiols and glutathione level 
in hPDLFs in vitro 
Analyte (nmol/10⁶ cells) LG HG 
Total protein thiols 23.1 ± 1.5 28.5 ± 1.86** 
Protein thiols  16.0 ± 1.6 23.1 ± 1.9*** 
Cellular GSH 7.01 ± 0.33 5.43 ± 0.33 ** 
Cellular GSSG 0.0116 ± 0.0020 0.0088 ±0.0012*** 
Cellular total GSH 7.03 ± 0.33 5.45 ± 0.33 * 
% Total GSH as GSH 99.7 99.7 
% Total GSH as GSSG 0.3 0.3 
S-D-Lactoylglutathione < LOD  <LOD 
Data are mean ± SD, n = 5. Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively (t-test), with respect to low glucose control. Key: LG, low 
glucose (8 mM); HG, high glucose (25 mM). LOD for S-D-Lactoylglutathione 
was 1.1 (pmol/10⁶ cells). 
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3.2.8 Effect of high glucose concentration on protein glycation, oxidation 
and nitration adduct content of hPDLFs cellular protein and flux of 
free adduct formation in vitro 
Protein glycation, oxidation and nitration adducts were measured as adduct 
residues of hPDLFs cell protein and as flux of free adduct formation released in 
the cell culture by cell proteolysis of glycated, oxidised and nitrated protein after 3 
days of culture. Results are shown in Table 27. 
The cellular content of MG-H1 and FL increased in high glucose by 85% 
and 64% (P<0.01 and P<0.05) respectively comparing with the level in low 
glucose. FL degrades oxidatively to CML, level of CML was increased two fold 
in high glucose compare to low glucose (P<0.05) – Figure 46. The level of 
CML/FL showed no change in high glucose culture and which indicate no change 
in the oxidative stress. Dicarbonyls are reactive glycating agents and target 
specifically arginine residues but not exclusively. It is expected to find a 
significant increase in protein glycation markers. 
The free adduct found in the media are mainly formed by proteolysis of 
cellular proteins – Table 28. The free adducts MG-H1 and FL increased 2 folds in 
high glucose compared to control (P<0.001 and P<0.01 respectively). The level of 
free adducts 3DG-H1 was increased more than three folds in high glucose 
(P<0.001). CMA free adduct was increased by 45% in high glucose (P<0.05) –
Figure 47. The significant increase of glycation free adducts is indicative of 
increased flux of protein damage by glycation and effective clearance of damaged 
cell proteome by proteolysis in the proteasomes. Oxidation and nitration markers 
did not change between the two conditions 
The changes in glyoxalase pathway and its metabolites in hyperglycaemic 
condition in hPDLFs indicate a significant role of dicarbonyls in periodontal 
inflammation and diseases.   
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Table 27: Effect of high glucose concentration on cellular protein glycation, 
oxidation and nitration adduct content of hPDLFs cells in vitro 
Protein adduct residue LG HG 
FL (mmol/mol lys) 1.78 ± 0.33 3.34 ± 0.553*** 
CML (mmol/mol lys) 0.100 ± 0.036 0.186 ± 0.028** 
CEL (mmol/mol lys) 0.026 ± 0.016 0.041 ± 0.017 
MOLD (mmol/mol lys) 0.003 ± 0.002 0.004 ± 0.003 
CMA (mmol/mol arg) 0.068 ± 0.034 0.081 ± 0.037 
MG-H1 (mmol/mol arg) 0.330 ± 0.163 0.763 ± 0.201** 
G-H1 (mmol/mol arg) 0.018 ± 0.014 0.023 ± 0.007 
3DG-H (mmol/mol arg) 0.225 ± 0.123 0.227 ± 0.135 
3NT (mmol/mol tyr) 0.0031 ± 0.0011 0.0019 ± 0.0009 
DT (mmol/mol tyr) 0.080 ± 0.055 0.046 ± 0.037 
NFK (mmol/mol trp) 0.109 ± 0.042 0.091 ± 0.03 
MetSO (mmol/mol met) 1.66 ± 1.53 1.14 ± 0.43 
CML/FL  0.059 ± 0.026 0.058 ± 0.017 
Data are mean ± SD, n = 4. Significance: *, P<0.05 and **, P<0.01 (t-test) with 
respect to low glucose (control). Key: LG, low glucose (8 mM); HG, high glucose 
(25 mM). 
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Figure 46: Effect of high glucose concentration on cellular protein glycation, 
oxidation and nitration adduct residue content of hPDLFs cells in vitro.  
hPDLFs cells were cultured in medium containing 8 mM and 25 mM glucose for 
3 days. (A) MG-H1 (B) FL. (C) CML. Data are mean ± SD, n = 4. Significance: * 
and **, P<0.05 and P<0.01 (t-test) with respect to low glucose (control). Key: LG, 
low glucose (8 mM); HG, high glucose (25 mM). 
 
Table 28: Effect of high glucose concentration on flux of protein glycation 
and oxidation free adducts of hPDLFs cells in vitro. 
Free adduct production 
(pmol/106 cells/day) 
LG HG  
FL 404 ± 203  882 ± 281* 
CML 38.3 ± 11.2 44.8 ± 14.8 
CEL 2.80 ± 1.58 3.94 ± 2.02 
CMA 5.42 ± 0.60 7.89 ± 1.56* 
MG-H1 2.87 ± 0.43 5.66 ± 0.73*** 
G-H1 2.44 ± 1.53 0.906 ± 0.433 
3DG-H 1.61 ± 0.44 5.07 ± 0.89*** 
Data are mean ± SD, n = 4. Significance: *, P<0.05, **, P<0.01 and ***, P<0.001 
(t-test) with respect to low glucose (control). Key: LG, low glucose (8 mM); HG, 
high glucose (25 mM). 
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Figure 47: Effect of high glucose concentration on flux of protein glycation 
and oxidation free adducts of hPDLFs cells in vitro.  
hPDLFs cells were cultured in medium containing 8 mM and 25 mM glucose for 
3 days. (A) MG-H1. (B) 3DG-H1. (C) FL. (D) CMA. Data are mean ± SD, n = 4. 
Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001, respectively (t-test) 
with respect to low glucose (control). Key: LG, low glucose (8 mM); HG, high 
glucose (25 mM). 
 
3.2.9 Effect of exogenous methylglyoxal on the growth and viability of 
hPDLFs in vitro 
Primary hPDLFs were incubated with and without 25 - 1000 μM MG for 
48 h and cell growth and viability assessed. At ≥ 50 μM MG there was a decrease 
in hPDLFs viable cell number and ≥ 200 μM MG there was decrease in cell 
viability. This suggestes that with addition of exogenous MG of progressively 
increased concentration, there is initially growth arrest of hPDLFs and the both 
growth arrest and cytotoxicity at ≥ 200 μM MG. The MG concentration – cell 
growth response curve is shown in Figure 48 and the MG concentration – cell 
viability response is given in Figure 49. From this the median growth inhibitory 
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concentration GC50 value of MG was 250 ± 3 µM and n, the logistic regression 
coefficient (also known as the Hill coefficient) was 1.23 ± 0.17. A growth curve 
of hPDLFs with and without 200 μM MG was studied over 4 days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: The MG concentration – cell growth response curve for hPDLFs 
in vitro.  
Data were fitted to the MG concentration - response equation and solved for GC50 
and n by non-linear regression. GC50 = 250 ± 3 µM, n = 1.23 ± 0.17 (N = 18). 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: The MG concentration – cell viability response for hPDLFs in 
vitro.  
Data are mean ± SD (n = 3). Significant: ***, P<0.001; (t-test). 
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3.2.10 Effect of 200 μM methylglyoxal on the growth and viability of human 
periodontal ligament fibroblasts in low and high glucose concentration 
in vitro 
Primary hPDLFs were seeded in 6-well plate and incubated with 8 mM 
glucose, 8 mM glucose + 200 μM MG and 25 mM glucose + 200 μM MG. Viable 
and non-viable cells were counted every day for 4 days. Addition of MG 
decreased cell growth and viability to similar extent in both low and high glucose 
conditions - Figure 50 and 51. 
 
Figure 50: Effect of 200 μM methylglyoxal on growth and viability of 
hPDLFs in low and high glucose conditions in vitro.  
Primary hPDLFs were seeded at a density of 5000 cells per cm². Key:       , 8 mM 
glucose;       , 25 mM glucose;        , 8 mM glucose + 200 μM MG; and       , 25 
mM glucose + 200 μM MG. Data are mean ± SD (n = 3). 
 
 
Figure 51: Effect of 200 μM methylglyoxal on cell viability for hPDLFs in 
vitro.  
Key:       , 8 mM glucose + 200 μM MG; and       , 25 mM glucose + 200 μM MG. 
Data are mean ± SD (n = 3). 
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3.3 Effect of glyoxalase 1 inducers on the glyoxalase system and MG 
metabolism in hPDLFs in vitro in low and high glucose concentrations 
The host research team identified tRSV as an inducer of Glo1. A stable 
transfectant luciferase reporter cell line with transcriptional regulatory elements 
was developed from human HepG2 cells, as described for quinone reductase ARE 
(NQO1-ARE) (Xue et al., 2015a), incorporating regulatory elements: GLO1-ARE 
or functionally inactive mutant as negative control - ARE-1 and ARE1m in 
previous work (Xue et al., 2012a). Nrf2-dependent transcriptional response was 
verified by siRNA silencing of Nrf2. After screening of ca. 100 dietary bioactive 
compounds with Nrf2 activator activity, the highest Emax was produced by tRSV. 
In corroboration of this, Cheng et al. reported that 10 µM tRSV induced increased 
Glo1 protein in HepG2 cells in vitro (Cheng et al., 2012). The lowest EC50 for 
GLO1-ARE transcriptional activity was found with HSP. For tRSV, EC50 = 2.52 ± 
0.19 µM and Emax 100 ± 2%; and for HSP, EC50 = 0.59 ± 0.01 µM and Emax 24.4 ± 
0.1%. In previous clinical studies, dietary supplementation of 150 mg HSP achieved 
a peak plasma concentration of 6.7 µM (Takumi et al., 2012), suggesting that HSP 
may be a competent Glo1 inducer for clinical use but with low maximal effect; and 
dietary supplementation of 500 mg tRSV achieved a peak plasma concentration of 
ca. 0.3 µM (Takumi et al., 2012), 8-fold lower than the EC50 for GLO1-ARE 
response. To enhance efficacy we studied the pharmacological synergism of tRSV 
and HSP together. Study of the GLO1-ARE transcriptional response of 5 µM HSP 
with 0.625 – 10 µM tRSV showed that HSP combined synergistically with tRSV, 
decreasing the EC50 of tRSV ca. 2-fold to 1.46 ± 0.10 µM whilst maintaining the 
Emax – Figure 52C). The predicted increase of GLO1-ARE transcriptional response 
from concentration response curves of  0.1 – 1.0 tRSV in the presence of 5 µM HSP 
was 3 – 79 fold, including up to 80% increase over additive effects  - Figure 52D. 
This suggests marked benefits may accrue from use of tRSV+HSP co-formulation. 
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Figure 52. Induction of glyoxalase 1 expression by trans-resveratrol and 
hesperetin.  
GLO1-ARE transcriptional response reporter assay. Data of normalised responses 
for varied bioactive concentrations were fitted by non-linear regression to the 
equation E = Emax x [Bioactive]
n/(EC50
n + [Bioactive]n), solving for Emax, EC50 and 
n (Hill coefficient). A: Concentration-response curve for tRSV. Data are mean ± 
SD (n = 3) for 5 concentrations. Non-linear regression (red curve): E (%) = 100 x 
[tRSV]3.92/( 2.523.92 + [tRSV]3.92). B: Concentration-response curve for HSP. Data 
are mean ± SD (n = 3 - 8) for 6 concentrations. Non-linear regression (blue 
curve): E (%) = 24.4 x [HSP]2.01/(0.59.2.01 + [HSP]2.01). C: Concentration-response 
curve for tRSV in the presence of 5.0 μM HSP. Data are mean ± SD (n = 3 - 6) for 
5 concentrations. Non-linear regression (red curve): E (%) = (83.4 x 
[tRSV]1.36/(1.46.1.36 + [tRSV]1.36)) + 11.6;  green curve – tRSV+ 5.0  μM HSP, red 
dotted curve – tRSV only (as for A:). 
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One of the objectives of this project is to evaluate effect of Glo1 inducers 
on the glyoxalase system and MG metabolism in hPDLFs cultured in low and 
high glucose concentrations in vitro. To achieve this objective, hPDLFs were 
cultured in low glucose concentration (8 mM glucose) and high glucose 
concentration (25 mM glucose) with and without 10 µM tRSV, HSP and 10 µM 
tRSV and HSP in combination with (tRSV+HSP). Cells were incubated for three 
days. 
 
3.3.1 The viability of hPDLFs grown in media containing 8 mM and 25 mM 
glucose with Glo1 inducers in vitro 
Primary hPDLFs (5000 cells/cm2) were seeded in 6 well plates and 
incubated for 3 days in MEM medium containing 8 mM glucose or 25 mM 
glucose with and without 10 µM Glo1 inducer for 3 days and the viable cell 
number was counted in all the study groups. The viable cell number increased 
throughout the culture period and show a steady increase in all the groups with no 
significant change in the viability under any condition – Figure 53. The cell 
viability was 0.813 ± 0.133 x 106 in control cultures and was unchanged with 
treatments. 
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Figure 53: The viability of hPDLFs grown in media containing 8 mM glucose 
and 25 mM glucose with and without Glo1 inducers in vitro.  
hPDLFs cells were cultured in 8 mM glucose and 25 mM glucose-containing 
medium for 3 days with or without: (A) tRSV (10 µM); (B) HSP (10 µM); and 
(C) tRSV+HSP (10 µM). Data are mean ± SD, n = 3. 
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3.3.2 Effect of Glo1 inducers on the enzymatic activities of glyoxalase 
system in hPDLFs cells in vitro 
3.3.2.1 Effect of Glo1 inducers on the activity of glyoxalase 1 in hPDLFs 
cells in vitro 
Primary hPDLFs cells were cultured in low and high glucose 
concentrations for 3 days with and without 10 µM tRSV, 10 µM HSP and 10 µM 
tRSV+HSP. Incubation of hPDLFs with Glo1 inducers in LG conditions produced 
different effects: incubation with tRSV did not increase Glo1 activity significantly 
where incubation with HSP increased the activity of Glo1 ca. 22% (P<0.05) and 
incubation with tRSV+HSP increased the activity of Glo1 ca. 20% (P<0.05). 
When hPDLFs were incubated in HG culture conditions, the activity of Glo1 was 
decreased by ca. 43% (P<0.001), compared to LG controls. This decrease in 
activity of Glo1 was prevented by incubation with tRSV, HSP and with 
tRSV+HSP combined (P’<0.001 with respect to HG control). With tRSV+HSP 
combined treatment under HG conditions, there was a 15% increase in activity 
above LG control value which approached significance (P = 0.061, t-test). This 
suggests that Glo1 inducers may increase Glo1 activity in normal glycaemic 
conditions and prevent a deficit of Glo1 activity in model hyperglycaemia - Figure 
54 and Table 29.   
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Figure 54: Effect of Glo1 inducers on enzymatic activity in hPDLFs grown in 
media containing 8mM and 25mM glucose in vitro.  
Panels A, B and C show Glo1 activity in hPDLFs cells incubated for 3 days with 
10 µM tRSV, 10 µM HSP and 10 µM tRSV+HSP, respectively. Data are mean ± 
SD, n = 4. Significance: *, P<0.05 and ***, P<0.001 (t-test) with respect to low 
glucose control; and ooo, P<0.001 (t-test) with respect to high glucose control. 
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Table 29: Effect of Glo1 1 inducers on Glo1 activity in hPDLFs in vitro 
Glo1 activity 
(mU/mg protein) 
LG 
LG + Glo1 
inducer 
HG 
HG+ Glo1 
inducer 
10 µM tRSV 928 ± 84 1028 ± 78 529 ± 106** 967 ± 88 ooo 
10 µM HSP 972 ± 74 1181 ± 146* 526 ± 84.5*** 971 ± 99 ooo 
10 µM tRSV+HSP 946 ± 99 1137 ± 120* 485 ± 77.6*** 1089 ± 75 ooo 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001 (t-test) with respect to low glucose control; ooo, P<0.001 (t-test) with 
respect to high glucose control. 
 
3.3.2.2 Effect of Glo1 inducers on glyoxalase 1 protein content of hPDLFs 
in vitro 
Primary hPDLFs cells were cultured in 8 mM and 25 mM glucose for 3 
days with and without 10 µM tRSV, 10 µM HSP and 10 µM tRSV+HSP 
combined. Glo1 protein content of cell protein was assessed by immunoblotting. 
In LG conditions, there was no significant increase in Glo1 protein with Glo1 
inducers. Data dispersion in the estimate of Glo1 protein of LG control cultures 
(coefficient of variation 13%, n = 3) indicated a change of ca. 29% is just 
detectable at the 5% significance level. In HG conditions, there was a decrease in 
Glo1 protein of 30% (P<0.05). tRSV, HSP and tRSV+HSP combined prevented 
the decrease in Glo1 protein (+tRSV, P<0.047; + HSP, P<0.041; tRSV+HSP, 
P’<0.012 with respect to HG control) – Figure 55. 
 
3.3.2.3 Effect of trans-resveratrol on glyoxalase 1 expression in hPDLFs 
cells in vitro 
Cells were treated with trans-resveratrol (10 µM) for 3 days in low and 
high glucose. Glo1 gene expression was quantified in all four study groups by RT-
PCR and normalized to β-actin mRNA. The levels of Glo1 mRNA did not change 
as before and tRSV has no affect either. Normalized GLO1 mRNA to β-actin 
mRNA level was: low glucose control, 0.771 ± 0.007, high glucose control 0.768 
± 0.005, low glucose with tRSV, 0.786 ± 0.007 and high glucose with tRSV 0.773 
± 0.018.
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Figure 55: Effect of Glo1 inducers on Glo1 protein content of hPDLFs in vitro.  
(A) Glo1 protein blot, (B) Glo1 protein blot interpretation. hPDLFs cells were cultured in 8 mM glucose medium (LG) and 8 mM glucose 
medium with 10 µM tRSV (LG+tRSV), 10 µM HSP (LG+HSP) and 10 µM tRSV and HSP (LG+tRSV-HSP), and 25 mM glucose medium 
(HG) and 25 mM glucose medium with 10 µM tRSV (HG+tRSV), 10 µM HSP (HG+HSP) and 10 µM tRSV and HSP (HG+tRSV-HSP) 
for 3 days. Data are mean ± SD, n = 3. Significance: *, P<0.05 (t-test) with respect to low glucose control; o, P<0.05 (t-test) with respect to 
high glucose control.
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3.3.3 The effect of trans-resveratrol on the half-life of Glo1 protein in vitro 
A possible explanation for the prevention of decrease in Glo1 activity and 
protein without change in Glo1 expression by tRSV in hPDLFs incubated in high 
glucose concentration is an effect on Glo1 stability. To test this I planned a 
conventional experiment to measure the half-life of Glo1 protein in hPDLFs with 
high glucose concentration cultures with and without tRSV. This uses 
cycloheximide to block protein synthesis and then quantify the rate of decrease in 
Glo1 protein.     
 
3.3.3.1 Time course curve for hPDLFs treated with cycloheximide in vitro 
In preparation for the Glo1 protein half-life study, the effect of 
cycloheximide on hPDLFs growth and viability was assessed. hPDLFs were 
cultured in MEM in low glucose concentration. After 24 hours, new MEM 
medium was added to each well with 10 µM cycloheximide (CHX) for 2 days. 
Addition of CHX induced growth arrest and toxicity in hPDLFs: viable cell 
number decreased by 48% at day 1 and 75% at day 2, compared to the control - 
Figure 56.  
 
 
Figure 56: Effect of cycloheximide on the growth and viability of hPDLFs in 
vitro.  
Data are mean ± SD (n = 3). Key: ○-○, control; ●-●, + 10 µM cycloheximide. 
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3.3.3.2 Effect of cycloheximide on glyoxalase 1 protein expression in the 
presence of trans-resveratrol in hPDLFs in vitro 
Primary hPDLFs cells were cultured in MEM in low and high glucose 
concentration. After 24 h, the medium was replaced with the fresh medium 
supplemented with CHX (10 µM) with and without tRSV (10 µM) and incubated 
for 2 days. Immunoblotting was performed as described in the method section. 
Glo1 protein band intensity was decreased with addition of CHX in low and high 
glucose treated cells however, it was stabilised by tRSV treatment - Figure 57A. 
The intensity value of each sample of each treatment group was fitted to first-
order exponential decay - Figure 57B and Table 30. The rates of Glo1 protein 
degradation and half-life indicated that high glucose concentration de-stabilised 
Glo1 protein and tRSV corrected this. 
 
Table 30: the effect of tRSV on the half-life of Glo1 protein in hPDLFs in 
vitro. 
 
 
8mM (CHX, 10 
µM) 
25mM (CHX, 10 
µM) 
25mM (CHX 10µM, 
tRSV 10 µM) 
kDeg  (Day-1) 0.302 ± 0.048 0.531 ± 0.059 0.188 ± 0.047 
T1/2 (days) 2.30 1.31 3.66 
Data are mean ± SD, n = 3 
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Figure 57: Time course of Glo1 protein intensity.  
(A) Protein expression, (B1) 8 mM glucose control, (B2) 8 mM glucose + CHX, 
(B3) 25 mM glucose + CHX and (B4) 25 mM glucose + tRSV + CHX. 
 
 
y = 3256.5e0.0108x
0
1000
2000
3000
4000
0 1 2
In
te
n
s
it
y
Incubation period (Day)
y = 2081.3e-0.298x
0
1000
2000
0 1 2
In
te
n
s
it
y
Incubation period (Day)
y = 3227.3e-0.469x
0
1000
2000
3000
4000
0 1 2
In
te
n
s
it
y
Incubation period (Day)
y = 2946.1e-0.171x
0
1000
2000
3000
4000
0 1 2
In
te
n
s
it
y
Incubation period (Day)
B1. B2. 
B3. B4. 
A. 
  
229 
 
 
3.3.4 Effect trans-resveratrol on other enzymatic activity related to 
dicarbonyl metabolism in hPDLFs cells in vitro 
The effects of the Glo1 inducer, tRSV, on other enzymatic activities 
related to dicarbonyl metabolism in hPDLFs cells was studied. The activity of the 
second enzyme of the glyoxalase pathway, Glo2, was not affected by tRSV. 
Metabolism by MG reductase and MG dehydrogenase are alternative fates 
to the glyoxalase pathway for MG metabolism. There was low activity of MG 
reductase in hPDLFs which was not changed by tRSV or in HG conditions. The 
activity of MG dehydrogenase was below the limit of detection. The glyoxalase 
pathway is, therefore, likely the major pathway for MG metabolism in hPDLFs –
Table 31. 
 
Table 31: Values of different enzymatic activities of the glyoxalase system 
performed on hPDLFs cells incubated in media contains high and low 
glucose with Glo1 inducers in vitro 
Analyte LG LG + tRSV HG HG + tRSV 
Glo1 activity 
(mU/mg protein) 
928 ± 84 1028 ± 78 529 ± 106**   967 ± 88 ooo 
Glo2 activity 
(mU/mg protein) 
4.63 ± 0.67 4.03 ± 0.99 4.64 ± 0.99 3.36 ± 1.21 
MG reductase 
(mU/mg protein) 
0.09 ± 0.02 0.07 ± 0.02 0.08 ± 0.01 0.06 ± 0.03 
MG dehydrogenase 
(mU/mg protein) 
<LOD <LOD <LOD <LOD 
Data are mean ± SD, n = 4. Significance: **, P<0.01 respect to low glucose 
control (8 mM glucose) (t-test). ooo, P<0.001 (t-test) with respect to high glucose 
control (8 mM glucose). LOD for MG dehydrogenase was 0.0005 mU/mg protein. 
 
3.3.5 Effect of Glo1 inducers on flux of formation of D-lactate and L-lactate 
in hPDLFs cells in vitro 
Primary hPDLFs cells were cultured in 8 mM glucose and 25 mM glucose 
for 3 days with and without 10 µM tRSV, 10 µM HSP and 10 µM tRSV+HSP. 
The flux of formation of D-lactate was increased significantly in hPDLFs cells in 
high glucose without tRSV by 41% (P<0.01) and also in high glucose with tRSV 
by 40% (P<0.01) – Figure 58 and Table 32. However in the presence of HSP, the 
flux of D-lactate formation in low glucose concentration was decreased 13% 
(P<0.05); and in high glucose concentration cultures, the flux of D-lactate 
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formation was increased by + 53% (P<0.01) with respect to low glucose control in 
the absence of HSP and this increase was lowered to + 22% in the presence of 
HSP (P<0.01 with respect to low glucose control; P’<0.05 with respect to high 
glucose control) – Figure 58 and Table 32. These effects were sustained in low 
glucose and further enhanced in high glucose with tRSV+HSP combined 
supplementation. The flux of D-lactate formation in low glucose concentration 
was decreased 12% (P<0.05); and in high glucose concentration cultures, the flux 
of D-lactate formation was increased by + 44% (P<0.001) with respect to low 
glucose control in the absence of tRSV+HSP combined supplementation and this 
increase was prevented in the presence of tRSV+HSP combined supplementation 
(P’<0.001 with respect to high glucose control) – Figure 58 and Table 32. The 
formation of L-lactate did not change in high glucose compare to low glucose 
cultures and the treatment with Glo1 inducers had no effect on the formation of L-
lactate - Table 33. 
 
Table 32: Effect of Glo1 inducers on formation of D-lactate in hPDLFs cells 
in vitro 
D-Lactate production (nmol/day/10⁶ cells) in culture medium 
 
LG 
LG + Glo1 
inducer 
HG 
HG + Glo1 
inducer 
10 µM tRSV 7.00 ± 0.36 6.82 ± 0.63 9.90 ± 1.08** 9.78 ± 0.78** 
10 µM HSP 6.57 ± 0.54 5.72 ± 0.31* 10.1 ± 1.03*** 7.99 ± 0.59**, o 
10 µM 
tRSV+HSP 
6.79 ± 0.47 5.99 ± 0.39* 9.74 ± 0.42*** 6.91 ± 0.69 ooo 
Data are mean ± SD, n = 4. Significance: *, **, and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to low glucose control; o and ooo, P<0.05 and 
P<0.001, respectively, compared to high glucose control (t-test). 
 
Table 33: Effect of Glo1 inducers on L-lactate concentration in hPDLFs cells 
in vitro 
L-Lactate production (nmol/day/10⁶ cells) in culture medium 
 
LG 
LG + Glo1 
inducer 
HG 
HG + Glo1 
inducer 
10 µM tRSV 276 ± 34 275 ± 54 252 ± 17  248 ± 33  
10 µM HSP 277 ± 28 302 ± 33 256 ± 26 252 ± 41  
10 µM tRSV+HSP 277 ± 28 243 ± 33 256 ± 26 234 ± 33 
Data are mean ± SD, n = 4.  
 
 
  
231 
 
 
 
 
 
 
 
 
Figure 58: Effect of Glo1 inducers on flux of formation of D-lactate in 
hPDLFs cells in vitro.  
hPDLFs cells were cultured in 8 mM glucose (LG) and 25 mM glucose (HG) 
medium with or without: (A) 10 µM tRSV, (B) 10 µM HSP and (C) 10 µM 
tRSV+HSP for 3 days. Data are mean ± SD, n = 4. Significance: *, **, and ***, 
P<0.05, P<0.01 and ***, P<0.001, respectively, compared to low glucose control; 
o and ooo, P<0.05 and P<0.001, respectively, compared to high glucose control (t-
test). 
B. 
A. 
C. 
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3.3.6 Effect of Glo1 inducers on consumption of D-glucose by hPDLFs cells 
in vitro 
Glucose consumption was measured in hPDLFs cultures. Cells were 
cultured as before in low and high glucose with and without the Glo1 inducers (10 
µM tRSV, HSP and tRV+HSP combined). In experiments with tRSV 
supplementation, in low glucose cultures addition of 10 µM tRSV did not change 
glucose consumption. In high glucose cultures, glucose consumption was 
increased 95% with respect to low glucose control (P<0.001) and this was not 
changed by tRSV (P<0.001 with respect to low glucose control) – Figure 59 and 
Table 34. In experiments with HSP supplementation, in low glucose cultures, 10 
µM HSP decreased glucose consumption by 20% (P<0.05). In high glucose 
cultures, glucose consumption was increased 89% with respect to low glucose 
control (P<0.01) and this was lowered to an increase 56% with HSP (P<0.01 with 
respect to low glucose control; P’<0.05 with respect to high glucose control) – 
Figure 59 and Table 34. In experiments with tRSV+HSP combined 
supplementation, in low glucose cultures, 10 µM tRSV+HSP combined decreased 
glucose consumption by 24% (P<0.05). In high glucose cultures, glucose 
consumption was increased 80% with respect to low glucose control (P<0.01) and 
this was corrected by tRSV+HSP combined supplementation – Figure 59 and 
Table 34. 
 
Table 34: Effect of Glo1 inducers on D-glucose consumption in hPDLFs cells 
in vitro 
D-Glucose Consumption (μmol/day/10⁶ cells) in culture medium 
 
LG 
LG + Glo1 
inducer 
HG 
HG + Glo1 
inducer 
10 µM tRSV 5.16 ± 0.39 4.90 ± 0.31 10.1 ± 0.37*** 9.29±0.77*** 
10 µM HSP 5.83 ± 0.58 4.67 ± 0.27* 11.0 ± 0.86** 9.12±0.68**,o 
10 µM 
tRSV+HSP 
5.92 ± 0.71 4.49 ± 0.49* 10.7 ± 1.14** 7.53 ± 1.10 o 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to low glucose control; o, P<0.05 with respect to 
high glucose control (t-test). 
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The flux of D-lactate formation as percentage of glucotriose was also 
calculated as described previously. This was decreased 16 – 30% in high glucose 
cultures, compared to low glucose control. Glo1 inducers did not change this 
derived compound variable - Table 35. 
 
Table 35: Effect of Glo1 inducers on D-lactate flux in hPDLFs cells in vitro 
D-lactate flux (% glucotriose) 
 
LG 
LG + Glo1 
inducer 
HG 
HG + Glo1 
inducer 
10 µM tRSV 0.068 ± 0.006 0.070 ± 0.010 0.048 ± 0.006** 0.053 ± 0.006* 
10 µM HSP 0.057 ± 0.004 0.061 ± 0.002  0.048 ± 0.002* 0.044 ± 0.003** 
10 µM 
tRSV+HSP 
0.058 ± 0.007 0.067 ± 0.005 0.046 ± 0.002* 0.046 ± 0.008 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to low glucose control (t-test)). 
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Figure 59: Effect of Glo1 inducers on consumption of D-glucose by hPDLFs 
cells in vitro. 
 hPDLFs cells were cultured in 8 mM glucose medium (LG) and 25 mM glucose 
medium (HG) for 3 days without or with: (A) 10 µM tRSV, (B) 10 µM HSP, and 
(C) 10 µM tRSV+HSP. Data are mean ± SD, n = 4. Significance: *, ** and ***, 
P<0.05, P<0.01 and P<0.001, respectively, compared to low glucose control; o, 
P<0.05 with respect to high glucose control (t-test)). 
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3.3.7 Effect of trans-resveratrol on the concentration of dicarbonyls in 
hPDLFs incubated in low and high glucose in vitro 
Primary hPDLFs cells were incubated in either 8 mM glucose or 25 mM 
glucose with or without 10 µM tRSV for 3 days. Cellular and culture medium 
levels of dicarbonyls were evaluated by the LC-MS/MS. 
The cellular content of MG was not changed by addition of tRSV in low 
glucose cultures. The cellular content of MG was increased by 160% in high 
glucose culture (P<0.001) and 100% in high glucose culture with tRSV (P<0.05), 
with respect to low glucose control. There was a trend for addition of tRSV to 
decrease cellular concentration of MG (-60%) but this did not reach significance 
(P = 0.07). The cellular content of glyoxal in low glucose culture was decreased 
56% by addition of tRSV (P<0.001). The cellular content of glyoxal was not 
increased in high glucose culture and was decreased 57% by addition of tRSV 
(P<0.001, with respect to low glucose control; P’<0.01 with respect to high 
glucose control) – Figure 60. The cellular content of 3-DG in low glucose culture 
was not decreased by addition of tRSV. The cellular content of 3-DG was 
increased 82% in high glucose culture (P<0.05) and was unchanged by addition of 
tRSV – Table 36.  
The concentration of MG in the culture medium was not changed by 
addition of tRSV in low glucose cultures. The concentration of MG in the culture 
medium was increased by 62% in high glucose culture (P<0.05), with respect to 
low glucose culture control, and was corrected by addition of tRSV (P<0.05 with 
respect to high glucose control. The concentration of glyoxal in the culture 
medium was decreased 42% by addition of tRSV in low glucose cultures 
(P<0.05). The concentration of glyoxal in the culture medium was not increased in 
high glucose culture, with respect to low glucose culture control, but was 
decreased 45% by addition of tRSV (P<0.05 with respect to low glucose control; 
P<0.01 with respect to high glucose control) - Figure 61. The concentration of 3-
DG in the culture medium was not changed by addition of tRSV in low glucose 
cultures. The concentration of 3-DG in the culture medium was increased 110% in 
high glucose culture (P<0.001), with respect to low glucose culture control, and 
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was not decreased by addition of tRSV (P’<0.001 with respect to low glucose 
control) – Table 36. 
 
Table 36: Effect of trans-resveratrol on dicarbonyls levels in human 
periodontal ligament fibroblasts and medium in vitro 
  
Methylglyoxal Glyoxal 3-DG 
  
(pmol/10⁶cells) (pmol/10⁶cells) (pmol/10⁶cell) 
hPDLFs  
LG 3.98 ± 1.00 7.79 ± 2.43 1.94 ± 0.70 
LG+tRSV 4.47 ± 0.95 2.31 ± 0.83 *** 1.41 ± 0.65 
hPDLFs  
HG 10.4 ± 0.6*** 6.29 ± 0.93 3.53 ± 0.60* 
HG+tRSV 7.97 ± 2.10* 1.77 ± 0.92***,oo 3.98 ± 1.08* 
  
(nM) (nM) (nM) 
Medium 
LG 276 ± 82 362 ± 46 313 ± 51 
LG+tRSV 269 ± 81 210 ± 58* 290 ± 72 
Medium 
HG 449 ± 38* 422 ± 78 658 ± 66*** 
HG+tRSV 351 ± 36o 234 ± 43oo 723 ± 95*** 
Data are mean ± SD, n = 4. Significance: * and ***, P<0.05 and P<0.001, 
respectively, compared to low glucose control; o and oo, P<0.05 and P<0.01, 
respectively, compared to high glucose control (t-test).  
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Figure 60: Effect of trans-resveratrol on cellular levels of dicarbonyls in 
hPDLFs cells in vitro.  
hPDLFs cells were cultured in 8 mM and 25 mM glucose medium with or without 
tRSV (10 µM) for 3 days. (A) MG. (B) Glyoxal. Data are mean ± SD, n = 4. 
Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001, respectively, compared 
low glucose control; oo, P<0.01 with respect to high glucose control (t-test). 
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Figure 61: Effect of trans-resveratrol on levels of dicarbonyls in the medium 
of hPDLFs cells in vitro.  
hPDLFs cells were cultured in 8 mM and 25 mM glucose medium with or without 
tRSV (10 µM) for 3 days. (A) MG. (B) Glyoxal. Data are mean ± SD, n = 4. 
Significance: *, P<0.05 compared low glucose control; o and oo, P<0.05 and 
P<0.01, respectively, compared to high glucose control (t-test). 
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3.3.8 Effect of hesperetin and trans-resveratrol and hesperetin combined on 
the concentration of dicarbonyls in hPDLFs incubated in low and high 
glucose with tRSV in vitro 
In further experiments primary hPDLFs cells were incubated in either 8 
mM glucose or 25 mM glucose with or without 10 µM HSP and 10 µM 
tRSV+HSP for 3 days. Cellular dicarbonyls were evaluated by the LC-MS/MS. 
The cellular content of MG was not changed by addition of HSP and tRSV 
with HSP combined in low glucose cultures. The cellular content of MG was 
increased by 128% in high glucose culture (P<0.001), 78% in high glucose culture 
with HSP and corrected to low glucose control levels tRSV with HSP combined. 
The cellular content of glyoxal in low glucose culture was not changed by 
addition of HSP and tRSV with HSP combined. The cellular content of glyoxal 
was not increased in high glucose culture and was not changed by additions of 
HSP and tRSV with HSP combined – Figure 62 and Table 37. The cellular 
content of 3-DG in low glucose culture was not changed by addition of HSP and 
tRSV with HSP combined. The cellular content of 3-DG was increased 33% in 
high glucose culture (P<0.05) and this was corrected by addition of HSP and 
tRSV+HSP combined - Figure 62 and Table 37.
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Figure 62: Effect of hesperetin and trans-resveratrol and hesperetin combined on cellular levels of dicarbonyls in hPDLFs cells in 
vitro.  
hPDLFs cells were cultured in 8 mM glucose (LG) and 25 mM glucose medium (HG) with or without 10 µM HSP and 10 µM tRSV + HSP 
for 3 days. Key: (A) MG. (B) 3-DG. Data are mean ± SD, n = 4. Significance: * and ***, P<0.05 and P<0.001, respectively. compared to 
low glucose control; o and oo, P<0.05 and P<0.01, respectively. compared to high glucose control (t-test). 
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Table 37: Effect of Glo1 inducers on dicarbonyls levels in human periodontal 
ligament fibroblasts and medium in vitro 
Glucose Methylglyoxal Glyoxal 3-DG 
 
(pmol/10⁶cells) (pmol/10⁶cells) (pmol/10⁶cell) 
LG 4.24 ± 0.94 6.74 ± 2.14 2.17 ± 0.38 
LG+HSP 4.88 ± 2.25 6.72 ± 0.82 2.70 ± 0.38 
LG+tRSV+HSP 5.28 ± 0.82 5.86 ± 1.61 2.16 ± 0.56 
HG 9.67 ± 0.57*** 6.02 ± 2.34 2.90 ± 0.20* 
HG+HSP 7.54 ± 0.94oo 5.77 ± 1.18 2.08 ± 0.36oo 
HG+tRSV+HSP 6.40 ± 1.86o 4.25 ± 1.92 2.02 ± 0.64o 
Data are mean ± SD, n = 4. Significance: * and ***, P<0.05 and P<0.001, 
respectively. compared to low glucose control; o and oo, P<0.05 and P<0.01, 
respectively. compared to high glucose control (t-test). 
 
3.3.9 Effect of trans-resveratrol on the availability of thiols and glutathione 
in hPDLFs cells in vitro 
Most of the reactive dicarbonyls, glyoxal and MG, detected in cells are 
bound reversibly to protein and non-protein thiols which limits their reactivity to 
produce other irreversible protein modifications. In low glucose cultures, the total 
cell thiols in hPDLFs, mainly protein cysteine thiols + GSH, was 27.5 ± 0.9 
nmol/106 cells. This was unchanged by addition of tRSV. Surprisingly total cell 
thiols were increased ca, 13% in hPDLFs cells with high glucose, compare to low 
glucose control (P<0.001). This was prevented by addition of 10 µM tRSV – 
Figure 63 and Tabl 38. Protein thiols were determined by subtracting GSH level 
from the samples. In low glucose cultures, the protein thiols content of hPDLFs 
was 20.2 ± 1.3 nmol/106 cells. Protein thiols were increased ca, 25% in hPDLFs 
cells with high glucose, compare to low glucose control (P<0.01). Protein thiols of 
hPDLFs were decreased by addition of 10 µM tRSV. In low glucose culture, 
protein thiols decreased ca. 15%, with respect to low glucose control. In high 
glucose culture, protein thiols decreased ca, 12%, with respect to low glucose 
control (P<0.05 with respect to low glucose control and P’<0.001 with respect to 
high glucose control) - Figure 63 and Tabl 38. 
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Figure 63: Effect of trans-resveratrol on the cell thiols in hPDLFs cells in 
vitro.  
hPDLFs cells were cultured in 8 mM and 25 mM glucose medium with or without 
10 µM tRSV for 3 days. Data are mean ± SD, n = 4. Significance: *, P<0.05, **, 
P<0.01 and ***, P<0.001 with respect to low glucose control; oo, P<0.01 and ooo, 
P<0.001 with respect to high glucose control (t-test). 
  
To explore the changes in GSH metabolism, GSH and GSSG were 
measured and also total GSH deduced. In low glucose cultures, the GSH content 
of hPDLFs was 7.21 ± 0.93 nmol/106 cells. This was increased 21% by tRSV 
(P<0.05). In high glucose cultures, the GSH content of hPDLFs was decreased by 
21% (P<0.05). Addition of tRSV corrected the decrease in GSH of hPDLFs and, 
moreover, increased GSH by 35%, with respect to low glucose control (P<0.01 
with respect to low glucose control; P’<0.001 with respect to high glucose 
control). In low glucose cultures, the GSSG content of hPDLFs was 0.00814 ± 
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0.00054 nmol/106 cells. This was unchanged by tRSV. In high glucose cultures, 
the GSSG content of PDLFs was decreased by 20% (P<0.01). Addition of tRSV 
did not correct this decrease (P<0.05 with respect to low glucose control). In low 
glucose cultures, the total GSH content of hPDLFs was 7.23 ± 0.94 nmol/106 
cells. This was increased 21% by tRSV (P<0.05). In high glucose cultures, the 
total GSH content of hPDLFs was unchanged. Addition of tRSV increased total 
GSH by 35% with respect to the low glucose control (P<0.01) - Figure 64 and 
Table 38. 
 
Table 38: Effect of trans-resveratrol on glutathione levels in primary hPDLFs 
cells in vitro. 
Analyte  LG LG+tRSV HG HG+tRSV 
Total thiols 
(nmol/10⁶ cells) 
27.5±0.90 25.9±1.31 31.1±1.45* 27.5±0.79 oo 
Protein thiols 
(nmol/10⁶ cells) 
20.2 ± 1.3 17.2  ± 1.47 25.4 ± 1.93 17.8  ± 1.0 
GSH (nmol/10⁶ 
cells) 
7.21 ± 0.94 8.71 ± 0.65* 5.68 ± 1.28* 9.75 ± 0.63**,oo 
GSSG (nmol/10⁶ 
cells) 
0.00814 ± 
0.00054 
0.00760 ± 
0.0010 
0.00648 ± 
0.00053** 
0.00692 ± 
0.00047* 
Total GSH 
(nmol/10⁶ cells) 
7.23 ± 0.94 8.72 ± 0.65* 5.70 ± 1.28* 9.76 ± 0.63**,ooo 
% Reduced (GSH) 99.8 99.8 96.7 99.9 
% Oxidised (GSSG) 0.2 0.2 3.3 0.1 
Data are mean ± SD, n = 4. Significance: * and **, P<0.05 and P<0.01 with 
respect to low glucose control; oo and ooo, P<0.01 and P<0.001 with respect to high 
glucose control (t-test).  
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Figure 64: Effect of trans-resveratrol on glutathione metabolism in hPDLFs 
cells in vitro. 
 hPDLFs cells were cultured in 8 mM glucose (LG) and 25 mM glucose (HG) 
medium with or without 10 µM tRSV for 3 days. (A) GSH, (B) GSSG, and (C) 
Total GSH. Data are mean ± SD, n = 4. Significance: * and **, P<0.05 and 
P<0.01, respectively, compared to low glucose control; ooo, P<0.001 with respect 
to high glucose control (t-test). 
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3.3.10 Effect of trans-resveratrol on glycation, oxidation and nitration 
adduct residue content of cytosolic protein extracts of hPDLFs cells in 
vitro 
Primary hPDLFs were cultured for 3 days in low and high glucose with or 
without 10 µM tRSV and glycation, oxidation and nitration adduct residue content 
of cytosolic protein extracts analysed. In low glucose cultures, the MG-H1 residue 
content of cell protein was 0.416 ± 0.059 mmol/mol arg. This was unchanged by 
addition of tRSV. In high glucose cultures, the MG-H1 residue content of cell 
protein was increased 74% compared to low glucose control (P<0.01) which was 
corrected by addition of tRSV. In low glucose cultures, the FL residue content of 
cell protein was 0.123 ± 0.022 mmol/mol lys. This was unchanged by addition of 
tRSV. In high glucose cultures, the FL residue content of cell protein was 
increased by 242% compared to low glucose control (P<0.001). This increase was 
decreased to +108 by addition of tRSV (P<0.05 with respect to low and high 
glucose controls). In low glucose cultures, the CML residue content of cell protein 
was 0.076 ± 0.007 mmol/mol lys. This was unchanged by addition of tRSV. In 
high glucose cultures, the CML residue content of cell protein was increased by 
51% compared to low glucose control (P<0.01). This increase was unchanged by 
addition of tRSV (P<0.01 with respect to low glucose control). In low glucose 
cultures, the CMA residue content of cell protein was 0.062 ± 0.011 mmol/mol 
arg. This was decreased 46% by addition of tRSV (P<0.01). In high glucose 
cultures, the CMA residue content of cell protein was unchanged but it was 
decreased 51% in high glucose by addition of tRSV (P<0.01 with respect to low 
and high glucose controls).  
The level of CML/FL in low glucose cultures is 0.085 ± 0.025. This was 
unchanged in high glucose culture or with addition of tRSV to hPDLFs in low and 
high glucose culture. This indicated no change in the oxidative stress with 
addition of tRSV hPDLFs in low or high glucose culture. The glycation and 
oxidation adduct residue content of cell protein are presented in Figure 65 and 
Table 39.  
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Figure 65: Effect of trans-resveratrol on cellular protein glycation adduct 
content of hPDLFs cells in vitro.  
(A) MG-H1. (B) FL. (C) CMA. Data are mean ± SD, n = 4. Significance: *, ** 
and ***, P<0.05, P<0.01 and P<0.001, respectively, compared to low glucose 
control; o and oo, P<0.05 and P<0.01 respectively, compared to high glucose 
control (t-test).
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Table 39: Effect of trans-resveratrol on cellular protein content of protein glycation and oxidation adduct residues of hPDLFs 
cells in vitro 
Protein adduct residue LG LG+tRSV HG HG+tRSV 
FL (mmol/mol lys) 0.972 ± 0.390 0.867 ± 0.628 3.40 ± 0.96** 1.76 ± 0.553oo 
CML (mmol/mol lys) 0.076 ± 0.007 0.085 ± 0.004 0.114 ± 0.015** 0.114 ± 0.013** 
CEL (mmol/mol lys) 0.030 ± 0.009 0.027 ± 0.006 0.035 ± 0.010 0.034 ± 0.010 
MOLD (mmol/mol lys) 0.0055 ± 0.0038 0.0045 ± 0.0026 0.0043 ± 0.0021 0.0032 ± 0.0016 
CMA (mmol/mol arg) 0.062 ± 0.011 0.033 ± 0.008** 0.066 ± 0.006 0.030 ± 0.011oo 
MG-H1 (mmol/mol arg) 0.416 ± 0.059 0.462 ± 0.037 0.727 ± 0.122** 0.540 ± 0.085o 
G-H1 (mmol/mol arg) 0.012 ± 0.007 0.019 ± 0.009 0.015 ± 0.013 0.027 ± 0.015 
3DG-H (mmol/mol arg) 0.182 ± 0.100 0.123 ± 0.045 0.148 ± 0.032 0.132 ± 0.082 
3NT (mmol/mol tyr) 0.0013 ± 0.0002 0.0017 ± 0.0003 0.0013 ± 0.0005 0.0014 ± 0.0002 
DT (mmol/mol tyr) 0.036 ± 0.008 0.033 ± 0.009 0.037±0.007 0.046 ± 0.019 
NFK (mmol/mol trp) 0.199 ± 0.044 0.209 ± 0.052 0.217 ± 0.095 0.232 ± 0.036 
MetSO (mmol/mol met) 2.09 ± 0.28 1.72 ± 0.49 2.13±0.55 2.01 ± 0.21 
CML/FL 0.085 ± 0.025 0.107 ± 0.061 0.086 ± 0.010 0.069 ± 0.023 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001 with respect to low glucose control; o and oo, 
P<0.05 and P<0.01 with respect to high glucose control (t-test). 
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3.3.11 Effect of trans-resveratrol on flux of glycation, oxidation and nitration 
free adducts of hPDLFs cells in vitro 
Primary hPDLFs were cultured for 3 days in low and high glucose with or 
without 10 µM tRSV. The concentration of glycation, oxidation and nitration free 
adducts were measured in culture medium at baseline and at 3 days and the flux of 
free adduct increase deduced. 
In low glucose cultures, the flux of MG-H1 free adduct formation was 
2.10 ± 0.67 pmol/106 cells/day. This was unchanged by addition of tRSV. In high 
glucose cultures, the flux of MG-H1 free adduct formation was increased 52% 
compared to low glucose control (P<0.05) which was corrected by addition of 
tRSV. In low glucose cultures, the flux of CML free adduct formation was 10.0 ± 
7.2 pmol/106 cells/day. This was unchanged by addition of tRSV. In high glucose 
cultures, the flux of MG-H1 free adduct formation was increased 196% compared 
to low glucose control (P<0.01). This increase was lowered to + 121% by addition 
of tRSV (P<0.05 with respect to low glucose control; P’<0.01 with respect to high 
glucose control) – Figure 66 and Table 40. 
In low glucose cultures, the flux of 3DG-H free adduct formation was 
0.678 ± 0.559 pmol/106 cells/day. This was increased by + 617% in high glucose 
incubation (P<0.001). In low glucose cultures, MetSO free adduct formation was 
0.678 ± 0.559 pmol/106 cells/day. This was increased by 527% in high glucose 
incubation (P<0.001). In low glucose cultures, the flux of CMA free adduct 
formation was 0.678 ± 0.559 pmol/106 cells/day. This was increased by 25% in 
high glucose incubation (P<0.05). 3DG-H, MetSO and CMA free adduct 
formation levels were unchanged by addition of tRSV in low or high glucose 
incubations - Table 40. 
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Figure 66: Effect of trans-resveratrol on flux of protein glycation free adducts 
formed by hPDLFs cells in culture in vitro.  
(A) MG-H1. (B) CML. Data are mean ± SD, n = 4. Significance: * and **, P<0.05 
and P<0.01, respectively, compared to low glucose control; o and oo, P<0.05 and 
P<0.01 respectively, compared to high glucose control (t-test). 
 
Table 40: Effect of trans-resveratrol on flux of protein glycation and 
oxidation free adducts formed by hPDLFs cells in vitro 
Free 
adduct 
LG LG+tRSV HG HG LG+tRSV 
FL 323 ± 110 312 ± 102 1032 ± 425* 1133 ± 429** 
CML  10.0 ± 7.2 19.9 ± 3.6 29.5 ± 1.7** 22.0 ± 2.5 oo 
MetSO  0.506 ± 0.160 0.514 ± 0.151 3.17 ± 0.56*** 3.10 ± 0.88*** 
CMA  4.55 ± 0.29 4.22 ± 0.54  5.66 ± 0.61* 6.36 ± 0.50** 
MG-H1  2.09 ± 0.67 2.33 ± 0.53 3.18 ± 0.59* 1.82 ±0.83 o 
GH1  1.25 ± 0.85 1.73 ± 0.99 0.479 ± 0.339 0.756 ± 0.580 
3DG-H   0.678 ± 0.559 0.697 ± 0.263 4.77 ± 0.30*** 4.59±1.37*** 
Data are mean ± SD (pmol/day/106 cells; n = 4). Significance: *, ** and ***, 
P<0.05, P<0.01 and P<0.001, respectively, compared to low glucose control; o and 
oo, P<0.05 and P<0.01, respectively, compared to high glucose control (t-test). 
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3.3.12 Studying the effect of highly and minimally glycated protein on 
inflammatory signalling activated by RAGE in hPDLFs in vitro 
Bierhaus and colleagues published preliminary evidence that activation of 
RAGE by proteins highly modified by AGEs decreased expression of Glo1 
(Bierhaus, 2006). Studies in OVE26 mice with and without RAGE expression had 
change in Glo1 expression supporting this (Reiniger et al., 2010). The mechanistic 
details are still unclear. It now seems unlikely that protein glycated minimally by 
AGEs as found in vivo do not bind RAGE (Thornalley, 2007) and the claim that 
CML-modified proteins bind RAGE contested (Kistinger et al., 1999, Buetler et 
al., 2008). Albumin highly modified by AGEs and aggregated, however, does 
bind RAGE (Valencia et al., 2004). Since the hPDLFs may be exposed to the 
highly glycated protein from food with epithelial barrier breakdown in 
periodontitis, the effect of albumin highly modified by CML (CML-HSA) and 
glucose-derived AGEs (AGE-HSA) was investigated. I hypothesised that the 
decrease in Glo1 activity may occur in hPDLFs when RAGE binds CML-HSA 
and AGE-HSA and activates NF-κB. Crosstalk between NF-κB and Nrf2 (Liu et 
al., 2008) is expected to downregulated basal and inducible expression of Glo1 
(Xue et al., 2012a). This was investigated in this project. 
 
3.3.12.1 Effect of AGE-HSA and CML-HSA on the viability of hPDLFs in 
vitro 
Primary hPDLFs were incubated for 3 days in MEM medium containing 8 
mM glucose with unmodified HSA (100 µg/ml), AGE-HSA (50 – 100 µg/ml) and 
CML-HSA (50 – 100 µg/ml). In day 3 the viable cell number was counted in all 
the study groups. The viable cell number increased throughout the culture period 
and shows a steady increase in all the groups with no significant change in the 
vitality under any condition – Figure 67. 
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Figure 67: Effect of AGE-HSA and CML-HSA on the viability of hPDLFs in 
vitro.  
(A) The viability of hPDLFs treated with AGE-HSA (50 – 100 µg/ml). (B) The 
viability of hPDLFs treated with CML-HSA (50 – 100 µg/ml). Data are mean ± 
SD, n = 3. 
 
3.3.12.2 Endotoxin content of albumin derivatives highly modified AGEs 
The concentration of endotoxin in the modified albumin was measured by 
a quantitative chromogenic limulus assay. The data shows low levels of 
endotoxins in modified albumin proteins which are lower than level of endotoxin 
in body plasma (0.5 EU/mL) - Table 41. 
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Table 41: The levels of endotoxin in modified albumin derivatives. 
Sample Endotoxin  (EU/mg) 
CML-HSA 0.112 ± 0.040 
CMLmin-HSA 0.127 ± 0.028 
Unmodified HSA control (CML-HSA) 0.153 ± 0.031 
AGE-HSA 0.170 ± 0.077 
Unmodified HSA control (AGE-HSA) 0.216 ± 0.027 
AGEmin-HSA 0.143 ± 0.018 
Unmodified HSA control (AGEmin-HSA) 0.198 ± 0.021 
Data are mean ± SD, n = 3. 
 
3.3.12.3 Effect of highly glycated albumin derivatives on activation of 
transcription factor NF-κB in hPDLFs in vitro 
Primary hPDLFs were cultured for 3 days in cultures with 8 mM glucose 
in presence of highly glycated albumin derivatives proteins (100 µg/ml). Cell 
nuclear extracts were prepared and an aliquot of nuclear extract (10 µg) was tested 
for activated p65. The outcome showed no significant activation of NF-kB, as 
indicated by level of nuclear DNA bound p65. This suggests that highly AGE-
modified albumin did not activate inflammatory signalling in hPDLFs. Previous 
studies may have endotoxin contamination in the protein preparation that caused 
activation of the RAGE receptor. In this study a great care was taken to avoid 
endotoxin contamination (see Table 41). Table 42 shows average of the 
expression in 10 µg of hPDLFs nuclear extract. 
 
Table 42: The effect of modified albumin protein derivatives on the 
activation of transcription factor NF-κB in hPDLFs in vitro. 
Sample 
DNA-bound p65 (% of 
control) 
Control 0.801 ± 0.035 
Positive control (Jurkat nuclear extract) 1.25   ± 0.017 
TNFα (100 nM) 0.818 ± 0.053 
CML-HSA  0.824 ± 0.047  
CMLmin-HSA 0.831 ± 0.095 
Unmodified HSA control (CML-HSA)  0.822 ± 0.027 
AGE-HSA 0.865 ± 0.037 
Unmodified HSA control (AGE-HSA) 0.834 ± 0.062 
AGEmin-HSA 0.844 ± 0.013 
Unmodified HSA control (AGEmin-HSA) 0.800 ± 0.059 
Data are mean ± SD, n = 3.  
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3.3.12.4 The effect of modified albumin proteins on the Glo1 gene 
expression in hPDLFs in vitro 
Primary hPDLFs were incubated for 3 days in MEM medium in low 
glucose containing highly glycatyed and unglycated control HSA derivatives (50 
and 100 µg/ml). Glo1 gene expression was quantified in all study groups. The 
levels of Glo1 mRNA showed no change in response to glycated and unglcated 
albumin derivatives  - Table 43. 
 
Table 43: The effect of modified albumin proteins on the Glo1 gene 
expression in hPDLFs in vitro. 
Analyte Control 
Unmodified 
HSA 
control  
(100 μg /ml) 
AGE-HSA 
(50 μg/ml) 
AGE-HSA 
(100 μg/ml) 
GLO1 mRNA 
(normalized to β-actin 
mRNA) 
0.740 ± 
0.006 
0.749 ± 
0.006 
0.735 ± 
0.011 
0.732 ± 
0.018 
 
Control 
Unmodified 
HSA 
control  
(100μg /ml) 
CML-HSA 
(50 μg/ml) 
CML-HSA 
(100 μg/ml) 
GLO1 mRNA 
(normalized to β-actin 
mRNA) 
0.737 ± 
0.006 
0.746 ± 
0.003 
0.735 ± 
0.007 
0.730 ± 
0.024 
Data are mean ± SD, n = 3. 
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3.4 Effect of Glyoxalase 1 inducers on the adhesion and function 
of hPDLFs to collagen and modified collagen in vitro  
3.4.1 The expression of collagen-I, collagen-III and collagen-XII in hPDLFs 
cells in vitro 
Primary hPDLFs were cultured for 3 days in 8 mM glucose and 25 mM 
glucose supplemented with or without tRSV (10 µM). Expression of collagen-I, 
collagen-III and collagen-XII genes (COL1, COL3 and COL12) was measured by 
RT-PCR in hPDLFs cells. The expression of COL1 was decreased significantly in 
high glucose treatment by 11% (P<0.05) compared to low glucose and trans-
resveratrol (10 µM) corrected the decrease - Figure 68. tRSV supplementation 
increased the expression of COL1 by 12% (P<0.01) and the expression of COL3 
and COL12 by 5% (P<0.001) in high glucose treated hPDLFs with respect to 
controls - Table 44. 
 
Table 44: The effect of trans-resveratrol and high glucose on collagen gene 
expression in hPDLFs in vitro. 
 
COL1 mRNA COL3 mRNA COL12 mRNA 
LG  0.799 ± 0.007 1.19 ± 0.008 1.44 ± 0.014 
LG + tRSV  0.787 ± 0.021 1.21 ± 0.012* 1.45 ± 0.016 
HG  0.714 ± 0.054* 1.20 ± 0.014 1.46 ± 0.020 
HG + tRSV  0.814 ± 0.007*,# ,o 1.26 ± 0.013***,ooo 1.54 ± 0.038**,oo 
Data are mean ± SD, n = 4. Significance: *, **, and ***, P<0.05, P<0.01 and 
P<0.001 with respect to low glucose control; oo and ooo, P<0.01 and P<0.001 with 
respect to high glucose control; # P<0.05 with respect to low glucose with tRSV 
(t-test). 
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Figure 68: The effect of trans-resveratrol and high glucose on collagen genes 
expression in hPDLFs in vitro.  
(A) COL1 expression, (B) COL3 expression and (C) COL12 expression. Data are 
mean ± SD, n = 4. Significance: *, **, and ***, P<0.05, P<0.01 and P<0.001 with 
respect to low glucose control; oo and ooo, P<0.01 and P<0.001 with respect to high 
glucose control; # P<0.05 with respect to low glucose with tRSV (t-test). 
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3.4.2 Effect of glyoxalase 1 inducers on the adhesion efficiency of hPDLFs 
to collagen-I in vitro 
Cell adhesion assay was performed on previously treated hPDLFs which 
were cultured for 3 days in MEM with low glucose and high glucose with or 
without tRSV, HSP and tRSV+HSP (10 µM). The ability of hPDLFs adhesion to 
ECM collagen-I was assessed.  
When hPDLFs  were incubated in high glucose concentration, there was a 
ca. 30% decrease in adhesion of the cells to collagen, compared to low glucose 
concentration control (P<0.05). Glo1 inducers both individually, tRSV and HSP, 
and in combination, tRSV+HSP, increased adhesion of hPDLFs to collagen-I by 
ca. 52%, 40% and 57%, respectively, when incubated in the low glucose 
concentration conditions (P<0.05). In high glucose concentration, Glo1 inducers 
increased the adhesion to Collagen-I ca. 3-fold, compared to high glucose control 
and 2-fold compared to low glucose control – Figure 69.   
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Figure 69: Effect of glyoxalase 1 inducer on the adhesion efficiency of hPDLFs to collagen-I in vitro.  
Data are mean ± SD, n = 3. Significance: * and **, P<0.05 and P<0.01, respectively, compared to low glucose control; ooo, P<0.001 
compared to high glucose control (t-test).  
 
0.00
0.04
0.08
0.12
0.16
0.20
LG LG+tRSV LG+HSP LG+tRSV-HSP HG HG+tRSV HG+HSP HG+tRSV-HSP
A
b
s
o
rb
a
n
c
e
 a
t 
5
9
5
n
m
*
*
*
*
**
**ooo
ooo
**
ooo
  
258 
 
 
3.4.3 Effect of glyoxalase 1 inducers on the adhesion efficiency of hPDLFs 
to collagen-I modified by conditioned media in vitro 
Culture medium from PDLFs incubated with and without tRSV, HSP and 
tRSV+HSP for 3 days was collected. This was incubated with and without 500 
µM aminoguanidine (AG) for 3 h in 37 ᴼC to scavenge dicarbonyls with AG. 
Collagen-I coated plates were incubated with the conditioned media for 24 h and 
adhesion of hPDLFs to the collagen-I was studied. 
The results of incubating cells on to pre-conditioned collagen coated plates 
gave similar trend in adhesion as found in the section above. The only difference 
was that the level of attachment to collagen was lower in all study groups when 
preconditioned with media without AG. The cell adhesion was decreased ca. 60% 
to collagen incubated with high glucose medium without AG compared to with 
AG (P<0.01). Glyoxalase 1 inducers alone or in combination (tRSV, HSP and 
tRSV+HSP) increased the attachment of hPDLFs to collagen-I by ca. 30% in low 
glucose groups (P<0.05). In high glucose concentration, the attachment capability 
increased more than 2-fold with the addition of the Glo1 inducers with respect to 
high glucose control - Figure 70 and 71. Table 45 shows the difference in 
attachment level of hPDLFs to the preconditioned collagen with or without 
aminoguanidine (AG, 500µM). 
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Figure 70: Effect of glyoxalase 1 inducer on the adhesion efficiency of hPDLFs to modified collagen-I in vitro.  
Data are mean ± SD, n = 3. Significance: *and **, P<0.05 and P<0.01, respectively, compared to low glucose control; oo and ooo, P<0.01 
and P<0.001, respectively, compared to high glucose control (t-test). 
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Figure 71: Effect of glyoxalase 1 inducer on the adhesion efficiency of hPDLFs to modified collagen-1 incubated with 
aminoguanidine in vitro.  
Data are mean ± SD, n = 3. Significance: * and **, P<0.05 and P<0.01, respectively, compared to low glucose control without AG; ##, 
P<0.01 with respect to low glucose with AG; o and ooo, P<0.05 and P<0.001, respectively, compared to high glucose control without AG; 
¤¤, P<0.01 with respect to high glucose with AG;^^^, P<0.001 with respect to high glucose with tRSV (t-test). Key: LG, low glucose (8 
mM); HG, high glucose (25 mM); tRSV, trans-resveratrol (10 µM); HSP, Hesperetin (10 µM) and tRSV+HSP, HSP in combination 
with tRSV (10 µM); AG, aminoguanidine (500 µM). 
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Table 45: The difference in attachment level of hPDLFs to the 
preconditioned collagen with or without aminoguanidine 
 Adhesion of  hPDLFs to the preconditioned collagen 
Conditions Media Media + AG P.Value 
LG 0.062 ± 0.008 0.081 ± 0.006 <0.05 
LG+tRSV 0.085 ± 0.008 0.127 ± 0.013 <0.01 
LG+HSP 0.086 ± 0.009 0.139 ± 0.012 <0.01 
LG(tRSV+HSP) 0.098 ± 0.012 0.129 ± 0.011 <0.05 
HG 0.035 ± 0.003 0.082 ± 0.003 <0.001 
HG+tRSV 0.080 ± 0.011 0.103 ± 0.005 <0.05 
HG+HSP 0.100 ± 0.010 0.140 ± 0.018 <0.05 
HG(tRSV+HSP) 0.104 ± 0.019 0.144 ± 0.012 <0.05 
Data are mean ± SD, n = 3.  
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3.5 Study of the Glo1 protein acetylation in hPDLFs in vitro 
The prevention of decline of Glo1 in hPDLFs incubated in high glucose 
concentration by tRSV may be related to the activation of sirtuins by tRSV and 
prevention of acetylation of Glo1. Acetylation of human Glo1 at K148 is known 
(Lundby et al., 2012) and this likely undergoes de-acetylation by cytosolic sirtuin-
2 (Rauh et al., 2013). tRSV may activate both SIRT1 and SIRT2 in situ through 
increased provision of NAD+ cofactor (Guarente, 2013). Our latest research 
indicates that cell dysfunction driven by high glucose involves decreased Glo1 
protein and activity driven by acetylation-activated ubiquitination and proteolysis 
(Thornalley et al., 2014). 
I hypothesised that the effect of tRSV on Glo1 to counter dicarbonyl stress 
in hPDLFs, therefore, is likely stabilisation of Glo1 protein to degradation, 
probably by suppressing acetylation-linked ubiquitination. In order to test this 
hypothesis, acetylation of Glo1 protein by immunoblotting, SIRT1 and SIRT2 
protein level and mRNA expression were examined in hPDLFs, which were 
incubated in low and high glucose concentrations with or without tRSV (10 μM) 
for three days. In addition, I determined the effect of inhibitors of deacetylases on 
Glo1 activity in hPDLFs. The half life of Glo1 protin is 60 h (Xue et al., 2012a)., 
therefore incubating the hPDLFs for 72 h is reasonable time to detect any change 
in Glo1 activity by acetylation or deacetylation. 
 
3.5.1 Effect of low and high glucose on Glo1 acetylation in vitro 
Primary hPDL fibroblasts were incubated with MEM containing low 
glucose and high glucose with or without tRSV (10 μM) for three days. Glo1 
protein was precipitated by Dynabeads as described in the method section. The 
pulled down Glo1 was blotted and the acetylation was determined and normalized 
by Glo1 level – Figure 72. There was no change in the acetylation through all 
samples under any condition. 
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Figure 72: the effect of trans-resveratrol and high glucose on Glo1 acetylation 
in vitro. 
Glo1 protein was precipitated by Dynabeads. The pulled down Glo1 was blotted 
and the acetylation was determined and normalized by Glo1 level. Kys: LG, low 
glucose (8 mM); HG, high glucose (25 mM); tRSV, trans-resveratrol (10 µM); Ab 
HC, antibody high chain; Ab LC, antibody low chain. 
 
3.5.2 The effect of inhibitors of deacetylases compound and high glucose on 
hPDLFs in vitro 
3.5.2.1 The viability of hPDLFs treated with different concentrations of 
acetylation compound (Trichostatin A, TSA) in vitro 
Primary hPDLFs were treated for 48 hours with or without 100, 150, 200 
and 300 nM TSA. After 48 h the viable cell number was counted. The viable cell 
number increased throughout the culture period and show a steady increase in all 
the groups with no significant change in the viability with any concentration. 
However, there is a tendency of decrease in the viability when the concentration 
increase. The cell viability response for hPDLFs in vitro is shown in Figure 73. A 
growth curve of hPDLFs with and without 300 nM TSA was studied over 4 days 
in LG and HG.  
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Figure 73: The TSA concentration – cell viability response for hPDLFs in 
vitro.  
Data are mean ± SD (n = 3).  
 
3.5.2.2 Time course curve for hPDLFs treated with 300 nm trichostatin A 
in vitro 
Primary hPDLFs were treated for four days with (300 nm) trichostatin A. 
TSA causes no significant changes in the growth of the cells. After 24 hours, the 
growth of treated hPDLFs was stable compared with the control group. In day 
three and four, the growth started to decline by 10% compare to the controls but 
this was not significant - Figure 74. 
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Figure 74: The viable cell number of treated and untreated hPDLFs with 300 
nM of TSA over four days in vitro.  
Key:       , 8 mM glucose;        , 25 mM glucose;       , 8 mM glucose + 300 nM 
TSA and       , 25 mM glucose + 300 nM  TSA. Data are mean ± SD (n = 3). 
 
3.5.3 The effect of inhibitors of deacetylases and high glucose on hPDLFs in 
vitro 
3.5.3.1 The viability of hPDLFs treated with different concentrations of 
sirtuin 1&2 inhibitors in vitro 
Sirt 1 inhibitor (EX-527) 
Primary hPDLFs were incubated with and without 10 - 1000 nM EX-527 
for 48 h and cell growth and viability assessed. At ≥ 100 nM EX-527 there was a 
decrease in PDLFs viable cell number and cell viability. This suggested that with 
addition of exogenous EX-527 of progressively increased concentration, there is 
initially growth arrest of hPDLFs and both growth arrest and cytotoxicity at ≥ 100 
nM EX-527. The EX-527 concentration – cell growth response curve is shown in 
Figure 75 and the EX-527 concentration – cell viability response is given in 
Figure 76. From this the median growth inhibitory concentration GC50 value of 
EX-527 was 364 ± 38 nM and n, the logistic regression coefficient (also known as 
the Hill coefficient) was 2.04 ± 0.36. A growth curve of hPDLFs with and without 
100 nM EX-527 was studied over 4 days in LG and HG. 
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Figure 75: The EX-527 concentration – cell growth response curve for 
hPDLFs in vitro.  
Data were fitted to the EX-527 concentration - response equation and solved for 
GC50 and n by non-linear regression. GC50 = 364 ± 38 nM, n = 2.04 ± 0.36 (N = 
21).  
 
 
 
Figure 76: The EX-527 concentration – cell viability response for hPDLFs in 
vitro.  
Data are mean ± SD (n = 3). Significant: *, P<0.05, **, P<0.01 and ***, P<0.001; 
t-test. 
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Sirt 2 inhibitor (AGK-2) 
Primary hPDLFs were incubated with and without 0.5 - 20 µM AGK-2 for 
48 h and cell growth and viability assessed. At ≥ 4 µM AGK-2 there was a 
decrease in PDLFs viable cell number and ≥ 8 µM AGK-2 there was decrease in 
cell viability. This suggested that with addition of exogenous AGK-2 of 
progressively increased concentration, there is initially growth arrest of hPDLFs 
and both growth arrest and cytotoxicity at ≥ 8 µM AGK-2. The AGK-2 
concentration – cell growth response curve is shown in Figure 77 and the AGK-2 
concentration – cell viability response is given in Figure 78. From this the median 
growth inhibitory concentration GC50 value of AGK-2 was 7.21 ± 0.38 µM and n, 
the logistic regression coefficient (also known as the Hill coefficient) was 2.24 ± 
0.26. A growth curve of hPDLFs with and without 4 µM AGK-2 was studied over 
4 days in LG and HG. 
 
 
Figure 77: The AGK-2 concentration – cell growth response curve for 
hPDLFs in vitro.  
Data were fitted to the EX-527 concentration - response equation and solved for 
GC50 and n by non-linear regression. GC50 = 7.21 ± 0.38 µM, n = 2.24 ± 0.26 (N 
= 24).  
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Figure 78: The AGK-2 concentration – cell viability response for hPDLFs in 
vitro.  
Data are mean ± SD (n = 3). Significant: *, P<0.05 and ***, P<0.001; t-test. 
 
3.5.3.2 Time course curve for hPDLFs treated sirtuin 1&2 inhibitors in 
vitro 
Sirtuin 1 inhibitors EX-527 
Primary hPDLFs were treated for 4 days with (100 nM) EX-527. EX-527 
causes a no significant changes in the growth of the cells. After 24 hours, the 
growth of treated hPDLFs was stable compared with the control group. In day 
four the growth started to decline by ca. 15% compare to the controls but this was 
not significant - Figures 79. 
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Figure 79: The viable cell number of treated and untreated hPDLFs with 100 
nM of EX-527 over four days in vitro.  
Key:       , 8 mM glucose;        , 25 mM glucose;       , 8 mM glucose + 100 nM of 
EX-527 and       ,25 mM glucose + 100 nM of EX-527. Data are mean ± SD (n = 
3). 
 
Sirtuin 2 inhibitors AGK-2 
Primary hPDLFs were treated for four days with (4 µM) AGK-2. AGK-2 
causes a no significant inhibition in the growth of the cells. The growth of treated 
hPDLFs was stable compared with the controls over 4 days of incubation with 4 
µM AGK-2 – Figure 80.  
 
 
Figure 80: The viable cell number of treated and untreated hPDLFs with 4 
µM of AGK-2 over four days in vitro.  
Key:       , 8 mM glucose; :       , 25 mM glucose;       , 8 mM glucose + 4 µM of 
AGK-2 and       , 25 mM glucose + 4 µM of AGK-2. Data are mean ± SD (n = 3). 
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3.5.4 Effect of acetylation and deacetylation compound on glyoxalase 1 
activity and gene expression in hPDLFs in vitro 
No changes were found in SIRT1 and SIRT2 mRNA and protein levels in 
hPDLFs incubated in high glucose concentration, with respect to low glucose 
concentration control, and no effects of added tRSV – Table 46. Furthermore, the 
deacetylase and SIRT inhibitors had no effect on Glo1 activity and mRNA 
expression level in hPDLFs incubated in low and high glucose – Table 47, 48 and 
49. 
 
Table 46: the effect of trans-resveratrol and high glucose on SIRT1 and 
SIRT2 genes expression in hPDLFs in vitro. 
Analyte  
SIRT1 mRNA  
(normalized to β-actin mRNA) 
SIRT2 mRNA (normalized 
to β-actin mRNA) 
LG 0.653 ± 0.009 0.587 ± 0.032 
LG+tRSV 0.642 ± 0.026 0.584 ± 0.010 
HG 0.645 ± 0.012 0.586 ± 0.014 
HG+tRSV 0.647 ± 0.013 0.602 ± 0.020 
Data are mean ± SD, n = 4.  
 
Table 47: Effect of TSA on glyoxalase 1 activity and gene expression in 
hPDLFs in vitro. 
Analyte  
Glo1 activity  
(mU/mg protein) 
GLO1 mRNA 
 (normalized to β-actin mRNA) 
LG 914 ± 50 1.25 ± 0.002 
LG + (TSA, 300 nM) 826 ± 87 1.27 ± 0.015 
HG 538 ± 72** 1.27 ± 0.014 
HG + (TSA, 300 nM) 484 ± 33** 1.27 ± 0.014 
Data are mean ± SD, n = 4. Significance: **, P<0.01 (t-test) with respect to low 
glucose control.  
 
Table 48: Effect of sirtuin 1 inhibitor on glyoxalase 1 activity and expression 
in hPDLFs in vitro 
Data are mean ± SD, n = 4. Significance: ***, P<0.001 with respect to low 
glucose control (t-test).  
Analyte  
Glo1 activity 
(mU/mg protein) 
GLO1 mRNA  
(normalized to β-actin mRNA) 
LG 920 ± 60 1.24 ± 0.021 
LG + (EX-527, 100 nM) 817 ± 42 1.24 ± 0.013 
HG 529 ± 39** 1.24 ± 0.035 
HG + (EX-527, 100 nM) 466 ± 52** 1.22 ± 0.035 
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Table 49: Effect of sirtuin 2 inhibitor on glyoxalase 1 activity and expression 
in hPDLFs in vitro 
Data are mean ± SD, n = 4. Significance: **, P<0.01 with respect to low glucose 
control (t-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte  
Glo1 activity 
(mU/mg protein) 
GLO1 mRNA  
(normalized to β-actin mRNA) 
LG 989 ± 47 1.24 ± 0.021 
LG + (AGK-2, 4 µM) 858 ± 88 1.24 ± 0.002 
HG 531 ± 75** 1.24 ± 0.009 
HG + (AGK-2, 4 µM) 475 ± 46** 1.24 ± 0.009 
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3.6 Studying the modification of cytosolic proteins in hPDLFs: high mass 
resolution proteomics analysis 
Primary hPDLFs cells were cultured in low and high glucose in triplicate 
for 3 days. Cytosolic protein was subjected to trypsin and tryptic peptides were 
analysed in high resolution mass spectrometer Orbitrap for identification of the 
protein and the changes occurring to the proteome in high glucose concentration. 
Reproducibility of the biological replicates was examined and found high 
correlation within the low and high glucose groups. In this study two proteomic 
software programmes were used to analyse and quantify proteomics data. 
1. Scaffold 
This is a bioinformatics tool for validation of proteomics data. The 
scaffold analysis workflow combines several peptides and protein validation 
methods after an initial data-base search engine analysis using MASCOT and 
SEQUEST. The search engine analyses peptide molecular ion and fragment ion 
series spectra to produce probability scores of peptide and protein identification 
(Searle, 2010). The total identified proteins by Scaffold in all 3 replicates of 
hPDLFs cultures in low and high glucose are given in Figure 81A. Mascot 
searches based on MS2 data is required to identify peptides and protein in 
Scaffold. This analysis cannot quantify peptide ion responses and related amounts 
of peptides and proteins in the samples. 
2. Progenesis 
This is a second software programme used in this study to quantify 
peptides and proteins that requires both MS1 and MS2 data. Progenesis is a simple 
and more popular software for label free quantification compare to MaxQuant 
software. Non-conflicting peptides were used for label-free quantification in 
Progenesis. A total of 1105 cytosolic protein were quantified and identified in 
hPDLFs. There are 1077 proteins were found in the cytosol of hPDLFs in both 
low and high glucose concentration conditions - Figure 81B. The spectra of 16 
proteins were found only in low glucose and 12 proteins only in high glucose 
culture of hPDLFs suggesting a relatively low abundance of these proteins in low 
and high glucose cultures – Figure 81.      
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Figure 81: Proteome analysis of hPDLFs cell lysate cultured in low and high glucose.  
Cell lysate (triplicate) from low and high glucose culture was digested, each sample was analysed by LCMS on Orbitrap. (A) Number of 
protein identification (in Scaffold) without match between runs (yellow) and with match between runs option (red and blue). (B) Total 
proteome identified and quantified in Progenesis. (C)3D and (D)1D image of a peptide of GAPDH. The peptide sequence of GAPDH is 
IISAPSADAPMFVMGVNHEK. Data are mean ± SD, n = 3. Blue colour indicates low glucose and red colour indicates high glucose  
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A specimen of 3D and 1D image of a peptide of GAPDH -
VIISAPSADAPMFVMGVNHEK - found in low and high glucose conditions is 
given in Figure 81. The cluster of all identified proteins in two conditions is 
shown in Figure 82. 
The level of ca. 39 of 1077 proteins identified in low and high glucose 
concentration conditions were changed significantly: 18 proteins in hPDLFs 
cytosol were up regulated in high glucose - including Putative 
adenosylhomocysteinase involved in 143 molecular and biological pathways 
identified using Reactome.org for ontology analysis. This protein is also involved 
in many signalling pathways e.g. signalling by VEGF and FGFR1- 4, innate 
immunity system, muscle contraction and regulation of insulin signalling. Other 
protein like Hexokinase was expected to be up regulated in high glucose because 
of its roles in glycolysis, glucose transport and metabolism, regulation of gene 
expression in beta cells and beta cells development etc. Twenty one proteins were 
down regulated in hPDLFs cell lysate from cells incubated in high glucose 
concentration. Only 13 proteins were identified by the Reactome pathway analysis 
programme and placed these proteins in 116 pathways. HMGB1, involved in 
inflammation, was found to be decreased in the hPDLFs cell lysate when cultured 
in high glucose concentration. A list of the down- regulated and up-regulated 
proteins is given in Table 50.  
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Figure 82: Protein cluster.    
(A) All identified proteins in two conditions (B) 39 protein change significantly in low and high glucose. (C) down and (C) up regulated 
in HG. Blue colour indicates low glucose and red colour indicates high glucose.  
C. 
A. B. 
D. 
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Table 50: Cytosolic proteins down and up regulated significantly in hPDLFs incubated in high glucose concentration.  
Protein 
accession 
numbers 
Protein name 
Gene 
accession 
numbers 
Log 2 
(change) 
Unique 
peptide 
Percentage 
sequence 
coverage 
Anova 
(p) 
CND1 Condensin complex subunit 1  NCAPD2  2 5.4% 0.016 
Q99707 Methionine synthase  MTR   2 2.5% 0.016 
P43034 Platelet-activating factor acetylhydrolase IB subunit alpha  PAFAH1B1  5 32.2% 0.000 
Q12797 Aspartyl/asparaginyl beta-hydroxylase  ASPH  1 2.4% 0.027 
A8MTY9 Down syndrome critical region protein 3  DSCR3  2  0.033 
Q32Q12 Nucleoside diphosphate kinase  NME1-NME2    2 30.7% 0.036 
HMGB1 High mobility group protein B1  HMGB1  4 26.5% 0.023 
O14617 Isoform 5 of AP-3 complex subunit delta- AP3D1  7 10.1% 0.046 
I3L459 Phosphatidylinositol transfer protein alpha isoform  PITPNA  1 29.6% 0.050 
ARC1B Actin-related protein 2/3 complex subunit 1B  ARPC1B  6 32.8% 0.021 
Q9BRP8-2 Isoform 2 of Partner of Y14 and mago  WIBG  2 25.0% 0.014 
Q96HC4 PDZ and LIM domain protein 5    PDLIM5  6 15.9% 0.027 
O95816 BAG family molecular chaperone regulator 2  BAG2  3 33.6% 0.021 
Q9H3H3-2 Isoform 2 of UPF0696 protein C11orf68  C11orf68  2 14.4% 0.036 
HOOK3 Protein Hook homolog 3  HOOK3  4 10.3% 0.046 
C9J0J7 Profilin-2   PFN2  2 49.5% 0.041 
Q9UHD8-2 Isoform 2 of Septin-9   SEPT9  19  0.048 
Q9NUQ8-2 Isoform 2 of ATP-binding cassette sub-family F member 3 ABCF3  2 5.4% 0.044 
P63241-2 Isoform 2 of Eukaryotic translation initiation factor 5A-1  EIF5A  11 32.1% 0.017 
COMD8 COMM domain-containing protein 8  COMMD8  2 8.2% 0.012 
MOES Moesin  MSN  25 40.6% 0.012 
A0A087X0S5 Collagen alpha-1(VI) chain  COL6A1  20 28.5% 0.017 
LYPA2 Acyl-protein thioesterase 2  LYPLA2  2 22.1% 0.033 
E5RIH5 TELO2-interacting protein 2  TTI2  2 4.4% 0.019 
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P98082-3 Isoform 3 of Disabled homolog 2  DAB2  4  0.048 
O43865 Putative adenosylhomocysteinase 2  AHCYL1  2 11.7% 0.040 
Q14240-2 Isoform 2 of Eukaryotic initiation factor 4A-II  EIF4A2  6 34.6% 0.017 
TBL1R F-box-like/WD repeat-containing protein TBL1XR1  TBL1XR1  4 15.4% 0.012 
Q05519-2 Isoform 2 of Serine/arginine-rich splicing factor 11  SRSF11  2 6.0% 0.036 
G3XAI2 Laminin subunit beta-1  LAMB1  3 3.5% 0.033 
Q14697-2 Isoform 2 of Neutral alpha-glucosidase AB  GANAB  3 36.1% 0.030 
Q9UMX0 Ubiquilin-1  UBQLN1  2 14.1% 0.031 
E9PB90 Hexokinase  HK2  2 3.4% 0.024 
O15085-2 Isoform 2 of Rho guanine nucleotide exchange factor 11  ARHGEF11  2  0.043 
A0A087X0I4 Coatomer subunit epsilon  COPE  3 48.2% 0.034 
P38117-2 Isoform 2 of Electron transfer flavoprotein subunit beta  ETFB  2 25.5% 0.026 
Q96BJ3 Axin interactor, dorsalization-associated protein  AIDA  2 17.6% 0.027 
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1  HUWE1  4 9.2% 0.026 
ABCE1 ATP-binding cassette sub-family E member 1 ABCE1  2 19.0% 0.012 
Data are mean ± SD, n = 3.        Down regulated proteins           upregulated proteins. 
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Sixteen proteins were found only in hPDLFs in low glucose incubations – 
Table 51. One of these proteins is isoform 2 of glycogen synthase kinase-3 beta 
which is involved in many molecular functions. It contributes to NF-κB binding 
and p53 binding which function as dimeric transcription factors that regulate the 
expression of genes influencing a broad range of biological processes including 
innate and adaptive immunity, inflammation, stress responses, B-cell 
development, and lymphoid organogenesis (Perkins, 2006). In addition, aldehyde 
dehydrogenase, dimeric NADP-preferring is found in low glucose incubation. It 
catalyzes oxidation-reduction (redox) reaction in which an aldehyde or ketone 
(oxo) group acts as a hydrogen or electron donor and reduces NAD or NADP (Ko 
et al., 2012). 
On the other hand, twelve proteins were detected uniquely in hPDLFs 
incubated in high glucose – Table 52. Isoform 3 of E3 ubiquitin-protein ligase is 
one of the identified proteins and it involves in NF-κB signaling pathway. As it 
mentioned previously, NF-κB signaling pathway influences a broad range of 
biological processes. In addition, isoform 5 of glycogen debranching enzyme was 
detected in high glucose incubation. It has a role in glucose metabolism and 
glycogen breakdown. 
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Table 51: Proteins detected in cytosolic extracts of hPDLFs only when incubated in low glucose concentration. 
Protein 
accession 
numbers 
Protein name 
Gene 
accession 
numbers 
GO: molecular function 
O15085-2 
Isoform 2 of Rho guanine 
nucleotide exchange factor 11   
ARHGEF11  
G-protein coupled receptor binding, GTPase activator activity and Rho 
guanyl-nucleotide exchange factor activity 
H0YBD7 
Heterogeneous nuclear 
ribonucleoprotein H  
HNRNPH1 Nucleic acid binding and nucleotide binding 
Q9UKV8-2 
Isoform 2 of Protein 
argonaute-2  
AGO2 
Core promoter binding, double-stranded RNA binding, endoribonuclease 
activity, endoribonuclease activity, cleaving miRNA-paired mRNA, 
endoribonuclease activity, cleaving siRNA-paired mRNA, metal ion 
binding, miRNA binding, mRNA binding, poly(A) RNA binding, 
protein C-terminus binding, RNA 7-methylguanosine cap binding, RNA 
polymerase II core binding, single-stranded RNA binding, siRNA 
binding and translation initiation factor activity 
Q5SSJ5 
Heterochromatin protein 1-
binding protein 3 
HP1BP3 DNA binding and nucleosome binding 
Q99879 Histone H2B type 1-M HIST1H2BM DNA binding 
P61764-2 
Isoform 2 of Syntaxin-binding 
protein 1  
STXBP1  
Identical protein binding, poly(A) RNA binding, SNARE binding, 
syntaxin-1 binding and syntaxin binding 
E9PNN6 
Aldehyde dehydrogenase, 
dimeric NADP-preferring 
ALDH3A1 3-chloroallyl aldehyde dehydrogenase activity 
A0A0A0MRM8 Unconventional myosin-VI  MYO6 ATP binding and motor activity 
A0A087WWE2 
DNA-directed RNA 
polymerase  
POLR2A Core promoter binding and DNA-directed RNA polymerase activity 
K7EMW4 Nicalin  NCLN 
Protein destabilization, regulation of protein complex assembly and 
regulation of signal transduction 
O94992 Protein HEXIM1 HEXIM1 7SK snRNA binding, cyclin-dependent protein serine/threonine kinase 
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inhibitor activity and snRNA binding 
O15344-2 
Isoform 2 of E3 ubiquitin-
protein ligase Midline-1  
MID1 
Identical protein binding, ligase activity, microtubule binding, 
phosphoprotein binding, protein heterodimerization activity, protein 
homodimerization activity, ubiquitin protein ligase binding and zinc ion 
binding 
C9JEJ2 
Choline-phosphate 
cytidylyltransferase A 
PCYT1A Catalytic activity 
Q5JSL3 
Dedicator of cytokinesis 
protein 11  
DOCK11 Rho guanyl-nucleotide exchange factor activity 
A0A087WWM0 
Trafficking protein particle 
complex subunit 3  
TRAPPC3 ER to Golgi vesicle-mediated transport 
P49841-2 
Isoform 2 of Glycogen 
synthase kinase-3 beta  
GSK3B 
ATP binding, beta-catenin binding, kinase activity, NF-κB binding, p53 
binding, protein kinase A catalytic subunit binding, protein kinase 
binding, protein serine/threonine kinase activity, RNA polymerase II 
transcription factor binding, au-protein kinase activity and ubiquitin 
protein ligase binding 
Data are mean ± SD, n = 3.
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Table 52: Proteins detected in cytosolic extracts of hPDLFs only when incubated in high glucose concentration.  
Protein 
accession 
numbers 
Protein name 
Gene 
accession 
numbers 
GO: molecular function 
Q05519-2 
Isoform 2 of Serine/arginine-rich splicing 
factor 11 
SRS11 
RNA splicing, Transport of Mature Transcript to 
Cytoplasm etc 
A0A0C4DGQ5 Calpain small subunit 1  CAPNS1 Ca2+ binding, Proteolysis 
E7EMW7 
 
E3 ubiquitin-protein ligase UBR5  
 
UBR5 
Ligase, Ubl conjugation pathway, Ubiquitin-protein 
transferase activity 
Q96EP0-3 Isoform 3 of E3 ubiquitin-protein ligase  RNF31 
TNFR1-induced NFκB signalling pathway death Receptor 
Signalling, Regulation of TNFR1 signalling 
P35222  Catenin beta-1  CTNNB1 
Cell-cell communication, developmental biology, disease, 
immune system, metabolism of proteins and signal 
transduction, apoptosis etc. 
Q9NS86 LanC-like protein 2  LANCL2 
ATP binding, catalytic activity, Positive regulation of 
absciasic acid activated signalling etc. 
P33991 DNA replication licensing factor MCM4 MCM4 Cell cycle and DNA replication 
P35573-2  Isoform 5 of Glycogen debranching enzyme  AGL Glucose metabolism, Glycogen breakdown  
P23634-6 
Isoform XB of Plasma membrane calcium-
transporting ATPase 4  
ATP2B4 
Platelet calcium homeostasis, Platelet and ion 
homeostasis,  Cardiac conduction, etc 
Q52LW3  Rho GTPase-activating protein 29  ARHGAP29 Signal transduction,  Rho GTPase cycle 
Q9NQZ2 Something about silencing protein 10  UTP3 Chromatin regulator, Developmental protein 
P49750-4 Isoform 4 of YLP motif-containing protein 1 YLPM1 Repressor, transcription, transcription regulation 
Data are mean ± SD, n = 3.
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Thirty proteins were found modified in hPDLFs. Ten of these proteins 
were found modified in hPDLFs in low glucose incubation and twenty proteins 
were detected in high glucose incubations – Table 53 and 54. A total of 173 
proteins were modified by MG-H1 were detected in the positive control, where 
hPDLFs cell lysate incubated with MG – Table 55. Vimentin protein is found 
modified in the positive control, low incubation and high incubation. There are 
two other proteins found modified in positive control and in high incubation 
includes the following; isoform SV of 14-3-3 protein epsilon and actin 
cytoplasmic 2. Isoform SV of 14-3-3 protein epsilon was modified by CEL in 
peptide k3. Actin cytoplasmic 2 protein share the same modified peptide (r21) 
with the positive control. This protein involves in the following biological 
process: ATP binding, protein binding, structural constituent of cytoskeleton and 
ubiquitin protein ligase binding. There is one protein was modified by MG-H1 in 
low and high incubation which is echinoderm microtubule-associated protein-like 
1. 
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Table 53: Modified proteins in cytosolic extracts of hPDLFs incubated in low glucose concentration.  
Protein 
accession 
numbers 
Protein name 
Gene 
accession 
numbers 
Percentage 
sequence 
coverage 
Variable modifications 
identified by spectrum 
P62310  U6 snRNA-associated Sm-like protein LSm3  LSM3 20.6% MG-H1:r1 
E9PEB9 Dystonin  DST 4.79% MG-H1:r9 
Q6UXN9 WD repeat-containing protein 82  WDR82  8.95% MG-H1:r8 
P08670 Vimentin VIM 62.7% FL:k1 and k2 
Q9P2R6 Arginine-glutamic acid dipeptide repeats protein RERE 3.00% MG-H1:r16, r7 and FL:k5 
F8W717 Echinoderm microtubule-associated protein-like 1  EML1  4.73% MG-H1:r12 
P19525 Interferon-induced, double-stranded RNA-activated protein kinase  EIF2AK2 9.07% FL:k10 and k11 
P23921 Ribonucleoside-diphosphate reductase large subunit RRM1 10.4% FL:k8 
Q5SW96 Low density lipoprotein receptor adapter protein 1  LDLRAP1 8.77% MG-H1:r13 
Q8IVF2 Protein AHNAK2  AHNAK2 0.86% MG-H1:r11 
Data are mean ± SD, n = 3
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Table 54: Modified proteins in cytosolic extracts of hPDLFs incubated in high glucose concentration.  
Protein 
accession 
numbers 
Protein name 
Gene 
accession 
numbers 
Percentage 
sequence 
coverage 
Variable modifications 
identified by spectrum 
Q04446  1,4-alpha-glucan-branching enzyme GBE1 27.8% CML:K9 
Q60FE5 Filamin A  FLNA  45.0% CML:k13 and  MG-H1:r8 
Q2TAL8 Glutamine-rich protein 1  QRICH1 3.35% MG-H1:r5 
Q01780-2 Isoform 2 of Exosome component 10 EXOSC10 3.60% FL:k6 
Q96KG9-2 Isoform 2 of N-terminal kinase-like protein  SCYL1 8.22% CML:k3, k9 and r8 
P35659-2 Isoform 2 of Protein DEK  DEK 14.4% CEL:k21 
P08237 Isoform 3 of ATP-dependent 6-phosphofructokinase, muscle type  PFKM 16.2% FL:k7 
P62258-2 Isoform SV of 14-3-3 protein epsilon YWHAE 64.4% CEL:k3 
E7EVA0 Microtubule-associated protein  MAP4  14.7% CEL:k8 
P27816 Microtubule-associated protein 4  MAP4 33.1% CEL:k8 
A0A0A0MT60 Peptidyl-prolyl cis-trans isomerase FKBP15  7.72% CEL:k11 
Q5TZA2 Rootletin CROCC 0.000% CEL:k6 
P63313 Thymosin beta-10 TMSB10  50.0% CML:k3 
P60709 Actin, cytoplasmic 1  ACTB  64.0% MG-H1:r21 
Q9UL25 Ras-related protein Rab-21  RAB21 22.7% MG-H1:r10  
P23921 Ribonucleoside-diphosphate reductase large subunit  RRM1 7.95% FL:k8 
P08670 Vimentin  VIM 64.2% FL:k1, k4 and k2 
P63261 Actin, cytoplasmic 2  ACTG1  64.0% MG-H1:r21 
F8W717 Echinoderm microtubule-associated protein-like 1  EML1  1.49% MG-H1:r12 
Q9H2D6 TRIO and F-actin-binding protein TRIOBP  1.99% MG-H1:r2, r6 and r10 
Data are mean ± SD, n = 3.
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Table 55: Proteins with MG-H1 residues modification in cytosolic extracts of hPDLFs incubated with exogenous methylglyoxal 
(MG modification positive control).  
Protein 
accession 
numbers 
Protein name 
Gene accession 
numbers 
Percentage 
sequence 
coverage 
RMG-H1  (+54.01) 
identified  
P62857 Ribosomal protein S28  RPS28  46.4%  r11  
P60468 Protein transport protein Sec61 subunit beta  SEC61B 30.2% r28 
P06703 Protein S100-A6  S100A6 88.9% r8, r15, r8 and r15 
P61604 10 kDa heat shock protein, mitochondrial  HSPE1 53.9% r6 and r7 
P60903 Protein S100-A10  S100A10 76.3% r4 
Q15836 Vesicle-associated membrane protein 3  VAMP3 24.0% r7 
Q99584 Protein S100-A13  S100A13 25.5% r6 
P05387 60S acidic ribosomal protein P2   RPLP2  93.0% r13 
P31949 Protein S100-A11  S100A11 85.7% r7 and r9 
P09382 Galectin-1  LGALS1  82.2% r10, r12 and r4 
P07737 Profilin-1  PFN1 35.0% r14 
P08708 40S ribosomal protein S17  RPS17 17.0% r1 
Q14019 Coactosin-like protein  COTL1 41.5% r16 
A0A0A0MTI5 Acyl-CoA-binding protein   DBI  32.2% r11 
Q8NI22 Multiple coagulation factor deficiency protein 2  MCFD2 68.5% r24 
P63241 Eukaryotic translation initiation factor 5A-1  EIF5A 50.6% r1 
F5H265 Polyubiquitin-C  UBC  45.0% r9, r11 and r6 
P61088 Ubiquitin-conjugating enzyme E2 N  UBE2N 38.2% r4 
P62937 Peptidyl-prolyl cis-trans isomerase A  PPIA 47.9% r15 
P63208 S-phase kinase-associated protein 1  SKP1 55.8% r1 
P14209 CD99 antigen  CD99 31.9% r14 
P49006 MARCKS-related protein  MARCKSL1  69.2% r3 
A0A087X271 Calponin  CNN2  33.5% r5 
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Q99497 Protein deglycase DJ-1  PARK7 57.1% r7 
P30086 Phosphatidylethanolamine-binding protein 1  PEBP1 61.0% r2 
Q8WZA0 Protein LZIC  LZIC 23.7% r8 
O00264 Membrane-associated progesterone receptor component 1  PGRMC1 57.9% r3 
E7EMB3 Calmodulin  CALM2 47.4% r13 and r44 
P37802 Transgelin-2  TAGLN2 61.8% r9 
Q01995 Transgelin  TAGLN  43.3% r7and r6 
E9PK25 Cofilin-1  CFL1 49.5% r3 
P04792 Heat shock protein beta-1  HSPB1 46.3% r17 
P52565 Rho GDP-dissociation inhibitor 1  ARHGDIA 50.5% r16 
P23284 Peptidyl-prolyl cis-trans isomerase B  PPIB  55.1% r11 and r9 
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3  SH3BGRL3 14.6% r8 
O15173 Membrane-associated progesterone receptor component 2  PGRMC2 34.1% r2 
P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1  UCHL1 44.8%  r18 
P49755 Transmembrane emp24 domain-containing protein 10  TMED10 35.6% r4 
P30041 Peroxiredoxin-6  PRDX6 53.1% r9 
Q8TEA8 D-tyrosyl-tRNA(Tyr) deacylase  DTD1  32.7% r5 
F8W1A4 Adenylate kinase 2, mitochondrial  AK2  41.4% r17 
O00299 Chloride intracellular channel protein 1  CLIC1 56.4% r27 
Q9BVK6 Transmembrane emp24 domain-containing protein 9  TMED9 25.5% r2 
P78417 Glutathione S-transferase omega-1  GSTO1 32.0% r3 
P30048 Thioredoxin-dependent peroxide reductase, mitochondrial  PRDX3 29.7% r4 
P63104 14-3-3 protein zeta/delta YWHAZ 71.0% r5, r6 and r4 
P67936 Tropomyosin alpha-4 chain  TPM4 53.6% r11 
P30040 Endoplasmic reticulum resident protein 29 ERP29 44.4% r1 
P06753-2 Isoform 2 of Tropomyosin alpha-3 chain  TPM3 33.1% r10 
P62258 14-3-3 protein epsilon  YWHAE 62.7%  r10 
B1AK87 Capping protein (Actin filament) muscle Z-line, beta, CAPZB 67.3% r2 
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isoform CRA_a  
P09651-3 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A1  HNRNPA1 50.2% r20, r10 and r1 
P22392-2 Isoform 3 of Nucleoside diphosphate kinase B  NME2 46.1% r2 
O15260 Surfeit locus protein 4 SURF4 7.81% r18 
P21796 Voltage-dependent anion-selective channel protein 1   VDAC1 58.0% r2, and r19 
Q07021 
Complement component 1 Q subcomponent-binding 
protein, mitochondrial  
C1QBP 40.8% r14 
P30084 Enoyl-CoA hydratase, mitochondrial  ECHS1 47.9% r11 
P29966 Myristoylated alanine-rich C-kinase substrate MARCKS 47.6% r7 
P45880 Voltage-dependent anion-selective channel protein 2  VDAC2 47.3% r16 
P06748 Nucleophosmin  NPM1 37.8% r14 
Q9P0L0-2 
Isoform 2 of Vesicle-associated membrane protein-
associated protein A  
VAPA 19.7% r2  
Q99623 Prohibitin-2  PHB2 27.1% r9 
P00387 NADH-cytochrome b5 reductase 3  CYB5R3 45.2% r17 and r19 
P40926 Malate dehydrogenase, mitochondrial  MDH2 52.4% r6 and r7 
P09525 Annexin A4   ANXA4 36.7% r15 and r27 
P08758 Annexin A5  ANXA5 72.5% r3 and r15 
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 66.3% r14 
P07195 L-lactate dehydrogenase B chain LDHB 70.1% r9 and r22 
P00338 L-lactate dehydrogenase A chain  LDHA 63.0% r9 
P51665 26S proteasome non-ATPase regulatory subunit 7 PSMD7 57.1% r17 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1  HNRNPA2B1 37.1% r10 and r16 
Q96D15 Reticulocalbin-3  RCN3 48.5% r13 
P37837 Transaldolase   TALDO1 42.4% r9 
P07355 Annexin A2   ANXA2 65.8%  r24 
P04083 Annexin A1 ANXA1 64.5% r11 and r16 
Q15293 Reticulocalbin-1  RCN1 62.8% r12 and r4 
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B4DY09 Interleukin enhancer-binding factor 2  ILF2 54.0% r23 
P04075 Fructose-bisphosphate aldolase A  ALDOA 66.2% r8 and r1 
B4DFG0 Protein DEK  DEK 15.6% r8 
Q15019 Septin-2  SEPT2 19.9% r14 
P63261 Actin, cytoplasmic 2 ACTG1 83.7% r21 and r13 
Q70UQ0-4 
Isoform 4 of Inhibitor of nuclear factor kappa-B kinase-
interacting protein 
IKBIP 38.7% r1 and r15 
Q6NZI2 Polymerase I and transcript release factor  PTRF 27.2% r18 
Q13561 Dynactin subunit 2 DCTN2 62.8% r15 
P00558 Phosphoglycerate kinase 1 PGK1 63.1% r7, r15 and r10 
E9PBS1 Multifunctional protein ADE2  PAICS 17.2% r12 
P52597 Heterogeneous nuclear ribonucleoprotein F  HNRNPF 21.9% r3 
O60664-4 Isoform 4 of Perilipin-3  PLIN3 36.7% r15 and r14 
G5E972 Lamina-associated polypeptide 2, isoforms beta/gamma  TMPO 18.1% r16 
P05455 Lupus La protein  SSB 29.2% r6 
Q9BS26 Endoplasmic reticulum resident protein 44 ERP44 26.8% r15 and r8 
P06733 Alpha-enolase ENO1 70.5% r4 
Q8NBS9 Thioredoxin domain-containing protein 5  TXNDC5 55.8%  r16 
Q15084 Protein disulfide-isomerase A6 PDIA6 47.7% r11, r24, r10 and r2 
P27797 Calreticulin  CALR 79.1% r13, r9 and r15 
P36957 
Dihydrolipoyllysine-residue succinyltransferase component 
of 2-oxoglutarate dehydrogenase complex, mitochondrial 
DLST 38.9% r11 
P68104 Elongation factor 1-alpha 1  EEF1A1 48.1% r12 
P07954-2 Isoform Cytoplasmic of Fumarate hydratase, mitochondrial FH 45.8% r18 
A0A087WSV8 Nucleobindin 2, isoform CRA_b  NUCB2 41.7% r2 
B4DJV2 Citrate synthase CS 22.7% r2 and r16 
P50395 Rab GDP dissociation inhibitor bet GDI2 54.8% r3 
E9PAM4 Uncharacterized protein E9PAM4 4.55% r1 
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Q01518 Adenylyl cyclase-associated protein 1 CAP1 37.9% r12 
P07099 Epoxide hydrolase 1  EPHX1 24.6% r23 
P52209 6-phosphogluconate dehydrogenase, decarboxylating  PGD 39.1% r5 
P08670 Vimentin VIM 77.7% 
r2, r5, r10, r16, r37, 
r22, r8, r7, r5 and r9 
C9J813 Caldesmon  CALD1 26.8% r7 
P50995 Annexin A11 ANXA11 25.1% r15 
P06576 ATP synthase subunit beta, mitochondrial ATP5B 28.7% r24 
P30101 Protein disulfide-isomerase A3 PDIA3 52.5% r15 and r10 
P07237  Protein disulfide-isomerase P4HB 70.9% r6, r15, r1 and r16 
P49257 Protein ERGIC-53  LMAN1 32.9% r1 
P14618 Pyruvate kinase PKM  PKM 42.4% r16 
C9JIZ6 Prosaposin PSAP 12.7% r7 
P25705 ATP synthase subunit alpha, mitochondrial ATP5A1 32.2% r17 and r1 
K7ELL7 Glucosidase 2 subunit beta PRKCSH 38.5% r2, r19 and r13 
P13674 Prolyl 4-hydroxylase subunit alpha-1 P4HA1 43.6% r4 and r1 
P10809 60 kDa heat shock protein, mitochondrial HSPD1 53.2% r25 and r1 
P00367 Glutamate dehydrogenase 1, mitochondrial  GLUD1 45.9% r13, r4 and r6 
P31948 Stress-induced-phosphoprotein 1 STIP1 34.1% r4 
A0A0A0MTS2 Glucose-6-phosphate isomerase  GPI 33.9% r7 and r9 
Q07065 Cytoskeleton-associated protein 4  CKAP4 63.0% r6, r1, r24, r18 and r16 
P26038 Moesin  MSN 52.5% r10, r17 and r21 
P04843 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit1  
RPN1 38.7% r12 
O60506 Heterogeneous nuclear ribonucleoprotein Q  SYNCRIP 35.5% r3, r18 and r5 
E7EX17 Eukaryotic translation initiation factor 4B EIF4B 13.5% r28 
P12956 X-ray repair cross-complementing protein 6 XRCC6 44.3% r1 
P49748 Very long-chain specific acyl-CoA dehydrogenase, ACADVL 23.5% r13 
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mitochondrial 
P11142 Heat shock cognate 71 kDa protein HSPA8 56.8% r12, r5, r14 and r18 
P11021 78 kDa glucose-regulated protein HSPA5 64.1% 
r12, r6, r2, r18, r17, 
r9, r15, r5 and r14 
P13667 Protein disulfide-isomerase A4 PDIA4 56.4% r6, r10, r12 r2 and r4 
P38646 Stress-70 protein, mitochondrial  HSPA9 45.7% 
r12, r9, r2, r4, r3, r14, 
r19 and r11 
P02545 Prelamin-A/C LMNA 42.3% 
r12, r4, r11, r5, r1 and 
r14 
P08133 Annexin A6 ANXA6 70.0% r5, r4, r9, r6 and r15 
P19338 Nucleolin NCL 26.6% r10 and r8 
P16070-7 Isoform 7 of CD44 antigen CD44 9.68% r13 
P06396-2 Isoform 2 of Gelsolin GSN 26.9% r11 
P13010  X-ray repair cross-complementing protein 5  XRCC5 42.9% r12 
P08238 Heat shock protein HSP 90-beta HSP90AB1 47.5% r13 and r15 
P07900 Heat shock protein HSP 90-alpha HSP90AA1 46.9% r5 
Q9UHB6 LIM domain and actin-binding protein 1 LIMA1 14.1% r11 
A2A274 Aconitate hydratase, mitochondrial ACO2 36.0% r2 
P05556 Integrin beta-1 ITGB1 21.2% r11 
P14625 Endoplasmin  HSP90B1 56.7% 
r10, r9, r14, r2, r11, 
r12, r1 and r7 
Q12906 Interleukin enhancer-binding factor 3 ILF3 22.9% r16 
P13639 Elongation factor 2  EEF2 30.7% r9 
Q9Y2J2-2 Isoform 2 of Band 4.1-like protein 3  EPB41L3 14.3% r5 
P35221 Catenin alpha-1 s  CTNNA1 29.6% r2 
P12814 Alpha-actinin-1 ACTN1 51.9% r13 
O43707 Alpha-actinin-4  ACTN4 53.5% r13, r11, r2 and r12 
P12110 Collagen alpha-2(VI) chain COL6A2 8.24% r27 
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Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 24.9% r7 
O95197 Reticulon-3  RTN3 3.29% r11 
Q5JRX3 Presequence protease, mitochondrial  PITRM1 17.1% r6 
P82094 TATA element modulatory factor TMF1 3.84% r13 
P18206 Vinculin VCL 47.3% r21 and r3 
Q16531 DNA damage-binding protein 1 DDB1 12.9% r21 
A0A087WTA8 Collagen alpha-2(I) chain COL1A2 16.5% r16 
A0A087WYK8 Nardilysin  NRD1 6.71% r11 
P02452 Collagen alpha-1(I) chain  COL1A1 26.2% r4, r3, r16 and r10 
E7EQT4 Apoptotic chromatin condensation inducer in the nucleus  ACIN1 2.92% r7 
A0A0A0MRV0 Ribosome-binding protein 1  RRBP1 27.9% r6, r2 and r18 
P42704 Leucine-rich PPR motif-containing protein, mitochondrial LRPPRC 17.6% r14 
P11047 Laminin subunit gamma-1 LAMC1 11.4% r8 
E9PAV3 
Nascent polypeptide-associated complex subunit alpha, 
muscle-specific form  
NACA 2.55% r4 
Q9Y490 Talin-1  TLN1 31.0% r26 and r14 
P46821 Microtubule-associated protein 1B  MAP1B 31.6% r19 and r1 
P21333 Filamin-A  FLNA 39.1% r2, r18, r5, r14 and r6 
Q14315 Filamin-C  FLNC P 17.5% r5 
P12111 Collagen alpha-3(VI) chain COL6A3 12.2% r13 
A0A087WV66 Antigen KI-67 MKI67 0.768% r12 
Q15149 Plectin PLEC 27.0% 
r6, r9, r8, r12, r5, r10, 
r2 and r3 
Q09666 Neuroblast differentiation-associated protein AHNAK 35.4% r15, r13, r3 and r11 
Data are mean ± SD, n = 3.
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3.7 Characterisation of protein glycation, oxidation and nitration markers 
in plasma protein of healthy subject, subjects with chronic 
periodontitis and periodontitis patients with co-morbidities 
Plasma protein collected from patients with periodontitis and patients with 
periodontitis and other comorbid diseases such as diabetes and CKD was analysed 
for protein damage markers using gold standard analytical technique LC-MS/MS 
with stable isotope dilution analysis.  
In healthy people, FL residue content of plasma protein was 4.67 ± 1.50 
mmol/mol lys. This was significantly decreased in periodontitis patients ca. 61% 
compared to healthy patients (P<0.001). In addition, the residue content of FL in 
plasma of diabetic, CKD and periodontitis was decreased ca. 33% compared to 
healthy people (P<0.001) however, FL level was increased significantly by72% 
(P<0.001) compared to patients with periodontitis only. CML residue content of 
plasma protein in health people was 0.121 ± 0.062 mmol/mol lys. This was 
markedly decrease in periodontitis patients and patient with diabetic, CKD and 
periodontitis by 64% and 54% respectively compared to healthy people 
(P<0.001). The level of CEL residue in health people was 0.019 ± 0.007 
mmol/mol lys. This was increased significantly 149% (P<0.001) in the plasma 
protein of patient with comorbidities only. In healthy people, G-H1 residue was 
decreased 70% in periodontitis patients (P<0.01) and 60% in patient with diabetic, 
CKD and periodontitis compared to healthy people (P<0.05). MG-H1 residue 
content of plasma protein was unchanged in periodontitis patients and patient with 
diabetic, CKD and periodontitis compare to control group. However, 3DG-H 
residue content of plasma protein was increased significantly in plasma protein of 
patients with periodontitis by 93% (P<0.001) and in patient with diabetic, CKD 
and periodontitis by 154% (P<0.01 with respect to health people) and by 31% 
(P<0.01 with respect to periodontitis patients). Level of MOLD residue was 
increased significantly in plasma protein of patients with periodontitis by 36 folds 
(P<0.001 with respect to health people) and in patient with diabetic, CKD and 
periodontitis by 49 folds (P<0.01 with respect to health people). The increase of 
MetSO residue content was highly significant in both groups, patients with 
periodontitis (P<0.001) and in patient with diabetic, CKD and periodontitis 
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(P<0.001) compared to health control group. In healthy people, NFK residue 
content of plasma protein was 0.360 ± 0.378 mmol/mol trp. This was increased 
significantly in plasma protein of patients with periodontitis by 716% (P<0.001) 
and in patient with diabetic, CKD and periodontitis by 613% (P<0.01) with 
respect to health people. 3-NT residue content of plasma protein was also 
increased in plasma protein of patients with periodontitis by 96% (P<0.01) and in 
patient with diabetic, CKD and periodontitis by 97% (P<0.05) with respect to 
health people. CMA residue content of plasma protein was decreased 27% in 
periodontitis patients (P<0.01) with respect to health people. The protein 
glycation, oxidation and nitration markers in plasma of healthy people, 
periodontitis patients and periodontitis patients with Co-morbidities are presented 
in Table 56 and Figure 83.  
 
Table 56: Protein glycation, oxidation and nitration markers in plasma of 
healthy people, periodontitis patients and periodontitis patients with Co-
morbidities 
mmol/mol amino acid modified 
 Control subjects 
Periodontitis 
subjects 
Diabetic, CKD and 
periodontitis subjects 
FL 4.67 ± 1.50 1.81 ± 0.29***↓ 3.13 ± 0.42***↓ooo↑ 
CML 
0.075 (0.043 – 
0.135) 
0.041 (0.031 - 
0.051)***↓ 
0.051 (0.049 - 0.066)***↓ 
CEL 0.019 ± 0.007 0.019 ± 0.009 0.047 ± 0.012**↑ooo↑ 
G-H1 
0.019 (0.033 – 
0.006) 
0.011 (0.008 - 
0.013)**↓ 
0.016 (0.009 - 0.019)*↓ 
MG-H1 0.213 ± 0.115 0.261 ± 0.038 0.272 ± 0.059 
3DG-H 0.054 ± 0.039 0.104 ± 0.018***↑ 0.137 ± 0.035**↑oo↑ 
MOLD 0.0007 ± 0.0004 0.026 ± 0.015***↑ 0.034 ±0.012**↑ 
MetSO 0.015 ± 0.029 3.72 ± 0.70***↑ 9.67 ± 1.91***↑oo↑ 
NFK 
0.205 (0.076 – 
0.593) 
2.83 (2.58 - 
3.24)***↑ 
2.63 (2.42 - 2.68)***↑ 
3-NT 0.0053 ± 0.0033 0.010 ± 0.002**↑ 0.010 ± 0.004*↑ 
CMA 0.024 ± 0.007 0.018 ± 0.005**↓ 0.020 ± 0.016 
Data are means ± SD or median (lower – upper quartile) Statistical analysis was 
performed using independent samples t-test. *, **, and ***, P<0.05, P<0.01 and 
P<0.001 with respect to healthy people; oo and ooo, P<0.01 and P<0.001 with 
respect to periodontitis patients.
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Figure 83: Protein glycation, oxidation and nitration markers in plasma of healthy people, periodontitis patients and periodontitis 
patients with Co-morbidities.  
(A) CEL. (B) 3DG-H. (C) NFK. and (D) 3-NT. Data are means ± SD or median (lower – upper quartile) Statistical analysis was performed 
using independent samples t-test. *, **, and ***, P<0.05, P<0.01 and P<0.001 with respect to healthy people; oo and ooo, P<0.01 and 
P<0.001 with respect to periodontitis patients.
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4. Discussion 
Periodontal ligament (PDL) inflammation, or periodontitis, is the most 
common chronic inflammatory disease in the oral cavity. It is characterised by 
breakdown of the supporting structures of the teeth including the periodontal 
ligament. Many factors contributes in PDL inflammation can be external such as 
excessive plaque accumulation around the tooth (Selwitz et al., 2007), or systemic 
such as chronic systemic diseases as diabetes (Chang and Lim, 2012). 
Epidemiological data confirm that diabetes is a major risk factor for periodontitis – 
with risk of periodontitis increased ca. 3-fold in diabetes. Increased hyperglycaemia 
is linked to increased severity of periodontitis. The mechanisms that link 
hyperglycaemia to periodontitis are not clearly understood but are thought to involve 
disturbance of immune function, neutrophil responses to infection and soluble 
immune response mediators such as cytokines. There is also evidence to suggest that 
periodontitis influences glycaemia control – with treatment of periodontitis 
improving HbA1c by 0.4%. The presence of diabetic nephropathy also exacerbates 
periodontitis and CVD in the presence of diabetic nephropathy is exacerbated by 
periodontitis (Preshaw et al., 2013). Mechanisms underlying the link of glycaemia 
control to periodontitis are likely similar to those linking hyperglycemia to vascular 
complications. A key driver in this relationship that has emerged in the last decade is 
dicarbonyl stress – particularly the accumulation of the reactive metabolite, MG 
(Rabbani and Thornalley, 2015). 
Methylglyoxal is the precursor of quantitatively major AGEs. MG-derived 
AGE modification of proteins is functionally damaging whereas glycation by 
glucose has less marked functional effect. Increased MG in diabetes is driven by 
increased formation with increased flux of glucose metabolism in hyperglycemia in 
cells with GLUT1 glucose transport and by down regulation of Glo1 expression and 
protein stability by inflammation and other mechanisms. Increased levels of MG-
derived AGEs and decreased Glo1 activity are found in the kidney, retina and nerve 
in diabetes and are associated with the development of diabetic nephropathy, 
retinopathy and neuropathy. Overexpression of Glo1 prevents the development of 
nephropathy, retinopathy and neuropathy in experimental diabetes (Rabbani and 
Thornalley, 2015). 
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In this project I hypothesised that increased concentration of MG is produced 
in hPDLFs by exogenous MG, hyperglycaemia associated with diabetes and 
inflammatory signalling leading to increased extracellular matrix modification 
causing hPDLFs dysfunction and extracellular matrix detachment. The aim of this 
study is to test this hypothesis and to study MG metabolism by the glyoxalase 
system in hPDLFs primary cell culture. The major experimental model for this 
hPDLFs cells in primary culture. This is a widely used cell culture model of 
mechanisms of cell dysfunction and injury leading to periodontitis (Mariotti and 
Cochran, 1990). hPDLFs are key cells mediating dysfunction in periodontitis in 
diabetes (Somerman et al., 1990). 
 
4.1  Effect of glucose concentration on growth and viability of hPDLFs in vitro 
I investigated the effect of glucose concentration on the growth of hPDLFs in 
primary culture. When hPDLFs incubated in medium containing 5.5 mM, 8.0 and 
25.0 mM glucose, there was similar rapid growth in 8.0 and 25.0 mM glucose over 3 
days but partial growth arrest without decrease in viability in 5.5 mM glucose. 
Subculture with new medium restored high cell growth and hence, over the passage 
range studied, hPDLFs maintained reproducible growth kinetics. The normal 
salivary glucose level in a healthy subject is ca. 8.0 mM glucose and in patients with 
diabetes mellitus the plasma concentrations of glucose is often 25.0 mM or higher 
(Aydin, 2007). In subsequent experiments to study effects of low and high glucose 
on metabolism and function of hPDLFs, cultures with 8.0 mM glucose were 
employed as the “low glucose concentration” (LG) conditions and cultures with 25.0 
mM glucose were employed as the “high glucose concentration” (HG) conditions. 
hPDLFs with similar growth rate were compared in LG and HG conditions but the 
5.5 mM glucose culture was not used. Primary hPDLFs were maintained in 8.0 mM 
glucose and 25.0 mM glucose for 3 days without change of medium. Use of 8.0 and 
25.0 mM glucose was chosen for these conditions as cultures gave similar growth 
kinetics and hence differences found in cell function were not due to low glucose 
concentration-induced growth arrest. 
The recommended growth conditions for hPDLFs in primary culture from a 
commercial supplier was medium containing 25 mM glucose. This is likely to 
provide a medium rich in nutrient for culture up to 6 days but does not provide 
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optimum function – see below. hPDLFs maintained rapid growth characteristics and 
the hPDLFs phenotype over the passages used herein (passages 3 - 5). hPDLFs 
growth was stimulated again in subsequent sub-cultures and this suggests that the 
slowing of cell growth was linked to depletion of nutrients rather than a cumulative 
cell doubling limited growth – known as the Hayflick limit (Effros and Walford, 
1984). In subsequent experiments hPDLFs sub-cultured and grown for up to 3 days. 
The population doubling time was ca. 0.62 days in medium containing 8 and 25 mM 
glucose which is relatively rapid and similar to human foetal fibroblasts: cf. 
population doubling time for human dermal BJ fibroblasts, ca. 4 days, and of lung 
foetal fibroblasts 0.8 days (Sitte et al., 2000, Chen et al., 1995). 
Culture of hPDLFs herein for 3 days at an initial density of 5000 cells/cm2 in 
8 mM and 25 mM glucose did not produce a decrease in cell viability. Previous 
studies seeding hPDLFs at 20,000 cells/cm2 and incubating cells for 3 days and then 
exposure to different glucose concentrations for 24 h found increased apoptosis with 
25 mM glucose (Liu et al., 2013). However, this was likely due to the high cell 
density used by the authors and rapid confluence conditions achieved by day 3 where 
after there is confluence-driven apoptosis (Yasaka et al., 1996). Other studies did not 
find decreased viabiluity of hPDLFs when cultured at 20 and 25 mM gluocse, as 
found herein (Nishimura et al., 1996, Ohgi and Johnson, 1996). 
 
4.2 The glyoxalase system and dicarbonyl metabolism in hPDLFs cells in vitro 
To my knowledge, this is the first time the glyoxalase system has been 
studied in hPDLFs. The activity of Glo1 in low glucose concentration was 985 ± 148 
mU per mg protein; cf. 110 mU per mg protein in human RBCs (McLellan et al., 
1994b) and ca. 1,500 mU per mg protein in human aortal endothelial cells in primary 
culture (Thornalley et al., 2014). hPDLFs, therefore, have a relatively high activity 
of Glo1 – similar to that of vascular cells. Glo1 activity markedly exceeded activities 
of MG reductase and dehydrogenase, so the glyoxalase pathway is the major route 
for detoxification of MG. The activity of Glo2 in hPDLFs in low glucose 
concentration was relatively low at 4.20 ± 2.71 mU per mg protein; cf. ca. 64 mU per 
mg protein in human RBCs (McLellan et al., 1994b). However, the relative activities 
of Glo1 and Glo1 in situ with physiological concentrations of substrate, taking into 
account KM and kcat for the reactions catalysed, are such that the intermediate S-D-
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lactoylglutathione is <0.1% of total cell GSH (Rabbani et al., 2014b) and this was 
also found for hPDLFs – see below. 
The concentration of MG in hPDLFs in low glucose concentration was ca. 8 
pmol per 106 cells. Fibroblast cell volume is ca. 2.5 pl per cell (Mitsui and 
Schneider, 1976). This suggests the concentration of MG in hPDLFs is ca. 3 µM. 
This is keeping with the concentration of MG in other human cells of 2 - 4 µM 
(Rabbani and Thornalley, 2014c). The cellular concentration of glyoxal was similar 
and that of 3-DG was ca. 10-fold lower. MG is more reactive than glyoxal towards 
protein glycation and hence poses the greatest threat to cell protein modification and 
dysfunction. The flux of D-lactate in hPDLFs in low glucose concentration was ca. 6 
nmol/106 cells/day, equivalent to ca. 0.06% flux of glucotriose. This is similar to 
flux of D-lactate found previously in human RBCs and endothelial cells (Thornalley, 
1988, Thornalley et al., 2014, Shinohara et al., 1998) and is consistent with MG 
mainly being formed by non-enztymatic degradration of triosephosphates (Phillips 
and Thornalley, 1993). There was no significant metabolism of exogenous D-lactate 
added to primary hPDLFs cultures, suggesting that D-lactate formation by the 
glyoxalase system in this case represents the flux of MG formation. 
The concentration of GSH and GSSG in hPDLFs was ca. 7 and 0.012 nmol 
per 106 cells, respectively, suggesting only 0.3% of GSH is oxidised under low 
glucose condistions. A previous estimate of GSH in hPDLFs was ca. 30 nmol per 
mg protein (Chang et al., 2003), equivalent to ca. 6 nmol GSH and in reasonable 
agreement with the estimate here. The concentration of GSH in hPDLFs was 
therefore ca. 3 mM and GSSG ca. 5 µM, suggesting hPDLFs have a strongly 
reducing cytosol. The glyoxalase system intermediate, S-D-lactoylglutathione, was 
<1.1 pmol per 106 cells, equivalent to < 0.4 µM or < 0.02% total GSH. 
 
4.3 The effect of high glucose and dicarbonyl stress on the glyoxalase system 
and dicarbonyl metabolism in hPDLFs cells in vitro 
In high glucose concentration media, there is expected increased uptake and 
metabolism of glucose by hPDLFs. Cell of the fibroblast lineage express GLUT1, 
GLUT3 and GLUT4 glucose transporters (Longo et al., 1989). When incubated 
medium containing 25 mM glucose (HG), the flux of glucose metabolism was 
increased ca. 2-fold but the flux of net L-lactate formation was unchanged. This is 
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consistent with increased uptake and metabolism of glucose in HG medium. 
Methylglyoxal made mainly from triphosphate intermediates of glycolysis process. 
Hence, increased glucose consumption is reflected in increased triphosphate 
intermediates, increased degradation to MG and increased flux of D-lactate 
formation. The increase in flux of D-lactate was less than the increase in glucose 
consumption, however, and may indicate increased metabolism of glucose by the 
pentosephosphate pathway in HG cultures. There was no indication of oxidative 
stress in hPDLFs incubated in high glucose concentration as the concentration of 
cellular total cell thiols and protein thiols were both increased in HG cultures. The 
cellular concentration of GSH and GSSG were both decreased by 22% and 23%, 
suggesting GSH synthesis may be modestly impaired. The cellular activity of Glo1 
was decreased 45% in HG cultures. The increased flux of MG formation, as 
indicated by increased flux of D-lactate, the decreased activity of Glo1 and 
decreased cellular GSH concentration synergise to increase MG concentration in HG 
cultures. MG concentration of the medium and MG content of cells was increased by 
ca. 60% and 41%, respectively, in HG cultures. The concentration of glyoxal was 
unchanged in cells and medium of HG cultures. As glyoxal is mainly produced by 
oxidative processes, this is also indicative of no increase in oxidative stress in HG 
cultures. The cellular and medium concentration of 3-DG was increased ca. 4-fold in 
HG cultures and this is likely originating mainly from the glucose in the medium 
undergoing slow dehydration to 3-DG. It does not pose a great threat to hPDLFs 
since its reactivity towards glycation and AGE formation is ca. 200-fold lower than 
MG and the cellular and medium concentrations are ca. 8-fold lower and 2-fold 
higher than MG, respectively. 
The glycation status of hPDLFs was assessed by quantifying the content of 
glycation adducts of a cytosolic protein extract and flux of increase of glycation free 
adducts increasing in the cell culture medium with time. FL and MG-H1 were major 
early glycation and AGE of cell protein, respectively. Both were increased ca. 2-fold 
in the high glucose culture, reflecting increase in glucose and MG exposure in the 
HG culture. Oxidative markers were unchanged in cell protein of HG cultures – 
CML/FL ratio, MetSO, NFK, DT and 3-NT, suggesting HG conditions did not 
increase cellular oxidative stress. This was supported by increased cell thiols and 
unchanged GSH/GSSG ratio. Fluxes of FL and AGE free adducts, CMA, MG-H1 
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and 3DG-H, were increased in HG cultures, suggesting increased proteolysis of 
glycated proteins; with a minor contribution from increased direct formation by 
glycation of arg and lys in the culture medium. This indicates that hPDLFs in HG 
culture suffer increased glycation by glucose and dicarbonyl stress and not increased 
oxidative or nitrative stress. 
I investigated the likely mechanism of decrease in Glo1 activity of hPDLFs 
in HG medium. Decrease in Glo1 protein has been found previously in cells in HG 
culture where it has been claimed to be due to decreased Glo1 expression or 
increased Glo1 degradation (Bierhaus, 2006, Giacco et al., 2014, Thornalley et al., 
2014). In hPDLFs, with decreased Glo1 activity in HG culture there was no related 
decrease in Glo1 mRNA but there a related decrease in Glo1 protein, suggesting 
increased proteolysis of Glo1 in the HG cultures. I investigated the possible 
acetylation of Glo1 promoting its degradation; human Glo1 protein undergoes 
acetylation at K148 and likely de-acetylation by cytosolic sirtuin-2 (Lundby et al., 
2012). In immunoprecipitation and proteomics studies, I found no evidence of 
increased Glo1 acetylation in HG cultures. In conventional cylcoheximide block of 
protein synthesis studies, I found evidence of decreased half-life of Glo1 protein and 
increased proteolysis in HG cultures. It therefore appears that hPDLFs in HG culture 
activates a process of increased proteolysis that exacerbates dicarbonyl stress by de-
stabilising Glo1 to proteolysis. A possible mechanisms is activation of autophagy as 
this may be activated by expsosure of cells to high glucose concentration – e.g. 
endothelial cells (Panieri et al., 2010), and Glo1 degradation may be thereby 
enhanced (Kristensen et al., 2008). 
 
4.4 Sensitivity of hPDLFs cells to toxicity of exogenous methylglyoxal in vitro 
Primary hPDLFs were incubated with exogenous MG for 48 h and cell 
growth and viability assessed. The results show that at ≥ 50 μM MG there was a 
decrease in hPDLFs viable cell number without decrease in cell viability – indicative 
of growth arrest, and with ≥ 200 μM MG there was decrease in cell growth and 
viability. This suggested that with addition of exogenous MG of progressively 
increased concentration, there is initially growth arrest of hPDLFs and the both 
growth arrest and cytotoxicity at ≥ 200 μM MG. Addition of 200 μM MG decreased 
cell growth and viability to similar extent in both low and high glucose conditions. 
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These effects of exogenous MG show a similar concentration-response relationship 
to the effect of MG on other proliferating cells (Kang et al., 1996) but effective 
concentrations far exceed those achieved physiologically (Rabbani and Thornalley, 
2014c). This concentration also exceeds the concentration of MG in many foods and 
beverages (Degen et al., 2012) but is found in particularly types of honey – e.g. 
Manuka honey (Mavric et al., 2008). Alternatively, the bacteriocidal activity of MG 
in Manuka honey has been investigated and found to decrease dental plaques; 
Manuka honey was applied to the gingival sulcus of all the teeth, 3 times and twice 
per day, leaving the honey in the mouth for 5 min. It is likely that short term topical 
application limits toxicity to the surface layer of the tooth-gum junction (Nayak et 
al., 2010).The study was also an open trial with subjects aware of the treatment. A 
similar study with a chewable “honey leather” also found decreased dental plaque 
and gingival bleeding scores with 3 daily, 10 min exposures for 21 days (English et 
al., 2004). Again, this was an open study. It would be of interest to compare high and 
low MG content honey of similar appearance to control for placebo effects. The high 
activity of Glo1 in hPDLFs and periodontal epithelial cells may provide host 
protection against MG toxicity where micro-organisms may be more vulnerable. 
Increased physiological levels of MG may drive hPDLFs dysfunction and 
detachment from the extrecellular matrix – as found for vascular endothelial cells in 
high glucose cultures (Dobler et al., 2006). This may be particularly damaging for 
sustaining the periodontal ligament, secure attachement of teeth in the jaw socket 
and epithelial barrier to infection. 
 
4.5 The effect of glyoxalase 1 inducers on glyoxalase system and MG 
metabolism in hPDLFs in vitro 
tRSV has received much attention as a potential health beneficial dietary 
supplement for prevention and treatment of obesity, cardiovascular disease, cancer, 
diabetes and hypertension (Bradamante et al., 2004, Jang et al., 1997, Fröjdö et al., 
2008, Baur and Sinclair, 2006). Whil benefits have been found in experimental 
models, clinical translation has been difficult to achieve – for example, see meta-
analysis of benefit in obesity and diabetes (Liu et al., 2014). A contributary factor 
has been the use of concentrations of tRSV in in vitro studies that are readily 
translatable (Boocock et al., 2007) and high doses in animal models that unsafe and 
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toxic clinically. Recent review of tRSV safety by the European Food Safety 
Authority suggest an upper tolerable clinical dose of  <14 mg/kg (ca. 1 g per day in 
an adult) (EFSA, 2016). tRSV has been claimed to function as a direct activator of 
SIRT1 but this is limited to concentrations of 50 – 100 μM not achieved (Milne et 
al., 2007). Lower concentrations of tRSV (3 - 10 μM) inhibit phosphodiesterases, 
increased cAMP and NAD+, increasing in situ activity of sirtuins (Park et al., 2012). 
In recent studies our team have identified tRSV as also an activator of Nrf2 and 
inducer of Glo1 with inducer activity in the range 1 – 10 μM. They also recognised 
that this concentraion of tRSV was difficult to achieve clinically with safe clinical 
doses, they discovered HSP was also an activator of Nrf2 and inducer of Glo1 at 
concentrations achieved clinically and highly safe doses - albeit with low maximal 
response, and they developed tRSV and HSP in synergistic combination as a potent 
Glo1 inducer at clinically translatable concentrations and highly safe doses (Xue et 
al., 2016). The effect of tRSV, HSP and tRSV-HSP combination on dicarbonyl stress 
and function of hPDLFs in LG and HG cultures was therefore investigated. 
HepG2 cells stably transfected to express lucerifase under GLO-ARE 
promoter incubated with 0.625 - 20 µM tRSV showed induction of lucerifase 
expression whereas HepG2 cells stably transfected with a non-functional mutant 
GLO1-ARE showed no activity. HSP showed similar activity except with a lower 
EC50 and lower Emax. Combined together, tRSV and HSP were synergistic – inducing 
reporter activity with 5 μM HSP and 0.1 – 1 μM tRSV. These hits were validated by 
measuring increase of Glo1 protein in HepG 2 cells and human aortal endothelial 
cells and dermal BJ fibroblasts in primary culture (Xue et al., 2016). Other 
investigators had found corroborative evidence of induction of Glo1 expresion by 
tRSV in HepG2 cells in vitro (Cheng et al., 2012). Recent studies from our group 
(Xue et al., 2015a, Xue et al., 2015c) and of others (Yang et al., 2014) suggest tRSV 
activates Nrf2 by preventing nuclear acetylation and inactivation of Nrf2. HSP may 
activate Nrf2 through induction and activation of protein kinase A, upstream of Fyn 
kinase which drives Nrf2 translocational oscillations and ARE-linked gene expression 
(Xue et al., 2015c, Hwang et al., 2012). HSP is a partial agonist (which is likely due to 
inhibitory nuclear acetylation of Nrf2 blocking a high Emax). Combination with tRSV 
and HSP provides for faster nuclear translocation and decreased inactivation of Nrf2 
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and thereby a high transcriptional response at relatively low activator concentrations 
(Xue et al., 2015a, Xue et al., 2015c). 
Glo1 inducers had interesting effects on Glo1 activity in hPDLFs in culture. 
Incubation of hPDLFs cells with tRSV, HSP and tRSV-HSP in combination  in LG 
and HG conditions did not change cell growth and viability. In LG control cultures, 
HSP and tRSV-HSP combined increased Glo1 activity by 20 – 22% whereas tRSV 
alone did not, suggesting that HSP may be more effective in LG cultures. In HG 
cultures, tRSV, HSP and tRSV-HSP combined all prevented the decrease of Glo1 
activity of the HG control. This was associated with prevention of a decrease in Glo1 
protein in HG cultures and a classical cycloheximide protein half-life study with 
tRSV suggests the recovery of Glo1 protein was due to prevention of HG-induced 
increased Glo1 degradation. Cycloheximide protein half-life studies have problems 
of interpretation, however, as cycloheximide blocks all protein synthesis and hence 
may change the rate of Glo1 degradation as well as the intended blocking of Glo1 
synthesis. The effect of HG culture and tRSV treatment on Glo1 turnover requires 
future corroboration with proteome dynamics studies. 
tRSV treatment stabilized the Glo1 protein and increased the half-life of Glo1 
protein. Low concentrations of tRSV have been claimed to inhibit cellular proteases 
at 2 – 10 μM (Qureshi et al., 2012). If tRSV is a general protease inhibitor, however, 
it is suprising that protein damage modifications in cell protein did not all increase. 
Further studies are required as to how tRSV stabilises Glo1. 
No effects for tRSV, HSP and tRSV-HSP combined were found on Glo2 and 
MG reductase and MG dehydrogenase, suggesting an effect specific for Glo1. The 
effect of tRSV, HSP and tRSV-HSP combined on glucose metabolism, D- and L-
lactate formation was also remarkable. HSP and tRSV-HSP combined decreased 
glucose consumption by hPDLFs in LG cultures whereas tRSV did not, suggesting a 
caloric restriction mimetic effect induced by HSP. In HG cultures, tRSV did not 
reverse increased glucose consumption compared to LG control whereas HSP partly 
corrected and tRSV-HSP combined totally corrected increased glucose consumption, 
suggesting a caloric restriction mimetic effect induced by HSP which is potentiated 
and synergised by tRSV. Flux of D-lactate showed similar effects suggesting that the 
flux of D-lactate and hence flux of MG formation is influenced by flux of glucose 
consumption and may be decreased by HSP and tRSV-HSP combined in LG cultures 
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and the HG-induced increase prevented partly by HSP and totally by tRSV-HSP 
combined. 
Studies of dicarbonyls in cells and medium were performed only with tRSV 
and showed that tRSV reversed partly the HG-induced increase of MG in cells and 
culture medium and decreased glyoxal in cells and culture medium but did not affect 
HG-induced increases in 3-DG. This suggests that tRSV partly corrects dicarbonyl 
stress induced by HG in cultures of hPDLFs. Cellular dicarbonyls were also studied 
with HSP and tRSV-HSP combined and this showed that HSP alone and tRSV-HSP 
combined provided complete protection against dicarbonyl stress in HG conditions, 
the combination of prevention of decline in Glo1 activity and increased MG 
formation both likely contributing to this effect. 
A further contributory factor to protection against dicarbonyl stress by tRSV 
was the effect on cellular GSH. Cellular GSH was increased by tRSV in both LG 
and HG cultures such that the HG-induced decrease in cellular GSH was corrected 
and indeed increased above LG control levels. Previously periodontitis is associated 
with elevated oxidative stress and poor glycemic status in patients with diabetes 
(Allen et al., 2011). tRSV was found to be an effective antioxidant to protect human 
gingival fibroblasts (HGFs) from damage under oxidative stress induced by H2O2 
(Orihuela-Campos et al., 2015). tRSV antioxidant mechanisms may relate to its 
ability to stimulate synthesis of GSH. tRSV produced a small decrease in protein 
thiols in LG and HG cultures. The reason for this is unclear but as cellular GSH 
concentration was increased, it seems to relate to decreased activity of thiol 
transferases – such as glutaredoxin (Lillig et al., 2008). 
I studied the effect of tRSV on protein damage markers in hPDLFs cell 
protein. There were no improvements in oxidative damage markers – DT, MetSO, 
NFK and 3-NT – induced by tRSV in either LG or HG conditions, suggesting any 
functional benefit of tRSV on hPDLFs are not mediated through correction of 
oxidative damage. There were improvements of glycation damage, however. For 
early glycation damage, cellular protein FL content increase in HG cultures was 
corrected by tRSV. This may relate to increased clearance of FL-modified protein as 
the flux of FL free adducts was not changed by tRSV. Decrease in FL by tRSV in 
HG cultures probably also explains the correction of HG-induced increase in CML 
as oxidative degradation of FL is the major source of formation of CML. tRSV 
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decreased AGE content of cell protein: decreasing CMA in LG and HG cultures and 
correcting increased MG-H1 in HG cultures. This is linked to the improvement of 
dicarbonyl stress by tRSV. Relatedly, increased flux of MG-H1 free adduct 
formation in HG cultures was prevented by tRSV. Increased flux of formation of 3-
DG in HG cultures was not prevented and as there was not related increase of 3DG-
H in cell protein, this may relate to increased 3DG-H formation in the culture 
medium. MetSO free adduct is metabolised by MetSO reductase and was increased 
in HG cultures and not corrected by tRSV. This may reflect decreased MetSO 
reductase activity in HG cultures which was not corrected by tRSV.  
 
4.6 The effect of glyoxalase 1 inducers on hPDLFs function in vitro 
To assess hPDLFs function and effects of Glo1 inducers, I assessed the effect 
of tRSV on ECM component expression by hPDLFs and binding of hPDLFs to 
ECM. The minor decrease in expression of COL1 in high glucose treatment was 
corrected by tRSV. tRSV also produced a minor increase in expression of COL3 and 
COL12. These may contribute to improved ECM deposition by hPDLFs. 
Hyperglycaemia significantly affects collagen homeostasis, synthesis and 
maturation. In patients with diabetes, there is a decrease in the collagen production 
with an increase in collagenase activity in gingival tissues (Mealey, 1999). tRSV was 
found to upregulate the production of collagen-I gene after 3 h of incubation post-
induction of oxidative stress (Orihuela-Campos et al., 2015). 
Previous studies have shown that MG targets functional RGD and GFOGER 
integrin binding sites in the ECM and stimulates cell detachment, as shown for 
endothelial cells and pancreatic beta-cells (Dobler et al., 2006, Tym et al., 2014). I 
therefore investigated effects of tRSV, HSP and tRSV-HSP combined on hPDLFs 
bidning to the ECM – using collagen-1 as the ECM target. 
When hPDLFs were incubated in HG, there was a ca. 30% decrease in 
adhesion of the cells to collagen-I. Glo1 inducers both individually and combination 
increased adhesion of hPDLFs to collagen-I in LG and HG conditions. This suggests 
integrin expression was increased and/or MG modification and functional 
impairment of it was decreased. We previously showed that overexpression of Glo1 
in endothelial cells corrected HG-induced decreased attachment to collagen-IV 
where MG modification of a function arg in integrins was implicated (Ahmed et al., 
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2008). With respect to integrin-ECM binding, it has been claimed that there is a high 
affinity binding site of tRSV on integrin αVβ3 – based on binding to purified integrin 
fragments, and binding of tRSV to this induces extracellular-regulated kinases 1 and 
2 (ERK1/2)- and serine-15-p53- dependent phosphorylation leading to apoptosis 
(Lin et al., 2006). Expresion of αVβ3 integrin has been found in hPDLFs in vivo 
(Steffensen et al., 1992). Effects of HSP on integrins are known. Integrins binding 
collagens on hPDLFs are a1b1, a2b1 and a11b1; only a2b1 and a11b1 have been shown, 
by immunohistochemistry, to be present in the periodontal ligament in vivo. In vitro, 
a1b1, a2b1 and a11b1 all contribute to cell attachment to collagens-I and -III, and cell 
migration on collagen-I (Popova et al., 2007, Barczyk et al., 2009). The role of 
integrins in hPDLFs function has been expertly reviewed by Barczyk et al. (Barczyk 
et al., 2013). It is likely, therefore, that tRSV and HSP have increased functionally of 
a1b1, a2b1 and a11b1 integrins. In the previous work on this group, MG modification 
blocked functionally of a1b1 and a2b1 integrins (Dobler et al., 2006) and hence 
increasing the functionality of these integrin is suspected. 
Studies of binding of hPDLFs to collagen-I modified with MG and 
conditioned medium with and without prior dicarbonyl scavenging with 
aminoguanidine suggested that MG modification of collagen-I, regardless of whether 
the source of the MG is exogenous or leaking from hPDLFs, impairs binding of 
hPDLFs and this is prevented by the Glo1 inducers. In collagen-I the major motif 
that is modified by MG is GFOGER (Barczyk et al., 2013, Dobler et al., 2006). MG 
modification of GFOGER likely causes detachment of hPDLFs, anoikis and 
decreased cell movements in wound healing. Independent previous studies have 
reported a tRSV, ferulic acid and tetrahydrocurcuminoid combination increased 
hPDLFs function in a model of wound healing (San Miguel et al., 2010). This may 
be linked to improved ECM function. 
Impaired hPDLFs-ECM interaction in dicarbonyl stress may explain tissue 
breakdown of periodontium in periodontal diseases in hyperglycaemia. Recently, it 
was found that administration of tRSV to a rat model of periodontitis produced 
inhibition of periodontitis-mediated loss of alveolar bone and tissue breakdown in 
the periodontium (Bhattarai et al., 2016). As tRSV increases Glo1 activity and 
protein in hPDLFs incubated with high glucose, this decreases MG concentration 
and MG-H1 formation. This will minimise the MG modification of integrins and 
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integrin binding sites in the ECM and improve the cell binding. Tissue breakdown of 
the periodontium is thereby prevented and the attachment of the tooth to the 
periodontium will be improved. 
 
4.7 AGE-RAGE axis as a potential source of dicarbonyl stress in hPDLFs in 
vitro 
Hyperglycaemia increases AGEs accumulation in plasma and tissues by 
oxidation and non-enzymatic glycation of proteins. AGEs cause alteration of matrix 
molecules cross-linking, damage of the growth factors efficiency, elevation of 
oxidative stress in diabetic conditions, and exaggeration of inflammation – possibly 
through engagement of cellular RAGE (Chang et al., 2013). Glycation of collagen-I 
and fibronectin in hPDLFs modify cell function, including decrease in cell migration 
which causes alteration in periodontal wound healing in diabetic individuals (Murillo 
et al., 2008). There are modest increases of AGEs and RAGE without histologic 
destruction in periodontium of animals with diabetes and without periodontitis. 
However, periodontal breakdown in mice with diabetes and periodontitis was 
aggressive with evidence of increased AGEs and RAGE expression. Furthermore, in 
healthy animals with periodontitis, AGE accumulation and RAGE expression were 
found. The AGE-RAGE axis may contribute to inflammation (Chang et al., 2013) 
and RAGE was found to be expressed in hPDLFs (Hasegawa, 2008). RAGE may 
have a significant role in model periodontal disease (Lalla et al., 2000). 
There is a preliminary evidence that activation of RAGE by proteins highly 
modified by AGEs decreased expression of Glo1 (Bierhaus, 2006). The mechanistic 
details are still unclear. The decrease in Glo1 activity may occur in hPDLFs when 
RAGE binds CML-HSA and AGE-HSA and activates NF-κB. Crosstalk between 
NF-κB and Nrf2 (Liu et al., 2008) is expected to downregulated basal and inducible 
expression of Glo1 (Xue et al., 2012a). Culture of hPDLFs for 3 days with highly 
glycated albumin derivatives, however, gain no indication of activation of NF-kB, as 
judged by nuclear concentration of p65-DNA binding, nor decrease in Glo1 mRNA 
or activity. This suggests that the AGE-RAGE axis in hPDLFs in culture is not 
functional for activation of NF-kB and down regulation of Glo1. Rather dicarbonyl 
stress in high glucose cultures was linked to increased proteolysis of Glo1 and 
decreased Glo1 activity, modest decrease in cellular GSH concentration and 
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increased formation of MG linked to increased glucose metabolism. This was 
corrected by Glo1 inducers. 
 
4.8 The effect of high glucose concentration on the cytosolic proteome of 
hPDLFs in vitro 
I examined the cytosolic proteome of hPDLFs incubated in LG and HG 
conditions by high resolution mass spectrometry proteomics analysis. This was the 
same type of extract as used in protein glycation, oxidation and nitration adduct 
residue analysis reported above where increased total MG-H1 residue content was 
found in HG cultures. This analysis detects modified and unmodified proteins but 
with limited total sequence coverage: the mean sequence coverage of proteins 
detected was 16.7%. Hence, some MG-H1 and FL residues sites are likely 
undetected. 
There was 1105 proteins were identified in hPDLFs cytosolic extracts: 1077 
proteins were found in extracts from LG and HG cultures; 16 proteins were only in 
LG extracts and 12 proteins only in HG extracts. Of the 1077 proteins common to 
LG and HG conditions, 21 were down regulated and 18 were up-regulated in HG 
conditions. 
Actin-related protein 2/3 complex subunit 1B is one of down regulated 
proteins in hPDLFs with high glucose incubation. This protein involves in innate 
immune system specifically in Fc-gamma receptor (FCGR) dependent phagocytosis 
pathway which responsible about the process of phagocytosis to eliminate invading 
infectious agents. FCGR is specific types of phagocytic receptors (Nimmerjahn and 
Ravetch, 2006). Downregulation of actin-related protein 2/3 complex subunit 1B 
may affect the process of removing the infectious agent which could increase the 
inflammatory process in the periodontium and increase the tissue breakdown in 
hyperglycaemic condition.  
High mobility group protein B1 was downregulated in hPDLFs incubated in 
high glucose. This protein involves in many pathways in the innate immune system 
and programmed cell death. The innate immune system pathways include toll-like 
receptors cascades, advanced glycosylation endproduct receptor signalling, TRAF6 
mediated NF-kB activation and cytosolic sensors of pathogen-associated DNA. Toll-
like receptors (TLR) family that identify exact components conserved among 
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microorganisms. TLRs activation leads to the initiation of inflammatory responses 
and to the development of antigen-specific adaptive immunity. The TLR-induced 
inflammatory response is dependent on a common signalling pathway that is 
facilitated by the adaptor molecule MyD88 (Takeda et al., 2003). Advanced 
glycosylation endproduct receptor signalling also known as receptor for advanced 
glycation end-products (RAGE). The major inflammatory pathway activated by 
RAGE activation is NF-κB (Bierhaus, 2006). High mobility group protein B1 also 
involves in programmed cell death pathway specifically in apoptosis induced DNA 
fragmentation. As HMGB1 involves in inflammation and found to be decreased in 
the hPDLFs cell lysate when cultured in high glucose concentration, this suggests 
leaking out of the cell and starting the inflammation signalling cascade via RAGE 
interaction. 
The E3 ubiquitin-protein ligase HUWE1 was also down-regulated in high 
glucose incubation. This protein is involved in adaptive immune system specifically 
in Class I MHC mediated antigen processing and presentation pathway. This will 
affect the ability of identify and counter bacteria and viruses invading to 
periodontium tissues in hyperglycaemia, with decreased resistance to invading of 
infectious agents which may cause initiation of inflammatory process and tissue 
breakdown in the periodontium in hyperglycaemia.  
Signal transducer and activator of transcription 1-alpha/beta protein was also 
downregulated in hPDLFs in high glucose incubations. Many pathways are affected 
by this protein - including FGFR1, interleukin-6, growth hormone receptor 
signalling, and PDGF and SCF-KIT. Alpha-enolase protein was down regulated with 
high glucose incubation in hPDLFs. Cytosolic enolase dimer catalyses the reversible 
reaction of phosphoenolpyruvate and to form 2-phosphoglycerate (Giallongo et al., 
1986). 
Aldo-keto reductase family 1 member C3 was up-regulated in hPDLFs when 
incubated in high glucose. This protein involves in the metabolism of lipids and 
lipoproteins, metabolism of vitamins and cofactors, visual phototransduction and 
signalling by retinoic acid. 
Sixteen proteins were found only in hPDLFs in low glucose incubations and 
may have been down regulated and thereby undetectable in the HG cultures. The 
proteins included: glycogen synthase kinase-3β (isoform-2) – influencing NF-κB 
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binding and p53 signaling (Perkins, 2006); and NADP-dependent aldehyde 
dehydrogenase (Ko et al., 2012). Twelve proteins were detected only in HG cultures. 
Transcription changes in HG conditions may have increased their expression such 
that they became detectable. These proteins included: E3 ubiquitin-protein ligase 
(isoform 3); and glycogen debranching enzyme (isoform 5) – involved in glucose 
metabolism and glycogen breakdown. 
Pathways analysis of proteins down-regulated and up-regulated by HG 
cultures indicate many and diverse pathways were changed. Mechanisms other than 
dicarbonyl stress and MG glycation may be involved. 
 
4.9 Cytosolic dicarbonyl proteome in hPDLFs in vitro 
To identify proteins that are susceptible to MG modification, I prepared a cell 
extract with increased modification with exogenous MG. This showed 173 proteins 
were modified by MG-H1. Protein modifications were also analysed in cytosolic 
extracts from LG and HG incubations. Only one of the 173 proteins modified in the 
positive control samples was found also modified in a cell extract: that was of actin 
cytoplasmic 2 protein or γ-actin in HG cultures. γ-Actin is a ubiquitous protein 
essential for the actin filament cytoskeleton in all non-muscle cells. It is required for 
reinforcement and long-term stability of F-actin–based structures (Belyantseva et al., 
2009). This may disrupt actin polymerisation. Older studies suggest MG promotes or 
stabilises actin polymerisatioon (Fésüs et al., 1981). 
In LG cell extracts there were 7 proteins detected with MG-H1 adduct 
residues. These were not detected in the positive control and so their modfication 
requires further confirmation. In HG cell extracts there were 7 proteins detected with 
MG-H1 adduct residues – incluing actin. These were not detected in the positive 
control and so their modfication requires further confirmation. As the related 
unmodified proteins were not detected in the cell extracts, it is conceivable that MG 
modification leads to their accumulation during the cell culture to a detectable level. 
Moesin was detected with MG-H1 adduct in the MG modification postive control 
and the unmodified protein was detected and decreased in the HG incubations. It is 
conceivable that MG modification of Moesin occurs in cells and increase of this 
leads to decreased half-life and lower concentration of unmodified moesin in HG 
cultures. Moesin was detected as MG-modified in human aorta and carotid arteries 
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of diabetic patients by immunohistochemistry and mass spectrometry (Lund et al., 
2011).  
From the incubations in LG and HG, evidence for some other modifications 
were found: FL, CML and CEL. Vimentin protein is found modified by FL in the 
positive control, LG and HG conditions. It was previously claimed that vimentin was 
selectively modified by CML residues (Kueper et al., 2007) but this is unlikely as 
CML originates mostly from FL degradation. It may be that in previous studies that 
FL residues in vimentin were degraded to CML residues in pre-analytic processing. 
Vimentin is structurally important for the mechanical integrity of cells and 
localization of intracellular components (Guo et al., 2013). Echinoderm microtubule-
associated protein-like 1 was modified by MG-H1 in LG and HG conditions. This 
protein involves in regulation of microtubules in the cytoskeleton. 
 
4.10 Characterisation of protein glycation, oxidation and nitration markers in 
plasma protein of healthy subject, subjects with chronic periodontitis and 
periodontitis patients with co-morbidities 
Plasma protein was collected from patients with periodontitis and patients 
with periodontitis and other comorbid diseases such as diabetes and CKD. Plasma 
was analysed for protein damage markers using gold standard analytical technique 
LC-MS/MS with stable isotope dilution analysis. The result shows significant 
changes in the level of protein damage markers in the plasma of patients with 
periodontitis and patients with periodontitis, diabetes and CKD. The level of 3DG-H, 
MOLD, MetSO, NFK and 3-NT was increased significantly in patients with 
periodontitis and patients with periodontitis, diabetes and CKD as compared with 
healthy subjects. MetSO, NFK and 3-NT are oxidative markers and it was found that 
periodontitis is associated with oxidative stress and worsened by poor glycaemic 
status in patients with diabetes (Allen et al., 2011). The residue content of MetSO in 
plasma of diabetic, CKD and periodontitis was higher by 160% compared to patients 
with periodontitis only. This findings suggest the ability of local periodontal 
inflammation to cause potential systematic effects. 
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4.11 Potential impact of Glo1 inducers on the periodontal diseases 
Manuka honey was claimed to decrease dental plaque around the tooth by its 
bacteriocidal activity of MG (Nayak et al., 2010). The level of MG in Manuka honey 
exceeds the concentration of MG in many foods and beverages (Degen et al., 2012). 
The bacteriocidal activity of Manuka honey depends on its content of sugar, H2O2, 
MG, and bee defensin-1. Indeed, elimination of MG alone from Manuka honey did 
not decrease its bacteriocidal activity (Kwakman et al., 2010). 
In this project rather Glo1 inducers, decreasing dicarbonyl stress, improved 
the functionality of hPDLFs in vitro. Applying Glo1 inducers to dental tissues 
clinically may be achieved through tablets, mouth wash, tooth paste and chewing 
gum. This could improve prevention of the tissue breakdown at early stages of the 
disease and improve the outcome of clinical procedures such as teeth scaling and 
root planning and periodontal surgeries. In addition, Glo1 inducers could decrease 
the need of antibiotics in treatment of periodontitis and help decrease the 
development of antibiotic resistance. Also, in patients with diabetes Glo1 inducers 
could decrease the level of tissue breakdown and improve the periodontal health 
status. Periodontitis in patients was found to increase the levels of protein glycation, 
oxidation and nitration markers in plasma. This may impact on systemic health status 
in patient with and without diabetes, increasing the risk of impaired glycaemic 
control and related complications. 
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5. Conclusions and further work 
5.1 Conclusion 
Multiple aspects of hPDLFs function in periodontitis were studied in this 
PhD project: 
(i) MG metabolism by the glyoxalase pathway in hPDLFs in vitro was studied for 
the first time and its dysfunction in high glucose concentration was 
characterised; 
(ii) The effect of Glo1 inducers on the formation and metabolism of MG in 
hyperglycaemia and protein damage in hPDLFs in vitro was investigated; 
(iii) The effect of dicarbonyl stress and its alleviation by Glo1 inducers on hPDLFs 
binding to collagen-1 was investigated;  
(iv) The effect of high glucose concentration on the cytosolic proteome of hPDLFs 
in vitro was studied; and 
(v) A pilot investigation of plasma protein glycation, oxidation and nitration in 
clinical periodontitis was completed. 
Glyoxalase system, dicarbonyls, markers of protein damage and whole 
proteomics have, for the first time as far as I am aware, been comprehensively 
quantified in human periodontal ligament fibroblasts cells an in in vitro 
hyperglycaemic model. The findings have shown that there is a risk of dicarbonyl 
stress and increased protein damage in periodontal diseases whereby MG formation 
is increased and Glo1 is down-regulated by increased proteolysis. Glo1 induction 
may now be viewed as a future target for pharmacological therapies to treat and 
prevent periodontal diseases if the findings of the high glucose model of hPDLFs 
culture can be translated to mechanisms of periodontitis clinically. 
hPDLFs cultured in medium containing a higher glucose concentration have 
an increased glucose consumption, increased flux of formation of D-lactate, 
decreased Glo1 activity and modestly decreased GSH content that imposes  
dicarbonyl stress. There was no evidence for increased oxidative stress and increased 
oxidative damage in high glucose concentration cultures. There was an increase in 
the cellular concentration of MG and 3-DG in high glucose, although there was no 
change in glyoxal. High glucose concentration associated decline in Glo1 activity 
was due to decreased Glo1 protein and decreased Glo1 protein half-life. Increase 
cellular content of MG cause an increased in MG-H1 free adduct and MG-H1 
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residue content of cells suggests that there is increased MG glycation of cellular 
protein in high glucose concentrations in vitro. In addition, impaired adhesion to 
collagen -I was found following MG-glycation of collagen and this was suggestive 
of altered hPDLFs function in cell-cell and cell-matrix interactions. Increased release 
of MG from hPDLFs and glycation of extracellular matrix proteins and increased 
turnover of cellular proteins via MG-H1 modification may contribute to breakdown 
of periodontium in hyperglycaemia. 
Treatment of periodontal ligament fibroblasts model, hPDLFs, with Glo1 
inducers protected the cells against decline in the Glo1 activity in high glucose 
concentrations in vitro. Furthermore, increased formation of MG and other 
dicarbonyls in high glucose concentrations were returned to control levels. Glo1 
inducers prevented increased AGE adduct residues in cell protein and flux of 
formation in high glucose concentrations. In addition, the adhesion study shows that 
the Glo1 inducers not only prevent impaired collagen-I adhesion of hPDLFs in high 
glucose culture but even enhance the adhesion ability of the cells to collagen-1 in 
low glucose culture too, suggesting a remarkable ability to improve hPDLFs 
function in primary cultures in relatively low glucose concentrations. These findings, 
if they can be translated to mechanisms of periodontitis clinically, suggests that Glo1 
inducer is a promising pharmacological agent which may improve protection from 
periodontal tissue breakdown in periodontal diseases. Stimulation of Glo1 
expression may contribute to health benefits of Glo1 inducers and they may protect 
against the development of periodontal diseases in diabetes. 
A limitation of this study has been that hPDLFs is a primary cell population 
and the cells used in this study were only from 3 different donors. However, the 
primary effects were found and validated in all 3 different donor hPDLFs samples. 
However, this thesis has shown that glycation occurs within cultured hPDLFs and 
that MG accumulates in high glucose exposure, driving dicarbonyl stress. 
Periodontitis is a further disease wherein dicarbonyl stress may be implicated as a 
pathological mechanism. 
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5.2 Further work 
In this study I investigated the effect of high glucose concentration on 
periodontal ligament fibroblasts in vitro and beneficial role of Glo1 inducer in 
countering dicarbonyl stress. However I did not examine the possible mechanism 
related with the protecting effects of a Glo1 inducer against dicarbonyl stress. It 
would be of interest to silence Glo1 in control and tRSV, HSP and tRSV-HSP 
treated cells to assess if the benefits of tRSV, HSP and tRSV-HSP are Glo1 
dependent. In activating Nrf2 and influencing other targets, tRSV, HSP and tRSV-
HSP may have many other effects as well as Glo1 induction and stabilisation in 
hPDLFs. Previously, tRSV has received significant attention as either a potential 
therapy or preventive agent against chronic diseases such as diabetes, cardiovascular 
atherosclerosis, cancer and hypertension. However, the bioavailability of tRSV in 
human subjects is low after oral administration. This is mainly due to the rapid 
metabolism of tRSV and excretion of conjugates. HSP is also a Glo1 inducer and 
together with tRSV the synergism produces an effective binary formulation for 
induction of Glo1 and related effects – for example, caloric restriction mimetic effect 
seen herein. Deliberate design of synergistic pharmaceutical dose co-formulations of 
dietary bioactive compounds may be an effective strategy to achieve health benefits 
clinically in prevention and treatment of periodontitis and other disease. tRSV-HSP 
co-formulation could be a suitable treatment of periodontitis. This will explored in 
future. 
The studies with hPDLFs cells require follow-up with more investigation 
about contribution of glycation on periodontal breakdown. Finally, it will be 
important to study glyoxalase system, dicarbonyl stress and glycation on other cell 
lines originated from oral tissues and study its effect on other oral diseases.   
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Appendix I – Table of total identified cytosolic proteins in 
hPDLFs   
Table 57: Total identified cytosolic proteins in hPDLFs   
Protein 
accession 
numbers 
Protein name 
Gene 
accession 
numbers 
P43034 Platelet-activating factor acetylhydrolase  PAFAH1B1 
Q9Y281 Cofilin-2  CFL2 
Q12873-3 
Isoform 3 of Chromodomain-helicase-DNA-binding 
protein 3  
CHD3 
A0A087X0S5 Collagen alpha-1(VI) chain  COL6A1 
P26038 Moesin  MSN 
Q9BZK7 F-box-like/WD repeat-containing protein  TBL1XR1 
P61221 ATP-binding cassette sub-family E member 1  ABCE1 
Q9NX08 COMM domain-containing protein 8  COMMD8 
Q9UHD9 Ubiquilin-2  UBQLN2 
Q9BRP8-2 Isoform 2 of Partner of Y14 and mago  WIBG 
Q99707 Methionine synthase  MTR 
Q15021 Condensin complex subunit 1  NCAPD2 
P63241-2 
Isoform 2 of Eukaryotic translation initiation factor 
5A-1  
EIF5A 
E5RIH5 TELO2-interacting protein 2  TTI2 
O15143 Actin-related protein 2/3 complex subunit 1B  ARPC1B 
O95816 BAG family molecular chaperone regulator 2  BAG2 
P09429 High mobility group protein B1  HMGB1 
Q7Z6Z7 E3 ubiquitin-protein ligase  HUWE1 
P38117-2 
Isoform 2 of Electron transfer flavoprotein subunit 
beta  
ETFB 
P35241-5 Isoform 5 of Radixin RDX 
P42224 
Signal transducer and activator of transcription 1-
alpha/beta  
STAT1 
Q96BJ3 Axin interactor, dorsalization-associated protein  AIDA 
Q96HC4| PDZ and LIM domain protein 5 PDLIM5 
H0YBD7 
Heterogeneous nuclear ribonucleoprotein H 
(Fragment) 
HNRNPH1  
A0A0B4J269 Tubulin beta-3 chain  TUBB3 
P06733 Alpha-enolase  ENO1 
G3XAI2 Laminin subunit beta-1  LAMB1  
A8MTY9 Down syndrome critical region protein 3  DSCR3 
O95372 Acyl-protein thioesterase 2  LYPLA2 
Q9H3H3-2 Isoform 2 of UPF0696 protein C11orf68  C11orf68 
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Q05519-2 Isoform 2 of Serine/arginine-rich splicing factor 11  SRSF11 
Q32Q12 Nucleoside diphosphate kinase  NME1-NME2 
C9J0J7 Profilin-2  PFN2 
O15085-2 
Isoform 2 of Rho guanine nucleotide exchange factor 
11 
ARHGEF11 
Q9NUQ8-2 
Isoform 2 of ATP-binding cassette sub-family F 
member 3  
ABCF3 
P42330 Aldo-keto reductase family 1 member C3  AKR1C3 
O14617-5 Isoform 5 of AP-3 complex subunit delta-1  AP3D1 
Q86VS8 Protein Hook homolog 3 HOOK3 
Q9UHD8-2 Isoform 2 of Septin-9 SPET9 
P98082-3 Isoform 3 of Disabled homolog 2  DAB2 
P48507 Glutamate--cysteine ligase regulatory subunit  GCLM  
P78371 T-complex protein 1 subunit beta  CCT2 
A0A0A0MR5
0 
Cullin-4A  CUL4 
A0A0C4DGQ
5 
Calpain small subunit 1  CAPNS1 
Q14157-5 Isoform 5 of Ubiquitin-associated protein 2-like  UBAP2L 
Q9Y680-2 Isoform 2 of Peptidyl-prolyl cis-trans isomerase  FKBP7 
P29401-2 Isoform 2 of Transketolase  TKT 
Q13045-2 Isoform 2 of Protein flightless-1 homolog  FLII 
P20042 Eukaryotic translation initiation factor 2 subunit 2  EIF2S2 
Q16822 
Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial  
PCK2 
P22059 Oxysterol-binding protein 1  OSBP 
P08708 40S ribosomal protein S17-like  RPS17L  
E7EMW7 E3 ubiquitin-protein ligase UBR5  UBR5  
Q96PU8-3 Isoform 2 of Protein quaking  QKI 
P35241 Ezrin  EZR  
P26885 Peptidyl-prolyl cis-trans isomerase FKBP2  FKBP2 
P28074-3 Isoform 3 of Proteasome subunit beta type-5  PSMB5 
P68371 Tubulin beta-4B chain  TUBB4B 
Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2  IGF2BP2 
F8VXU5 Vacuolar protein sorting-associated protein 29  VPS29 
P41091 Eukaryotic translation initiation factor 2 subunit 3  EIF2S3 
Q99832 T-complex protein 1 subunit eta CCT7 
Q8TEX9-2 Isoform 2 of Importin-4  IPO4 
P18085 ADP-ribosylation factor 4  ARF4 
P07437 Tubulin beta chain  TUBB 
O75083 WD repeat-containing protein 1  WDR1 
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E7EQV9 Ribosomal protein L15 (Fragment)  RPL15 
Q9NT62-2 Isoform 2 of Ubiquitin-like-conjugating enzyme  ATG3 
Q13885 Tubulin beta-2A chain  TUBB2A 
B5MCX3 Septin-2  Sep-02 
Q9NQZ2 Something about silencing protein 10 UTP3 
P31942-2 
Isoform 2 of Heterogeneous nuclear ribonucleoprotein 
H3  
HNRNPH3 
Q13347 Eukaryotic translation initiation factor 3 subunit I EIF3 
Q12906 Isoform 2 of Interleukin enhancer-binding factor 3  ILF3 
P12956 X-ray repair cross-complementing protein 6  XRCC6 
P19784 Casein kinase II subunit alpha  CSNK2A2 
P42677 40S ribosomal protein S27  RPS27 
Q9Y617 Phosphoserine aminotransferase  PSAT1 
P04040 Catalase  CAT 
Q96EP0-3 Isoform 3 of E3 ubiquitin-protein ligase  RNF31 
H0Y804 Aldo-keto reductase family 1 member C1 (Fragment) AKR1C1 
F8VPD4 CAD protein  CAD 
P05387 60S acidic ribosomal protein P2  RPLP2 
O43264 Centromere/kinetochore protein zw10 homolog  ZW10 
P35580-3 Isoform 3 of Myosin-10  MYH10 
P35579 Myosin-9 MYH9 
P52597 Heterogeneous nuclear ribonucleoprotein F HNRNPF  
A0A0A0MRE
5 
Arf-GAP with SH3 domain, ANK repeat and PH 
domain-containing protein 1  
ASAP1 
Q9BS26 Endoplasmic reticulum resident protein 44  ERP44 
H7C0A4 Vigilin (Fragment)  HDLBP 
P49773 Histidine triad nucleotide-binding protein 1 HINT1 
D6REX3 Protein transport protein  SEC31A 
Q9Y4G6 Talin-2  TLN2 
P62937 Peptidyl-prolyl cis-trans isomerase A  PPIA 
A0A0A0MRJ
6 
Protein-L-isoaspartate(D-aspartate) O-
methyltransferase  
PCMT1 
Q8N122-3 Isoform 3 of Regulatory-associated protein of mTOR  RPTOR 
Q9NR28 Diablo homolog, mitochondrial  DIABLO 
Q8TD19 
 
Serine/threonine-protein kinase  NEK9 
Q9UDY2-3 Isoform C1 of Tight junction protein ZO-2  TJP2 
J3QRS3 Myosin regulatory light chain 12A MYL12A 
Q93008-1 
Isoform 2 of Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X 
USP9X 
Q9UKV8-2 Isoform 2 of Protein argonaute-2  AGO2 
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Q9UNE7-2 Isoform 2 of E3 ubiquitin-protein ligase CHIP STUB1 
Q9BRK5 45 kDa calcium-binding protein  SDF4 
O00754-2 Isoform 2 of Lysosomal alpha-mannosidase  MAN2B1 
P36507 
Dual specificity mitogen-activated protein kinase 
kinase 2  
MAP2K2 
Q06830 Peroxiredoxin-1  PRDX1 
P50454 Serpin H1  SERPINH1 
Q13642-1 Isoform 1 of Four and a half LIM domains protein 1  FHL1 
P24844 Myosin regulatory light polypeptide 9  MYL9 
P49915 GMP synthase [glutamine-hydrolyzing]  GMPS  
J3KND3 Myosin light polypeptide 6  MYL6 
P04075 Fructose-bisphosphate aldolase A  ALDOA  
Q02750 
Dual specificity mitogen-activated protein kinase 
kinase 1  
MAP2K1 
Q9HAU0-2 
Isoform 2 of Pleckstrin homology domain-containing 
family A member 5  
PLEKHA5 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1  HNRNPA2B1 
P17931 Galectin-3  LGALS3 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1  CAND1 
J3KNL6 Protein transport protein Sec16A  SEC16A 
Q9NXG2 THUMP domain-containing protein 1  THUMPD1 
Q6XQN6-3 Isoform 3 of Nicotinate phosphoribosyltransferase  NAPRT 
O60664-2 Isoform 2 of Perilipin-3  PLIN3 
O43252 
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate 
synthase 1  
PAPSS1 
Q9Y3I0 tRNA-splicing ligase RtcB homolog RTCB 
A0A087X0I4 Coatomer subunit epsilon  COPE 
Q9NYU2-2 
Isoform 2 of UDP-glucose:glycoprotein 
glucosyltransferase 1  
UGGT1 
Q8TDZ2-4 
Isoform 4 of Protein-methionine sulfoxide oxidase 
MICAL1  
MICAL1 
P26196 Probable ATP-dependent RNA helicase  DDX6 
P35222 Catenin beta-1  CTNNB1 
Q15008-4 
Isoform 4 of 26S proteasome non-ATPase regulatory 
subunit 6  
PSMD6 
P49721 Proteasome subunit beta type-2  PSMB2 
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain 1  DYNC1LI1 
J3KTN0 Eukaryotic initiation factor 4A-I  EIF4 
V9GYM8 Rho guanine nucleotide exchange factor 2 ARHGEF2 
Q92900-2 Isoform 2 of Regulator of nonsense transcripts 1  UPF1 
O94903 
Proline synthase co-transcribed bacterial homolog 
protein  
PROSC 
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P53618 Coatomer subunit beta  COPB1 
Q16531 DNA damage-binding protein 1  DDB1 
Q96AC1-3 Isoform 3 of Fermitin family homolog 2 FERMT2 
Q9UHB9 Signal recognition particle subunit SRP68 SRP68 
Q13325-2 
Isoform 2 of Interferon-induced protein with 
tetratricopeptide repeats 5  
IFIT5 
P20700 Lamin-B1  LMNB1 
Q92905 COP9 signalosome complex subunit 5  COPS5 
O00154-6 
Isoform 6 of Cytosolic acyl coenzyme A thioester 
hydrolase  
ACOT7 
Q5T9B7 Adenylate kinase isoenzyme 1  AK1 
Q00341-2 Isoform 2 of Vigilin  HDLBP 
Q14155-5 Isoform 5 of Rho guanine nucleotide exchange factor 7  ARHGEF7 
Q13177 Serine/threonine-protein kinase PAK 2  PAK2 
Q14258 E3 ubiquitin/ISG15 ligase  TRIM25 
Q9Y230 RuvB-like 2  RUVBL2 
P53004 Biliverdin reductase A BLVRA 
P55010 Eukaryotic translation initiation factor 5  EIF5 
P40222 Alpha-taxilin  TXLNA 
A0A075B6Q0 Ras-related protein Rap-1A (Fragment)  RAP1A 
Q99471 Prefoldin subunit 5  PFDN5 
P58004 Sestrin-2  SESN2 
A0A0A0MRI
2 
Sorting nexin 6, isoform CRA_b SNX6 
Q92841 Probable ATP-dependent RNA helicase  DDX17 
Q92616 Translational activator GCN1  GCN1L1 
A0A0A0MQS
9 
Laminin subunit alpha-4  LAMA4 
Q9UK76 Hematological and neurological expressed 1 protein  HN1 
P04792 Heat shock protein beta-1 HSPB1 
P00813 Adenosine deaminase  ADA 
Q9UHD1 
Cysteine and histidine-rich domain-containing protein 
1  
CHORDC1 
Q08211 ATP-dependent RNA helicase A  DHX9 
Q9P2R3-4 Isoform 4 of Rabankyrin-5  ANKFY1 
P31946-2 Isoform Short of 14-3-3 protein beta/alpha  YWHAB 
P38919 Eukaryotic initiation factor 4A-III  EIF4 
P28070 Proteasome subunit beta type-4  PSMB4 
Q96ST2 Protein IWS1 homolog  IWS1 
P15880 40S ribosomal protein S2  RPS2 
O94832 Unconventional myosin-Id  MYO1D 
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RABP2 Cellular retinoic acid-binding protein 2  CRABP2 
P60842 Eukaryotic initiation factor 4A-I (Fragment)  EIF4 
F5GX11 Proteasome subunit alpha type-1  PSMA1 
P40121 Macrophage-capping protein  CAPG 
P53621 Coatomer subunit alpha  COPA 
P07355-2 Isoform 2 of Annexin A2  ANXA2 
P13489 Ribonuclease inhibitor  RNH1 
P55060-3 Isoform 3 of Exportin-2  CSE1L 
Q99961 Endophilin-A2 SH3 
P40763-3 
Isoform 3 of Signal transducer and activator of 
transcription 3  
STAT3 
P06737 Glycogen phosphorylase, brain form PYGB  
A5YKK6-2 
Isoform 2 of CCR4-NOT transcription complex 
subunit 1  
CNOT1 
Q13418 Integrin-linked protein kinase  ILK  
Q9NVA2-2|  Isoform 2 of Septin-11 SPET11 
P55145 Mesencephalic astrocyte-derived neurotrophic factor MANF 
F8WAE5 Eukaryotic translation initiation factor 2A EIF2A  
O14908 PDZ domain-containing protein  GIPC1 
E7EU96 Casein kinase II subunit alpha' CSNK2A1 
Q9NZL4-3 Isoform 3 of Hsp70-binding protein 1  HSPBP1 
P61163 Alpha-centractin  ACTR1A 
O00273 DNA fragmentation factor subunit alpha  DFFA  
O43488 Aflatoxin B1 aldehyde reductase member 2  AKR7A2 
Q13557-10 
Isoform Delta 10 of Calcium/calmodulin-dependent 
protein kinase type II subunit delta  
CAMK2D 
E9PLK3 Puromycin-sensitive aminopeptidase  NPEPPS 
Q9NZI8-2 
Isoform 2 of Insulin-like growth factor 2 mRNA-
binding protein 1  
IGF2BP1 
O14818 Proteasome subunit alpha type-7  PSMA7 
O00203-3 Isoform 2 of AP-3 complex subunit beta-1  AP3B1 
Q5SSJ5 Heterochromatin protein 1-binding protein 3  HP1BP3 
Q8NBF2 NHL repeat-containing protein 2  NHLRC2 
P55263-2 Isoform 2 of Adenosine kinase  ADK 
P49593 Protein phosphatase 1F  PPM1F 
P25789 Proteasome subunit alpha type-4 PSMA4 
C9JLV4 Apoptotic protease-activating factor 1  APAF1 
B8ZZZ7 
DNA polymerase-transactivated protein 6, isoform 
CRA_b 
SPATS2L 
P09104 Gamma-enolase  ENO2  
P09960 Leukotriene A-4 hydrolase  LTA4H 
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B4E0K5 Mitogen-activated protein kinase 14  MAPK14 
Q9NRS6 Sorting nexin-15  SNX15 
P54727 UV excision repair protein RAD23 homolog B  RAD23B 
O43390 Heterogeneous nuclear ribonucleoprotein R  HNRNPR  
Q9Y224 UPF0568 protein C14orf166  C14orf166 
Q6DKJ4 Nucleoredoxin  NXN 
P53602 Diphosphomevalonate decarboxylase  MVD 
Q9Y5P6-2 
Isoform 2 of Mannose-1-phosphate guanyltransferase 
beta  
GMPPB 
Q13242 Serine/arginine-rich splicing factor 9 SRSF9 
Q9NQG5 
Regulation of nuclear pre-mRNA domain-containing 
protein 1B  
RPRD1B 
O95340-2 
Isoform B of Bifunctional 3'-phosphoadenosine 5'-
phosphosulfate synthase 2 
PAPSS2 
Q06210-2 
Isoform 2 of Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1  
GFPT1 
Q8NEU8 DCC-interacting protein 13-beta  APPL2 
P68104 Elongation factor 1-alpha 1  EEF1A1 
P29218-3 Isoform 3 of Inositol monophosphatase 1  IMPA1 
F5H5D3 Tubulin alpha-1C chain  TUBA1C 
Q3SY69 
Mitochondrial 10-formyltetrahydrofolate 
dehydrogenase  
ALDH1L2 
O15144 Actin-related protein 2/3 complex subunit 2  ARPC2 
O95793-3 
Isoform 3 of Double-stranded RNA-binding protein 
Staufen homolog 1  
STAU1 
P49407-2 Isoform 1B of Beta-arrestin-1  ARRB1 
Q99879 Histone H2B type 1-M  HIST1H2BM 
P58546 Myotrophin  MTPN 
E9PDF6 Unconventional myosin-Ib MYO1B 
Q07954 Prolow-density lipoprotein receptor-related protein 1  LRP1 
Q9NTX5 Ethylmalonyl-CoA decarboxylase  ECHDC1  
O00505 Importin subunit alpha-4  KPNA3 
O00267-2 Isoform 2 of Transcription elongation factor SPT5  SUPT5H 
H3BP20 Beta-hexosaminidase  HEXA 
F8W9J4 Dystonin  DST  
Q9UBS4 DnaJ homolog subfamily B member 11  DNAJB11 
Q6WCQ1-2 
Isoform 2 of Myosin phosphatase Rho-interacting 
protein  
MPRIP 
Q9Y285-2 Isoform 2 of Phenylalanine--tRNA ligase alpha subunit  FARSA 
A6PVN5 Serine/threonine-protein phosphatase 2A activator  PPP2R4 
O14841 5-oxoprolinase  OPLAH  
P48163 NADP-dependent malic enzyme  ME1 
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P68363 Tubulin alpha-1B chain  TUBA1B 
Q12797 Aspartyl/asparaginyl beta-hydroxylase  ASPH 
J3KR97 Tubulin-specific chaperone D  TBCD 
H7BZT7 S-formylglutathione hydrolase (Fragment)  ESD 
O4317 D-3-phosphoglycerate dehydrogenase  PHGDH 
H3BR70 Pyruvate kinase  PKM 
P26639-2 Isoform 2 of Threonine--tRNA ligase, cytoplasmic  TARS 
Q12874 Splicing factor 3A subunit 3  SF3A3 
Q96HE7 ERO1-like protein alpha ERO1 
Q9NS86 LanC-like protein 2 LANCL2 
P30043 Flavin reductase (NADPH)  BLVRB  
P23246 Splicing factor, proline- and glutamine-rich  SFPQ 
O14974-3 
Isoform 3 of Protein phosphatase 1 regulatory subunit 
12A  
PPP1R12A 
P61201 COP9 signalosome complex subunit 2  COPS2 
Q92783-2| Isoform 2 of Signal transducing adapter molecule 1  STAM 
Q9BR76 Coronin-1B  CORO1 
P13010 X-ray repair cross-complementing protein 5  XRCC5 
P33991 DNA replication licensing factor  MCM4 
O95433-2 
Isoform 2 of Activator of 90 kDa heat shock protein 
ATPase homolog 1  
AHSA1 
A0A087WUK
2 
Heterogeneous nuclear ribonucleoprotein D-like HNRNPDL  
A0A0C4DGG
9 
Isoform 2 of Chromodomain-helicase-DNA-binding 
protein 4  
CHD4 
P19838-2 Isoform 2 of Nuclear factor NF-kappa-B p105 subunit  NFKB1 
P54725-3 
Isoform 3 of UV excision repair protein RAD23 
homolog A  
RAD23A 
P61764-2 Isoform 2 of Syntaxin-binding protein 1  STXBP1 
Q15056-2 
Isoform Short of Eukaryotic translation initiation 
factor 4H  
EIF4H 
Q9H267 Vacuolar protein sorting-associated protein 33B VPS33B 
Q9UKG1 DCC-interacting protein 13-alpha  APPL1 
F8VYY9 5'-AMP-activated protein kinase subunit gamma-1  PRKAG1 
J3KNQ4 Alpha-parvin  PARVA 
F6TLX2 Glyoxalase domain-containing protein 4  GLOD4 
B7WPG3 Heterogeneous nuclear ribonucleoprotein L-like  HNRNPLL  
P07602-3 Isoform Sap-mu-9 of Prosaposin  PSAP 
U3C7B4 UPF0364 protein C6orf211  C6orf211 
P46108-2 Isoform Crk-I of Adapter molecule crk  CRK 
O60664-3 Isoform 3 of Perilipin-3  PLIN3 
Q13439-4 Isoform 4 of Golgin subfamily A member 4  GOLGA4 
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D6RBV2 Vesicular integral-membrane protein VIP36  LMAN2 
Q9Y678 Coatomer subunit gamma-1 COPG1 
Q14103-3 
Isoform 3 of Heterogeneous nuclear ribonucleoprotein 
D0 
HNRNPD 
P49756 RNA-binding protein 25  RBM25 
O75165 DnaJ homolog subfamily C member 13  DNAJC13 
P40227 T-complex protein 1 subunit zeta  CCT6A 
Q7Z4V5 Hepatoma-derived growth factor-related protein 2  HDGFRP2 
P00441 Superoxide dismutase [Cu-Zn]  SOD1 
Q9Y305 Acyl-coenzyme A thioesterase 9, mitochondrial  ACOT9 
P62280 40S ribosomal protein S11  RPS11 
B0QZ18 Copine-1  CPNE1 
Q12792 Twinfilin-1  TWF1 
Q13185 Chromobox protein homolog 3  CBX3 
O75368 SH3 domain-binding glutamic acid-rich-like protein  SH3BGRL 
P46940 Ras GTPase-activating-like protein  IQGAP1 
Q6P2E9 Enhancer of mRNA-decapping protein 4 EDC4 
A0A0D9SFS3 2-oxoglutarate dehydrogenase, mitochondrial  OGDH  
H9KV75 Alpha-actinin-1 ACTN1 
P50579-3 Isoform 3 of Methionine aminopeptidase 2  METAP2 
P19367-2 Isoform 2 of Hexokinase-1  HK1 
B0YIW6 Archain 1, isoform CRA_a  ARCN1 
Q8N8S7-2 Isoform 2 of Protein enabled homolog  ENAH 
O75592-2 Isoform 2 of E3 ubiquitin-protein ligase  MYCBP2 
P25788-2 Isoform 2 of Proteasome subunit alpha type-3  PSMA3 
E9PNN6 Aldehyde dehydrogenase, dimeric NADP-preferring  ALDH3A1 
P08758 Annexin A1  ANXA5 
Q15942 Zyxin  ZYX 
Q02809-2 
Isoform 2 of Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1  
PLOD1 
Q9NQW7-3 Isoform 3 of Xaa-Pro aminopeptidase 1  XPNPEP1 
A0A0B4J1W
3 
N-alpha-acetyltransferase 15, NatA auxiliary subunit  NAA15 
P62195-2 Isoform 2 of 26S protease regulatory subunit 8  PSMC5 
Q96QK1 Vacuolar protein sorting-associated protein 35  VPS35 
Q9Y570-4 Isoform 4 of Protein phosphatase methylesterase 1  PPME1 
Q14315 Filamin-C  FLNC  
P32119 Peroxiredoxin-2  PRDX2 
P02769 Serum albumin ALB 
A0A087WUT
6 
Eukaryotic translation initiation factor 5B  EIF5B  
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P12814-3 Isoform 3 of Alpha-actinin-1  ACTN1 
O94855-2 Isoform 2 of Protein transport protein Sec24D  SEC24D 
B4DJV2 Citrate synthase  CS 
Q99459 Cell division cycle 5-like protein  CDC5 
Q14764 Major vault protein  MVP 
P06737-2 Isoform 2 of Glycogen phosphorylase, liver form  PYGL 
O43707 Alpha-actinin-4  ACTN4 
P36578 60S ribosomal protein L4  RPL4 
Q8IYI6 Exocyst complex component 8  EXOC8 
M0R061 Coatomer subunit epsilon  COPE 
P62424 60S ribosomal protein L7a  RPL7A 
P18124 60S ribosomal protein L7  RPL7 
Q12768 WASH complex subunit strumpellin  KIAA0196 
P21964-2 Isoform Soluble of Catechol O-methyltransferase  COMT 
P61088 Ubiquitin-conjugating enzyme E2 N  UBE2N 
J3KTA4 Probable ATP-dependent RNA helicase  DDX5 
P06733-2 Isoform MBP-1 of Alpha-enolase  ENO1 
O43615 
Mitochondrial import inner membrane translocase 
subunit  
TIMM44 
O00425 Insulin-like growth factor 2 mRNA-binding protein 3  IGF2BP3 
P00760 Cationic trypsin TRY1 
Q6ZVM7-5 Isoform 5 of TOM1-like protein 2  TOM1L2 
P10253 Lysosomal alpha-glucosidase  GAA 
P62906 60S ribosomal protein L10a  RPL10A 
Q9HC35 Echinoderm microtubule-associated protein-like 4  EML4 
E5RK69 Annexin A6 ANXA6 
P04406-2 
Isoform 2 of Glyceraldehyde-3-phosphate 
dehydrogenase  
GAPDH 
P04083 Annexin  ANXA1 
P30086 Phosphatidylethanolamine-binding protein 1  PEBP1 
H0Y449 
Nuclease-sensitive element-binding protein 1 
(Fragment)  
YBX1 
P23526 Adenosylhomocysteinase  AHCY 
A0A0D9SF53 ATP-dependent RNA helicase   DDX3X 
A0A0B4J2B4 40S ribosomal protein S15  RPS15 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  GAPDH 
Q92499 ATP-dependent RNA helicase  DDX1 
P10809 60 kDa heat shock protein, mitochondrial  HSPD1 
P55884-2 
Isoform 2 of Eukaryotic translation initiation factor 3 
subunit B  
EIF3B 
Q9BUF5 Tubulin beta-6 chain  TUBB6 
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P48735 Isocitrate dehydrogenase [NADP], mitochondrial  IDH2  
P30085 UMP-CMP kinase  CMPK1 
Q16576 Histone-binding protein  RBBP7 
P35573-2 Isoform 5 of Glycogen debranching enzyme  AGL 
P62753 40S ribosomal protein S6  RPS6 
B4DWR3 Prefoldin subunit 3  VBP1 
Q6ZN40 Tropomyosin 1 (Alpha), isoform CRA_f  TPM1 
Q96I99-2 
Isoform 2 of Succinyl-CoA ligase [GDP-forming] 
subunit beta, mitochondrial  
SUCLG2 
P23396-2 Isoform 2 of 40S ribosomal protein S3  RPS3 
Q9Y3P9 Rab GTPase-activating protein 1  RABGAP1 
H0YL52 Tropomyosin alpha-1 chain (Fragment)  TPM1 
Q92734-2 Isoform 2 of Protein TFG  TFG 
P49419-2 
Isoform 2 of Alpha-aminoadipic semialdehyde 
dehydrogenase  
ALDH7A1 
P00966 Argininosuccinate synthase  ASS1 
P78527 DNA-dependent protein kinase catalytic subunit  PRKDC  
Q9Y6D6 
Brefeldin A-inhibited guanine nucleotide-exchange 
protein 1  
ARFGEF1 
K7EN08 Nuclear factor 1  NFIX 
O00487 26S proteasome non-ATPase regulatory subunit 14  PSMD14 
Q8TDQ7-4 Isoform 4 of Glucosamine-6-phosphate isomerase 2  GNPDA2 
Q07666 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1  
KHDRBS1 
O60341-2 Isoform 2 of Lysine-specific histone demethylase 1A  KDM1A 
Q96P70 Importin-9 IPO9 
P00761 Trypsin TRYP 
Q14697-2 Isoform 2 of Neutral alpha-glucosidase AB  GANAB 
Q14204 Cytoplasmic dynein 1 heavy chain 1  DYNC1H1 
P21796 Voltage-dependent anion-selective channel protein 1  VDAC1 
Q8N1G4 Leucine-rich repeat-containing protein 47  LRRC47 
O75828 Carbonyl reductase [NADPH] 3  CBR3 
D6RF62 Multifunctional protein ADE2  PAICS 
Q60FE5 Filamin A  FLNA  
P13639 Elongation factor 2 EEF2 
A0A087X020 Ribosome maturation protein SBDS  SBDS 
P07737 Profilin-1 PFN1 
Q6NZI2 Polymerase I and transcript release factor  PTRF 
P62158 Calmodulin  CALM1 
P47755 F-actin-capping protein subunit alpha-2  CAPZA2 
P17812 CTP synthase 1  CTPS1 
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A0A0A0MR
M8 
Unconventional myosin-VI  MYO6 
A0A087WW
E2 
DNA-directed RNA polymerase POLR2A  
W4VSQ9 Cdc42-interacting protein 4  TRIP10 
Q9BT78 COP9 signalosome complex subunit 4  COPS4 
E9PB90 Hexokinase  HK2 
G5E972 Lamina-associated polypeptide 2, isoform alpha  TMPO 
Q14697 Neutral alpha-glucosidase AB  GANAB 
O43583 Density-regulated protein  DENR 
H7C2E7 Filamin-A  FLNA  
P52594-2 
Isoform 2 of Arf-GAP domain and FG repeat-
containing protein 1  
AGFG1 
D6RGG3 Collagen alpha-1(XII) chain  COL12 
P24534 Elongation factor 1-beta  EEF1 
Q9NZB2-6 
Isoform F of Constitutive coactivator of PPAR-
gamma-like protein 1  
FAM120A 
Q15293 Reticulocalbin-1 RCN1 
O15145 Actin-related protein 2/3 complex subunit 3  ARPC3 
M0QZR4 Rho guanine nucleotide exchange factor 1  ARHGEF1 
Q8TCT9-5 Isoform 5 of Minor histocompatibility antigen H13  HM13 
Q96K76-4 Isoform 4 of Ubiquitin carboxyl-terminal hydrolase 47  USP47 
P49589-3 Isoform 3 of Cysteine--tRNA ligase, cytoplasmic CARS 
P23634-6 
Isoform XB of Plasma membrane calcium-transporting 
ATPase 4  
ATP2B4 
Q92804-2 
Isoform Short of TATA-binding protein-associated 
factor 2N  
TAF15 
Q8WUM4-2 
Isoform 2 of Programmed cell death 6-interacting 
protein  
PDCD6IP 
K7EMW4 Nicalin  NCLN 
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase  SNRNP200 
Q9NRV9 Heme-binding protein 1  HEBP1 
O95817 BAG family molecular chaperone regulator 3  BAG3 
A6NMH6 Septin-8  Sep-08 
P05023-4 
Isoform 4 of Sodium/potassium-transporting ATPase 
subunit alpha-1  
ATP1A1 
Q96A49 Synapse-associated protein 1  SYAP1 
Q9UG63-2 
Isoform 2 of ATP-binding cassette sub-family F 
member 2 
ABCF2 
O60784 Target of Myb protein 1  TOM1 
F8W7C6 60S ribosomal protein L10  RPL10 
Q16658 Fascin  FSCN1  
A0A087WZZ Splicing factor 3B subunit 2 (Fragment) SF3B2 
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5 
Q14257-2 Isoform 2 of Reticulocalbin-2  RCN2 
P10599 Thioredoxin domain-containing protein 17  TXN 
Q9HB07 UPF0160 protein MYG1, mitochondrial  C12orf10 
Q9H0U4 Ras-related protein Rab-1B  RAB1B 
E9PIE3 Protein kinase C delta-binding protein  PRKCDBP 
P00558 Phosphoglycerate kinase 1  PGK1 
P55268 Laminin subunit beta-2  LAMB2 
O94760 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 
1  
DDAH1 
H0Y5F5 Polyadenylate-binding protein  PABPC4 
Q09028-3 Isoform 3 of Histone-binding protein  RBBP4 
F5GZ78 Paxillin PXN 
A8K7Q2 Heat shock cognate 71 kDa protein (Fragment)  HSPA8 
Q96G03 Phosphoglucomutase-2  PGM2 
C9JFV4 Proline-, glutamic acid- and leucine-rich protein 1  PELP1 
FKBP3 Peptidyl-prolyl cis-trans isomerase  FKBP3 
P17612-2 
Isoform 2 of cAMP-dependent protein kinase catalytic 
subunit alpha  
PRKACA 
P25787 Proteasome subunit alpha type-2  PSMA2 
E9PCA1 T-complex protein 1 subunit epsilon  CCT5 
P62917 60S ribosomal protein L8  RPL8 
O94992 Protein HEXIM1  HEXIM1 
Q9Y265 RuvB-like 1  RUVBL1 
P62701 40S ribosomal protein S4, X isoform  RPS4X 
Q13409-6 
Isoform 2F of Cytoplasmic dynein 1 intermediate 
chain 2  
DYNC1I2 
Q05639 Elongation factor 1-alpha 2  EEF1A2 
P35606 Coatomer subunit beta'  COPB2 
Q8TBA6-2 Isoform 2 of Golgin subfamily A member 5  GOLGA5 
Q5H909 Melanoma-associated antigen D2  MAGED2 
D3YTB1 60S ribosomal protein L32 (Fragment) RPL32  
Q13523 Serine/threonine-protein kinase PRP4 homolog  PRPF4B 
P68366-2 Isoform 2 of Tubulin alpha-4A chain  TUBA4A 
Q9HCN8 Stromal cell-derived factor 2-like protein 1  SDF2L1 
Q92973 Transportin-1  TNPO1 
P15121 Aldose reductase  AKR1B1 
Q9UBC2-2 
Isoform 2 of Epidermal growth factor receptor 
substrate 15-like 1 
EPS15L1 
P29590 Protein PML  PML 
P54652 Heat shock-related 70 kDa protein 2 HSPA2 
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P20908 Collagen alpha-1(V) chain  COL5 
Q6IBS0 Twinfilin-2  TWF2 
P62241 40S ribosomal protein S8  RPS8 
P50570-2 Isoform 2 of Dynamin-2  DNM2 
H7BYY1 Tropomyosin 1 (Alpha), isoform CRA_m  TPM1 
O00148 ATP-dependent RNA helicase  DDX39 
P07951-3 Isoform 3 of Tropomyosin beta chain  TPM2 
O95394-4 Isoform 3 of Phosphoacetylglucosamine mutase  PGM3 
O00231 26S proteasome non-ATPase regulatory subunit 11  PSMD11 
O95782-2 Isoform B of AP-2 complex subunit alpha-1  AP2A1 
Q5JRA6-2 Isoform 2 of Melanoma inhibitory activity protein 3  MIA3 
P25398 40S ribosomal protein S12  RPS12 
P50991 T-complex protein 1 subunit delta  CCT4 
J3KR44 Ubiquitin thioesterase  OTUB1 
HNRH2 Heterogeneous nuclear ribonucleoprotein H2 HNRNPH2 
Q16762 Thiosulfate sulfurtransferase  TST 
Q12931-2 Isoform 2 of Heat shock protein 75 kDa, mitochondrial  TRAP1 
B8ZZU8 
Transcription elongation factor B (SIII), polypeptide 2 
(18kDa, elongin B), isoform CRA_b  
TCEB2 
A0A0D9SGF
6 
A0A0D9SGF6_HUMAN Spectrin alpha chain, non-
erythrocytic 1  
SPTAN1 
A0A087WX
M6 
60S ribosomal protein L17 (Fragment)  RPL17  
P30050 60S ribosomal protein L12  RPL12 
P23284 Peptidyl-prolyl cis-trans isomerase B  PPIB 
Q08209-2 
Isoform 2 of Serine/threonine-protein phosphatase 2B 
catalytic subunit alpha isoform  
PPP3CA 
Q9Y2J2-2 Isoform 2 of Band 4.1-like protein 3  EPB41L3 
Q92538-2 
Isoform 2 of Golgi-specific brefeldin A-resistance 
guanine nucleotide exchange factor 1 
GBF1 
P54886 Delta-1-pyrroline-5-carboxylate synthase  ALDH18A1 
P30101 Protein disulfide-isomerase  PDIA3 
O75533 Splicing factor 3B subunit 1  SF3B1 
P49411 Elongation factor Tu, mitochondrial  TUFM  
Q04760 Lactoylglutathione lyase  GLO1  
Q9UQ80 Proliferation-associated protein 2G4  PA2G4 
P23142 Fibulin-1  FBLN1 
Q9P2J5 Leucine--tRNA ligase, cytoplasmic  LARS 
A0A0C4DG1
7 
40S ribosomal protein SA (Fragment)  RPSA 
P27348 14-3-3 protein theta  YWHAQ 
Q8IVL6-2 Isoform 2 of Prolyl 3-hydroxylase 3  LEPREL2 
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O43143 
Putative pre-mRNA-splicing factor ATP-dependent 
RNA helicase  
DHX15 
A0A0C4DGS
5 
Golgin subfamily A member 2  GOLGA2  
O60645-3 Isoform 3 of Exocyst complex component 3  EXOC3 
Q96KP4 Cytosolic non-specific dipeptidase  CNDP2  
Q13247-3 
Isoform SRP55-3 of Serine/arginine-rich splicing 
factor 6  
SRSF6 
P63104 14-3-3 protein zeta/delta  YWHAZ 
E9PK25 Cofilin-1 CFL1 
P17655 Calpain-2 catalytic subunit  CAPN2 
Q96D15 Reticulocalbin-3  RCN3 
Q13464 Rho-associated protein kinase 1  ROCK1 
Q13813-3 Isoform 3 of Spectrin alpha chain, non-erythrocytic 1  SPTAN1 
E5RJR5 S-phase kinase-associated protein 1  SKP1 
O43396 Thioredoxin-like protein 1  TXNL1 
Q14008-3 Isoform 3 of Cytoskeleton-associated protein 5  CKAP5 
Q4J6C6-4 Isoform 4 of Prolyl endopeptidase-like  PREPL 
P23219-2 Isoform 2 of Prostaglandin G/H synthase 1  PTGS1 
Q969E4 Transcription elongation factor A protein-like 3  TCEAL3 
Q13564-2 
Isoform 2 of NEDD8-activating enzyme E1 regulatory 
subunit  
NAE1 
P08133 Annexin A5  ANXA6 
H0Y3Y9 
26S proteasome non-ATPase regulatory subunit 4 
(Fragment)  
PSMD4 
Q9UMX0 Ubiquilin-1  UBQLN1 
P62495 Eukaryotic peptide chain release factor subunit 1  ETF1 
P06753-3 Isoform 3 of Tropomyosin alpha-3 chain  TPM3 
P17987 T-complex protein 1 subunit alpha  TCP1 
O43242 26S proteasome non-ATPase regulatory subunit 3  PSMD3 
P52735-2 
Isoform 2 of Guanine nucleotide exchange factor 
VAV2  
VAV2 
P18669 Phosphoglycerate mutase 1  PGAM1 
A0A0A0MTN
3 
Glutathione S-transferase Mu 3  GSTM3 
P14550 Alcohol dehydrogenase [NADP(+)]  AKR1A1 
Q8WWM7-2 Isoform 2 of Ataxin-2-like protein  ATXN2L 
Q9UBT2-2 Isoform 2 of SUMO-activating enzyme subunit 2  UBA2 
Q15233-2 
Isoform 2 of Non-POU domain-containing octamer-
binding protein  
NONO 
Q06124-2 
Isoform 2 of Tyrosine-protein phosphatase non-
receptor type 11  
PTPN11 
P30622-2 Isoform 3 of CAP-Gly domain-containing linker CLIP1 
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protein 1  
O15344-2 Isoform 2 of E3 ubiquitin-protein ligase Midline-1  MID1 
P08621 U1 small nuclear ribonucleoprotein 70 kDa  SNRNP70 
D3DQV9 
Eukaryotic translation initiation factor 4 gamma 2 
(Fragment)  
EIF4G2 
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog  SUGT1 
Q9NR45 Sialic acid synthase  NANS 
B4DLR8 NAD(P)H dehydrogenase [quinone] 1  NQO1 
Q02878 60S ribosomal protein L6  RPL6 
Q15365 Poly(rC)-binding protein 1  PCBP1 
P16152 Carbonyl reductase [NADPH] 1  CBR1 
P63267 Actin, gamma-enteric smooth muscle  ACTG2 
H3BQZ7 HCG2044799  HNRNPUL2 
Q9UEW8-2 
Isoform 2 of STE20/SPS1-related proline-alanine-rich 
protein kinase  
STK39 
P12270 Nucleoprotein TPR  TPR 
P42704 
Leucine-rich PPR motif-containing protein, 
mitochondrial  
LRPPRC 
Q9UHV9 Prefoldin subunit 2  PFDN2 
P68133 Actin, alpha skeletal muscle  ACTA1 
P02545-2 Isoform C of Prelamin-A/C  LMNA 
E9PHV5 Sperm-specific antigen 2  SSFA2 
Q96CV9-2 Isoform 2 of Optineurin  OPTN 
O14964 
Hepatocyte growth factor-regulated tyrosine kinase 
substrate  
HGS  
J3KN67 Tropomyosin alpha-3 chain  TPM3 
P31689 DnaJ homolog subfamily A member 1  DNAJA1 
Q12888-2 Isoform 2 of Tumor suppressor p53-binding protein 1  TP53BP1 
P33176 Kinesin-1 heavy chain  KIF5B 
P22102 Trifunctional purine biosynthetic protein adenosine-3  GART 
Q02252-2 
Isoform 2 of Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial  
ALDH6A1 
Q9NZ56 Formin-2  FMN2 
P04899-4 
Isoform sGi2 of Guanine nucleotide-binding protein 
G(i) subunit alpha-2  
GNAI2 
P26640 Valine--tRNA ligase  VARS 
P08243-3 
Isoform 3 of Asparagine synthetase [glutamine-
hydrolyzing]  
ASNS 
P46100-2 Isoform 1 of Transcriptional regulator ATRX  ATRX 
O60884 DnaJ homolog subfamily A member 2  DNAJA2 
Q7Z3J2 UPF0505 protein C16orf62  C16orf62 
F2Z2Y4 Pyridoxal kinase  PDXK 
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P05388 60S acidic ribosomal protein P0 RPLP0 
P49189| 4-trimethylaminobutyraldehyde dehydrogenase  ALDH9 
Q9NUY8-2 Isoform 2 of TBC1 domain family member 23  TBC1D23 
P02461 Collagen alpha-1(III) chain  COL3 
P62258 14-3-3 protein epsilon  YWHAE 
Q63HN8-4 Isoform 2 of E3 ubiquitin-protein ligase RNF213  RNF213 
P24752 Acetyl-CoA acetyltransferase, mitochondrial  ACAT1 
Q9UMS4 Pre-mRNA-processing factor 19  PRPF19 
Q15477 Helicase SKI2W  SKIV2 
D6RBW1 Eukaryotic translation initiation factor 4E  EIF4 
C9JEJ2 Choline-phosphate cytidylyltransferase A  PCYT1A 
A0A0C4DGS
1 
Isoform 3 of Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa subunit  
DDOST 
F5H6E2 Unconventional myosin-Ic  MYO1C 
Q9NSD9 Phenylalanine--tRNA ligase beta subunit  FARSB 
P61158 Actin-related protein 3  ACTR3 
P35637-2 Isoform Short of RNA-binding protein FUS  FUS 
P14735 Insulin-degrading enzyme  IDE  
A0A024R571 EH domain-containing protein 1  EHD1 
P07686 Beta-hexosaminidase subunit beta  HEXB 
Q08378 Golgin subfamily A member 3  GOLGA3 
Q9H1B7 Interferon regulatory factor 2-binding protein-like  IRF2BP 
Q92896-2 Isoform 2 of Golgi apparatus protein 1  GLG1 
P46063 ATP-dependent DNA helicase Q1  RECQL 
Q05707-2 Isoform 2 of Collagen alpha-1(XIV) chain  COEA1 
Q14152 Eukaryotic translation initiation factor 3 subunit A  EIF3 
P42765 3-ketoacyl-CoA thiolase, mitochondrial  ACAA2 
Q86WN1 F-BAR and double SH3 domains protein 1  FCHSD1 
P49902-2 Isoform 2 of Cytosolic purine 5'-nucleotidase NT5C2 
H3BN57 Protein BLOC1S5-TXNDC5  TXNDC5 
A0A087WUZ
3 
Spectrin beta chain, non-erythrocytic 1  SPTBN1 
P63261 Actin, cytoplasmic 2  ACTG1 
P13797 Plastin-3  PLS3 
E7ESC6 Exportin-7  XPO7 
P09972 Fructose-bisphosphate aldolase C ALDOC  
B4DXZ6 
Fragile X mental retardation syndrome-related protein 
1 
FXR1 
O76003 Glutaredoxin-3  GLRX3 
B4DDD6 Drebrin-like protein  DBNL 
O15305 Phosphomannomutase 2  PMM2 
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O14744 Protein arginine N-methyltransferase 5  PRMT5 
P36957 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial  
DLST 
O43852-3 Isoform 3 of Calumenin  CALU 
O43237 Cytoplasmic dynein 1 light intermediate chain 2  DYNC1LI2 
P36543 V-type proton ATPase subunit E 1  ATP6V1E1 
A0A087WTA
8 
Collagen alpha-2(I) chain  COL1A2 
P26599-2 Isoform 2 of Polypyrimidine tract-binding protein 1  PTBP1 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic  IDH1  
P07339 Cathepsin D  CTSD 
Q5SW79-2 Isoform 2 of Centrosomal protein of 170 kDa  CEP170 
H3BMS0 RNA-binding protein with serine-rich domain 1  RNPS1 
Q96M27 Protein PRRC1  PRRC1 
P52630-4 
Isoform 2 of Signal transducer and activator of 
transcription 2  
STAT2 
Q13561-2 Isoform 2 of Dynactin subunit 2  DCTN2 
P02452 Collagen alpha-1(I) chain  COL1 
P12111 Collagen alpha-3(VI) chain  COL6 
Q32P28 Prolyl 3-hydroxylase 1  LEPRE1 
A0A0A0MSA
7 
Eukaryotic translation initiation factor 4 gamma 3  EIF4G3 
Q9H4L5-2 
Isoform 1b of Oxysterol-binding protein-related 
protein 3 
OSBPL3 
A0A087WYT
3 
Prostaglandin E synthase 3  PTGES3 
P48739-3 
Isoform 3 of Phosphatidylinositol transfer protein beta 
isoform  
PITPNB 
P07195 L-lactate dehydrogenase B chain  LDHB 
Q9NYL9 Tropomodulin-3  TMOD3 
C9JFR7 Cytochrome c (Fragment)  CYCS 
O14558 Heat shock protein beta-6  HSPB6 
P49321 Nuclear autoantigenic sperm protein  NASP 
Q9H444 Charged multivesicular body protein 4b  CHMP4 
O14980 Exportin-1  XPO1 
Q01518 Adenylyl cyclase-associated protein 1  CAP1 
C9J7E5 Transportin-3 TNPO3 
P47897-2 Isoform 2 of Glutamine--tRNA ligase  QARS 
P46777 60S ribosomal protein L5  RPL5 
Q5JSL3 Dedicator of cytokinesis protein 11  DOCK11 
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2  HSD17B10  
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Q14789-2 Isoform 2 of Golgin subfamily B member 1  GOLGB1 
O95671-2 Isoform 2 of N-acetylserotonin  ASMTL 
K7ELL7 Glucosidase 2 subunit beta  PRKCSH  
Q15393 Splicing factor 3B subunit 3  SF3B3 
P18206-2 Isoform 1 of Vinculin  VCL 
P38606 V-type proton ATPase catalytic subunit A  ATP6V1A 
P62805 Histone H4  HIST1H4A 
Q01082-3 Isoform 2 of Spectrin beta chain, non-erythrocytic 1  SPTBN1 
P78318 Immunoglobulin-binding protein 1  IGBP1 
Q8IWE2-2 Isoform 2 of Protein NOXP20  FAM114A1 
A0A087WYV
8 
Fibrillin-2  FBN2  
B4DFG0 Protein DEK  DEK 
Q9H788 SH2 domain-containing protein 4A  SH2D4A 
Q5HY54 Filamin-A (Fragment)  FLNA  
Q9NYF8-2 Isoform 2 of Bcl-2-associated transcription factor 1  BCLF1 
P78559 Microtubule-associated protein 1A  MAP1B 
Q02790 Peptidyl-prolyl cis-trans isomerase  FKBP4 
Q9UNZ2-5 Isoform 3 of NSFL1 cofactor p47  NSFL1C 
H7C0E5 Zinc finger protein ZPR1 (Fragment)  ZPR1 
A0A087X1Z3 Proteasome activator complex subunit 2  PSME2 
Q9NX46 Poly(ADP-ribose) glycohydrolase ARH3  ADPRHL2 
I3L0K2 Thioredoxin  TXNDC17 
P28838-2 Isoform 2 of Cytosol aminopeptidase  LAP3 
Q15459 Splicing factor 3A subunit 1  SF3A1 
Q04917 14-3-3 protein eta  YWHAH 
P78417 Glutathione S-transferase omega-1  GSTO1 
Q14160-3 Isoform 3 of Protein scribble homolog  SCRIB 
P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1 
P28482 Mitogen-activated protein kinase 1 MAPK1 
P26641-2 Isoform 2 of Elongation factor 1-gamma  EEF1G 
Q96AE4-2 Isoform 2 of Far upstream element-binding protein 1 FUBP1 
Q92945 Far upstream element-binding protein 2  KHSRP  
A0A087WZH
7 
Myristoylated alanine-rich C-kinase substrate  MARCKS 
Q7L5N1 COP9 signalosome complex subunit 6  COPS6 
Q8WVM8-2 Isoform 2 of Sec1 family domain-containing protein 1  SCFD1 
P11021 78 kDa glucose-regulated protein  HSPA5 
Q14974 Importin subunit beta-1  KPNB1 
O00232 26S proteasome non-ATPase regulatory subunit 12  PSMD12 
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A0A087WW
M0 
Trafficking protein particle complex subunit 3  TRAPPC3 
1433G 14-3-3 protein gamma  YWHAG 
Q15435 Protein phosphatase 1 regulatory subunit 7  PPP1R7 
P49792 E3 SUMO-protein ligase RanBP2 RANBP2 
P35221 Catenin alpha-1  CTNNA1 
Q9BTT0 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member E  
ANP32E 
P27824-2 Isoform 2 of Calnexin  CANX 
P63010-2 Isoform 2 of AP-2 complex subunit beta  AP2B1 
P39019 40S ribosomal protein S19  RPS19 
P43487-2 Isoform 2 of Ran-specific GTPase-activating protein  RANBP1 
Q10567-2 Isoform B of AP-1 complex subunit beta-1  AP1B1 
Q9ULV4-2 Isoform 2 of Coronin-1C  CORO1C 
Q9Y2X3 Nucleolar protein 58  NOP58 
Q15436 Protein transport protein Sec23A  SEC23A 
Q06323 Proteasome activator complex subunit 1  PSME1 
P15586 N-acetylglucosamine-6-sulfatase  GNS 
E7ETU9 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  PLOD2 
H3BPE1 
Microtubule-actin cross-linking factor 1, isoforms 
1/2/3/5  
MACF1 
P45974-2 
Isoform Short of Ubiquitin carboxyl-terminal 
hydrolase 5  
USP5 
A0A087WXS
7 
ATPase ASNA1 ASNA1 
O14776-2 Isoform 2 of Transcription elongation regulator 1  TCERG1 
Q15084-5 Isoform 5 of Protein disulfide-isomerase A6 PDIA6 
Q96FQ6 Protein S100-A16  S100A16 
Q93009-3 Isoform 3 of Ubiquitin carboxyl-terminal hydrolase 7  USP7 
P12081 Isoform 4 of Histidine--tRNA ligase, cytoplasmic  HARS 
Q9HB71 Calcyclin-binding protein  CACYBP 
Q86UU1-2 
Isoform 2 of Pleckstrin homology-like domain family 
B member 1  
PHLDB1 
P80303-2 Isoform 2 of Nucleobindin-2  NUCB2 
Q2M389 WASH complex subunit 7  KIAA1033 
O60701-3 Isoform 3 of UDP-glucose 6-dehydrogenase  UGDH 
Q7KZF4 Staphylococcal nuclease domain-containing protein 1  SND1 
P62314 Small nuclear ribonucleoprotein Sm D1  SNRPD1 
P09601 Heme oxygenase 1  HMOX1 
P50395 Rab GDP dissociation inhibitor beta  GDI2 
O94804 Serine/threonine-protein kinase 10  STK10 
P09496-2 Isoform Non-brain of Clathrin light chain A  CLTA 
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P38646 Stress-70 protein, mitochondrial  HSPA9 
B4DDF4 Calponin  CNN2 
P14866 Heterogeneous nuclear ribonucleoprotein L  HNRNPL  
Q8TAT6-2 
Isoform 2 of Nuclear protein localization protein 4 
homolog  
NPLOC4 
H0Y9H6 Calpastatin (Fragment)  CAST 
Q9Y490 Talin-1  TLN1 
Q93052 Lipoma-preferred partner  LPP 
P67936-2 Isoform 2 of Tropomyosin alpha-4 chain  TPM4 
Q12906-4 Isoform 4 of Interleukin enhancer-binding factor 3  ILF3 
A0A0C4DG8
9 
Probable ATP-dependent RNA helicase  DDX46 
E9PKF6 
Serine/threonine-protein phosphatase 6 regulatory 
subunit 3 
PPP6R3 
P54578 Ubiquitin carboxyl-terminal hydrolase 14  USP14 
P53992 Protein transport protein Sec24C  SEC24C 
Q86UP2 Kinectin  KTN1 
O95373 Importin-7  IPO7 
Q9UBR2 Cathepsin Z  CTSZ 
P08670 Vimentin  VIM 
F5H4R6 Nucleosome assembly protein 1-like 1  NAP1L1 
Q9UDT6-2 
Isoform 2 of CAP-Gly domain-containing linker 
protein 2 
CLIP2 
H0YFY6 Nuclear mitotic apparatus protein 1  NUMA1 
A0A087X2H1 E3 ubiquitin-protein ligase  HECTD1 
A0A087WVC
1 
ATP-dependent RNA helicase  DDX50 
Q14914 Prostaglandin reductase 1  PTGR1 
Q8N0X7 Spartin  SPG20 
Q9BZQ8 Protein Niban  FAM129A 
G3V0E4 Mitochondrial-processing peptidase subunit beta  PMPCB 
E5RGA2 Eukaryotic translation initiation factor 3 subunit E  EIF3 
Q9UEW8 Serine/threonine-protein kinase OSR1  OXSR1 
Q13895 Bystin  BYSL 
Q8IX12-2 
Isoform 2 of Cell division cycle and apoptosis 
regulator protein 1  
CCAR1 
Q9H2G2 STE20-like serine/threonine-protein kinase  SLK 
P07951 Tropomyosin beta chain  TPM2 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8  PRPF8 
E7EQT4 
Apoptotic chromatin condensation inducer in the 
nucleus  
ACIN1 
P05997 Collagen alpha-2(V) chain  COL5 
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P07954 Fumarate hydratase, mitochondrial  FH  
P49368 T-complex protein 1 subunit gamma  CCT3 
H9KV28 Protein diaphanous homolog 1  DIAPH1 
A0A0B4J2C3 Translationally-controlled tumor protein  TPT1 
P27797 Calreticulin  CALR 
Q07960 Rho GTPase-activating protein 1  ARHGAP1 
Q9BSJ8-2 Isoform 2 of Extended synaptotagmin-1  ESYT1 
Q16204 Coiled-coil domain-containing protein 6  CCDC6 
Q9H3S7 Tyrosine-protein phosphatase non-receptor type 23  PTPN23 
P36776-3 Isoform 3 of Lon protease homolog, mitochondrial  LONP1 
O15460-2 Isoform IIa of Prolyl 4-hydroxylase subunit alpha-2  P4HA2 
O43665-3 Isoform 3 of Regulator of G-protein signaling 10  RGS10 
O75410-2 
Isoform 2 of Transforming acidic coiled-coil-
containing protein 1 
TACC1 
P49257 Protein ERGIC-53  LMAN1 
P30084 Enoyl-CoA hydratase, mitochondrial  ECHS1  
P25705 ATP synthase subunit alpha, mitochondrial  ATP5A1 
P67936 Tropomyosin alpha-4 chain  TPM4 
E9PGM4 1,4-alpha-glucan-branching enzyme  GBE1 
Q9UJ70-2 Isoform 2 of N-acetyl-D-glucosamine kinase  NAGK 
P06396-2 Isoform 2 of Gelsolin  GSN 
P05455 Lupus La protein  SSB 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic  ACAT2 
Q9Y3X0 Coiled-coil domain-containing protein 9 CCDC9 
P54577 Tyrosine--tRNA ligase, cytoplasmic  YARS 
P07237 Protein disulfide-isomerase A4 P4HB 
P06132 Uroporphyrinogen decarboxylase  UROD 
P12110 Collagen alpha-2(VI) chain  COL6 
G3V5R9 Kinesin light chain 1  KLC1 
Q15643 Thyroid receptor-interacting protein 11  TRIP11 
Q12904-2 
Isoform 2 of Aminoacyl tRNA synthase complex-
interacting multifunctional protein 1  
AIMP1 
G3V180 Dipeptidyl peptidase 3  DPP3 
O43776 Asparagine--tRNA ligase, cytoplasmic  NARS 
H0YB24 
Cell cycle and apoptosis regulator protein 2 
(Fragment)  
CCAR2 
Q4G0J3-3 Isoform 3 of La-related protein 7  LARP7 
Q16555 Dihydropyrimidinase-related protein 2  DPYSL2 
P53999 
Activated RNA polymerase II transcriptional 
coactivator p15  
SUB1 
X6RJP6 Transgelin-2 (Fragment) TAGLN2 
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Q16543 Hsp90 co-chaperone Cdc37  CDC37  
P37837 Transaldolase  TALDO1 
P36871 Phosphoglucomutase-1  PGM1 
G8JLD3 ELKS/Rab6-interacting/CAST family member 1  ERC1 
O60763-2 Isoform 2 of General vesicular transport factor p115  USO1 
O75534-4 Isoform 4 of Cold shock domain-containing protein E1  CSDE1 
H3BRE8 RNA polymerase II-associated protein 1  RPAP1 
P17174 Aspartate aminotransferase, cytoplasmic  GOT1 
A0A087WVQ
6 
Clathrin heavy chain  CLTC 
Q14240-2 Isoform 2 of Eukaryotic initiation factor 4A-II  EIF4A2 
Q9H1E3 
Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate 1  
NUCKS1 
P41250 Glycine--tRNA ligase  GARS  
P30041 Peroxiredoxin-6  PRDX6 
P17661 Desmin  DES 
O43852-7 Isoform 7 of Calumenin CALU 
P43490 Nicotinamide phosphoribosyltransferase  NAMPT 
Q8NC51-2 
Isoform 2 of Plasminogen activator inhibitor 1 RNA-
binding protein  
SERBP1 
Q02818 Nucleobindin-1  NUCB1 
P00338-3 Isoform 3 of L-lactate dehydrogenase A chain  LDHA 
E7EX17 Eukaryotic translation initiation factor 4B  EIF4B  
Q9P0K7-2 Isoform 2 of Ankycorbin  RAI14 
Q5T4S7-2 Isoform 2 of E3 ubiquitin-protein ligase  UBR4 
J3KR24 Isoleucine--tRNA ligase, cytoplasmic  IARS 
P07996 Thrombospondin-1  THBS1 
P62714 
Serine/threonine-protein phosphatase 2A catalytic 
subunit beta isoform  
PPP2CB 
A0A087X2I1 26S protease regulatory subunit 10B PSMC6 
O95336 6-phosphogluconolactonase  PGLS  
P09874 Poly [ADP-ribose] polymerase 1  PARP1 
Q14166 Tubulin--tyrosine ligase-like protein 12  TTLL12 
Q9Y5S2 Serine/threonine-protein kinase MRCK beta  CDC42BPB 
Q15717-2 Isoform 2 of ELAV-like protein 1  ELAV1 
I3L459 Phosphatidylinositol transfer protein alpha isoform  PITPNA 
O43399 Tumor protein D54  TPD52L2 
Q14694-2 Isoform 2 of Ubiquitin carboxyl-terminal hydrolase 10  USP10 
Q63ZY3-3 
Isoform 3 of KN motif and ankyrin repeat domain-
containing protein 2 
KANK2 
Q9Y520-5 Isoform 5 of Protein PRRC2C  PRRC2C 
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Q02952-2 Isoform 2 of A-kinase anchor protein 12  AKAP12 
Q15046-2 Isoform Mitochondrial of Lysine--tRNA ligase  KARS 
Q14566 DNA replication licensing factor MCM6  MCM6 
Q8WU90 Zinc finger CCCH domain-containing protein 15 ZC3H15 
H7C456 Microtubule-associated protein 1B  MAP4 
G3V1L9 
Tight junction protein 1 (Zona occludens 1), isoform 
CRA_a 
TJP1 
P61978-2 
Isoform 2 of Heterogeneous nuclear ribonucleoprotein 
K  
HNRNPK 
P55072 Transitional endoplasmic reticulum ATPase VCP 
Q13200 26S proteasome non-ATPase regulatory subunit 2  PSMD2 
Q05682 Caldesmon  CALD1 
P04844-2 
Isoform 2 of Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2 
RPN2 
Q96AY3 Peptidyl-prolyl cis-trans isomerase FKBP10 FKBP10 
Q9UNS2-2 Isoform 2 of COP9 signalosome complex subunit 3  COPS3 
A0AVT1 Ubiquitin-like modifier-activating enzyme 6  UBA6 
F8WCF6 Protein ARPC4-TTLL3  
ARPC4-
TTLL3 
P34931 Heat shock 70 kDa protein 1-like  HSPA1L 
Q99497 Protein deglycase DJ-1  PARK7 
Q01995 Transgelin  TAGLN 
Q15811-8 Isoform 8 of Intersectin-1  ITSN1 
P07814 Bifunctional glutamate/proline--tRNA ligase  EPRS 
Q9ULZ3-2 
Isoform 2 of Apoptosis-associated speck-like protein 
containing a CARD 
PYCARD 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial  IARS2 
Q9Y6Y8 SEC23-interacting protein  SEC23IP 
F8W031 Uncharacterized protein (Fragment)  F8W031 
Q08J23-2 
Isoform 2 of tRNA (cytosine(34)-C(5))-
methyltransferase  
NSUN2 
Q99873-4 Isoform 4 of Protein arginine N-methyltransferase 1  PRMT1 
M0R0P8 Unconventional myosin-IXb  MYO9B 
P46939-2 Isoform 2 of Utrophin  UTRN 
Q9UHB6-4 Isoform 4 of LIM domain and actin-binding protein 1  LIMA1 
P53396-2 Isoform 2 of ATP-citrate synthase  ACLY 
Q9NZN4 EH domain-containing protein 2  EHD2 
P13674 Prolyl 4-hydroxylase subunit alpha-1  P4HA1 
Q9Y450 HBS1-like protein  HBS1 
Q13263 Transcription intermediary factor 1-beta  TRIM28 
Q96TA1-2 Isoform 2 of Niban-like protein 1  FAM129B 
Q02543 60S ribosomal protein L18a  RPL18A 
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Q8WVC0-2 
Isoform 2 of RNA polymerase-associated protein 
LEO1  
LEO1 
Q16222-3 
Isoform 3 of UDP-N-acetylhexosamine 
pyrophosphorylase  
UAP1 
Q9Y696 Chloride intracellular channel protein 4 CLIC4 
Q09666 Neuroblast differentiation-associated protein  AHNAK 
P35998 26S protease regulatory subunit 7  PSMC2 
P51812 Ribosomal protein S6 kinase alpha-3  RPS6KA3 
O95302-3 Isoform 3 of Peptidyl-prolyl cis-trans isomerase  FKBP9 
P53985 Monocarboxylate transporter 1  SLC16A1 
Q01105-2 Isoform 2 of Protein SET SET 
P14618 Pyruvate kinase PKM  PKM 
Q9UBB4 Ataxin-10  ATXN10 
Q05682-5 Isoform 5 of Caldesmon  CALD1 
P28161 Glutathione S-transferase Mu 2  GSTM2 
A0A0C4DFR
6 
Isoform 2 of Protein SEC13 homolog  SEC13 
E9PM90 
Vacuolar protein sorting-associated protein 28 
homolog (Fragment)  
VPS28 
O15067 Phosphoribosylformylglycinamidine synthase  PFAS 
Q9H2M9 Rab3 GTPase-activating protein non-catalytic subunit  RAB3GAP2 
A0A087WTT
1 
Polyadenylate-binding protein (Fragment)  PABPC1 
Q9H4A4 Aminopeptidase B RNPEP 
P09211 Glutathione S-transferase P  GSTP1  
A2A274 Aconitate hydratase, mitochondrial  ACO2 
P13667 Protein disulfide-isomerase A3  PDIA4 
P0DMV8 Heat shock 70 kDa protein 1A  HSPA1A 
Q52LW3 Rho GTPase-activating protein 29  ARHGAP29 
J3KN16 Proteasome-associated protein ECM29 homolog  KIAA0368 
Q9NQC3 Reticulon-4  RTN4 
Q13547 Histone deacetylase 1  HDAC1 
P63279 SUMO-conjugating enzyme UBC9  UBE2I 
Q96I24 Far upstream element-binding protein 3  FUBP3 
Q6UXH1-5 
Isoform 5 of Cysteine-rich with EGF-like domain 
protein 2  
CRELD2 
Q9UQE7 Structural maintenance of chromosomes protein 3  SMC3 
P52788 Spermine synthase  SMS 
O60506-3 
Isoform 3 of Heterogeneous nuclear ribonucleoprotein 
Q 
SYNCRIP 
Q13501-2 Isoform 2 of Sequestosome-1  SQSTM1 
P52209-2 Isoform 2 of 6-phosphogluconate dehydrogenase, PGD 
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decarboxylating  
Q99536 Synaptic vesicle membrane protein VAT-1 homolog  VAT1 
Q7KZ85 Transcription elongation factor SPT6  SUPT6H 
Q01813 ATP-dependent 6-phosphofructokinase, platelet type  PFKP 
Q8IZ07 Ankyrin repeat domain-containing protein 13A  ANKRD13 
H7C2U0 T-complex protein 1 subunit theta (Fragment)  CCT8 
Q9H3U1-2 Isoform 2 of Protein unc-45 homolog A  UNC45A 
E9PM69 26S protease regulatory subunit 6A  PSMC3 
P23381 Tryptophan--tRNA ligase, cytoplasmic  WARS 
P07858 Cathepsin B  CTSB 
P49841-2 Isoform 2 of Glycogen synthase kinase-3 beta  GSK3B 
P11047 Laminin subunit gamma-1  LAMC1 
Q9Y295 Developmentally-regulated GTP-binding protein 1  DRG1 
Q9NTI5-2 
Isoform 2 of Sister chromatid cohesion protein PDS5 
homolog B  
PDS5B 
Q9HCE1 Putative helicase MOV-10 MOV10 
O15355 Protein phosphatase 1G  PPM1G 
F8W1A4 Adenylate kinase 2, mitochondrial  AK2 
O15371-2 
Isoform 2 of Eukaryotic translation initiation factor 3 
subunit D  
EIF3D 
Q9C0C9 E2/E3 hybrid ubiquitin-protein ligase  UBE2O 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase  GRHPR  
G3V2Q1 Heterogeneous nuclear ribonucleoproteins C1/C2  HNRNPC  
P40123 Adenylyl cyclase-associated protein 2  CAP2 
Q9BQS8-4 
Isoform 4 of FYVE and coiled-coil domain-containing 
protein 1  
FYCO1 
P46060 Ran GTPase-activating protein 1  RANGAP1 
Q99613 Eukaryotic translation initiation factor 3 subunit C  EIF3 
O75116 Rho-associated protein kinase 2  ROCK2 
C9J0I9 Nuclear-interacting partner of ALK ZC3HC1 
Q9Y3Z3 Deoxynucleoside triphosphate triphosphohydrolase  SAMHD1 
E5RIW3 Tubulin-specific chaperone A  TBCA 
O00429-2 Isoform 4 of Dynamin-1-like protein  DNM1L 
Q07065 Cytoskeleton-associated protein 4  CKAP4 
Q8WX93 Palladin  PALLD 
O75369-2 Isoform 2 of Filamin-B  FLNB 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 SLC9A3R1 
P31749 RAC-alpha serine/threonine-protein kinase  AKT1 
Q96T76-8 
Isoform 5 of MMS19 nucleotide excision repair 
protein homolog  
MMS19 
P42785 Lysosomal Pro-X carboxypeptidase  PRCP 
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P06576 ATP synthase subunit beta, mitochondrial  ATP5B 
E9PGC8 Microtubule-associated protein  MAP1A 
P16615-5 
Isoform 5 of Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2  
ATP2A2 
P15374 Ubiquitin carboxyl-terminal hydrolase isozyme L3  UCHL3 
P17096-2 
Isoform HMG-Y of High mobility group protein 
HMG-I/HMG-Y  
HMGA1 
Q9UH65 
 
Switch-associated protein 70  SWAP70 
Q9BXS5 AP-1 complex subunit mu-1  AP1M1 
Q9Y4E8 Ubiquitin carboxyl-terminal hydrolase 15  USP15 
Q9C0C2 182 kDa tankyrase-1-binding protein  TNKS1BP1 
P80723 Brain acid soluble protein 1  BASP1 
P30419 Glycylpeptide N-tetradecanoyltransferase 1  NMT1 
P21399 Cytoplasmic aconitate hydratase  ACO1 
Q27J81-2 Isoform 2 of Inverted formin-2  INF2 
A0A0C4DGX
4 
Cullin-1  CUL1 
A0A087WX0
8 
Gamma-adducin  ADD3  
E7EVA0 Microtubule-associated protein 4 (Fragment)  MAP4 
P35555 Fibrillin-1  FBN1 
P20073-2 Isoform 2 of Annexin A7  ANXA7 
Q4V328 GRIP1-associated protein 1  GRIPAP1  
GCP60 Golgi resident protein GCP60  ACBD3 
Q5T5C7 Serine--tRNA ligase, cytoplasmic  SARS 
Q8NC51-3 
Isoform 3 of Plasminogen activator inhibitor 1 RNA-
binding protein  
SERBP1 
Q70UQ0 
Inhibitor of nuclear factor kappa-B kinase-interacting 
protein  
IKBIP 
Q01518-2 Isoform 2 of Adenylyl cyclase-associated protein 1  CAP1 
Q15075 Early endosome antigen 1  EEA1 
Q9UMX5 Neudesin  NENF 
P21980 Protein-glutamine gamma-glutamyltransferase 2  TGM2 
Q12765-2 Isoform 2 of Secernin-1  SCRN1 
P43155-2 Isoform 2 of Carnitine O-acetyltransferase  CART 
Q9BU89 Deoxyhypusine hydroxylase  DOHH 
P39748 Flap endonuclease 1  FEN1 
E9PRQ7 UBX domain-containing protein 1  UBXN1 
P0CG38 POTE ankyrin domain family member I  POTEI 
P17096 High mobility group protein HMG-I/HMG-Y  HMGA1 
Q99460 26S proteasome non-ATPase regulatory subunit 1  PSMD1 
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P22314-2 
Isoform 2 of Ubiquitin-like modifier-activating 
enzyme 1  
UBA1 
P20810-10 Isoform 10 of Calpastatin  CAST 
P19174-2 
Isoform 2 of 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase gamma-1  
PLCG1 
P27361-2 Isoform 2 of Mitogen-activated protein kinase 3  MAPK3 
Q14696 LDLR chaperone MESD  MESDC2 
J3KQ32 Obg-like ATPase 1 OLA1 
Q8NF91 Nesprin-1  SYNE1 
P11586 C-1-tetrahydrofolate synthase, cytoplasmic  MTHFD1 
P50552 Vasodilator-stimulated phosphoprotein  VASP 
Q9NRY4 Rho GTPase-activating protein 35  ARHGAP35 
P50502 Hsc70-interacting protein  ST13 
P04080 Cystatin-B  CSTB 
P29692-3 Isoform 3 of Elongation factor 1-delta  EEF1D 
O14933 Ubiquitin/ISG15-conjugating enzyme E2 L6  UBE2L6 
E7EX90 Dynactin subunit 1  DCTN1 
Q68E01-2 Isoform 2 of Integrator complex subunit 3  INTS3 
P54687 
Branched-chain-amino-acid aminotransferase, 
cytosolic  
BCAT1 
P31948-2 Isoform 2 of Stress-induced-phosphoprotein 1  STIP1 
P43686 26S protease regulatory subunit 6B  PSMC4 
Q9P0J1-2 
Isoform 2 of [Pyruvate dehydrogenase [acetyl-
transferring]]-phosphatase 1, mitochondrial  
PDP1 
Q14247-2 Isoform 2 of Src substrate cortactin  CTTN 
A0A087WV0
5 
Protein GJA9-MYCBP  
GJA9-
MYCBP 
Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 
P04843 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1  
RPN1 
B0QY89 Eukaryotic translation initiation factor 3 subunit L  EIF3 
Q92598 Heat shock protein 105 kDa  HSPH1 
Q13492-2 
Isoform 2 of Phosphatidylinositol-binding clathrin 
assembly protein  
PICALM 
P49327 Fatty acid synthase  FASN  
Q5JSH3-2 Isoform 2 of WD repeat-containing protein 44  WDR44 
Q13308-6 Isoform 6 of Inactive tyrosine-protein kinase 7  PTK7 
Q15029-3 
Isoform 3 of 116 kDa U5 small nuclear 
ribonucleoprotein component  
EFTUD2 
Q9NVS9-3 Isoform 3 of Pyridoxine-5'-phosphate oxidase  PNPO 
Q14847 LIM and SH3 domain protein 1  LASP1 
P62328 Thymosin beta-4  TMSB4X 
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O43592 Exportin-T  XPOT  
P11766 Alcohol dehydrogenase class-3 ADH5 
P46937-5 Isoform 5 of Transcriptional coactivator YAP1 YAP1 
Q15149-3 Isoform 3 of Plectin  PLEC 
Q32MZ4-3 
Isoform 3 of Leucine-rich repeat flightless-interacting 
protein 1  
LRRFIP1 
Q15149-4 Isoform 4 of Plectin  PLEC 
P35658-2 Isoform 2 of Nuclear pore complex protein  NUP214 
P49588 Alanine--tRNA ligase, cytoplasmic  AARS 
Q15149 Plectin  PLEC 
P78357 Contactin-associated protein 1  CNTNAP1 
Q8IWV7 E3 ubiquitin-protein ligase  UBR1 
E9PGC0 Ras GTPase-activating protein 1  RASA1 
Q9UGI8-2 Isoform 2 of Testin  TES 
Q15181 Inorganic pyrophosphatase  PPA1  
B3KS98 Eukaryotic translation initiation factor 3 subunit H  EIF3 
D6R9B6 40S ribosomal protein S3a  RPS3A 
P05091 Aldehyde dehydrogenase, mitochondrial  ALDH2 
P06748-2 Isoform 2 of Nucleophosmin  NPM1 
O95352 Ubiquitin-like modifier-activating enzyme  ATG7 
Q8IVF2-3 Isoform 3 of Protein AHNAK2  AHNAK2 
P56537 Eukaryotic translation initiation factor 6  EIF6 
P14625 Endoplasmin  HSP90B1 
Q53EL6-2 Isoform 2 of Programmed cell death protein 4  PDCD4 
Q9Y2Q3 Glutathione S-transferase kappa 1  GSTK1 
Q9Y3F4-2 
Isoform 2 of Serine-threonine kinase receptor-
associated protein  
STRAP 
O00410-3 Isoform 3 of Importin-5  IPO5 
A8MXH2 Nucleosome assembly protein 1-like 4 (Fragment)  NAP1L4 
P30040 Endoplasmic reticulum resident protein 29  ERP29 
P16278-3 Isoform 3 of Beta-galactosidase  GLB1 
Q00839 Heterogeneous nuclear ribonucleoprotein U  HNRNPU  
P49441 Inositol polyphosphate 1-phosphatase  INPP1 
P30520 Adenylosuccinate synthetase isozyme 2  ADSS 
O96019 Actin-like protein 6A  ACTL6 
E5RHG8 
Transcription elongation factor B polypeptide 1 
(Fragment)  
TCEB1 
B5MDF5 GTP-binding nuclear protein Ran  RAN  
J9JID7 Lamin B2, isoform CRA_a  LMNB2  
O94973-2 Isoform 2 of AP-2 complex subunit alpha-2  AP2A2 
RAB9A Ras-related protein Rab-9A  RAB9A 
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E9PAV3 
Nascent polypeptide-associated complex subunit 
alpha, muscle-specific form  
NACA 
A0A087WY6
1 
Nuclear mitotic apparatus protein 1 (Fragment)  NUMA1 
P30533 Alpha-2-macroglobulin receptor-associated protein  LRPAP1 
P07900-2 Isoform 2 of Heat shock protein HSP 90-alpha  HSP90AA1 
Q5VZU9 Tripeptidyl-peptidase 2  TPP2 
PSMD7 26S proteasome non-ATPase regulatory subunit 7  PSMD7 
E9PHY5 Band 4.1-like protein 2 EPB41L2 
Q04637-9 
Isoform 9 of Eukaryotic translation initiation factor 4 
gamma 1  
EIF4G1 
E9PJ04 Splicing factor 3B subunit 2  SF3B2 
P60983 Glia maturation factor beta  GMFB  
R4GN77 Ubiquitin-conjugating enzyme E2 E3 (Fragment)  UBE2E3 
Q15654 Thyroid receptor-interacting protein 6  TRIP6 
O75436 Vacuolar protein sorting-associated protein 26A  VPS26A 
P08238 Heat shock protein HSP 90-beta  HSP90 
Q9Y2D5-4 Isoform 2 of A-kinase anchor protein 2  AKAP2 
A8MXP9 Matrin-3 MATR3 
P19338 Nucleolin  NCL 
O43149 
Zinc finger ZZ-type and EF-hand domain-containing 
protein 1  
ZZEF1 
F8W6I7 Heterogeneous nuclear ribonucleoprotein A1  HNRNPA1  
P51991 Heterogeneous nuclear ribonucleoprotein A3  HNRNPA3 
F5GWE5 
Phosphatidylinositol transfer protein alpha isoform 
(Fragment)  
PITPNA 
Q9NZ08-2 Isoform 2 of Endoplasmic reticulum aminopeptidase 1  ERAP1 
P78347-2 Isoform 2 of General transcription factor II-I  GTF2I 
Q6PGP7 Tetratricopeptide repeat protein 37  TTC37 
P52907 F-actin-capping protein subunit alpha-1  CAPZA1 
P48681 Nestin  NES 
A0A087WYS
1 
UTP--glucose-1-phosphate uridylyltransferase  UGP2 
Q9UHX1-2 Isoform 2 of Poly(U)-binding-splicing factor PUF60  PUF60 
J3KRC4 5'(3')-deoxyribonucleotidase, cytosolic type NT5C  
Q9HC07 Transmembrane protein 165  TMEM165 
Q9UKY7 Protein CDV3 homolog  CDV3 
Q9NRY5 Protein FAM114A2  FAM114A2 
O43865 Putative adenosylhomocysteinase 2  AHCYL1 
P54136 Arginine--tRNA ligase, cytoplasmic  RARS 
O76094 Signal recognition particle subunit  SRP72 
P49750-4 Isoform 4 of YLP motif-containing protein 1  YLPM1 
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F5H6I7 Atlastin-3  ATL3 
Q9P2E9 Ribosome-binding protein 1  RRBP1 
Q9Y2W1 Thyroid hormone receptor-associated protein 3 THRAP3 
Q5JRX3-2 Isoform 2 of Presequence protease, mitochondrial  PITRM1 
O00151 PDZ and LIM domain protein 1  PDLIM1 
P21589-2 Isoform 2 of 5'-nucleotidase  NT5E 
Q5LJA9 Ubiquitin carboxyl-terminal hydrolase (Fragment)  UCHL5 
P52306-5 
Isoform 5 of Rap1 GTPase-GDP dissociation 
stimulator 1  
RAP1GDS1 
P55084-2 
Isoform 2 of Trifunctional enzyme subunit beta, 
mitochondrial  
HADHB 
Q9UQ35 Serine/arginine repetitive matrix protein 2  SRRM2 
P00367 Glutamate dehydrogenase 1, mitochondrial GLUD1 
P56192 Methionine--tRNA ligase, cytoplasmic  MARS 
P34932 Heat shock 70 kDa protein 4  HSPA4 
Q16666-2 Isoform 2 of Gamma-interferon-inducible protein 16  IFI16 
B4DY09 Interleukin enhancer-binding factor 2  ILF2  
Q9NUQ9 Protein FAM49B FAM49B 
P50990-2 Isoform 2 of T-complex protein 1 subunit theta  CCT8 
P31939-2 
Isoform 2 of Bifunctional purine biosynthesis protein 
PURH  
PUR9 
Q9NZT2-2 Isoform 2 of Opioid growth factor receptor  OGFR 
Q96RF0-2 Isoform 2 of Sorting nexin-18  SNX18 
Q15691 
Microtubule-associated protein RP/EB family member 
1  
MAPRE1 
Q9UHD2 Serine/threonine-protein kinase TBK1  TBK1 
Q9Y263 Phospholipase A-2-activating protein PLAA 
Q14195-2 
Isoform LCRMP-4 of Dihydropyrimidinase-related 
protein 3  
DPYSL3 
J3KS95 
Mitotic spindle-associated MMXD complex subunit 
MIP18 (Fragment)  
FAM96B 
P51149 Ras-related protein Rab-7a  RAB7A 
B7Z7F3 Ran-binding protein 3  RANBP3 
P14868 Aspartate--tRNA ligase, cytoplasmic  DARS 
P00387-2 Isoform 2 of NADH-cytochrome b5 reductase 3  CYB5R3 
Q92934 Bcl2-associated agonist of cell death  BAD 
P30153 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform  
PPP2R1A 
Q15020 
Squamous cell carcinoma antigen recognized by T-
cells 3  
SART3 
B1AK87 
Capping protein (Actin filament) muscle Z-line, beta, 
isoform CRA_a  
CAPZB 
P62191 26S protease regulatory subunit 4 PSMC1 
  
420 
 
 
O00299 Chloride intracellular channel protein 1  CLIC1 
E9PK54 Heat shock cognate 71 kDa protein  HSPA8 
Q58FG1 Putative heat shock protein HSP 90-alpha A4 HSP90AA4P 
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Appendix II – Submitted manuscript 
Manuscript was submitted to Glycoconjugate journal (in press, 2016) 
 
Mass spectrometric determination of advanced glycation in biology 
Naila Rabbani,1 Amal Ashour2 and Paul J Thornalley1,2 
1Warwick Systems Biology Centre, Senate House, University of Warwick, Coventry 
CV4 7AL, U.K. and 2Clinical Sciences Research Laboratories, Warwick Medical 
School, University of Warwick, University Hospital, Coventry CV2 2DX, U.K. 
 
Corresponding author: Dr Naila Rabbani Tel +44 2476968593 Email: 
N.Rabbani@warwick.ac.uk 
 
Keywords: glycation; mass spectrometry; proteomics; glucose; methylglyoxal, 
fructosamine; hydroimidazolone; bioinformatics; Orbitrap. 
Word count: 3447. 
 
  
  
422 
 
 
Appendix III – Conference abstract  
1. Glyoxalase centennial conference (Coventry 2013 - Poster) 
 
Dicarbonyl Stress and the Glyoxalase System in Periodontal Ligament 
Fibroblasts in vitro 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
     Periodontal ligament (PDL) inflammation or periodontitis is a common disease 
characterized by gradual destruction of connective tissue fibres that attach a tooth to 
the alveolar bone within which it sits. Diabetes and inflammation enhances 
periodontal bone loss through enhanced resorption and diminished bone formation. 
PDL fibroblast attachment and function to type 1 collagen is impaired by 
methylglyoxal (MG) modification in vitro. We hypothesise that increased PDL 
detachment and dysfunction by MG may occur in biochemical dysfunction in 
hyperglycaemia and by increased exposure to exogenous MG by ingestion of high 
MG content food and beverages. The aim of this study was to evaluate the effects of 
low and high glucose concentrations and exogenous MG on the glyoxalase system in 
human periodontal ligament fibroblasts (hPDLFs) in vitro. 
     Primary hPDLFs were purchased from ScienCell (Carlsbad, USA) and cultured 
for three days with high glucose (25 mM) and low (8 mM) glucose to mimic 
hyperglycaemic conditions. There was a 37% decrease of glyoxalase 1 activity 
(p<0.01) in hPDLFs incubated in high glucose compared to control. The flux of MG 
formation, as judged by increase in D-lactate, was increased 42% (P<0.012). We 
conclude that the exposure of PDL cells to high glucose down regulate Glo1 which 
may increase MG glycation to collagen and playing a role in PDL dysfunction.  
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2. 7th Saudi Student Conference UK (Edinburgh 2014 - Poster)  
 
Dicarbonyl Stress and the Glyoxalase System in Periodontal Ligament 
Fibroblasts in vitro 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
Periodontal ligament (PDL) inflammation or periodontitis is a common disease 
characterized by gradual destruction of connective tissue fibres that attach a tooth to 
the alveolar bone. Diabetes and inflammation enhances periodontal bone loss 
through enhanced resorption and diminished bone formation. PDL fibroblast 
attachment and function to type 1 collagen is impaired by methylglyoxal (MG) 
modification in vitro. Glyoxalase 1 (Glo1) is the main enzyme catalysing the 
metabolism of MG in PDL fibroblasts. it is hypothesised that increased PDL 
detachment and dysfunction by MG may occur in biochemical dysfunction in 
hyperglycaemia and by increased exposure to exogenous MG by ingestion of high 
MG content food and beverages.  
The aim of this study was to evaluate the effects of low and high glucose 
concentrations and exogenous MG on the glyoxalase system in human periodontal 
ligament fibroblasts (hPDLFs) in vitro. 
Primary hPDLFs were cultured for three days with high glucose (25 mM) and low (8 
mM) glucose to mimic hyperglycaemic conditions. Glo1 activity was determined by 
measuring the initial rate of formation of S-D-lactoyl-glutathione from the 
hemithioacetal substrate formed non-enzymatically from methylglyoxal and reduced 
glutathione (GSH).The reaction is followed spectrophotometrically at 240 nm; Δε240 
= 2.86 mM−1 cm−1. D-glucose consumption and D-lactate formation were determined 
using end-point enzymatic assay spectrophotometrically at 340 nm and (λ
excitation 340 
and λemission 460 nm) respectively. Dicarbonyl content and protein damage markers of 
medium and cell protein were determined by stable isotopic dilution analysis using 
LC-MS/MS. 
There was a 49% decrease of glyoxalase 1 activity (p<0.0001) in hPDLFs incubated 
in high glucose compared to control. The flux of MG formation, as judged by 
increase in D-lactate, was increased 42% (P<0.01).  
To conclude, the exposure of PDL cells to high glucose down regulate Glo1 which 
may increase MG glycation to collagen and playing a role in PDL dysfunction.  
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3. European Association for the Study of Diabetes. (Vienna 2014 - Poster) 
Resveratrol corrects dicarbonyl stress in periodontal ligament fibroblasts in 
model hyperglycaemia in vitro. 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
Background and aim 
Diabetes and inflammation enhances periodontal bone loss through enhanced 
resorption and diminished bone formation. It has been shown that human PDL 
fibroblast (hPDLF) attachment and function to type 1 collagen was impaired by 
methylglyoxal (MG) modification in vitro. We found that increased 
hPDLFsdetachment and dysfunction was partly mediated by increased exposure to 
high glucose concentration with increased formation of MG, decreased metabolism 
of MG by glyoxalase 1 (Glo1) and increased formation of MG-derived advanced 
glycation endproducts (AGEs). The aim of this study was to evaluate the effect of 
resveratrol (RES) on MG metabolism in hPDLFs in vitro in high and low glucose 
concentration. 
Materials and methods 
hPDLFs were cultured for three days in medium containing low glucose 
concentration (LG, 8 mM) and also high glucose concentration (HG, 25 mM) to 
model hyperglycaemic conditions. The effect of addition of Res (10 µM) was 
studied. The activity of Glo1, D-glucose consumption and D-lactate formation were 
measured. The concentrations of MG and MG-derived AGE, MG-H1, were 
quantified by stable isotopic dilution analysis using LC-MS/MS.  
Results 
There was a significant decrease in Glo1 activity in HG (527 ± 97 versus 930 ± 85 
mU/mg protein, p<0.001). In HG there was an increase in D-lactate flux (4.71 ± 0.47 
versus 3.88 ± 0.47 nmol per million cells per day, p<0.012) and an increase in 
cellular concentration of MG (10.7 ± 1.5 versus 7.6 ± 0.5 pmol per million cells, 
p<0.002). The concentration of MG was increased in HG culture medium (448 ± 37 
nM versus 276 ± 82 nM; p<0.01). Decreased Glo1 activity in HG was corrected by 
RES treatment (964 ± 87 mU/mg protein, p<0.001 with respect to HG control). RES 
also decreased MG content of cells (6.74 ± 1.26 pmol per million cells; P< 0.023) 
and medium (351 ± 36 nM; P<0.018) with respect to corresponding HG control. 
Conclusion 
We conclude that hPDLFs suffer dicarbonyl stress and MG accumulation in high 
glucose concentration in vitro that may be corrected by treatment with RES.  
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4. 8th Saudi Student Conference UK (London 2015 - Poster)  
 
Dicarbonyls stress in periodontal ligament fibroblasts is corrected by 
Resveratrol in model hyperglycaemia in vitro. 
 
Amal Ashour1, Paul J Thornalley and Naila Rabbani 
 
Background and aim 
Diabetes and inflammation enhances periodontal bone loss through enhanced 
resorption and diminished bone formation. It has been shown that human PDL 
fibroblast (hPDLF) attachment and function to type1 collagen was impaired by 
methylglyoxal (MG) modification in vitro. We found that increased 
hPDLFsdetachment and dysfunction was partly mediated by increased exposure to 
high glucose concentration with increased formation of MG, decreased metabolism 
of MG by glyoxalase1(Glo1) and increased formation of advanced glycation 
endproducts(AGEs). The aim of this study was to evaluate the effect of resveratrol 
(RES) on MG metabolism in hPDLFs in vitro in high and low glucose concentration. 
Materials and methods 
hPDLFs were cultured for three days in medium containing low glucose 
concentration(LG, 8mM) and also high glucose concentration (HG, 25 mM) to 
model hyperglycaemic conditions. The effect of addition of RES (10 µM) was 
studied. The activity of Glo1, D-glucose consumption and D-lactate formation were 
measured. The concentrations of MG and MG-derived AGE, MG-H1, were 
quantified by stable isotopic dilution analysis LC-MS/MS.  
Results 
There was a significant decrease in Glo1 activity in HG (527±97 versus 930 ± 85 
mU/mg protein, P<0.001). In HG there was an increase in D-lactate flux (4.71±0.47 
versus 3.88 ± 0.47 nmol/million cells/day, P<0.012) and an increase in cellular 
concentration of MG (10.7±1.5 versus 7.6 ± 0.5 pmol/million cells, P<0.002). The 
concentration of MG was increased in HG culture medium (448±37 versus 276 ± 82 
nM; P<0.01). Decreased Glo1 activity in HG was corrected by RES treatment (964 ± 
87 mU/mg protein, P<0.001 with respect to HG control). RES decreased MG content 
of cells (6.74 ± 1.26 pmol /million cells; P<0.023) and medium (351 ± 36 nM; 
P<0.018) with respect to corresponding HG control. 
Conclusion 
We conclude that hPDLFs suffer dicarbonyl stress and MG accumulation in high 
glucose concentration in vitro that may be corrected by RES treatment. 
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5. EuroPerio 8 conference (London 2015 - Poster) 
 
Resveratrol corrects dicarbonyl stress in periodontal ligament fibroblasts in 
model hyperglycaemia in vitro. 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
Aim: The aim of this study was to evaluate the effect of resveratrol (RES) on 
glyoxalase1 (Glo1) activity and methylglyoxal (MG) metabolism in human PDL 
fibroblast (hPDLFs) in vitro in high and low glucose concentration. 
Material and Methods: hPDLFs were cultured for three days in medium containing 
low glucose concentration (LG, 8mM) and also high glucose concentration (HG, 
25mM) to model hyperglycaemic conditions. The effect of addition of Res (10µM) 
was studied. The activity of Glo1, D-glucose consumption and D-lactate formation 
were measured. The concentrations of MG and MG-derived AGE, MG-H1, were 
quantified by stable isotopic dilution analysis using LC-MS/MS. 
Results: There was a significant decrease in Glo1 activity in HG (529 ± 106 versus 
930 ± 84 mU/mg protein, p<0.001). In HG there was an increase in D-lactate flux 
(4.95 ± 0.42 versus 3.48 ± 0.52 nmol per million cells per day, p<0.003) and an 
increase in cellular concentration of MG (8.66 ± 1.51 versus 3.98 ± 1.00 pmol per 
million cells, p<0.003). The concentration of MG was increased in HG culture 
medium (449 ± 38 nM versus 276 ± 82 nM; p<0.05). Decreased Glo1 activity in HG 
was corrected by RES treatment (996 ± 55 mU/mg protein, p<0.0007 with respect to 
HG control). RES also decreased MG content of cells (6.74 ± 2.34 pmol per million 
cells; P<0.024) and medium (351 ± 36 nM; P<0.018) with respect to corresponding 
HG control. 
Conclusion: hPDLFs suffer dicarbonyl stress and MG accumulation in high glucose 
concentration in vitro that may be corrected by RES treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
427 
 
 
6. Warwick Medical School Student Symposium (Coventry 2015 - Talk)  
 
Resveratrol corrects dicarbonyl stress in periodontal ligament fibroblasts in 
model hyperglycaemia in vitro. 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
Background and aim 
Periodontal ligament inflammation (periodontitis) is a common disease 
characterized by gradual destruction of connective tissue fibres that attach a tooth to 
the alveolar bone within which it sits. Diabetes and inflammation enhances 
periodontal bone loss through enhanced resorption and diminished bone formation. It 
has been shown that PDL fibroblast attachment and function to type 1 collagen was 
impaired by methylglyoxal (MG) modification in vitro. We hypothesise that 
increased PDL detachment and dysfunction by MG may be mediated by increased 
exposure to not only endogenous MG but also by exogenous MG by ingestion of 
high MG content food and beverages. The aim of this study was to evaluate the 
effects of high and low glucose concentrations on MG metabolism in human 
periodontal ligament fibroblasts (hPDLFs) with and without resveratrol (RSV) 
treatment  
Materials and methods 
Primary hPDLFs were cultured for three days in medium containing low glucose 
concentration (LG, 8 mM) and also high glucose concentration (HG, 25 mM) to 
model hyperglycaemic conditions. The effect of addition of RSV (10 µM) was 
studied. The activity of Glo1, D-glucose consumption and D-lactate formation were 
measured. The concentrations of MG and MG-derived AGE, MG-H1, were 
quantified by stable isotopic dilution analysis using LC-MS/MS. The efficiency of 
hPDLFsadhesion to collagen type 1 was tested by colorimetric cell adhesion assay. 
Results 
There was a significant decrease in Glo1 activity and increase in D-lactate flux and 
cellular concentration of MG and MG-H1 in HG compare to LG and this was 
corrected with RSV treatment. The table below summarises the results of the study. 
 
 
Data are mean ± SD, n = 4. Significance: **, P<0.01 and ***, P<0.001 with respect to low 
glucose (control) (8mM) (t-test). Significance: oo, P<0.01 and ooo, P<0.001 with respect to 
high glucose (control) (25mM) (t-test). 
 
The efficiency of hPDLFsadhesion to collagen type 1 was decreased by 37% in HG. 
This was also corrected by RSV. 
Conclusion 
Assay 
Low glucose 
(control) 
High glucose 
(control) 
High glucose 
+RSV (10µM) 
Glo1 activity 
mU/mg protein 
928 ± 84 529 ± 109** 964 ± 87ooo 
D-Lactate 
nmol per million cells per day 
7.00 ± 0.36 9.90 ± 1.08** 9.78± 078 *** 
MG 
pmol per million cells 
3.98 ± 1.00 10.6 ± 1.07 6.98 ± 0.89oo 
MG-H1(mmol/mol Arg) 0.431 ± 0.061 0.806 ± 0.184 * 0.560 ± 0.088oo 
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We conclude that hPDLFs suffer dicarbonyl stress increasing MG levels in model 
hyperglycaemia in vitro that was corrected by RSV treatment. Functional 
impairment of hPDLFswas also reversed by RSV. 
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7. 12th International Symposium on the Maillard Reaction (Tokyo 2015 – 
Poster) 
 
DICARBONYL STRESS IMPAIRS FUNCTION OF PERIODONTAL 
LIGAMENT FIBROBLASTS IN MODEL HYPERGLYCAEMIA 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
Background and aim 
Periodontal ligament inflammation (periodontitis) is a common disease characterized 
by gradual destruction of connective tissue fibres that attach a tooth to the alveolar 
bone within which it sits. Diabetes and inflammation enhances periodontal bone loss 
through enhanced resorption and diminished bone formation. PDL fibroblast 
attachment to type 1 collagen and function was impaired by methylglyoxal (MG) 
modification in vitro. We hypothesise that increased PDL detachment and 
dysfunction may be exacerbated by increased endogenous MG in hyperglycemia 
associated with diabetes. The aim of this study was to evaluate the effects of high 
and low glucose concentrations on MG metabolism in human periodontal ligament 
fibroblasts (hPDLFs) with and without resveratrol (RSV) treatment  
Materials and methods 
Primary hPDLFs were cultured for three days in medium containing low glucose 
(LG, 8 mM) and high glucose concentration (HG, 25 mM) to model hyperglycaemic 
conditions with and without RSV (10 µM). The activity of Glo1, D-glucose 
consumption and D-lactate formation were measured. The concentrations of MG and 
MG-derived AGE, MG-H1, were quantified by stable isotopic dilution analysis 
using LC-MS/MS. The efficiency of hPDLFsadhesion to collagen type 1 was tested 
by colorimetric cell adhesion assay. 
Results 
In hPDLFs incubated with HG there was a significant decrease in Glo1 activity, 
increase in D-lactate flux, increase in cellular concentration of MG and increase in 
MG-H1 residue content of cell protein, compared to LG control. Decrease of Glo1 
activity and increase in MG and MG-G1 residue content of cell protein was 
corrected with RSV treatment.  The results are summarised in the table below. 
 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to LG; oo and ooo, P<0.01 and P<0.001 compared to 
HG. 
 
Analyte 
Low glucose 
(8 mM) 
High glucose 
(25 mM) 
High glucose 
+RSV (10µM) 
Glo1 activity 
(mU/mg protein) 
928 ± 84 529 ± 109** 964 ± 87ooo 
D-Lactate 
(nmol per million cells / day) 
7.00 ± 0.36 9.90 ± 1.08** 9.78 ± 0.78 *** 
MG 
(pmol / million cells) 
3.98 ± 1.00 10.6 ± 1.07 6.98 ± 0.89oo 
MG-H1 
(mmol/mol arg) 
0.431 ± 0.061 0.806 ± 0.184 * 0.560 ± 0.088oo 
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The efficiency of hPDLFsadhesion to collagen type 1 was decreased by 37% in HG 
and was corrected by RSV. 
Conclusion 
We conclude that hPDLFs suffer dicarbonyl stress and functional impairment in 
model hyperglycaemia in vitro which is corrected by RSV treatment.  
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8. 1st Reunion Meeting of BIOCLAIMS and 5th International Symposium of 
the Human Nutrition & Metabolism Research and Training Centre (Graz 
2015, Talk) 
 
Resveratrol corrects dicarbonyl stress in periodontal ligament fibroblasts in 
model hyperglycaemia in vitro. 
 
Amal Ashour, Paul J Thornalley and Naila Rabbani 
 
Background and aim 
Periodontal ligament inflammation (periodontitis) is a common disease characterized 
by gradual destruction of connective tissue fibres that attach a tooth to the alveolar 
bone within which it sits. Diabetes and inflammation enhances periodontal bone loss 
through enhanced resorption and diminished bone formation. PDL fibroblast 
attachment to type 1 collagen and function was impaired by methylglyoxal (MG) 
modification in vitro. We hypothesise that increased PDL detachment and 
dysfunction may be exacerbated by increased endogenous MG in hyperglycemia 
associated with diabetes. The aim of this study was to evaluate the effects of high 
and low glucose concentrations on MG metabolism in human periodontal ligament 
fibroblasts (hPDLFs) with and without resveratrol (RSV) treatment  
Materials and methods 
Primary hPDLFs were cultured for three days in medium containing low glucose 
(LG, 8 mM) and high glucose concentration (HG, 25 mM) to model hyperglycaemic 
conditions with and without RSV (10 µM). The activity of Glo1, D-glucose 
consumption and D-lactate formation were measured. The concentrations of MG and 
MG-derived AGE, MG-H1, were quantified by stable isotopic dilution analysis 
using LC-MS/MS. The efficiency of hPDLFsadhesion to collagen type 1 was tested 
by colorimetric cell adhesion assay. 
Results 
In hPDLFs incubated with HG there was a significant decrease in Glo1 activity, 
increase in D-lactate flux, increase in cellular concentration of MG and increase in 
MG-H1 residue content of cell protein, compared to LG control. Decrease of Glo1 
activity and increase in MG and MG-G1 residue content of cell protein was 
corrected with RSV treatment.  The results are summarised in the table below. 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to LG; oo and ooo, P<0.01 and P<0.001 compared to 
HG. 
 
The efficiency of hPDLFsadhesion to collagen type 1 was decreased by 37% in HG 
and was corrected by RSV. 
Conclusion 
Analyte 
Low glucose 
(8 mM) 
High glucose 
(25 mM) 
High glucose 
+RSV (10µM) 
Glo1 activity 
(mU/mg protein) 
928 ± 84 529 ± 109** 964 ± 87ooo 
D-Lactate 
(nmol per million cells / day) 
7.00 ± 0.36 9.90 ± 1.08** 9.78 ± 0.78 *** 
MG 
(pmol / million cells) 
3.98 ± 1.00 10.6 ± 1.07 6.98 ± 0.89oo 
MG-H1 
(mmol/mol arg) 
0.431 ± 0.061 0.806 ± 0.184 * 0.560 ± 0.088oo 
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We conclude that hPDLFs suffer dicarbonyl stress and functional impairment in 
model hyperglycaemia in vitro which is corrected by RSV treatment.  
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9. 9th Saudi Student Conference UK (Birmingham 2016 - Poster) 
 
The effect of resveratrol on dicarbonyl stress in periodontal ligament 
fibroblasts in model hyperglycaemia. An in vitro study 
 
Amal Ashour1, Paul J Thornalley1 and Naila Rabbani1 
 
Background and aim 
Periodontal ligament inflammation (periodontitis) is a common disease characterized by 
gradual destruction of connective tissue fibres that attach a tooth to the alveolar bone within 
which it sits. Diabetes and inflammation enhances periodontal bone loss through enhanced 
resorption and diminished bone formation. PDL fibroblast attachment to type 1 collagen and 
function was impaired by methylglyoxal (MG) modification in vitro. We hypothesise that 
increased PDL detachment and dysfunction may be exacerbated by increased endogenous 
MG in hyperglycemia associated with diabetes. The aim of this study was to evaluate the 
effects of high and low glucose concentrations on MG metabolism in human periodontal 
ligament fibroblasts (hPDLFs) function with and without resveratrol (RSV) treatment  
Materials and methods 
Primary hPDLFs were cultured for three days in medium containing low glucose (LG, 8 
mM) and high glucose concentration (HG, 25 mM) to model hyperglycaemic conditions 
with and without RSV (10 µM). The activity of Glo1, D-glucose consumption and D-lactate 
formation were measured. The concentrations of MG and MG-derived AGE, MG-H1, were 
quantified by stable isotopic dilution analysis using LC-MS/MS. The efficiency of 
hPDLFsadhesion to collagen type 1 was tested by colorimetric cell adhesion assay. 
Results 
In hPDLFs incubated with HG there was a significant decrease in Glo1 activity, increase in 
D-lactate flux, increase in cellular concentration of MG and increase in MG-H1 residue 
content of cell protein, compared to LG control. Decrease of Glo1 activity and increase in 
MG and MG-G1 residue content of cell protein was corrected with RSV treatment.  The 
results are summarised in the table below. 
Data are mean ± SD, n = 4. Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001, 
respectively, compared to LG; oo and ooo, P<0.01 and P<0.001 compared to HG. 
 
The efficiency of hPDLFsadhesion to collagen type 1 was decreased by 37% in HG and was 
corrected by RSV. 
Conclusion 
We conclude that hPDLFs suffer dicarbonyl stress and functional impairment in model 
hyperglycaemia in vitro which is corrected by RSV treatment.  
 
 
 
 
 
 
Analyte 
Low glucose 
(8 mM) 
High glucose 
(25 mM) 
High glucose 
+RSV (10µM) 
Glo1 activity 
(mU/mg protein) 
928 ± 84 529 ± 109** 964 ± 87ooo 
D-Lactate 
(nmol per million cells / day) 
7.00 ± 0.36 9.90 ± 1.08** 9.78 ± 0.78 *** 
MG 
(pmol / million cells) 
3.98 ± 1.00 10.6 ± 1.07 6.98 ± 0.89oo 
MG-H1 
(mmol/mol arg) 
0.431 ± 0.061 0.806 ± 0.184 * 0.560 ± 0.088oo 
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10. Midlands Academy of Medical Sciences Festival (Birmingham 2016 – Talk) 
 
Resveratrol corrects dicarbonyl stress in periodontal ligament fibroblasts in 
model hyperglycaemia in vitro. 
 
AA Ashour, PJ Thornalley and N Rabbani 
 
Periodontal ligament inflammation (periodontitis) is a common disease characterized 
by gradual destruction of connective fibres that attach a tooth to the alveolar bone. 
Diabetes and inflammation enhances periodontal bone loss through enhanced 
resorption and diminished bone formation. Periodontal ligament (PDL) fibroblast 
attachment to type1 collagen and function were impaired by methylglyoxal (MG) 
modification in vitro1. We hypothesise that increased PDL detachment and 
dysfunction may be exacerbated by increased endogenous MG in hyperglycaemia 
associated with diabetes. The aim of this study was to evaluate the effects of high 
and low glucose concentrations on MG metabolism in human PDL fibroblasts 
(hPDLFs) with and without resveratrol (RSV) treatment. 
 
Primary hPDLFs were cultured for three days in medium containing low glucose 
(LG,8mM) and high glucose concentration (HG, 25mM) to model hyperglycaemic 
conditions with and without RSV (10 µM). The activity of Glo1, D-glucose 
consumption and D-lactate formation were measured. The concentrations of MG and 
MG-derived AGE, MG-H1, were quantified by stable isotopic dilution analysis 
using LC-MS/MS. The efficiency of hPDLFsadhesion to collagen type 1 was tested 
by colorimetric cell adhesion assay. 
 
In hPDLFs incubated with HG there was a significant decrease in Glo1 activity, 
increase in D-lactate flux, increase in cellular concentration of MG and increase in 
MG-H1 residue content of cell protein, compared to LG control. Decrease of Glo1 
activity and increase in MG and MG-H1 residue content of cell protein was 
corrected with RSV treatment. The results are summarised in the table below. 
 
Data are mean±SD, n=4. Significance: *,**and***, P<0.05, P<0.01 and P<0.001, 
respectively, compared to LG; ooandooo, P<0.01 and P<0.001 compared to HG. 
 
The efficiency of hPDLFsadhesion to collagen type1 was decreased by 37% in HG 
and was corrected by RSV. 
We conclude that hPDLFs suffer dicarbonyl stress and functional impairment in 
model hyperglycaemia in vitro which is corrected by RSV treatment.  
Analyte LG HG HG+RSV 
Glo1 activity 
(mU/mg protein) 
928±84 529±109** 964±87ooo 
D-Lactate 
(nmol per million 
cells/day) 
7.00±0.36 9.90±1.08** 9.78±0.78*** 
MG 
(pmol/million cells) 
3.98±1.00 10.6±1.07 6.98±0.89oo 
MG-H1 
(mmol/mol arg) 
0.431±0.061 0.806±0.184* 0.560±0.088oo 
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Reference: 
1. Murillo, J., et al., Advanced Glycation of Type I Collagen and Fibronectin 
Modifies Periodontal Cell Behavior. Journal of Periodontology, 2008. 
79(11): p. 2190-2199. 
 
 
 
 
 
 
